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ABSTRACT OF DISSERTATION 
 
 
 
RESPONSES OF BOVINE PITUITARY TRANSCRIPTOME PROFILES TO 
CONSUMPTION OF TOXIC TALL FESCUE AND FORMS OF SELENIUM IN 
VITAMIN-MINERAL MIXES 
 
The first goal of the current research was to determine whether gene expression 
profiles differed between whole pituitaries of growing beef steers grazing pastures 
containing high (HE) or low (LE) amounts of toxic endophyte-infected tall fescue. The 
global (microarray analysis) and selected targeted (RT-PCR) mRNA expression patterns 
of pituitaries collected from beef steers (BW = 266 ± 15.5 kg) that had been randomly 
assigned to undergo summer-long grazing (89 to 105 d) of either HE (0.52 ppm ergot 
alkaloids) or LE (< 0.03 ppm ergot alkaloids) pastures were compared. Gene expression 
data were subjected to one-way ANOVA. The pituitaries of HE steers had 542 
differentially expressed genes, and the pattern of altered gene expression was dependent 
on treatment. Targeted RT-PCR analysis corroborated these findings, including decreased 
expression of DRD2, PRL, POU1F1, GAL, and VIP and that of POMC and PCSK1, 
respectively. Canonical pathway analysis (Integrated Pathway Analysis, IPA) identified 
HE-dependent alteration in signaling of additional pituitary-derived hormones, including 
growth hormone and GnRH.  In conclusion, consumption of endophyte-infected tall fescue 
alters the pituitary transcriptome profiles of steers in a manner consistent with their 
negatively affected physiological parameters. The second goal of this project was to test 
the hypothesis that sodium selenite (ISe), SEL-PLEX (OSe), vs. a 1:1 blend (MIX) of ISe 
and OSe in a basal vitamin-mineral (VM) mix would differentially alter pituitary 
transcriptome profiles in growing beef steers (BW = 183 ± 34 kg) commonly grazing an 
endophyte-infected tall fescue (HE) pasture. Steers were randomly selected from herds of 
fall-calving cows grazing HE pasture and consuming VM mixes that contained 35 ppm Se 
as either ISe, OSe, or MIX forms. Steers were weaned, depleted of Se for 98 d, and 
subjected to summer-long common grazing of a 10.1 ha HE pasture containing 0.51 ppm 
ergot alkaloids. Steers were assigned (n = 8) to the same Se-form treatments on which they 
were raised. Selenium treatments were administered by daily top-dressing 85 g of VM mix 
onto 0.23 kg soyhulls, using in-pasture Calan gates. Pituitaries were collected at slaughter 
and changes in global (microarray) and selected (RT-PCR) mRNA expression patterns 
determined. The effects of Se treatment on relative gene expression were subjected to one-
way ANOVA. The form of Se affected the expression of 542 annotated genes. Integrated 
  
Pathway Analysis found a canonical pathway network between prolactin and 
POMC/ACTH/ α-MSH synthesis-related proteins, and that mitochondrial dysfunction was 
a top-affected canonical pathway. Targeted RT-PCR analysis found that the relative 
abundance of mRNA encoding prolactin and POMC/ACTH/ α-MSH synthesis-related 
proteins was affected by the form of Se, as were mitochondrial dysfunction-related proteins 
OSe steers appeared to have a greater prolactin synthesis capacity vs. ISe steers through 
decreased dopamine receptor D2 signaling, whereas MIX steers had a greater prolactin 
synthesis capacity and release potential by increasing TRH concentrations than ISe steers. 
OSe steers also had a greater ACTH and α-MSH synthesis potential than ISe steers. We 
conclude that form of Se in VM mixes affected genes responsible for prolactin and 
POMC/ACTH/α-MSH synthesis, and mitochondrial function in pituitaries of growing beef 
steers commonly grazing an HE pasture. The third goal was to test the hypothesis that 
sodium selenite (ISe), SEL-PLEX (OSe), vs. a 1:1 blend (MIX) of ISe and OSe in a basal 
vitamin-mineral (VM) mix would differentially alter selenoprotein profiles in pituitaries 
and livers of growing beef steers commonly grazing an endophyte-infected tall fescue (HE) 
pasture (i.e., the same steers used in Goal 2). The effects of Se treatment on relative gene 
expression were subjected to one-way ANOVA. The mRNA content of 6 selenoproteins in 
the pituitary was affected by Se treatments, along with two selenoprotein P receptors, 
whereas the expression of two selenoproteins was altered in the liver. We conclude that the 
change in selenoprotein gene expression in pituitaries indicates that OSe steers have a 
greater potential capacity to manage against oxidative damage, maintain cellular redox 
balance, and have a better quality control of protein-folding in their pituitaries than ISe 
steers. The change in selenoprotein gene expression by the liver indicates that MIX steers 
have a greater redox signaling capacity and capacity to manage oxidative damage than ISe 
steers. 
 
  KEYWORDS: Bovine pituitary, Ergot alkaloid, Fescue toxicosis, Prolactin, Selenium, 
Selenoprotein  
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CHAPTER 1. Introduction 
 
Epichloe coenophialum (formerly Neotyphodium coenophialum) is an endophytic 
fungus that infects most tall fescue (Lolium arundinaceum) pastures commonly used in 
animal grazing systems in the eastern half of the United States (Aiken and Strickland, 
2013). The interaction between E. coenophialum and tall fescue produces ergot alkaloids 
(Siegel and Bush, 1994). Consumption of ergot alkaloid-containing tall fescue impairs 
several metabolic, vascular, growth, and reproductive processes in cattle, collectively 
producing a clinical condition known as “fescue toxicosis” (Strickland et al., 2011). 
There are over 8.5 million cattle grazing endophyte-infected tall fescue pasture (Paterson 
et al., 1995), and that causes approximately one billion dollar losses to beef industry in 
the United States annually (Oliver, 1997). Reduced serum prolactin is a recognized 
marker of fescue toxicosis (Goetsch et al., 1987; Davenport et al., 1993). The anterior 
pituitary gland secretes hormones that affect control over several physiological processes 
altered by consumption of ergot alkaloid-containing forages, including hormones for 
metabolism (TSH), growth (GH), reproduction (LH, FSH), stress responses (ACTH), and 
lactation (prolactin) (Beardwell and Robertson, 1981). Despite these known relationships, 
reports that describe the effect of fescue toxicosis on pituitary genomic expression 
profiles are still very limited. 
Besides fescue toxicosis, another challenge faced by many southeastern United 
States cattle producers is selenium (Se) deficiency. Se-poor soils in this same geographic 
region result in Se-deficient forages necessitating the need to provide supplemental Se 
(Dargatz and Ross, 1996). Inorganic Se (ISe, sodium selenite) is the most common form 
of Se supplemented in cattle diets, whereas organic forms of Se (OSe) derived from 
2 
 
specially cultivated Saccharomyces cerevisiae also are available and approved for use in 
beef cattle diets. Serendipitously, it was found that expression of several genes 
downregulated in the liver (Liao et al., 2015) of steers grazing high vs. low endophyte-
infected forages were upregulated in cattle by consumption of a 1:1 blend of ISe:OSe 
(MIX) in vitamin-mineral (VM) mixes (Matthews and Bridges, 2014; Matthews et al., 
2014). Moreover, it was determined subsequently that steers subjected to summer-long 
grazing of endophyte-infected pasture and supplemented (3 mg/d) with MIX or OSe 
forms of Se had greater serum prolactin concentrations than ISe-supplemented steers (Jia 
et al., 2018). Hence, forms of Se seems to impact gene expression in steer pituitaries, 
specially genes associated with prolactin synthesis or secretion. However, the effects of 
forms of Se on gene expression profile in bovine pituitary has not been reported.  
In addition, to our knowledge, studies regarding the effects of forms of Se on 
selenoprotein profile in bovine pituitary and liver tissues have not been reported either. 
The goals of this dissertation are stated in Chapter 3.  
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CHAPTER 2. Literature Review 
 
2.1 Fescue toxicosis 
The perennial tall fescue (Lolium arundinaceum, formerly Festuca arundinacea) 
is an economically important cool-season bunch-grass, originally from Europe (Buckner 
et al., 1979). It was first introduced to the United States from Eurasia in the late 1800s, 
but was not cultivated widely until the 1940s and 1950s (Hoveland, 2009). It is well 
adapted and the most widely grown grass in the transition zone between the northern and 
southern regions of the eastern United States (Hemken et al., 1984; Paterson et al., 1995). 
Today it is estimated that tall fescue covers more than 15 million ha; and in the 
southeastern US, the most dominant cultivar is Kentucky-31 tall fescue (Buckner et al., 
1979; Schmidt and Osborn, 1993; McCulley et al., 2015).  
Tall fescue possesses many desirable properties including ease and wide range of 
establishment and adaptation, extended grazing season, tolerance to adverse climate, soil, 
and poor management regimes, pest resistance, and high-yield seed production (Ball et 
al., 1987; Stuedemann and Hoveland, 1988; Roberts et al., 2009). Many of these 
properties has been attributed to its symbiotic relationship with a fungal endophyte 
(Epichloe coenophialum, formerly Neotyphodium coenophialum)(Clay, 1990; Glenn et 
al., 1996; Schardl et al., 2004), which resides within the leaf, sheaths, and flower culms 
of tall fescue (Porter and Thompson, 1992). The biochemical basis for endophyte-
induced physiological changes in tall fescue is still a mystery, but association with 
endophytes has been reported to benefit tall fescue in growth, survival, and drought 
tolerance (Arachevaleta et al., 1989; Schardl et al., 2004).  
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Although endophyte-host relationship confers tall fescue with many desirable 
agronomic characteristics, grazing on endophyte-infected tall fescue usually reduces 
animal performance, especially for livestock like cattle, sheep, and horses (Porter and 
Thompson, 1992). There are over 8.5 million cattle grazing endophyte-infected tall 
fescue pasture (Paterson et al., 1995), and that causes approximately one billion dollar 
losses to beef industry in the United States annually (Oliver, 1997).  
Generally, there are three syndromes occurring on cattle grazing tall fescue: 
fescue foot, fat necrosis, and fescue toxicosis. Fescue foot is a dry and gangrenous 
condition of feet, which usually occurred with colder environmental temperatures (Bush 
and Buckner, 1973). Rear feet are most commonly affected (Thompson and Stuedemann, 
1993). The second syndrome fat necrosis is a condition of necrotic fat lesions 
surrounding the intestinal tract from the abomasum to the rectum (Bush and Buckner, 
1973). Those two syndromes above are less common to occur and easy to recover when 
the injured cow is removed from consuming endophyte-infected toxic tall fescue (Bush 
and Buckner, 1973; Stuedemann and Hoveland, 1988). With regard to the last syndrome, 
consumption of endophyte-infected tall fescue impairs several metabolic, vascular, 
growth, and reproductive processes in cattle, collectively producing a clinical condition 
known as “fescue toxicosis”, also referred to as summer lump or summer fescue toxicosis 
(Strickland et al., 2011). Specifically, clinical signs of fescue toxicosis in cattle include 
decreased feed intake, BW gain, milk production, and reproductive efficiency, and 
elevated body temperature and respiration rates, rough hair coats and preference for 
shade (Strickland et al., 1993; Brown et al., 2009). This frequently occurring and 
widespread syndrome over tall fescue pasture regions is the major culprit responsible for 
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the economic loss in beef industry mentioned above. The reduction of serum prolactin is 
a recognized and the most commonly analyzed physiologic hallmark of fescue toxicosis 
(Goetsch et al., 1987; Davenport et al., 1993). 
The symbiotic interaction between E. coenophialum and tall fescue yields ergot 
alkaloids (Siegel and Bush, 1994; Strickland et al., 2011). The distribution of ergot 
alkaloids within the tall fescue varies, with the highest concentration in seed heads 
(Rottinghaus et al., 1991). Unfortunately, ergot alkaloids are naturally occurring 
mycotoxins (Bush and Fannin, 2009), and consumption of ergot alkaloids is detrimental 
to animal productivity, especially for livestock like cattle, sheep, and horses (Porter and 
Thompson, 1992). Hence, ergot alkaloids have been reported to be responsible for the 
toxicity of endophyte-infected tall fescue (Lyons et al., 1986; Paterson et al., 1995; 
Guerre, 2015).  
2.2 Ergot alkaloids 
Ergot alkaloids are naturally occurring secondary metabolites produced by fungi 
including members of the Claviceps and Neotyphodium genera (Strickland et al., 2011). It 
was discovered that when administered appropriately, ergot alkaloids could be used to 
improve human health. In fact, the first isolated and identified ergot alkaloid was 
ergotamine, which was extracted from sclerotia of Claviceps for pharmaceutical use 
(Flieger et al., 1997). The beneficial and pharmacological effects of ergot alkaloids 
include: treatment of parkinsonism, migraine, thrombosis, cerebrovascular insufficiency, 
and stimulation of cerebral and peripheral metabolism, etc (Berde and Schild, 1978). 
However, for livestock producers, it is a totally different story. As mycotoxins, ergot 
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alkaloids significantly influence livestock health and productivity negatively around the 
world.  
The ergotism in livestock is directly related to the tetracyclic ergoline ring among 
all ergot alkaloids (Figure 2.1), similar to the ring structure of the biogenic amines, 
dopamine, epinephrine, norepinephrine, and serotonin (Berde and Stürmer, 1978; Pertz 
and Eich, 1999). Based on the type of substituent on C-8 of the ergoline ring (Figure 2.1), 
ergot alkaloids can be divided into 3 classes: clavines, ergopeptines, and lysergic acid and 
derivatives (Figure 2.2). Among ergopeptines, ergovaline was predominant in endophyte-
infected tall fescue pastures, accounting for over 80% of the total ergopeptines and 10 to 
50% of the total ergot alkaloids (Lyons et al., 1986). 
Ergot alkaloid exerts function through binding biogenic amine receptors, most of 
which belong to the G protein-coupled receptor family of transmembrane receptors 
(Goddard III and Abrol, 2007). In addition, ergot alkaloids can function as both agonists 
and antagonists as ligands (Berde, 1980) and bind with one or more receptor sites (Berde 
and Stürmer, 1978). Hence, a variety of biological problems are derived from the 
receptor-alkaloid interactions. The impact of consuming ergot alkaloids from endophyte-
infected tall fescue on multiple physiological systems (cardiovascular, growth, 
reproduction) in livestock has been intensively reviewed (Strickland et al., 2011). One 
evident influence of ergot alkaloid exposure on the reproductive system is prolactin 
depression in sera (Hurley et al., 1980) and pituitary glands (Schillo et al., 1988). This 
symptom is relatively consistent than many others caused by consumption of ergot 
alkaloids (Strickland et al., 1993). Therefore, reduced prolactin has been adopted as a 
serological sign of ergot alkaloid exposure. 
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2.3 Prolactin 
Bovine prolactin concentrations in plasma or serum are presented in Table 2.1. 
2.3.1 Prolactin structure 
 Based on its genetic, structural, and biological properties, prolactin belongs to the 
cytokine superfamily which also includes hormones like growth hormone and placental 
lactogen (Horseman and Yu-Lee, 1994). The genes encoding these 3 hormones were 
derived from a common ancestral gene by duplication (Niall et al., 1971), which occurred 
approximately 400 million years ago (Cooke et al., 1981). In addition, the members of 
this family share a tertiary structure of 4 α helix and bind to a non-tyrosine kinase, single-
pass transmembrane receptor (Trott et al., 2008).  
The single human prolactin gene that consists of 5 exons and 4 introns is found on 
chromosome 6, with a gene size of 10 kb (Cooke et al., 1981). The transcription of 
prolactin is controlled by two independent promoter regions (Figure 2.3). The proximal 
promoter is required for pituitary-specific prolactin expression, while a superdistal 
promoter located 5.8 kb upstream of pituitary start site directs extrapituitary expression 
(Berwaer et al., 1991; Berwaer et al., 1994). The proximal promoter contains multiple 
binding sites for pituitary-specific positive transcription factor 1 (Pit-1, encoded by 
POU1F1) which plays a pivotal role in prolactin gene transcription and development of 
lactotrophs in the anterior pituitary (Fox et al., 1990; Gourdji and Laverriere, 1994). In 
contrast, the superdistal promoter drives extrapituitary gene expression in a Pit-1-
independent manner (Gellersen et al., 1994).  
Mature bovine prolactin contains a single chain of 199 amino acids with three 
intramolecular disulfide bridges between six cysteine residues, and it shares 80% amino 
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acid sequence homology with human prolactin (Wallis, 1974). Although the major form 
of pituitary-derived prolactin is about 23 kDa, other variants have been identified in 
human, as results of alternative splicing, proteolytic cleavage, and other post-translation 
modification (e.g. phosphorylation and glycosylation) (Freeman et al., 2000).  
The predominant site for prolactin production is the anterior pituitary gland. 
Besides pituitary, prolactin has been reported to be expressed at much smaller amounts at 
multiple extrapituitary sites in human, including adipose tissue, brain, breast, 
endometrium, decidua, myometrium, immune cells, placenta, prostate, and skin (Ben-
Jonathan et al., 1996; Fitzgerald and Dinan, 2008; Diakonova, 2014). 
2.3.2 Prolactin receptor 
Prolactin was given the name according to the fact that it promotes lactation in 
mammals (Riddle et al., 1933). However, as a very ancient hormone and that exists in all 
vertebrates, prolactin has been reported to possess over 300 separate biological activities 
(Bole-Feysot et al., 1998), more than activities of all other pituitary hormones combined 
(Fitzgerald and Dinan, 2008). Pituitary-derived prolactin acts as a classical circulating 
hormone, whereas extrapituitary prolactin is thought to function as a cytokine (Ben-
Jonathan et al., 2007). Prolactin exerts its physiological function through interaction with 
its receptor. 
The prolactin receptor is a single-pass membrane-bound protein, which belongs to 
the class 1 cytokine receptor superfamily (Bazan, 1990a, b). It is devoid of intrinsic 
tyrosine kinase activity and capable of phosphorylation by cytoplasmic proteins (Ben-
Jonathan et al., 2007). Each prolactin receptor contains an extracellular region, a 
transmembrane region, and an intracellular region (Bole-Feysot et al., 1998). After the 
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extracellular domain of prolactin receptor binds to a ligand (e.g. prolactin), a ligand-
induced prolactin receptor dimerization occurs which is obligatory for subsequent signal 
transmission (Bernichtein et al., 2010). The role of the transmembrane region in prolactin 
receptor activation and signaling transmission is still unclear. In contrast, the intracellular 
domain has been known as a crucial component in the initiation of prolactin receptor-
mediated signal transduction (Freeman et al., 2000). After binding of prolactin to its 
receptor, several signaling pathways can be activated including the Janus kinase-signal 
transducer and activator of transcription (Jak-Stat), the mitogen-activated protein kinase 
(MAPK), and the phosphoinositide 3 kinase pathways (PI3K) (Clevenger et al., 2003), 
among which is the Jak-Stat cascade predominant pathway (Figure 2.4).  
Prolactin receptor isoforms, due to alternative splicing during transcription, have 
been identified in different mammals. In mice, three major prolactin receptor isoforms 
have been described including short, intermediate, and long forms (Bole-Feysot et al., 
1998). In human, six isoforms of prolactin receptor have been reported (Diakonova, 
2014). However, only two distinct prolactin receptor isoforms have been identified in 
cattle based on their amino acid sequence. In addition, it has been suggested that only the 
long isoform can mediate the Jak-Stat pathway (Brym et al., 2005). Moreover, elevated 
mRNA expression of long isoform has been observed in prolactin-overexpressing breast 
cancer cells and prolactin-transgenic mice (Ling et al., 2000; Liby et al., 2003). 
The prolactin receptor is ubiquitously expressed (Nagano and Kelly, 1994; 
Bakowska and Morrell, 1997; Bole-Feysot et al., 1998), which facilitates over 300 
biological functions of prolactin on certain level. The murine studies have shown that the 
ratio of isoforms varies based on tissues, development stages, and reproductive stages 
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(e.g. estrous cycle, pregnancy, lactation) (Nagano and Kelly, 1994; Bole-Feysot et al., 
1998).  
2.3.3 Biological functions of prolactin 
Although best known for the role in regulating lactation, prolactin affects a wide 
variety of biological functions including regulations of reproduction, osmoregulation, 
immune responses, metabolism, and growth and development. The biological functions 
of prolactin are summarized in Table 2.2. 
2.3.4 Prolactin synthesis and secretion by the anterior pituitary  
The pituitary is an endocrine gland composed of anterior, intermediate, and 
posterior lobes, with the anterior lobe occupying approximately 80% of the entire gland. 
An anatomic horizontal view of pituitary is shown in Figure 2.5. The anterior lobe is 
composed of five tropic cell types, which together secrete six hormones: corticotrophs 
(ACTH), gonadotrophs (FSH and LH), lactotrophs (prolactin), somatotrophs (GH), and 
thyrotrophs (TSH). Lactotrophs represent a dynamic population of cells (20-50% of the 
anterior pituitary cells) depending on the gender and physiological status of the animal 
(Freeman et al., 2000). In addition, lactotrophs exhibit functional heterogeneity with 
regard to their responsiveness to secretagogues (Boockfor and Frawley, 1987). 
Lactotrophs located in the outer zone of the anterior pituitary gland are more responsive 
to thyrotropin releasing hormone (TRH), whereas those located in the inner zone respond 
greater to dopamine (Boockfor and Frawley, 1987; Arita et al., 1991).  
Lactotrophs inherently possess a large storage capacity and a high basal secretory 
activity for prolactin. Hence, unlike other pituitary hormones such as LH or ACTH 
whose secretion regulation is provided in the form of positive stimulus by hypothalamus, 
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pituitary prolactin secretion is under tonic and predominantly inhibitory regulation by 
hypothalamus (Ben-Jonathan, 1985). The most influential hypothalamic prolactin-
inhibiting factor is dopamine. 
2.3.5 Dopaminergic regulation of prolactin secretion 
Dopamine or its agonists have been reported to exhibit potent ability to inhibit 
prolactin release both in vivo and in vitro (MacLeod, 1969; MacLeod et al., 1970; 
MacLeod, 1976). There are three hypothalamic dopaminergic neuronal systems including 
tuberoinfundibular (TIDA), tuberohypophysial (THDA), and periventricular (PHDA) 
dopaminergic neuronal population (Freeman et al., 2000; Ben-Jonathan and Hnasko, 
2001), among which the TIDA, residing in the arcuate nucleus and projecting to the 
external zone of median eminence, provides the major dopaminergic input to the anterior 
pituitary (Leong et al., 1983; Kawano and Daikoku, 1987). Dopamine exerts its inhibitory 
ability of prolactin secretion via binding to a G protein-coupled receptor expressed on the 
cell membranes of lactotrophs (Ben-Jonathan and Hnasko, 2001). This receptor (DRD2) 
belongs to D2 subclass of the dopamine receptor family (Caron et al., 1978; Meador-
Woodruff et al., 1989). In rats, two dopamine type two receptors isoforms (long and 
short) have been identified due to alternative splicing, and the long isoform is the 
predominant in the pituitary (Guivarc'h et al., 1995). Activation of either isoform in rat 
lactotrophs leads to repression of prolactin gene (PRL) expression (McChesney et al., 
1991). 
Dopamine inhibits prolactin gene expression by suppression of adenylyl cyclase 
activity. Most studies on inhibitory control of dopamine over prolactin expression used 
rats as models. In both male and female rat anterior pituitary homogenates, dopamine 
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inhibited basal and vasoactive intestinal peptide-induced adenylate cyclase in a dose-
dependent manner. A specific DRD2 antagonist, sulpiride, stereo-specifically 
antagonized the dopamine inhibition of pituitary adenylate cyclase (Enjalbert and 
Bockaert, 1983; Enjalbert et al., 1990).  Moreover, dopamine agonist bromocriptine 
inhibited prolactin gene promoter activity by 70%, and the inhibition was selective in that 
other viral or cellular promoters were unresponsive to bromocriptine. In addition to PRL 
promoter, dopamine caused a 60% decrease in transcription activity of Pit-1 promoter, 
and part of the inhibition was mediated by the two cAMP response elements (Elsholtz et 
al., 1991). Those findings combined suggest that DRD2-mediated inhibition of gene 
expressions of prolactin and Pit-1 by dopamine function through a canonical cAMP/PKA 
pathways. 
The inhibition of prolactin secretion by activation of DRD2 receptors has been 
reported to link to modification of several potassium and calcium channels (Israel et al., 
1987; Lledo et al., 1991). By binding with dopamine receptor DRD2, dopamine excites 
potassium conductance and inactivates voltage-sensitive calcium channels. As results, 
plasma membrane hyperpolarization is induced, intracellular calcium concentration is 
reduced, and prolactin secretion from secretory granules is inhibited. With the application 
of patch-clamp recording and use of antibodies raised against specific G proteins, it has 
been shown that the coupling of DRD2 to decreased calcium currents is via Gαo, whereas 
the coupling of DRD2 to increased potassium currents is via Gαi (Lledo et al., 1992). 
Therefore, the inhibition of prolactin release may be due to a combined function of 
DRD2 coupling with Gαi which evokes membrane hyperpolarization by opening 
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inwardly-rectifying potassium channel (indirect reduction in calcium influx) and DRD2 
coupling with Gαo inhibiting voltage-dependent calcium channels. 
Dopamine may suppress prolactin secretion through inhibition of inositol 
phosphate metabolism. In bovine pituitary cell preparation, dopamine agonists inhibited 
inositol phosphate accumulation and was prevented by DRD2 specific antagonists, 
suggesting that this effect is mediated through DRD2 activation (Simmonds and Strange, 
1985). Therefore, DRD2 may be negatively coupled with the phospholipase responsible 
for PIP2 hydrolysis, involved in the phosphatidylinositol signal pathway. Activation of 
either isoform of DRD2 inhibits adenylyl cyclase. However, only the short isoform is 
coupled to the phospholipase signaling pathway negatively (Caccavelli et al., 1992; 
Senogles, 2000). 
Ergot alkaloids ingested with consumption of endophyte-infested tall fescue 
structurally resemble various biogenic amines such as dopamine (Strickland et al., 2011). 
It is widely accepted that these ergot amines can bind to dopamine receptor DRD2, 
stimulate the receptors, and reduce basal level prolactin production and secretion through 
mechanisms described above. 
2.3.6 Prolactin short-loop feedback regulation 
PRL controls its own secretion by regulating the dopaminergic neuron through a 
short loop feedback mechanism (Figure 2.6). By interaction with prolactin receptor 
(PRLR) localized on TIDA neurons, prolactin stimulates an increase in dopamine 
synthesis in a time- and concentration-dependent manner. Specifically, it is achieved by 
stimulating site-specific (ser-19, -31, and -40) phosphorylation of tyrosine hydroxylase 
which is the rating-limiting enzyme in dopamine synthesis (Ma et al., 2005). In addition, 
14 
 
prolactin also exhibits the ability to elevate tyrosine hydroxylase mRNA expression 
levels in the arcuate nucleus (Arbogast and Voogt, 1991).  
2.3.7 Thyrotropin-releasing hormone regulation of prolactin secretion 
Thyrotropin-releasing hormone (TRH) is produced by the paraventricular nuclei 
in hypothalamus that is originally known to stimulate the release of thyroid-stimulating 
hormone from the anterior pituitary (Schally et al., 1966). Subsequently, it has been 
shown that TRH receptor is expressed on both thyrotrophs and lactotrophs (Pfleger et al., 
2004), and TRH stimulates prolactin release from lactotrophs in a dose-dependent 
manner both in vitro and in vivo (Bowers et al., 1971; Blake, 1974). Although the 
specific mechanism has not been fully elucidated, TRH was found to induce prolactin 
mRNA levels via activation of ERK signaling pathway with synergistic increase in 
intracellular Ca2+ (White and Bancroft, 1983; Kanasaki et al., 2002). In addition, TRH 
activates its G protein-coupled receptor and then membrane-bound phospholipase C 
signaling and calcium influx, which consecutively enhances Ca2+-dependent exocytosis 
of prolactin (Sikdar et al., 1989; Fomina and Levitan, 1995, 1997). 
2.3.8 Vasoactive intestinal peptide regulation of prolactin secretion 
Besides TRH, another hypothalamic pro-secretory agent of lactotrophs is 
vasoactive intestinal peptide (VIP). It was originally found in porcine small intestine 
(Said and Mutt, 1970). Subsequently, VIP was found in hypothalamus and median 
eminence (Besson et al., 1979; Dalcik and Phelps, 1993). Similar to TRH, VIP has been 
reported to stimulate prolactin secretion both in vivo and in vitro (Kato et al., 1978; 
Ruberg et al., 1978; Shaar et al., 1979). But unlike TRH, VIP is also synthesized in the 
lactotrophs, and the autocrine function of local production of VIP is thought to maintain 
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elevated basal prolactin release (Gómez and Balsa, 2004). By binding to high-affinity 
receptor on lactotrophs, VIP induces intracellular cAMP accumulation and then PKA 
activation (Miyata et al., 1989; Shivers et al., 1991), with a delayed increased in calcium 
concentration observed in the process (Samson et al., 1980; Bjøro et al., 1987).  
2.3.9 Galanin regulation of prolactin secretion 
Galanin is also known to stimulate prolactin release. Although galanin is also 
produced in arcuate nucleus of hypothalamus which projects to median eminence 
(Bedecs et al., 1995), it is primarily produced by the lactotrophs of the anterior pituitary 
(O’halloran et al., 1990). Specially, galanin peptide is found to be colocalized with 
prolactin in secretory granules of anterior pituitary cells (Hyde et al., 1991). Studies have 
shown that galanin secretion from cultured anterior pituitary cells is inhibited by 
somatostatin and dopamine, and stimulated by TRH and estrogen (Hyde and Keller, 
1991; Hammond et al., 1997). Galanin exerts its function by binding its G protein-
coupled receptor, which is present in the anterior lobe (Wynick et al., 1993). Although 
the mechanism has not been clearly defined, galanin is found to stimulate both basal and 
TRH-induced prolactin secretion in rats (Ottlecz et al., 1988). In addition, galanin may 
directly stimulate prolactin expression and act as a lactotroph growth factor, particularly 
when exposure to estrogen is high (Wynick et al., 1998). 
2.3.10 Autocrine autoregulation of prolactin secretion 
As mentioned above, prolactin regulates its own secretion by interacting with 
dopaminergic neurons in the hypothalamus. It has been reported that prolactin receptor 
also exists on the membrane of lactotrophs in the pituitary gland (Chiu et al., 1992). In 
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addition, it has shown that prolactin can inhibit its own secretion in an autocrine manner 
in human and rat in vitro studies (Hosojima and Wyche, 1985; Bentley and Wallis, 1987). 
Freeman et al. (2000) argued that since a great proportion of lactotrophs actively 
release VIP, galanin, and prolactin, it is very possible that VIP, galanin, and prolactin 
may also regulate prolactin secretion in a paracrine manner. 
2.4 Biosynthesis of proopiomelanocortin, ACTH, and α-melanocyte-stimulating 
hormone 
Previously, a study was conducted by our lab using an animal model of beef 
steers grazing high vs. low endophyte-infected tall fescue and consuming ad libitum 
amounts of inorganic selenium-containing vitamin mineral (VM) mix. We found that 
concentrations of prolactin in steers grazing high endophyte-infected tall fescue (HE) 
were only 10% of those of the steers grazing low endophyte-infected tall fescue (LE) 
(Brown et al., 2009). In addition, the liver tissues of the HE steers had increased amounts 
of mitochondrial mass, capacity for ATP synthesis, and amino acid-derived 
gluconeogenesis than those of the LE steers, and these processes have been implicated to 
be coordinated through the glucocorticoid receptor-mediated pathway (Liao et al., 2015). 
Since ACTH is the major hormone responsible for stimulation of the glucocorticoid 
biosynthesis and secretion by the cortex of adrenal glands (Simpson and Waterman, 
1988; Stocco and Clark, 1996), the ACTH synthesis pathway might be affected in bovine 
pituitary by fescue toxicosis. 
ACTH is synthesized within the anterior pituitary as part of a much larger 
precursor called proopiomelanocortin (POMC). POMC is mainly synthesized in the 
corticotrophs of the anterior pituitary and the melanotrophs of the intermediate pituitary, 
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respectively (Cawley et al., 2016). POMC in mammals consists of 3 exons, of which 
exons 2 and 3 are translated (Figure 2.7). It is post-translationally cleaved into smaller 
peptide hormones in a tissue-specific and cell-dependent manner by proprotein 
convertases. In the pituitary corticotrophs, proprotein convertase 1 (encoded by the 
PCSK1 gene) alone is expressed and cleaves POMC, producing the ACTH, β-endorphin, 
β-lipotrophin, amino-terminal peptide and joining peptide (Figure 2.7) (Millington, 
2007). 
ACTH also gives rise to a second peptide hormone, α-melanocyte-stimulating 
hormone (α-MSH) (Figure 2.7). Proprotein convertase 2 (encoded by the PCSK2) 
participates in production of α-MSH. In the intermediate pituitary, proprotein convertase 
2 cleaves peptide products initially produced by proprotein convertase 1 into small 
bioactive peptides (Seidah, 2013). After cleavage of ACTH1-39 into ACTH1-17 by 
proprotein convertase 2, carboxypeptidase E (encoded by the CPE) processes ACTH1-17 
to α-MSH with the cooperation of peptidylglycine α-amidating monooxygenase 2 
(encoded by the PAM) and an N-acetyltransferase (Kumar et al., 2016). 
2.5 Selenium deficiency 
The essential trace mineral selenium (Se) is of fundamental importance to animal 
health and performance. Bioavailable selenium in the forages affects animal health, 
depending on its deficiency or excess. Although it is harmful in excess, geographically, 
Se deficiency is a more severe problem to livestock production (Khanal and Knight, 
2010). The Se content of forages is dependent on the Se type available and Se content in 
the soil of a certain region (Mehdi and Dufrasne, 2016). When soil Se content is smaller 
than 0.5 mg/kg (Hefnawy and Tórtora-Pérez, 2010) or plant Se content smaller than 0.1 
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mg/kg (National Academies of Sciences and Medicine, 2016), Se deficiency is 
considered. Unfortunately, besides fescue toxicosis, the other challenge faced by many 
south-eastern United States cattle producers is Se deficiency due to low soil and forage 
selenium content (Dargatz and Ross, 1996). Se deficiency causes a variety of negative 
effects on beef cattle production including increased incidence of early embryonic death, 
retained placentas, cystic ovaries and weak heat periods (Corah, 1996), reduced growth 
rate and immune responses (Cerny et al., 2016), white muscle disease, and diarrhea 
(National Academies of Sciences and Medicine, 2016).  
2.6 Supplemental Se 
Se-deficient forages necessitate the need to provide supplemental Se. Some of the 
Se supplementations include direct injections, salt licks and drenches, addition in 
drinking water, implants (Khanal and Knight, 2010; Mehdi and Dufrasne, 2016). The 
nutritional requirement of Se for both growing and finishing beef cattle is around 0.1 ppm 
(100 µg/kg) dry matter (DM) per day (National Academies of Sciences and Medicine, 
2016). Both inorganic and organic forms of Se are approved by FDA for beef cattle 
production. Inorganic/mineral form of Se supplementation includes sodium selenate 
(SeO4) and sodium selenite (SeO3), and the latter is the most common form of Se 
supplemented in cattle diet. Organic form of Se supplementation includes selenocysteine 
(Sec) and selenomethionine (SeMet), both of which are the most common Se source in 
plants (Läuchli, 1993). They can also be produced from specially cultivated yeast 
Saccharomyces cerevisiae. This Se yeast, in which SeMet is predominant, is also 
approved for beef cattle production by FDA (Juniper et al., 2008).  
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2.6.1 Inorganic Se 
Most selenium supplementation adopts inorganic form of selenium. Selenate and 
selenite are taken by plant and then enter into food chain. Both dietary selenate and 
selenite can be absorbed efficiently. The absorption rate for selenite is above 50%, while 
the absorption rate for selenate is nearly 91% (Van Dael et al., 2001). Renal excretion of 
selenate is more rapid and higher compared with selenite. Hence, despite the large 
differences in absorption and renal excretion between selenate and selenite, when 
provided at dietary intake dose, both Se compounds result in roughly equivalent 
bioavailability of selenium (Van Dael et al., 2001). After absorption, selenate has to be 
reduced to selenite so it can be further metabolized. Selenite can be reduced by TrxR or 
by reacting with glutathione (GSH) to selenide (Ganther, 1971; Kumar et al., 1992).  
2.6.2 SeMet 
SeMet, a methionine analogue with a Se atom instead of a sulfur atom, is the 
major selenocompound in plants. It is synthesized and incorporated into protein in place 
of methionine since tRNA for methionine recognizes SeMet as methionine (Schrauzer, 
2000). After absorption via intestinal methionine transporter, dietary SeMet is either 
metabolized directly to reactive forms (selenide, then Sec) of Se via the transsulfuration 
pathway, mostly in liver, or randomly inserted into proteins in place of methionine 
(McConnell and Cho, 1967; Esaki et al., 1981; Wolffram et al., 1989). After SeMet-
containing proteins degrade, SeMet is released to free methionine pool again (Figure 2.8). 
It has been reported that availability of Se from both dietary SeMet and tissue SeMet can 
be modulated by dietary methionine level (Waschulewski and Sunde, 1988). SeMet-
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containing proteins serve as Se pool, especially when animal is exposed to a low-
selenium environment for a limited time (Burk and Hill, 2015).  
2.6.3 Sec 
Sec is considered to be the 21st amino acid, which is a cysteine analogue with a Se 
atom instead of a sulfur atom. Due to different chemical properties between Se and 
sulfur, the pKa of Sec is 5.2 while the pKa of Cys is 8.25 (Huber and Criddle, 1967). 
Hence, at physiological pH Sec is more reactive than Cys, because the selenol group of 
Sec is in its ionized form, while the thiol group of Cys is mainly protonated and less 
reactive (Johansson et al., 2005). Sec is considered as the most biologically active form 
of Se, and most selenoprotein enzymes are involved in redox reactions because of their 
active Sec residue (Papp et al., 2007). In plants, Sec is involved in the reverse 
transsulfuration pathway as an intermediate in which SeMet is made (Sors et al., 2005). 
Compared to SeMet, it is less abundant in plant proteins (Olson et al., 1970). 
Duo to its highly reactive properties, free Sec is methylated to Se-methylselenocysteine 
by some plants to detoxify it (Neuhierl et al., 1999). However, Se-methylselenocysteine 
is toxic to animals when they are exposed to it (Burk and Hill, 2015). In relation to 
absorption of dietary Sec, less is known compared to SeMet. However, studies have 
reported that selenocystine, oxidized form of Sec, can be taken up well by intestinal 
transporters for neutral and dibasic amino acids in cultured cells and competitively inhibit 
cystine absorption (Wolffram et al., 1989; Nickel et al., 2009). 
2.7 Selenoprotein synthesis 
Se exerts its biological function largely through the presence of Sec in 
selenoprotein. There are two unique features about selenoprotein mRNA than other 
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mRNA (Figure 2.9). One is a UGA codon in the open reading frame which encodes Sec. 
The UGA codon functions as both a codon for Sec biosynthesis and as a codon for 
protein synthesis termination in the nuclear genome (Leinfelder et al., 1988; Gladyshev 
and Hatfield, 1999). In mitochondrial, UGA also codes for tryptophan (Correa et al., 
2014). The other feature is the presence of Sec insertion sequence (SECIS) element, a cis-
acting stem-loop secondary structure downstream of the UGA codon, which locates in 
the 3’ untranslated region (Low and Berry, 1996). The SECIS element is necessary for 
recognition of in-frame UGA, as a signal for Sec insertion (Berry et al., 1993). 
Eukaryotic SECIS elements share several properties, consisting of two helices separated 
by an internal loop, a non-Watson-Crick GA quartet, and an apical loop or bulge 
(Walczak et al., 1996; Labunskyy et al., 2014). The differences among SECIS elements 
dictates translation efficiency by affecting binding of trans-acting factors (Low et al., 
2000; Latrèche et al., 2012). 
There are three unique trans-acting factors for selenoprotein synthesis (Figure 
2.9). Unlike other amino acid in eukaryotes, one interesting feature of Sec is that its 
biosynthesis occurs on its own tRNA, designated tRNA[Ser]Sec (Lee et al., 1989; Hatfield 
et al., 1994). tRNA[Ser]Sec is first aminoacylated with serine. This reaction is catalyzed by 
seryl-tRNA synthetase, and the newly formed seryl- tRNA[Ser]Sec become the backbone 
for biosynthesis of Sec (Lee et al., 1989; Leinfelder et al., 1989). Then seryl- tRNA[Ser]Sec 
is phosphorylated by O-phosphoseryl- tRNA[Ser]Sec kinase (Carlson et al., 2004). The 
newly formed intermediate phosphoseryl-tRNA[Ser]Sec serves as a substrate for Sec 
synthase to synthesize Sec, using monoselenophosphate as the Se donor which is 
generated by selenophosphate synthase 2 from selenide and ATP (Xu et al., 2006). The 
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other two trans-acting factors essential for selenoprotein synthesis in eukaryotes are 
SECIS binding protein 2 (SBP2) and the specific elongation factor EFsec. SBP2 is stably 
associated with SECIS elements and the ribosomes (Copeland et al., 2001). In addition, 
SBP2 also binds to EFsec (Copeland and Driscoll, 1999) which recruits selenocysteyl- 
tRNA[Ser]Sec and facilitates insertion of Sec into newly synthesized polypeptide 
(Tujebajeva et al., 2000).  
2.8 Twenty-five selenoproteins 
In recent years, it has been widely accepted that Se exerts its physiological 
functions through selenoproteins (Kim et al., 2011). There are 25 mammalian 
selenoproteins identified, in all of which Sec residues are present in the primary structure 
(Kryukov et al., 2003). Nearly all functionally characterized selenoproteins are redox 
enzymes in that Sec residues confer their catalytic redox activities (Papp et al., 2007). 
Selenoproteins have been classified according to their biological functions (1) antioxidant 
enzymes; (2) redox signaling; (3) Thyroid hormone metabolism; (4) Sec synthesis; (5) Se 
transportation and storage; (6) protein folding (7) unknown function (Figure 2.10).  
Glutathione peroxidases 
Glutathione peroxidase (GPx) was the first selenoprotein found (GPx1) in 
mammals (Flohe et al., 1973). There are eight known GPx homologs, five of which are 
selenoproteins (GPx1, GPx2, GPx3, GPx4, and GPx6). The other three GPx (GPx5, 
GPx7, and GPx8) homologs, and GPx6 homologs in some mammals (e.g. mouse), are not 
selenoenzymes because their active-sites contain Cys instead of Sec (Kryukov et al., 
2003). The five GPx (selenoproteins) are present in different compartments of cell and 
have distinct characteristics (e.g. substrate specificity) (Brigelius-Flohé and Maiorino, 
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2013). Collectively, the antioxidant GPx family catalyzes hydrogen peroxide (H2O2) or 
hydroperoxides reduction to affect signaling, to defend against oxidative damage, and to 
maintain cellular redox homeostasis (Margis et al., 2008).  
GPx1 is called classical or cytosolic glutathione peroxidase (also known as 
cGPx), although it can also be found in mitochondria (Brigelius-Flohé and Maiorino, 
2013). It is the most abundant mammalian selenoprotein, and also one of the most 
thoroughly characterized selenoproteins. GPx1 is expressed in all cell types and most 
abundant in the liver and kidney. Structurally, mammalian GPx1 forms a homotetramer 
(Flohe et al., 1971; Awasthi et al., 1975). This cytosolic enzyme scavenges H2O2 and 
soluble organic hydroperoxides in a glutathione (GSH)-dependent manner (Rotruck et al., 
1973; Gladyshev and Hatfield, 1999). It has been reported that H2O2 serves as an 
important signaling molecule, which is involved in regulation of various biological 
processes such as stress response, cell proliferation, and apoptosis (D'Autréaux and 
Toledano, 2007). Therefore, these biological processes are indirectly modulated by GPx1. 
Together with catalase and superoxide dismutase, GPx1 has been considered as one of 
the major antioxidant enzymes, protecting cells by reduction of toxic H2O2 (Lubos et al., 
2011). GPx1 knockout mice are viable but more susceptible to oxidative stress (Fu et al., 
1999). Hence, GPx1 seems to contribute to protection against oxidative stress, but is not 
indispensable. GPx1 is one of the most sensitive selenoproteins to Se deficiency. 
Dramatic decrease in GPx1 mRNA, protein, and activity has been observed in Se-
deficient rats (Sunde et al., 1997), and it has been proposed that GPx1 may also functions 
as a Se buffer or storage protein (Sunde, 1994).  
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GPx2 is known as the gastrointestinal-specific enzyme (GI-GPx) as well. 
Structurally and functionally, GPx2 highly resembles GPx1. It is a tetramer consisting of 
identical 22-kd subunits like GPx1, and GPx2 is also capable of reduce H2O2 in cytosol 
using GSH. However, unlike ubiquitously expressed GPx1, GPx2 is preferentially 
expressed in the epithelium of gastrointestinal system although its mRNA can also be 
found in liver (Arthur, 2001; Brigelius-Flohé and Maiorino, 2013). About half of the total 
Se-containing GPx activity comes from GPx2 in gastrointestinal tract (Esworthy et al., 
1998). Therefore, GPx2 plays an important role in defense against oxidative stress in this 
organ. In addition, it has been reported that GPx2 is important for protection of the 
gastrointestinal tract against inflammation and involved in cancer development, although 
the question that it is preventing or promoting carcinogenesis remains open (Chu et al., 
2004; Naiki-Ito et al., 2007; Banning et al., 2011). 
GPx3 is a glycosylated protein and the only extracellular Se-containing GPx (also 
known as pGPx). It is mainly secreted from kidney, but also present in adipose tissue, 
thyroid colloid lumen, etc (Maeda et al., 1997; Köhrle, 2005). Like GPx1 and GPx2, 
GPx3 is a tetramer, but its substrate specificity is broader. Even though GPx3 is capable 
of reducing H2O2 in the presence of GSH, as an efficient antioxidant in plasma it utilizes 
thioredoxin or glutaredoxin as reductants when the concentration of plasma GSH is fairly 
low. In fact, it has been reported that thioredoxin and glutaredoxin are better electron 
donors for GPx3 (Björnstedt et al., 1994). The promoter of GPx3 is frequently 
hypermethylated in a variety of tumors, so epigenetic regulation of GPx3 appears to be 
important in development of these tumors (Lee et al., 2005; Lodygin et al., 2005). GPx3 
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is widely considered as an indicator of Se status because it accounts for over 20% of total 
plasma Se (Gandin et al., 2009). 
GPx4, also known as PHGPx, is different from other Se-containing GPXs in that 
it can reduce phospholipid hydroperoxides that are associated with membrane function 
(Herbette et al., 2007). It utilizes protein thiols in addition to GSH as electron donors in 
mammalian cells (Ursini et al., 1999; Imai and Nakagawa, 2003). The lack of an internal 
loop in its monomeric structure enables GPx4 to interact with bulky phospholipid 
hydroperoxides (Sherrer et al., 2011). GPx4 is present in cytosolic (ubiquitously 
expressed), mitochondrial (testes), or nuclear form (testes) in a wide range of cell types 
and tissues, and is one of the most abundant selenoproteins (Brigelius-Flohe et al., 1994; 
Labunskyy et al., 2014). GPx4 is an essential antioxidant, and knockout of its gene is 
embryonic lethal (Yant et al., 2003). In addition, GPx4 plays a fundamental role in sperm 
maturation and male fertility. Disruption of mitochondrial GPx4 causes male infertility 
(Schneider et al., 2009). In contrast to GPx1, GPx4 levels are not sensitive to Se 
availability, and therefore it is considered as a housekeeping gene under Se deficiency 
condition (Bermano et al., 1995; Hara et al., 2001). 
GPx6 is the last identified Sec-containing glutathione peroxidase, and its 
homologs in some mammals (e.g. mouse) are not selenoenzymes. It has been reported 
that its mRNA is only found in embryos and olfactory epithelium (Kryukov et al., 2003). 
So far, the knowledge about GPx6 is very limited. It is suggested that GPx6 may have a 
tetrameric structure and is capable of reducing H2O2 and some soluble low-molecular-
weight hydroperoxides (Labunskyy et al., 2014). 
Thioredoxin reductases 
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Thioredoxin is a class of small, ubiquitous redox proteins present in all living 
cells, which protect cells against oxidative stress and facilitate redox signaling by 
catalyzing dithiol-disulfide exchange reactions of other proteins. The general description 
of enzymatic resections of thioredoxin system is presented in Figure 2.11. Oxidized 
thioredoxin need to be reduced by thioredoxin reductase (TrxR) to exert its functions 
again (Arnér, 2009). TrxR is a central component of the thioredoxin system because it is 
the only identified enzyme to catalyze the reduction of oxidized thioredoxin, in a 
NAPDH-dependent manner (Mustacich and Powis, 2000). There are three known TrxRs 
in mammals, all of which are homodimers and belong to the family of selenoproteins 
(Labunskyy et al., 2014). Unlike most of the selenoproteins containing Sec in the N-
terminal, each TrxR contains a Sec residue in the C-terminal, which plays an essential 
role for the enzymatic activity of TrxR (Gladyshev et al., 1996). 
TrxR1 is primarily present in cytosol, and is the major protein disulfide reductase 
in mammalian cells. TrxR1 reduces cytosolic thioredoxin as the major substrate (Arnér 
and Holmgren, 2000). Therefore, many thioredoxin-dependent physiological processes 
are reliant on TrxR1 including defense against oxidative stress, regulation of gene 
transcription, apoptosis and so on (Arnér and Holmgren, 2000; Nordberg and Arner, 
2001; Rundlöf and Arnér, 2004).  In addition, TrxR1 can also exerts its biological impart 
by reducing certain redox-active enzymes such as ribonucleotide reductases and 
methionine sulfoxide reductases (Stubbe and Riggs-Gelasco, 1998; Stadtman et al., 
2002). Moreover, various non-disulfide compounds like hydroperoxides and selenite can 
be reduced by TrxR1. Selenite can be reduced by TrxR1 to hydrogen selenide, which 
serves as the Se donor for Sec biosynthesis (Ganther, 1999). 
27 
 
TrxR2, also named as TR3, is located in mitochondria and expressed in various 
cell types (Rundlöf et al., 2001; Lillig and Holmgren, 2007). It catalyzes the reduction of 
mitochondrial thioredoxin and hence plays a role in regulation of mitochondrial redox 
processes and scavenging reactive oxygen species in mitochondria (Nalvarte et al., 2004). 
Studies suggest that TrxR2 may also be involved in regulation of cell signaling (Prasad et 
al., 2014) and cell proliferation (Kim et al., 2003). 
TrxR3, also known as thioredoxin glutathione reductase (TGR), exists primarily 
in testes (Arnér, 2009). Besides an FAD-binding domain, an NADPH-binding domain, 
and an interface domain like TrxR1 and TrxR2 (Biterova et al., 2005), it also contains an 
additional glutaredoxin domain in the N-terminal, which allows its glutathione and 
glutaredoxin reductase activity (Sun et al., 1999; Sun et al., 2001). Hence, this TrxR may 
be the bridge connecting thioredoxin and GSH systems. Due to its specific expression in 
testes, especially expressed at high level after puberty, TrxR3 is thought to play a role in 
sperm maturation (Su et al., 2005), although the most of its biological functions are still 
unknown. 
Iodothyronine deiodinase 
Another important selenoprotein family is thyroid hormone deiodinases, also 
designated iodothyronine deiodinases (DIOs). DIOs regulate activation and inactivation 
of thyroid hormones, which are essential for regulation of growth and development, 
thermogenesis, and energy expenditure (Mullur et al., 2014). The major thyroid hormone 
secreted by the thyroid gland is thyroxine (T4), which exhibits little intrinsic bioactivity 
and can be converted to biologically active 3,3’,5-triiodothyronine (T3) by reductive 
deiodination of T4 (Labunskyy et al., 2014). The metabolism of thyroid hormone by 
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DIOs is presented in Figure 2.12. There are three isoforms of DIOs, all of which form a 
homodimer structure and belong to Sec-containing membrane-bound enzymes (Lu and 
Holmgren, 2009). However, these DIOs occur in distinct subcellular locations and 
tissues. DIO1 and DIO3 are plasma membrane-bound enzymes, whereas DIO2 is located 
on the endoplasmic reticulum (Labunskyy et al., 2014). DIO1 is expressed primarily in 
liver, kidney, and thyroid; DIO2 in central nervous system, pituitary, thyroid, and brown 
adipose tissue; and DIO3 in vascular tissue, skin, and placenta (Mullur et al., 2014). 
DIO1 converts the prohormone T4 to active thyroid hormone T3 by outer ring 
deiodination. In turn, DIO1 is also capable of converting T3 and T4 by inner ring 
deiodination to produce inactive T2 and reverse T3 (rT3) (Bianco et al., 2002). Due to its 
ability to regulate thyroid hormone level in both ways, DIO1 was originally thought to be 
responsible for maintaining and regulating circulating levels of T3 (Gladyshev and 
Hatfield, 1999). In contrast, DIO2 and DIO3 were proposed to regulate local intracellular 
T3 level in a tissue-specific manner (Gereben et al., 2008a). However, it has been reported 
that DIO1 is dispensable for T3 action in DIO1 gene-knockout mice (Schneider et al., 
2006). In addition, recent studies show that DIO1 may be important to regulate high T4 
levels in hyperthyroid patients, but not in euthyroid human (Maia et al., 2005). 
Currently, DIO2 is considered as the major producer of circulating T3 in human 
(Maia et al., 2005). The activity of DIO2 can be elevated by low levels of serum T4 
(Gereben et al., 2008b). In addition, the intracellularly generated T3 by DIO2 rather than 
DIO1 is more effective in regulation of gene transcription (Sagar et al., 2007). DIO2 also 
plays an important role in regulation of intracellular T3 level in specific tissues. For 
example, in response to cold exposure, DIO2 regulates thermogenesis in brown adipose 
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tissue by elevating its expression level then increasing active T3 level in this tissue 
without affecting circulating T3 (Silva, 1995). 
DIO3 inactivates T3 and T4 by deiodination of their inner ring in a tissue-specific 
manner.  It is highly expressed in fetal and neonatal tissues and considered as the first 
expressed DIO developmentally (Mullur et al., 2014). It is expressed in highest level in 
placenta to prevent the access of maternal level thyroid hormones to a developing fetal 
tissues (Forhead and Fowden, 2014). 
Selenoprotein P 
Selenoprotein P (SelP) is an important selenoprotein in plasma of mammals. 
Unlike most other selenoproteins which usually contain one Sec residue, SelP contains 9-
12 Sec residues per molecule in mammals (Read et al., 1990). For example, human SelP 
contains 10 Sec residues (Mangiapane et al., 2014). This unique property enables SelP to 
account for approximately 50% of the total Se in plasma (Burk and Hill, 2005). 
According to a Se supplementation study, SelP is a better maker for Se nutritional status 
than another important plasma selenoprotein GPX3 (Xia et al., 2005). Moreover, it has 
been suggested that the main role of SelP is in selenium transport, delivery, and storage 
(Burk et al., 1991; Saito and Takahashi, 2002). SelP is mainly synthesized in liver, 
although its mRNA can be found in all tissues (Labunskyy et al., 2014) and locally 
expressed SelP is proposed to play essential role in some tissues like brain (Schweizer et 
al., 2005). SelP is then secreted into plasma in a glycosylated form and delivered to 
remote tissues.  After the degradation of SelP, its multiple Sec residues can be 
subsequently utilized to synthesize other selenoproteins (Richardson, 2005). In addition 
to selenium delivery and storage, studies have shown that SelP may also have heavy-
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metal-chelator capacity (Seiler et al., 2008) and antioxidant functions (Takebe et al., 
2002). 
SelP is delivered to peripheral tissues through a receptor-mediated mechanism. 
There are two endocytic receptors from low-density lipoprotein receptor family, 
apolipoprotein E receptor-2 (apoER2) (Olson et al., 2007) and megalin (Olson et al., 
2008). Both of these receptors have been identified as SelP receptors facilitating SelP 
entering into extrahepatic cells in a tissue-specific manner. ApoER2 is expressed highly 
in testis, bone marrow, placenta, brain, and muscle; moderately expressed in other tissues 
like thymus and spleen; and minimally expressed in liver and kidney (Burk and Hill, 
2015). It is suggested the tissue hierarchy for Se in largely determined by SelP binding to 
apoER2 (Burk and Hill, 2015). The other SelP receptor megalin plays an essential role 
for uptake of plasma SelP in kidney, and the uptake is proposed to provide Se for GPx3 
synthesis in kidney proximal tubules (Avissar et al., 1994). Megalin is also expressed in 
brain and reported to be involved in Se metabolism in brain (Chiu-Ugalde et al., 2010). 
Selenophosphate synthetase 2 
Selenophosphate synthetase 2 (SPS2) is homologous to selenophosphate 
synthetase 1 (SPS1) in mammals. However, unlike SPS1 in which the putative active 
center Sec is replaced by threonine, SPS2 belongs to the selenoprotein family (Low et al., 
1995). Selenophosphate synthetase 2 (SPS2) catalyzes the conversion of selenide to 
active Se donor selenophosphate, which is required for Sec biosynthesis (Xu et al., 2007). 
SPS2 is an interesting selenoprotein in that it possibly regulates its own biosynthesis 
(Guimarães et al., 1996) and therefore it is thought to plays an auto-regulatory role in 
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selenoprotein synthesis (Kim et al., 1997). Although it is a necessary component for the 
Sec synthesis machinery, other aspects of SPS2 biological function are still unclear. 
Selenoprotein W 
Selenoprotein W (SelW) is one of the earliest identified selenoproteins in 
mammals. In addition, SelW is also one of the most abundant selenoproteins in mammals 
(Labunskyy et al., 2014). It is localized in mainly the cytosol and bound to the cell 
membrane in a small fraction (Yeh et al., 1995).  SelW is ubiquitously expressed with the 
highest expression levels in muscles and brains (Gu et al., 2000). The expression of SelW 
is regulated by the availability of dietary Se (Howard et al., 2013). Its expression is 
downregulated in muscle, skin, prostate, heart, and intestine under Se deficiency while its 
expression in brain does not alter (Whanger, 2000). It has been proposed that SelW may 
play a role in redox-related process regulation because it binds GSH to form a complex 
with very high affinity (Beilstein et al., 1996). However, the molecular mechanisms 
involved remain to be elucidated. 
15-kDa selenoprotein (Selenoprotein F) 
The 15-kDa selenoprotein (Sep15) is one of the earliest identified selenoproteins. 
It is named by its molecular mass (Behne et al., 1997). A single Sec residue locates in the 
middle of the protein (Gladyshev et al., 1998). Sep15 is expressed in a wide range of 
tissues in mammals, with the highest levels in liver, kidney, prostate, and testis 
(Kumaraswamy et al., 2000). Its expression is sensitive to dietary Se intake (Ferguson et 
al., 2006). Sep15 has a thioredoxin-like domain, and N-terminal signal peptide, which is 
consistent with its location to the ER (Labunskyy et al., 2014). In addition, Sep15 
interacts with the UDP-glucose: glycoprotein glycosyltransferases (UGGT) to form a 
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tight complex. UGGT is an ER-resident chaperone which is involved in N-linked 
glycoproteins folding in ER (Hebert et al., 1995; Molinari and Helenius, 1999). Hence, 
Sep15 is proposed to be involved in disulfide-bond formation and quality control of some 
glycoproteins in the ER (Labunskyy et al., 2007). Moreover, studies also suggest that 
Sep15 may be involved in cancer etiology in various types of tissues (Kumaraswamy et 
al., 2000; Hu et al., 2001; Apostolou et al., 2004; Nasr et al., 2004; Irons et al., 2010). 
Selenoprotein H 
Like most of the selenoproteins, selenoprotein H (SelH) contains a Sec residue 
with the CXXU motif at the N-terminal (Barage et al., 2018). Uniquely, SelH is found to 
reside specifically in nucleoli (Novoselov et al., 2007). Its expression is regulated by 
dietary Se (Howard et al., 2013). It contains a motif of DNA-binding proteins, which is 
consistent with its subcellular localization (Labunskyy et al., 2014). Furthermore, SelH is 
found to possess GPx activity, so it is proposed that SelH may be play a nucleolar 
oxidoreductase role (Novoselov et al., 2007). 
Selenoprotein I 
Selenoprotein I (SelI) can be only found in vertebrate and considered as a recently 
evolved selenoprotein (Kryukov et al., 2003). Structurally, SelI is similar to choline and 
choline/ethanolamine phosphotransferases except that SelI contains a Sec residue in the 
C-terminal region (Labunskyy et al., 2014). However, currently the function of SelI is 
still unknown. 
Selenoprotein K 
In contrast to SelI, selenoprotein K (SelK) is one of the most widespread 
selenoproteins, which exists in nearly all Se-utilizing organisms (Labunskyy et al., 2014). 
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SelK contains a Sec residue at the C-terminal end. It is expressed in a variety of tissues, 
with the highest expression levels in heart and skeletal muscle (Papp et al., 2007). This 
protein is localized to the ER membrane (Lu et al., 2006) and implicated in degradation 
of misfolded proteins (Shchedrina et al., 2011). In addition, the possible role of SelK in 
antioxidant function (Lu et al., 2006), anti-inflammation (Vunta et al., 2007) and immune 
response has been proposed (Misu et al., 2010). 
Selenoprotein M 
Selenoprotein M (SelM) is distantly related to Sep15 (31% sequence identity). 
Like Sep15, SelM is a thioredoxin-like protein, which is localized on ER (Labunskyy et 
al., 2014). The Sec residue locates in the N-terminal region as a part of a CXXU motif 
(Korotkov et al., 2002). SelM shows the highest level of expression in brain and thyroid, 
and moderate level in heart, kidney, lung, and placenta (Korotkov et al., 2002). The 
physiological function of SelM still remains unclear, but it is proposed to be involved in 
neuroprotection against oxidative damage by H2O2 and regulation of Ca2+ release from 
ER in neurons (Reeves et al., 2010). 
Selenoprotein N 
Selenoprotein N (SelN) contains the Sec residue in the C-terminal region 
(Kryukov et al., 2003). SelN is a transmembrane glycoprotein, existing in the ER 
membrane. It is ubiquitously expressed in tissues, but highest expressed during 
embryonic development (Petit et al., 2003). In adult tissues, it is highly expressed in 
muscle; and it has been reported that SelN clearly plays a vital role in maintenance of 
muscle progenitor satellite cells and regeneration of impaired skeletal muscle (Castets et 
al., 2011). 
34 
 
Selenoprotein O 
Selenoprotein O (SelO) contains a Sec residue at the C-terminal (Kryukov et al., 
2003). It is the largest mammalian selenoprotein and present in mitochondrial of various 
tissues (Han et al., 2014). Currently, information about structural and physiological 
characterization of selenoprotein O (SelO) is very limited, besides SelO is proposed to be 
involved in redox interaction through its CXXU motif (Han et al., 2014). 
Selenoprotein R 
Selenoprotein R (SelR), also known as methionine sulfoxide reductase 
B1(MSRB1) or selenoprotein X, is a zinc-containing stereospecific methionine R 
sulfoxide reductase. It is predominantly localized in the nucleus and cytosol (Kim and 
Gladyshev, 2004). SelR is sensitive to dietary Se intake (Novoselov et al., 2005). It is the 
major mammalian methionine sulfoxide reductase B with the highest activity in liver and 
kidney (Kim and Gladyshev, 2004). SelR catalyzes the specific reduction of R-isomer of 
oxidized methionine in proteins. Therefore, it is required for repair of oxidative damaged 
proteins (Kryukov et al., 2002). In addition, it is reported that SelR is important for 
regulation of cellular functions by reduction of methionine residues of regulatory proteins 
(Lee et al., 2013). 
Selenoprotein S 
Selenoprotein S (SelS) one of the most widespread selenoproteins. It contains a 
Sec residue at the C-terminal end (Kryukov et al., 2003). Like SelK, SelS is also localized 
to the ER membrane and implicated in degradation of misfolded proteins (Labunskyy et 
al., 2014). In addition, the possible roles of SelS includes regulation of inflammatory and 
immune response (Curran et al., 2005; Gao et al., 2006). 
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Selenoprotein T 
Selenoprotein T (SelT) is a thioredoxin-like protein with a Sec residue located in 
the N-terminal region (Kryukov et al., 2003). It is primarily localized to ER membrane 
(Shchedrina et al., 2010). SelT is a ubiquitously expressed selenoprotein (Dikiy et al., 
2007). It is highly expressed in embryonic tissues. In adult tissues, SelT maintains a high 
expression level in endocrine organs like pituitary, thyroid, and pancreas (Tanguy et al., 
2011; Prevost et al., 2013). The biochemical function of SelT remains unclear. The 
proposed roles that SelT is involved in include: endocrine homeostasis, brain 
development and function, and neuroprotection (Youssef et al., 2018). 
Selenoprotein V 
Until now, selenoprotein V (SelV) is the least conserved mammalian and also the 
least characterized selenoproteins. It is only identified in testes of some placental 
mammals (Mariotti et al., 2012), and its function is still a mystery. 
2.9 Effects of forms of dietary Se on circulating Se and prolactin concentrations, and 
gene expression profile in cattle 
It has been reported that administration of organic Se leads to higher Se 
concentrations in biopsied liver tissue, jugular whole blood, and red blood cells compared 
to feeding the same doses of selenite in growing beef heifers (Liao et al., 2011). Later on, 
a 1:1 MIX (ISe:OSe) has been reported to be as potent as OSe in terms of elevating Se 
level of whole blood, red blood cells, serum, and liver in growing heifers, compared to 
dietary ISe (Brennan et al., 2011). In a beef cow/calf grazing study, cows supplemented 
with OSe had greater blood Se concentrations than cows consuming ISe or MIX. In 
addition, whole blood Se concentrations of OSe and MIX calves were greater than that of 
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ISe calves, and correlated to and affected by Se source from the dam (Patterson et al., 
2013). 
In agreement with previous studies, a most recent study shows that steers grazing 
endophyte-infected tall fescue with supplemental OSe and MIX in a basal vitamin-
mineral mix had greater whole blood Se than steers consuming ISe. In the same study, 
steers with MIX or OSe forms of Se was found to have greater serum prolactin 
concentrations than ISe-supplemented steers (Jia et al., 2018). 
In addition, forms of Se have been reported to influence gene expression profiles 
in bovine tissues, like the liver and testis (Liao et al., 2011; Matthews et al., 2014; Cerny 
et al., 2016). Serendipitously, it was found that expression of several genes 
downregulated in the liver of steers grazing high vs. low endophyte-infected forages were 
upregulated in cattle by consumption of a 1:1 blend of ISe:OSe (MIX) in vitamin-mineral 
mixes (Matthews and Bridges, 2014; Matthews et al., 2014; Liao et al., 2015). 
In contrast, to our knowledge, the effect of consumption of endophyte-infected 
tall fescue on pituitary transcriptome profiles has not been reported. In addition, little is 
known regarding the effect of Se form on transcriptome profiles in bovine pituitary. 
Moreover, effects of forms of Se on selenoprotein profile in specific bovine tissue have 
not been reported either. 
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Table 2.1. Bovine prolactin concentration in plasma or serum. 
 
  
Plasma/Serum Species Prolactin levels Reference 
Serum Cow 99.6~129.3 ng/mL (Ghorbani et al., 1991) 
Plasma Cow 5.3~7.9 ng/mL (Browning et al., 1998) 
Plasma Heifer 2.78~3.37 ng/mL (Pandey et al., 2017) 
Serum Heifer 25 ng/mL (Jones et al., 2008) 
Serum Steer 50~750 ng/mL (Trout and Schanbacher, 
1990) 
Serum Cow 20 ng/mL (Ahmadzadeh et al., 2006) 
Serum Steer 138.5-146.6 ng/mL (Aiken et al., 2006) 
Serum Steer 18-125 ng/mL (Fribourg et al., 1991) 
Plasma Cow 22-58 ng/mL (Do Amaral et al., 2009) 
Plasma Steer 5.3-11.8 ng/mL  (Auchtung and Dahl, 2004) 
Plasma Cow 6-19 ng/mL (Anchtung et al., 2005) 
Plasma Cow 14.4-25.2 ng/mL (Bluett et al., 2003) 
Serum Steer 3.6-36 ng/mL (Brown et al., 2009) 
Plasma Steer 16-20 ng/mL (Browning et al., 1997) 
Plasma Cattle 145.9-156.2 ng/mL (Browning et al., 1998) 
Plasma Steer 25-45 ng/mL (Browning, 2000) 
Serum Cattle 15-85 ng/mL (Campbell, 2014) 
Serum Steer 42.5-103.5 ng/mL (Carter et al., 2010) 
Serum Cattle 60-230 ng/mL (Drewnoski et al., 2009) 
Serum  Cattle 1-13 ng/mL  (Hill et al., 2000) 
Serum Steer  2-24 ng/mL (Kendall et al., 2003) 
Plasma Steer 8.83-18.03 ng/mL (Matthews et al. 2005) 
Serum Cattle 1.7-2.3 ng/mL (Merrill et al., 2007) 
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Table 2.2. Biological functions of prolactin in mammals. Adapted from Kelly et al. 
(1998) by removal of non-relevant data. For completeness, all the categories have been 
included whereas the underlined organ/target are thought to be especially relevant to this 
project. 
Organ or Target Effect 
Water and electrolyte balance 
Kidney ↓ Na+ and K+ excretion 
Sweat gland ↓Na+ and Cl- in sweat 
Intestine ↑ Water and salt absorption 
Uterus ↑Ca2+, Na+, K+, Cl- in flushings 
Placenta ↓Fluid volume in amnion 
Growth and development 
Body ↑Postnatal body growth 
Skin Proliferation of keratinocytes 
Hair loss for nest building 
Hair follicle Hair growth 
Fetal lung Maturation, surfactant production 
Heart ↑Ornithine decarboxylase (ODC) activity 
Liver Hepatocyte proliferation 
↓Cytokine gene expression in Kupffer cells 
Induction of growth factors 
Liver, kidney DNA hypomethylation 
Kidney ↑ODC activity 
Intestine ↑Intestinal mucosa 
Growth and changes in metabolism 
Muscle Proliferation of vascular smooth 
Induction of growth-related genes 
Adipocytes Preadipocyte differentiation 
Pancreas Proliferation of β-cell 
Increased β-cell-to-cell communication 
Adrenal ↑ODC activity 
Pituitary Proliferation of GH3 cells 
Germ cells ↑Maturation 
Gonads ↑Weight 
↑ODC activity 
Prostate Proliferation of human BPH epithelial cells 
↑Growth 
↑ODC activity 
Seminal vesicle ↑Growth 
Amnion ↑DNA synthesis and creatine kinase activity 
Brain 
 
Astrocyte proliferation 
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Table 2.2 (continued)  
Tuberoinfundibular hypothalamic 
development 
Immune system ↑Thymus and spleen weights 
Proliferation of lymphocytes 
Endocrinology and metabolism 
Brain Tissue-specific modulation of ATPases 
Modification of enzyme activities 
Fetal lung ↑Phospholipid synthesis 
Liver ↑Lipoprotein lipase activity 
↑Bile secretion 
↑ Na+ /taurocholate co-transport 
↑Glycogen phosphorylase a activity 
↑Ca2+ concentration 
↑PGF2α and PGE 
↑IGF-I production 
Pancreas ↑Insulin secretion 
↓Glucose threshold for insulin secretion 
↑Glucokinase and glucose transporter 2 
Adrenal ↑Steroidogenesis 
↑Adrenal androgens (DHEA, DHEA-S) 
↑Cortisol, altosterone 
↑21-Hydroxylase activity 
Skin ↑Steroidogenic enzyme (3βHSD) 
Many tissues ↑PRLR number 
Brain and behavior 
Brain, CNS Maternal behavior 
Grooming behavior 
Hyperphagia 
Adaptive stress responses 
Induced analgesia mimicking 
Psychosomatic reaction 
↓Libido 
↑REM sleep 
Sleep-wake cycle 
↑Lordosis behavior 
Hypothalamus, 
striatum 
↑Dopamine turnover 
Hypothalamus Maturation of neonatal neuroendocrine 
system 
↓GnRH secretion 
↓Frequency and pulsatility of LH 
↑Electrical activity of the VMH neurons 
↑PKC activity 
Retina ↓THR receptors 
↑Photoreceptor destruction 
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Table 2.2 (continued) 
Reproduction 
Mammary gland Lobuloalveolar growth 
↑Milk protein synthesis 
α-Casein 
β-Casein 
Whey acidic protein 
β-lactoglobulin 
Late lactation protein of marsupials 
↑Lactose synthesis 
Lactose synthetase 
↑Lipid metabolism 
Acetyl-CoA carboxylase 
Fatty acid synthase 
Malic enzyme 
Lipoprotein lipase 
↑IGF-I binding protein 
↑EGF 
↑I20-kDa protein 
↑Muc 1 (glycosylated mucin) 
↑PRL-inducible protein 
↑Parathyroid-like peptide 
Ovary Luteotropic and luteolytic actions 
Ovum maturation 
↓Folliculogenesis 
↓3β-HSD 
↓Aromatase 
Potentiate effects of LH on 3β-HSD 
↓Ovulation 
↓Plasmin generation in preovulatory 
follicles 
Granulosa cells ↓Estrogen production 
↓P450 aromatase 
↑Use of extracellular lipoproteins 
↑Progesterone production 
↑LH receptors 
↑20α-OH progesterone 
↓Progestins 
↓Luteinization 
↓cAMP and steroidogenesis 
Counteract morphological effects of LH 
↑Progesterone in cocultures of splenic 
macrophages removed at proestrus 
↑DAG 
↑1012-Macroglobulin 
Oocytes ↑Development competence and maturation 
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Table 2.2 (continued)  
Luteal cells Luteotropic action 
Luteolysis in pregnancy 
Luteolysis during estrous cycle 
↓20α-HSD 
↑Progesterone 
Control of delayed implantation and 
steroidogenesis 
↓37-kDa protein 
Uterus ↑Progesterone receptors and progesterone 
effects 
↑PGE2, phospholipase A2, prostaglandin 
G/H synthase 
↑Fluid loss 
↓Progesterone metabolism 
↑Estrogen receptors 
↓Myometrial contraction 
↑General secretory activity of endometrium 
↑Leucine aminopeptidase activity 
↑Uteroglobin production 
Promote blastocyst implantation 
↑Glucose amine synthetase activity 
Leydig cells Involved in maintenance of cell morphology 
↑LH receptors 
↑Aromatase activity 
↑Steroidogenesis and androgen production 
Sertoli cells ↑FSH receptors 
Germ cells ↑Total lipids 
↑Spermatocyte-spermatid conversion 
Spermatozoa ↑Ca2+ binding and/or transport of ejaculated 
and epididymal spermatozoa 
Energy metabolism 
↑ATPase activity 
↑Fructose rate 
↑Glucose oxidation 
↓Zn2+ content 
Maintenance of mobility and attachment to 
oocyte 
Shortening optimal preincubation period to 
acquire capacitation 
Epididymis 
 
 
 
 
 
↑Glycogenolysis and hexophosphate 
enzymes 
↑Sialic acid 
↑β-galactosidase and α-mannosidase 
activities 
↑Lipids 
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Table 2.2 (continued)  
↓Glycoprotein metabolism 
Seminal vesicle ↓Sperm fertilizing and mobility capacity 
Azoospermia 
↑Fluid lipids 
↑Lipogenesis 
↑Phosphomonoesterase and acid 
phosphatase 
↓Glycosylation 
Prostate ↑Weight 
↑Nuclear uptake of DHT 
↑Androgen receptor 
Improvement in estrogen-induced 
inflammation 
↑Epithelia secretory function 
Monosaccharide formation 
Amino acid oxidation and transamination 
↑Ornithine decarboxylase 
↑Citric acid secretion 
↑Mitochondrial aspartate 
Citrate oxidation and m-asconitase 
↑Pyruvate dehydrogenase E1α 
↑Aspartate transporter 
↑C3 subunit of prostatein, probasin, RWB 
gene 
↑ IGF-I and  IGF-I receptor 
Immunoregulation and protection 
Spleen ↑Weight 
Thymus ↑Weight 
↑Thymulin production 
Submandibular gland ↑Immunostimulatory activity 
Lymphocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑Hormonal immunity 
↑Adjuvant arthritis response 
↑Cellular immunity 
↑Antibody formation to sheep RBC 
↑IgG and IgM antibodies 
Reverse hypophysectomy-induced anemia, 
leukopenia, and thrombocytopenia 
↑Proliferation 
↑IL-2 receptors 
↑EPO receptors 
↑PRL receptors 
↓Apoptosis 
↑IFN-γ 
↑Graft rejection 
↑c-myc 
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Table 2.2 (continued)  
↑DNA synthesis 
↑T cell engraftment 
Nb2 cells ↑Proliferation 
↓Apoptosis 
IRF-1 gene induced 
c-myc  gene induced 
c-fos  gene induced 
ODC  gene induced 
Hsp 70  gene induced 
β-Actin  gene induced 
pim-1  gene induced 
gif-1  gene induced 
bcl-2  gene induced 
bax  gene induced 
T-cell receptor γ-chain  gene induced 
Cyclins D2 and D3  gene induced 
Cyclin E, cdk2, cdk5, E2F-1  gene induced 
Clone 15, nuclear movement protein  gene 
induced 
GnRH  gene induced 
GnRH receptor  gene induced 
Jak2 protein activated 
Fyn  protein activated 
Stat proteins activated 
Ras protein activated 
Raf protein activated 
Vav protein activated 
Grb2 protein activated 
Sos protein activated 
Shc protein activated 
MAP kinase protein activated 
Stathmin protein activated 
IRS-1 protein activated 
PTP-1D protein activated 
PKC protein activated 
Casein kinase II protein activated 
PTK protein activated 
PI3 kinase protein activated 
cbl protein activated 
S6 kinase protein activated 
G proteins activated 
PLC protein activated 
Amiloride-sensitive Na+/H+ exchange 
system protein activated 
NK cell ↑Susceptibility of primary leukemia cells 
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Table 2.2 (continued)  
↑Cytotoxic effects 
↑DNA synthesis 
Macrophages ↑Activation 
↑Cytokine gene expression in Kupffer cells 
following hemorrhage 
↓Monoblastic growth-synergy with IFN-γ 
↑Superoxide anion responsible for killing 
pathogenic organisms 
↑Nitric oxide and protection against 
bacterial infection 
Polymorphonuclear 
cells 
↓Direct and spontaneous migration 
Thymic nurse cell 
complexes 
Regulation of lymphocyte/epithelial cell 
adhesive interactions 
Mammary gland ↑IgA-secreting plasma cells 
Liver Induction of coagulation factor XII 
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Figure 2.1. (A) The tetracyclic ergoline ring common to all ergot alkaloids that is 
variously substituted on the C-8 which in this case has an amino acid ring system that 
varies at the R1 and R2 substituents to create the various ergopeptine alkaloids. (B) The 
structural similarities between the ergoline ring and the catecholamines norepinephrine, 
dopamine, and serotonin (in bold) (Klotz, 2015). 
 
  
46 
 
 
Figure 2.2 Chemical structures of the common ergoline ring structure, lysergic acid, and 
selected ergopeptines (Strickland et al., 2011). 
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Figure 2.3. Diagram of the human and rat PRL promoters, the PRL gene, and the human 
mRNA transcript (Ben-Jonathan et al., 2007). Arrows designate transcriptional start sites 
for the proximal pituitary promoter and the superdistal extrapituitary promoter. The 
superdistal promoter is unique to humans, and its start site is located 5.8 kb upstream of 
the pituitary start site. The human and rat proximal promoters differ in size and contain 
13 and 8 Pit-1 binding sites, respectively. A functional ERE is present in the rat promoter, 
whereas its presence in the human proximal promoter is questionable. In both species, the 
coding region in the pituitary consists of five exons that span approximately 10 kb. 
Transcription from either promoter produces mRNAs with identical protein coding 
sequences but differing in the 5’ UTR. Due to the presence of an additional codon in the 
human gene (1a), extrapituitary PRL mRNA is about 150 bp longer than the pituitary 
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transcript. A signal peptide coding for 28-30 residues lies downstream of the UTR, 
followed by the PRL transcript. 
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Figure 2.4. The predominant signal transduction pathway of prolactin (Fitzgerald and 
Dinan, 2008). Abbreviations: JAK, Janus kinase; Prl-R, prolactin receptor; STAT, signal 
transducer and transcription protein; TH, tyrosine hydroxylase. 
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Figure 2.5. Horizontal view of pituitary emphasizing distribution and percentage of 
anterior pituitary cell subtypes. Adapted from Ben-Shlomo and Melmed, 2010. 
Luteinizing hormone (LH) - and follicle-stimulating hormone (FSH)-secreting cells 
(gonadotrophs) are scattered throughout the anterior pituitary and constitute about 10% of 
cells. PRL, prolactin-secreting cells (lactotrophs, 15%); GH, growth hormone-secreting 
cells (somatotrophs, 50%); ACTH, adrenocorticotropin-secreting cells (corticotrophs, 
15%); TSH, thyroid-stimulating hormone-secreting cells (thyrotrophs, 5%).  
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Figure 2.6. Short-loop feedback mechanism of prolactin regulation (Fitzgerald and 
Dinan, 2008). Abbreviations: DA, dopamine; TIDA, tuberoinfundibular dopaminergic 
neuron; Prl-R, prolactin receptor; D2R, dopamine2 receptor; PRL, prolactin. 
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Figure 2.7. Gene structure and post-translational processing of POMC (Millington, 2007). 
Prohormone convertases 1 and 2 (PC1/2) break the parent POMC peptide into 
successively smaller peptides by cleavage at paired dibasic amino acid residues 
consisting of lysine (K) and/or arginine (R). The final products are generated in a tissue 
specific manner, for example α-MSH and ACTH are not produced by the same cells in 
the pituitary. They also involve additional enzymatic post translational modifications, 
such as the acetylation of α-MSH. The final products include the melanocortins (MSHs 
and ACTH), β-endorphin (β-end) and corticotrophin-like intermediate peptide (CLIP). 
There are intermediate peptides whose biological function remains unclear, such as β and 
γ lipotrophins (β-LPH, γ-LPH). 
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Figure 2.8. Initial metabolism of the principal dietary forms of selenium (Burk and Hill, 
2015). Abbreviations: met, methionine; Sec, Sec; Semet, SeMet. 
 
  
54 
 
 
Figure 2.9. Factors essential for selenoprotein synthesis (Burk and Hill, 2015). 
Abbreviations: 3’UTR, 3’ untranslated region; ORF, open reading frame; SECIS, 
selenocysteine insertion sequence element. 
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Figure 2.10. The human selenoproteome (Papp et al., 2007). The 25 human 
selenoproteins are outlined and classified by their determined or potential function. 
Selenoproteins with -CXXU- motifs are shown in the box. *-CXU- motif. 
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Figure 2.11. Scheme of oxidoreductase activities of the thioredoxin system (Arnér and 
Holmgren, 2000). The figure schematically depicts the reduction of the active site 
disulfide in oxidized thioredoxin, Trx-S2, to a dithiol in reduced thioredoxin, Trx-(SH)2, 
by thioredoxin reductase (TrxR) and NADPH. 
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Figure 2.12. Metabolism of thyroid hormone thyroxine (T4) by the types 1, 2, and 3 
deiodinases (DIO1, DIO2, DIO3) (Papp et al., 2007). DIO1 and DIO2 catalyze the 
reduction of T4 to yield the active form of hormone T3, or, reverse T3, rT3, to yield T2. 
DIO1 and DIO3 catalyze the deiodination of T4 to rT3, and of T3 to T2. 
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CHAPTER 3. Dissertation Objectives 
 
The goals of this dissertation were:  
(1) to determine whether gene expression profiles differed between whole 
pituitaries of growing beef steers grazing pastures containing high (HE) or low (LE) 
amounts of toxic endophyte-infected tall fescue (Chapter 4). 
(2) to determine whether the form of supplemental Se would alter pituitary 
transcriptome profiles of steers grazing endophyte-infected tall fescue (Chapter 5). 
(3) to determine whether the form of supplemental Se would alter selenoprotein 
transcriptome profiles in pituitaries and livers of growing steers subjected to summer-
long grazing of endophyte-infected pasture (Chapter 6). 
 
The specific objectives of the dissertation were to answer the following questions: 
(1) Does consumption of endophyte-infected tall fescue alter bovine pituitary 
transcriptome profiles? What canonical pathways are the differentially 
expressed genes involved in? Are there key upstream regulators associated 
with the differentially expressed genes? Does consumption of endophyte-
infected tall fescue affect prolactin gene (PRL)? Does consumption of 
endophyte-infected tall fescue affect pituitary genes responsible for 
production and/or secretion of prolactin and/or ACTH? (Chapter 4)  
(2) Does form of supplemental Se affect pituitary transcriptome of steers grazing 
endophyte-infected tall fescue? What canonical pathways are the differentially 
expressed genes involved in? Are there key upstream regulators associated 
with the differentially expressed genes? Does form of supplemental Se affect 
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prolactin gene (PRL)? Does form of supplemental Se affect pituitary genes 
responsible for production and/or secretion of prolactin and/or ACTH? Which 
form of supplemental Se could ameliorate the negative effect of consumption 
of endophyte-infected tall fescue in terms of elevating expression of genes 
associated with prolactin and ACTH production and/or secretion (Chapter 5) 
(3) Does form of supplemental Se affect selenoprotein profiles in pituitaries and 
livers of steers grazing endophyte-infected tall fescue? Which tissue is more 
responsive? Are there selenoproteins tightly correlated with each other in 
terms of expression pattern, positively or negatively? Which form of 
supplemental Se benefits the steers the most based on their respective 
selenoprotein profile? 
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CHAPTER 4. Pituitary Genomic Expression Profiles of Steers Are Altered by 
Grazing of High (HE) vs. Low (LE) Endophyte-infected Tall Fescue Forages1 
 
4.1 Abstract 
Consumption of ergot alkaloid-containing tall fescue grass impairs several 
metabolic, vascular, growth, and reproductive processes in cattle, collectively producing 
a clinical condition known as “fescue toxicosis.” Despite the apparent association 
between pituitary function and these physiological parameters, including depressed serum 
prolactin; no reports describe the effect of fescue toxicosis on pituitary genomic 
expression profiles. To identify candidate regulatory mechanisms, we compared the 
global and selected targeted mRNA expression patterns of pituitaries collected from beef 
steers that had been randomly assigned to undergo summer-long grazing (89 to 105 d) of 
a high-toxic endophyte-infected tall fescue pasture (HE; 0.746 μg/g ergot alkaloids; 5.7 
ha; n = 10; BW = 267 ± 14.5 kg) or a low-toxic endophyte tall fescue-mixed pasture (LE; 
0.023 μg/g ergot alkaloids; 5.7 ha; n = 9; BW = 266 ± 10.9 kg). As previously reported, 
in the HE steers, serum prolactin and body weights decreased and a potential for hepatic 
gluconeogenesis from amino acid-derived carbons increased. In this manuscript, we 
report that the pituitaries of HE steers had 542 differentially expressed genes (P < 0.001, 
false discovery rate ≤ 4.8%), and the pattern of altered gene expression was dependent (P 
< 0.001) on treatment. Integrated Pathway Analysis revealed that canonical pathways 
central to prolactin production, secretion, or signaling were affected, in addition to those 
related to corticotropin-releasing hormone signaling, melanocyte development, and 
pigmentation signaling. Targeted RT-PCR analysis corroborated these findings, including 
decreased (P < 0.05) expression of DRD2, PRL, POU1F1, GAL, and VIP and that of 
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POMC and PCSK1, respectively. Canonical pathway analysis identified HE-dependent 
alteration in signaling of additional pituitary-derived hormones, including growth 
hormone and GnRH. We conclude that consumption of endophyte-infected tall fescue 
alters the pituitary transcriptome profiles of steers in a manner consistent with their 
negatively affected physiological parameters. 
 
1Published by PloS one 12: e0184612. doi: 10.1371/journal.pone.0184612 
 
KEYWORDS: ACTH, DRD2, ergot alkaloids, gene expression, bovine pituitary, 
prolactin 
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4.2 Introduction 
Epichloe coenophialum is an endophytic fungus that infects most tall fescue 
(Lolium arundinaceum) pastures commonly used in animal grazing systems in the eastern 
half of the United States (Aiken and Strickland, 2013). The interaction between E. 
coenophialum and tall fescue produces ergot alkaloids (Siegel and Bush, 1994). 
Consumption of ergot alkaloid-containing tall fescue impairs several metabolic, vascular, 
growth, and reproductive processes in cattle, collectively producing a clinical condition 
known as “fescue toxicosis” (Strickland et al., 2011). 
The anterior pituitary gland secretes hormones that affect control over several 
physiological processes altered by consumption of ergot alkaloid-containing forages, 
including hormones for metabolism (TSH), growth (GH), reproduction (LH, FSH), stress 
responses (ACTH), and lactation (prolactin) (Beardwell and Robertson, 1981). Despite 
these known relationships, we are unaware of reports that describe the effect of fescue 
toxicosis on pituitary genomic expression profiles. 
The goal of the current research was to determine whether gene expression 
profiles differed between whole pituitaries of growing beef steers grazing pastures 
containing high (HE) or low (LE) amounts of toxic endophyte-infected tall fescue. We 
used transcriptome and targeted gene expression analyses to identify specific candidate 
molecules and signaling pathways responsible for the altered physiology of steers 
consuming HE forages. The global hypothesis tested was that consumption of endophyte-
infected tall fescue would alter pituitary transcriptome profiles and that at least the 
pituitary genes responsible for the production and secretion of prolactin would be down-
regulated and those for POMC/ACTH would be up-regulated.  
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4.3 Materials and methods 
4.3.1 Animal model 
 All procedures involving animals were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. The animal management regimen and 
model for steers that yielded the pituitary tissue of the present experiment have been 
reported. As described in detail previously (Brown et al., 2009; Matthews and Bridges, 
2014; Liao et al., 2015), 19 beef steers (predominately Angus) were denied access to feed 
and water for 14 h, weighed, and subdivided into 2 groups based on BW. The steers were 
randomly allotted (d0) within BW group to graze either a low-toxic endophyte tall 
fescue-mixed pasture (LE; 5.7 ha; 0.023 µg ergot alkaloids/g; n = 9; BW = 267 ± 14.5 
kg) or a high-toxic endophyte-infected tall fescue pasture (HE; 5.7 ha; 0.746 µg ergot 
alkaloids/g; n = 10; BW = 266 ± 10.9 kg) for an 89-d grazing period. Analysis of ergot 
alkaloid levels between the two pastures revealed that the HE steers were exposed to 25 
and 21 times more ergovaline/ergovalinine and lysergic acid/isolysergic acid, 
respectively, than were the LE steers (Brown et al., 2009). After the common 89-d 
grazing period on pastures, steers were slaughtered in the University of Kentucky Meat 
Laboratory (Lexington, KY) over a 17-day period. Throughout the slaughter period, 
steers continued to graze their respective treatment pastures. Details of the slaughter 
period and process have been reported (Brown et al., 2009).  
4.3.2 Sample collection and RNA preparation 
 Steers were stunned by captive bolt pistol and exsanguinated. Within 10 to 12 
minutes of death, the whole pituitary was collected from each animal, placed in a foil 
pack, flash-frozen in liquid nitrogen, and stored at -80°C. Three pituitary glands (1 LE, 2 
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HE) were not used in the microarray analysis because of tissue damage incurred during 
the collection process. As a result, eight pituitaries (n = 8) for both LE and HE treatment 
groups were subjected to RNA analyses. 
Total RNA was extracted from the whole frozen pituitary tissue using TRIzol Reagent 
(Invitrogen Corporation, Carlsbad, CA) following the manufacturer’s instructions. The 
RNA concentrations were determined using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE), which revealed that all samples had an 
average concentration of 678 ng/µl and were of high purity with 260:280 nm absorbance 
ratios ranging from 1.71 to 1.91 and 260:230 nm absorbance ratios ranging from 2.08 to 
2.55. The integrity of total RNA was examined by gel electrophoresis using an Agilent 
2100 Bioanalyzer System (Agilent Technologies, Santa Clara, CA) at the University of 
Kentucky Microarray Core Facility. All RNA samples had 28S:18S rRNA absorbance 
ratios greater than 1.7 and RNA integrity numbers greater than 8.7.  
4.3.3 Microarray analysis 
 The custom WT Btau 4.0 Array (version 1) GeneChip (Affymetrix, Inc., Santa 
Clara, CA) was used (Matthews et al., 2014) to investigate the effect of HE vs. LE 
consumption on bovine pituitary gene expression profiles. Microarray analysis was 
conducted according to the manufacturer’s standard protocol at the University of 
Kentucky Microarray Core Facility. Briefly, 3 g of RNA for each sample was first 
reverse-transcribed (RT) to cDNA and then from cDNA (double-stranded) to 
complementary RNA (cRNA; single-stranded), which was then labeled with biotin. The 
biotinylated cRNAs were further fragmented and used as probes to hybridize the gene 
chips in the GeneChip Hybridization Oven 640 (Affymetrix), using 1 chip per RNA 
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sample. After hybridization, the chips were washed and stained on a GeneChip Fluidics 
Station 450 (Affymetrix). The reaction image and signals were read with a GeneChip 
Scanner (GCS 3000, 7G; Affymetrix), and data were collected using the GeneChip 
Operating Software (GCOS, version 1.2; Affymetrix). The raw expression intensity 
values from the GCOS (i.e., 16 *.cel files from the raw methylation measurements) were 
imported into Partek Genomics Suite software (PGS, version 6.6; Partek Inc., St. Louis, 
MO). For GeneChip background correction, the algorithm of Robust Multichip 
Averaging adjusted with probe length and GC oligo contents was implemented (Irizarry 
et al., 2003; Wu et al., 2004). The background-corrected data were further converted into 
expression values using quantile normalization across all the chips and median polish 
summarization of multiple probes for each probe set. 
All the GeneChip transcripts were annotated using the NetAffx annotation 
database for Gene Expression on Bovine GeneChip Array ST 1.1, provided by the 
manufacturer (http://www.affymetrix.com/analysis/index.affx, last accessed in March 
2016, annotation file last updated in April 2014). Quality control of the microarray 
hybridization and data presentation was performed by MA plot on all the gene expression 
values and by box plot on the control probe sets on the Affymetrix chips (data not 
shown). Pearson (Linear) Correlation generated the similarity matrix (last accessed in 
March 2016, Partek Genomics Suite 6.6 6.15.0422). The average correlation between any 
pair of the 16 GeneChips was 0.98, and all GeneChips were further analyzed. Principal 
component analysis (PCA) was performed to elucidate the quality of the microarray 
hybridization and visualize the general data variation among the chips (Partek, 2015). To 
assess treatment effects (HE vs. LE) on the relative expression of the pituitary gene 
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transcripts, qualified microarray data were subjected to one-way ANOVA using the same 
PGS software. To achieve a higher degree of confidence (i.e., a more conservative 
approach), transcripts showing treatment effects at the significance level of P < 0.001 
(false discovery rate of ≤ 4.8%) were defined as differentially expressed. These 
differentially expressed genes/gene transcripts (DEGs) were subjected to hierarchical 
clustering analysis using PGS software and to canonical, functional, and network 
pathway analyses using the Core Analysis program of Ingenuity Pathway Analysis online 
software (IPA, Build version 430059M, Content version 31813283; 
http://www.ingenuity.com [accessed in December, 2016]; Ingenuity Systems, Inc., 
Redwood City, CA). 
All the microarray *.cel files collected by GCOS plus the GC Robust Multichip 
Averaging-corrected data processed by PGS software of this manuscript have been 
deposited in the National Center for Biotechnology Information’s Gene Expression 
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) [released October 23, 2014]), are 
minimum information about a microarray experiment (MIAME) compliant (Brazma et 
al., 2001), and are accessible through GEO series accession number GSE62570. 
4.3.4 Real-time RT-PCR analysis 
Primer sets for genes selected for real-time reverse transcription (RT) PCR 
analysis (Table 4.6) were designed using the NCBI Pick Primers online program against 
RefSeq sequences (accessed January to June 2016). Real-time RT-PCR was performed 
using an Eppendorf Mastercycler ep realplex2 system (Eppendorf, Hamburg, Germany) 
with iQ SYBR Green Supermix (Bio-RAD, Hercules, CA), as described (Bridges et al., 
2012). Briefly, cDNA was synthesized using the SuperScript III 1st Strand Synthesis 
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System (Invitrogen), with 1 μg of RNA used for each reverse transcription reaction. Real-
time RT-PCR was performed with a total volume of 25 μL per reaction, with each 
reaction containing 5 μL of cDNA, 1 μL of a 10 μM stock of each primer (forward and 
reverse), 12.5 μL of 2× SYBR Green PCR Master Mix, and 5.5 μL of nuclease-free 
water. Gene expression was analyzed by the 2−ΔΔCT method (Livak and Schmittgen, 
2001). 
The resulting real-time RT-PCR products were purified using a PureLink Quick 
Gel Extraction Kit (Invitrogen) and sequenced at Eurofins Scientific (Eurofins, 
Louisville, KY). Sequences were compared with the corresponding RefSeq mRNA 
sequences used as the templates for primer set design. The sequences of the primers and 
the resulting sequence-validated real-time RT-PCR reaction amplicons for selected DEGs 
and the endogenous control genes ACTB, PPIA, and UBC are presented in Table 4.6 and 
Figure 4.2, respectively. Primers for ACTB were from Lisowski et al. (Lisowski et al., 
2008), and primers for s-PRLR and l-PRLR were from Thompson et al. (Thompson et al., 
2011). All sequenced amplicons had at least 98% identity with their template sequences. 
The raw CT values of ACTB, PPIA, and UBC in pituitary tissue of HE and LE steers did 
not differ (P = 0.57, 0.42, 0.82; respectively). Accordingly, the geometric mean 
expression of ACTB, PPIA, and UBC was used to normalize the relative quantities of the 
selected DEGs mRNA expression, and all RT-PCR reactions were conducted in 
triplicate. 
4.3.5 Selected miRNA-target gene interactions 
 To identify (predict) microRNAs (miRNAs) that might regulate (Thompson et al., 
2011; Agarwal et al., 2015) prolactin or POMC/ACTH production, microarray-identified 
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differentially expressed miRNAs (DEMs) were uploaded into TargetScan online 
software (Release 7.1, http://www.targetscan.org/), and the species-specific “Cow” filter 
applied. The resulting miRNA candidates were ranked based on cumulative weighted 
context++ scores (Agarwal et al., 2015) and then reduced to only those predicted to bind 
mRNA of genes involved in prolactin or POMC/ACTH production or to bind to mRNA 
coding known transcription factors of prolactin and POMC/ACTH pathway genes. 
4.3.6 Statistical analyses 
           To test for HE vs. LE treatment effects on the relative expression of the pituitary 
gene transcripts, microarray hybridization data were subjected to one-way ANOVA using 
the PGS software as described in the “Microarray Analysis” section above. To determine 
the effect of treatment, the relative expression levels of selected DEGs analyzed by real-
time RT-PCR were subjected to one-way ANOVA using the GLM procedure of the SAS 
statistical software package (version 9.4; SAS Inst., Inc., Cary, NC), with the endophyte 
level as the fixed effect. For these data, significance was declared when P ≤ 0.05, and a 
tendency to differ was declared when 0.10 ≥ P > 0.05. 
4.4 Results 
4.4.1 Differentially expressed genes 
Principal component analysis of all microarray data was performed to examine 
the correlation and variation among the chips, revealing a total variance of 30.9% (Figure 
4.3). The first principal component (PC #1, x-axis) included genes with a median degree 
of variance (12.3%), whereas PC #2 (y-axis) and PC #3 (z-axis) encompassed genes that 
had low ranges of variance (9.84% and 8.75%, respectively). Overall, PCA clearly 
demonstrated that the chips within each treatment group were clustered closely together. 
69 
 
Individual ANOVA was conducted to identify altered expression of RNA 
transcripts in the pituitary tissue of HE vs. LE steers. At the P < 0.01 level and a false 
discovery rate of < 16%, 1,715 gene transcripts were identified. To refine this analysis, 
genes with the criteria of a false discovery rate of less than 4.8% and P < 0.001 were 
considered to be DEGs (Table 4.7). Of these 542 DEGs, 227 (10 non-annotated) were up-
regulated, 5.5% to 79.8%, and 315 (14 non-annotated) were down-regulated, 5.7% to 
69.0%, in HE vs. LE steers. 
Hierarchical cluster analysis of the 542 DEGs revealed that all steers were clearly 
separated into either the LE or HE treatment group (Figure 4.4). Relative to LE steers, 
approximately 40% of the genes in the HE steers were up-regulated and 60% down-
regulated. 
4.4.2 Functional, canonical pathway, and gene network analyses 
To determine the physiological significance of HE-induced DEGs (Table 4.7), 
bioinformatic analysis of canonical, functional, and network pathway analyses was 
performed. Canonical pathway analysis revealed (P < 0.001) that the top 7 pathways were 
the following: axonal guidance signaling (26 genes), role of NFAT in cardiac 
hypertrophy (16 genes), P2Y purigenic receptor signaling pathway (13 genes), cardiac 
hypertrophy signaling (17 genes), Tec kinase signaling (14 genes), ErbB signaling (10 
genes), and CXCR4 signaling (13 genes) (Table 4.1). Additionally, several affected 
pathways central to prolactin production, secretion, or signaling were identified (Table 
4.2), including dopamine receptor signaling, Gαi signaling, cAMP-mediated signaling, 
protein kinase A signaling, and prolactin signaling. Moreover, canonical pathway 
analysis also identified affected pathways involved in the signaling of other pituitary-
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derived hormones (Table 4.3): corticotropin-releasing hormone signaling, melanocyte 
development and pigmentation signaling, growth hormone signaling, and GnRH 
signaling. 
To refine this analysis to pituitary-specific metabolism, IPA analysis was re-run 
after applying the pituitary gland-specific filter. Diseases and Bio Function Analysis 
found (P ≤ 0.01) putative changes in diseases and disorders, molecular and cellular 
functions, and physiological system development and function, resulting from the 
differential expression of 5 genes (DRD2, PRL, ESR1, POMC, and TCF7L2).  
To gain insight into potentially interacting canonical pathways, pathway network 
analysis revealed one network that included 13 DEGs (BTC, CPE, DRD2, ESR1, 
HAPLN1, IGF2, LAMA1, NCOA1, PCSK1, POMC, PRKCA, PRL, and REV3L). 
Overlaying of canonical pathways revealed cross talk among several cell signaling 
pathways (Figure 4.1), including glucocorticoid receptor signaling (ESR1, IL2, NCOA1, 
POMC, PRL, TGFB1), GnRH signaling (EGR1, FSHB, LHB, PRKCA), growth hormone 
signaling (CSHL1, IGF1, IGF2, PRKCA), eNOS signaling (ESR1, PRKCA, VEGFA), 
dopamine receptor signaling (DRD2, PRL), and prolactin signaling (PRKCA, PRL). 
4.4.3 Real-time reversed-transcribed PCR analysis of selected mRNA 
 Real-time RT-PCR analysis was used to corroborate the microarray analysis-
identified altered expression of key genes responsible for prolactin synthesis and 
secretion and POMC/ACTH production in HE vs. LE steers (Table 4.4). The results of 
these two analyses were consistent for all the targeted genes, with the exception of PRLR, 
although the statistical significance (ANOVA P-value) and fold changes measured by the 
two analytical techniques differed for some genes. For PRLR, unlike the microarray 
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analysis, RT-PCR analysis was designed to delineate the long form (l-PRLR) and short 
form (s-PRLR). In the microarray analysis, PRLR was down-regulated in HE steers (P < 
0.001), whereas in RT-PCR analysis, expression of s-PRLR was not altered (P = 0.21) 
and expression of l-PRLR had a tendency to differ (P < 0.07) in HE vs. LE steers. 
Although microarray analysis did not identify them as DEGs (Table 4.8), the 
expression of 3 genes was assessed by RT-PCR analyses because they are known targets 
of POU1F1 (GH1, TSHB) or are involved in CRH stimulation of ACTH production 
(CRHR1). RT-PCR analysis corroborated the microarray analysis that pituitary 
expression of these genes did not differ between HE and LE steers (Table 4.4). 
4.4.4 Differentially expressed miRNAs (DEMs) and their predicted target genes 
associated with prolactin and POMC/ACTH production 
The microarray chips used for this study detected 574 miRNAs. Of these, only 6 
were differentially expressed (P < 0.001) in HE vs. LE steers (Table 4.7). Specifically, 
miR-380 (42%), miR-2318 (17%), miR-329B (36%), and miR-544A (38%) were down-
regulated in HE vs. LE steers, whereas miR-2356 (38%) and miR-2400 (8%) were up-
regulated. The target genes of these DEMs that were associated with prolactin or 
POMC/ACTH production are listed in Table 4.5. Although no miRNAs known to directly 
target mRNA for prolactin were differentially expressed, every DEM targeted multiple 
prolactin transcription factors, stimulators, and (or) inhibitors, including miR-544A that 
targeted all the PRL-associated genes. Overall, the mRNA for three transcription factors 
(POULF1, ESR1, PREB), two transcription stimulators (EGF, IKZF1), and one 
transcription inhibitor (PKIA) of PRL were predicted to be targets of the DEMs. With 
72 
 
specific regard to microarray-identified DEGs (Table 4.4) targeted by DEMs, PRLR was 
predicted to be the target of five DEMs and ESR1 the target of four DEMs.  
Analogously, for POMC/ACTH production genes, whereas no miRNAs were 
differentially expressed that targeted POMC per se, TargetScan predicted that DEMs 
would interact with the mRNA of three transcription factors (TBX19, NEUROD1, JUN), 
two transcription stimulators (LEP, LIF), and three transcription inhibitors (NR3C1, 
SMARCA4, HDAC2) of the POMC production pathway. With specific regard to 
microarray-identified DEGs targeted by DEMs, PCSK1 was the target of a single miRNA 
(miR-380).  
Because POMC expression was altered and miR-380 is predicted to target two 
POMC transcription factors (NEUROD1, TBX19), the expression of NEUROD 1 and 
TBX19 was evaluated by RT-PCR, although their expression was not altered as 
determined by microarray analysis (Table 4.8). However, consistent with the microarray 
analysis, the expression of NEUROD 1 and TBX19 based on RT-PCR analysis was not 
altered (Table 4.4).  
Although the expression of NR3C1 was not affected based on microarray analysis 
(Table 4.8), the expression was evaluated by RT-PCR because glucocorticoid receptor 
complex represses the POMC gene through a negative glucocorticoid response element 
of POMC promoter (Drouin et al., 1993). However, RT-PCR analysis found no 
difference in NR3C1 abundance in the pituitaries of HE and LE steers (Table 4.4).  
4.5 Discussion 
The pituitary is an endocrine gland composed of anterior, intermediate, and 
posterior lobes, with the anterior lobe occupying approximately 80% of the entire gland. 
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The anterior lobe is composed of five tropic cell types, which together secrete six 
hormones: corticotrophs (ACTH), gonadotrophs (FSH and LH), lactotrophs (prolactin), 
somatotrophs (GH), and thyrotrophs (TSH). Previous studies show that hormone 
production by all five anterior pituitary cell types is affected by the consumption of ergot 
alkaloids in cattle (Browning et al., 1997; Browning et al., 1998), with decreased 
concentrations of serum prolactin one of the most common serological signs (Hurley et 
al., 1980; Lipham et al., 1989).  
To our knowledge, the effect of ergot alkaloid consumption on pituitary 
transcriptomic profiles has not been reported. To obtain this information, we conducted 
transcriptome analysis of pituitaries collected from previously described (Brown et al., 
2009) beef steers suffering from fescue toxicosis induced by summer-long grazing (89 to 
105 d) of HE and LE pastures. Importantly, concentrations of prolactin in the serum of 
HE steers were only approximately 10% of those of the LE steers (Brown et al., 2009), 
and the glucocorticoid receptor-mediated pathway was implicated in observed changes in 
carbohydrate metabolism in HE steers (Liao et al., 2015). As noted in the Introduction, 
the goal of the current research was to determine whether gene expression profiles 
differed between whole pituitaries of HE and LE steers using transcriptome and targeted 
gene expression analysis and to identify specific candidate molecules and signaling 
pathways responsible for the altered physiology of steers consuming ergot alkaloid-
containing tall fescue. The global hypothesis tested was that consumption of endophyte-
infected tall fescue would alter pituitary transcriptome profiles. At the P < 0.001 level, 
the microarray analysis approach revealed the differential expression of 542 RNA 
transcripts by the pituitary. Importantly, the pattern of altered gene expression was clearly 
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dependent on treatment according to hierarchical cluster analysis (Figure 4.4). Thus, the 
first salient finding of this study is that summer-long grazing of endophyte-infected tall 
fescue alters the pituitary transcriptome; thus, the global hypothesis is accepted. 
More specifically, given that the serum prolactin concentrations of HE steers were 
only approximately 10% of those of the LE steers (Brown et al., 2009), and that the 
glucocorticoid receptor-mediated pathway was implicated in observed changes in 
carbohydrate metabolism in HE steers (Liao et al., 2015), the expectation was that the 
expression pattern for pituitary genes responsible for the production and secretion of 
prolactin would be consistent with a down-regulated capacity, whereas that for 
POMC/ACTH would be consistent with an up-regulated capacity. Conclusions reached 
about these hypotheses, as well as the possible roles of miRNA in these processes, are 
discussed below. 
4.5.1 Fescue toxicosis and prolactin synthesis and secretion 
The effect of ergot alkaloid consumption on prolactin production and secretion is 
best understood through the interactive pathway of dopamine receptors located on the 
surface of lactotrophs. Dopamine is one of the most influential regulators of prolactin 
secretion. Activation of the dopamine receptor suppresses PRL gene expression via the 
inhibition of adenylyl cyclase and prolactin exocytosis through modification of several 
potassium and calcium channels (Fitzgerald and Dinan, 2008). One way by which ergot 
alkaloid consumption directly affects lactotrophs is through the binding and stimulation 
of dopamine type two receptors (DRD2) on the cell surface (Fitzgerald and Dinan, 2008). 
Ergot alkaloids ingested with consumption of endophyte-infested tall fescue structurally 
resemble various biogenic amines, such as dopamine (Strickland et al., 2011). These 
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ergot amines can bind to dopamine type two receptors, stimulate the receptors, and 
reduce basal level prolactin production and secretion as described above (Larson et al., 
1999). Consistent with this understanding, the HE steers in this study had serum prolactin 
concentrations that were only 10% of those of the LE steers (Brown et al., 2009). The 
lower prolactin found in serum of steers exposed to HE pasture directly corresponded to 
the microarray and real-time RT-PCR results regarding the gene expression of DRD2, 
POU1F1 (a.k.a. Pit1), PRL and PRLR genes (Table 4.4). Based on real-time RT-PCR 
results, the expression of these genes decreased by approximately 53%, 32%, 82%, and 
22% (long isoform of prolactin receptor with tendency to differ), respectively, in HE vs. 
LE steers. POU1F1 plays a pivotal role in PRL expression by binding to specific sites of 
promoter elements in the PRL gene (Fox et al., 1990). Therefore, decreased expression of 
POU1F1 might explain reduced PRL mRNA expression in HE steers to a certain extent.  
An apparently associated finding was the accompanying down regulation of both 
DRD2 and PRLR genes. Although speculative, a decrease in the expression of DRD2 may 
have been a preventive measure by the lactotrophic cells to counteract the suppression of 
prolactin production due to the activation of the dopamine receptors, whereas the down 
regulation of prolactin receptor mRNA in pituitary tissue may be the result of a decreased 
requirement for prolactin binding in a prolactin-poor environment. Additionally, 
expression of GAL (galanin/GMAP prepropeptide) and VIP (vasoactive intestinal 
peptide) also decreased in HE vs. LE steers according to both microarray and real-time 
RT-PCR results (Table 4.4). Galanin is known to stimulate prolactin release (Koshiyama 
et al., 1987; Wynick et al., 1998), although the mechanism has not been clearly defined. 
Additionally, galanin may directly stimulate prolactin expression and act as a lactotroph 
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growth factor, particularly when exposure to estrogen is high (Wynick et al., 1998). 
Vasoactive intestinal peptide also stimulates prolactin secretion in multiple species, with 
receptors found on lactotrophs (Gourdji et al., 1979; Frawley and Neill, 1981; Samson et 
al., 1981; Macnamee et al., 1986). Although the mechanism by which vasoactive 
intestinal peptide stimulates prolactin release is not well delineated, as for galanin, cAMP 
accumulation and a delayed increase in calcium concentration were observed in the 
process (Samson et al., 1981; Bjøro et al., 1987). Thus, our hypothesis that at least the 
pituitary genes responsible for the production and secretion of prolactin would be down-
regulated is also accepted. 
In addition to prolactin, POU1F1 activates growth hormone (GH1) promoter 
transcriptionally (Mangalam et al., 1989) and is involved in thyrotropin-releasing 
hormone (TRH) stimulation of the beta subunit of thyroid-stimulating hormone (TSHB) 
expression (Steinfelder et al., 1991). However, RT-PCR (Table 4.4) analysis corroborated 
the microarray (Table 4.8) findings that neither GH1 nor TSHB was differentially 
expressed in HE vs. LE steers. 
Although best known for the role in regulating lactation, prolactin affects a wide 
variety of biological functions (Lamberts and Macleod, 1990; Freeman et al., 2000), 
including reproduction, osmoregulation, antiangiogenic activity, regulation of immune 
responses, regulation of insulin release, and control of growth. With regard to growth, 
prolactin is associated with food intake and body weight and may interact with 
hypothalamic neurons responsible for appetite regulation (Ben-Jonathan et al., 2006; 
Naef and Woodside, 2007). Moreover, as described in detail previously (Brown et al., 
2009), the average daily gain of HE steers was 31% less than that of LE steers (P < 0.05), 
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and the final body weight of HE steers was 7.4% less than that of LE steers (P < 0.05). 
Hence, reduced prolactin concentrations in HE steers might account for these 
observations to a certain degree. 
4.5.2 Fescue toxicosis, POMC/ACTH synthesis, and gluconeogenesis 
As noted in the Introduction, increased mitochondrial mass and capacity for ATP 
synthesis and amino acid-derived gluconeogenesis (Brown et al., 2009) are postulated to 
be coordinated through the glucocorticoid receptor-mediated pathway (Liao et al., 2015). 
Therefore, a reasonable hypothesis is that the capacity for glucocorticoid synthesis 
(POMC/ACTH production) would be elevated in the pituitaries of HE vs. LE steers. 
However, although we did not measure ACTH stimulation of cortisol release by the 
adrenal glands, canonical pathway analysis of pituitary DEGs indicated (z-score less than 
-2.00) the down-regulation of the corticotropin-releasing hormone (CRH) signaling 
pathway (BDNF, POMC, ADCY8, PRKCA, and PRKAR1A) in HE steers (Table 4.3). As 
part of the hypothalamic-pituitary-adrenal axis, the primary function of CRH is to 
stimulate ACTH production from the pituitary through interaction with CRHR1, the 
predominant pituitary-expressed CRH receptor. According to the microarray and RT-
PCR analyses (Table 4.4, Table 4.8), CRHR1 mRNA expression level was not affected in 
HE vs. LE steers, whereas CRHR2 was not qualified for RT-PCR analysis because of the 
low expression level. These findings are consistent with the understanding that CRHR1 is 
highly expressed by the pituitary, whereas CRHR2 is predominately expressed by brain 
and peripheral tissues (Holsboer, 1999). ACTH is synthesized within the anterior 
pituitary as part of the much larger precursor molecule proopiomelanocortin (POMC), 
which is cleaved into smaller peptide hormones in a tissue-specific manner by proprotein 
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convertases. In pituitary corticotrophs, proprotein convertase 1 (encoded by the PCSK1 
gene) alone is expressed and cleaves POMC, producing ACTH, β-endorphin, β-
lipotrophin, amino-terminal peptide, and joining peptide (Millington, 2007). According to 
the microarray and real-time RT-PCR analyses (Table 4.4), the abundance of both POMC 
and PCSK1 mRNA was reduced in the pituitaries of HE vs. LE steers. Thus, the 
hypothesis that expression of pituitary genes responsible for the production of 
POMC/ACTH would be increased is rejected. 
Despite the importance to adrenal steroidogenesis, research describing the effects 
of fescue toxicosis on blood ACTH is lacking. Moreover, although studies have been 
conducted to better understand the relationship between fescue toxicosis and circulating 
cortisol in cattle, their results are discordant (Aldrich et al., 1993; Schuenemann et al., 
2005; Looper et al., 2010). To resolve the apparent enigma that HE steers displayed a 
reduced potential for pituitary synthesis of ACTH (this study), yet increased hepatic 
gluconeogenesis capacity (Brown et al., 2009; Liao et al., 2015), further research is 
required.  
4.5.3 Role of miRNAs in regulating prolactin and POMC/ACTH pathways 
Messenger RNA abundance is regulated by a combination of pre-transcription and 
post-transcription events. Transcription factors contribute to mRNA abundance at the 
pre-transcription level by binding to DNA and either positively or negatively regulating 
gene transcription (Latchman, 1997). MicroRNAs regulate mRNA abundance at the post-
transcriptional level through complementary binding of target mRNA transcripts, 
resulting in repressed translation or enhanced degradation of bound mRNA (Engels and 
Hutvagner, 2006). Thus, decreased expression of a given miRNA would result in 
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increased target mRNA abundance and vice versa. miR-544A, which putatively regulates 
multiple transcription factors and stimulators (ESR1 (Waterman et al., 1988), EGF 
(Murdoch et al., 1982), IKZF1 (Ezzat et al., 2005), POU1F1 (Nelson et al., 1988), PREB 
(Fliss et al., 1999), VIP (Bredow et al., 1994)) of the prolactin gene (Table 4.5), was 
down-regulated 38% in HE vs. LE steers; however, expression of PRL decreased in HE 
vs. LE steers. Inconsistency between the abundance of miR-380 and its target gene was 
also found. Because miR-380 is predicted to target PCSK1 and two POMC transcription 
factors, NEUROD1 (Poulin et al., 1997) and TBX19 (Lamonerie et al., 1996) (Table 4.5), 
we expected the decrease in expression of miR-380 (42%) in the pituitaries of HE vs. LE 
steers to result in increased expression of POMC and PCSK1. However, microarray 
(Table 4.8) and RT-PCR (Table 4.4) results showed no difference in expression level of 
NEUROD1 and TBX19 mRNA in pituitaries of HE vs. LE steers, whereas both POMC 
and PCSK1were down-regulated.  
Although evidence shows that miRNAs can also up-regulate gene expression 
(Vasudevan et al., 2007), an alternative explanation to the above inconsistencies could be 
due to the stringency level of P-values that was applied to the microarray analysis. Any 
given gene is usually regulated by numerous miRNAs, and the complements of these 
miRNAs decide the fate of the transcription of the gene. Thus, a stringent significant 
cutoff criterion (P < 0.001) could filter out potential miRNAs targeting genes of interest. 
For example, one striking finding listed in Table 4.5 is that no DEMs were identified that 
targeted DRD2, PRL, or POMC. However, when the P-value was relaxed to 0.05, then 
multiple miRNAs predicted to target DRD2 (miR-141, miR-214, miR-584, miR-631, 
miR-2316, miR-2350, miR-2373, miR-2382, miR-2418, miR-2464) were identified (data 
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not shown). Additionally, miR-2335 and miR-2399 (predicted to target both VIP and its 
transcription factor NURR1 (Luo et al., 2007) (encoded by NR4A2)) also became 
candidate regulators of PRL expression. Collectively, the evidence suggested that altered 
expression of miRNAs might have affected mRNA abundance by affecting both pre- and 
post-transcription events of genes regulating prolactin and POMC/ACTH pathways. 
This experiment is part of a comprehensive study to understand the whole body 
and tissue-specific effects of ergot alkaloid consumption in cattle (Brown et al., 2009; 
Jackson et al., 2015; Liao et al., 2015). The unique pituitary-specific findings of this 
study are an important contribution to our understanding of how ergot alkaloids exert 
their deleterious effects on cattle production. In summary, the findings indicate that 
anterior pituitary functions were globally impaired in steers consuming high-toxic 
endophyte-infected tall fescue. In addition to inhibiting the abilities to synthesize and 
secrete prolactin (a function of lactotrophs), ACTH synthesis capacity (a function of 
corticotrophs) might have been reduced. Canonical pathway analysis also indicated that 
growth hormone signaling and GnRH signaling were altered in HE vs. LE steers (Table 
4.3). A larger implication of this research may be that it allows for selective breeding for 
genotypes with a higher resistance to endophyte toxicosis, because the specific genes and 
networks of genes have now been identified that are susceptible to ergot alkaloids 
contained in endophyte-infected tall fescue. Likewise, with the identification of putative 
ergot alkaloid sensitive mechanisms within the pituitary gland, this new knowledge may 
help to develop dietary treatments that ameliorate the effects of ergot alkaloid ingestion 
(Matthews and Bridges, 2014). 
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Table 4.1. Top seven IPA-identified canonical pathways of genes differentially expressed 
by pituitary tissue of steers grazing high (HE) vs. low (LE) endophyte-infected forages. 
Canonical 
Pathway 
Number
1 
Gene Symbol Ratio2 
-log (P-
value) 
Axonal 
Guidance 
Signaling 
26 ITSN1,BDNF,PIK3R1,UNC5B,GNB5,
ABLIM1,SEMA4C,PLCD1,GNB4,SRG
AP2,ABLIM2,ACE,GNG12,PRKCA,E
PHA7,PLXNC1,PRKCQ,FES,PAK6,F
GFR1,ITGA2,GNG3,PLCL2,WIPF1,S
EMA3C,PRKAR1A 
0.06 5.38 
Role of 
NFAT in 
Cardiac 
Hypertroph
y 
16 MAP2K6,PRKCQ,FGFR1,PIK3R1,SL
C8A3,GNB5,GNG3,PLCL2,PLCD1,G
NB4,MAPK10,RCAN3,ADCY8,GNG1
2,PRKAR1A,PRKCA 
 
0.08 5.33 
P2Y 
Purigenic 
Receptor 
Signaling 
Pathway 
 
13 PRKCQ,FGFR1,PIK3R1,CREB3,GNB
5,GNG3,PLCL2,PLCD1,GNB4,ADCY
8,GNG12,PRKCA,PRKAR1A 
 
0.09 5.04 
Cardiac 
Hypertroph
y Signaling 
17 MAP2K6,DIRAS3,PIK3R1,FGFR1,IL6
R,GNB5,GNG3,MAP3K5,PLCL2,PLC
D1,GNB4,RHOQ,MAPK10,ADCY8,M
AP3K3,GNG12,PRKAR1A 
0.07 4.80 
Tec Kinase 
Signaling 
14 GNB4,PRKCQ,RHOQ,PAK6,DIRAS3,
PIK3R1,FGFR1,ITGA2,GNB5,MAPK1
0,GNG3,FRK,GNG12,PRKCA 
0.08 4.77 
ErbB 
Signaling 
10 GNB4,PRKCQ,RHOQ,PAK6,DIRAS3,
PIK3R1,FGFR1,GNB5,MAPK10,GNG
3,ADCY8,GNG12,PRKCA 
0.10 4.41 
CXCR4 
Signaling 
13 GNB4,PRKCQ,RHOQ,PAK6,DIRAS3,
PIK3R1,FGFR1,GNB5,MAPK10,GNG
3,ADCY8,GNG12,PRKCA 
0.08 4.14 
1The number of genes (listed in the “Symbol” column) associated with the particular 
canonical pathway. 
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Table 4.1 (continued) 
2The ratio is calculated as the number of genes in a given pathway that meet cutoff 
criteria (e.g., the ANOVA P-value for the differential expression between HE and LE 
groups is less than 0.001) divided by the total number of genes that make up that 
pathway. 
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Table 4.2. IPA-identified canonical pathways of genes central to prolactin production, 
secretion, or signaling differentially-expressed by pituitary tissue of steers grazing high 
(HE) vs. low (LE) endophyte-infected forages. 
Canonical 
Pathway 
Number
1 
Gene Symbol Ratio2 
-log (P-
value) 
Dopamine 
Receptor 
Signaling 
4 PRL,ADCY8,DRD2,PRKAR1A 0.04 0.91 
Gαi 
Signaling 
 
9 
 
GABBR2,GNB4,GNB5,HTR1F,GNG3,
ADCY8,DRD2,GNG12,PRKAR1A 
 
 
0.07 
 
2.95 
cAMP-
mediated 
Signaling 
9 PDE8A,GABBR2,PKIB,CREB3,HTR1F
,ADCY8,DRD2,CNGA3,PRKAR1A 
 
0.04 
 
1.31 
Protein 
Kinase A 
Signaling 
 
20 
 
PRKCQ,PTPRD,CREB3,MYLK3,GNB5
,GNG3,PLCL2,CNGA3,PDE8A,PLCD1
,GNB4,DUSP10,ADCY8,PTPRN,EYA1,
KDELR2,GNG12,TCF7L2,PRKCA,PR
KAR1A 
 
 
0.05 
 
3.45 
Prolactin 
Signaling 
 
6 PRKCQ,PRL,PIK3R1,FGFR1,PRLR,P
RKCA 
0.07 2.04 
1The number of genes (listed in the “Symbol” column) associated with the particular 
canonical pathway. 
2The ratio is calculated as the number of genes in a given pathway that meet cutoff 
criteria (e.g., the ANOVA P-value for the differential expression between HE and LE 
groups is < 0.001) divided by the total number of genes that make up that pathway. 
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Table 4.3. IPA-identified canonical pathways of genes involved in signaling of selected 
pituitary-derived hormones differentially-expressed by pituitary tissue of steers grazing 
high (HE) vs. low (LE) endophyte-infected forages.  
Canonical 
Pathway 
Number
1 
Gene Symbol Ratio2 
-log (P-
value) 
Melanocyte 
Developme
nt and 
Pigmentatio
n Signaling 
 
7 PIK3R1,FGFR1,CREB3,POMC,RPS6
KA5,ADCY8,PRKAR1A 
0.07 2.38 
Corticotropi
n-releasing 
Hormone 
Signaling 
 
7 PRKCQ,BDNF,CREB3,POMC,ADCY
8,PRKCA,PRKAR1A 
0.06 1.87 
Growth 
Hormone 
Signaling 
6 IGF2,PRKCQ,PIK3R1,FGFR1,RPS6K
A5,PRKCA 
0.07 2.06 
GnRH 
Signaling 
10 MAP2K6,PRKCQ,PAK6,CREB3,MAP
K10,MAP3K5,ADCY8,MAP3K3,PRK
CA,PRKAR1A 
0.07 3.26 
1The number of genes (listed in the “Symbol” column) associated with the particular 
canonical pathway.  
2The ratio is calculated as the number of genes in a given pathway that meet cutoff 
criteria (e.g., the ANOVA P-value for the differential expression between HE and LE 
groups is less than 0.001) divided by the total number of genes that make up that 
pathway. 
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Table 4.4. Comparison of microarray and real-time RT-PCR identification of selected 
genes by pituitary tissue of steers grazing high (HE) vs. low (LE) endophyte-infected 
forages. 
Gene Gene Name Microarray Real-time RT-PCR 
  
Chang
e2 
 
Ratio3 P-value Change2 
 
Ratio3 P-value 
ACTB1 Actin, beta 1.03 1.03 0.084 1.01 1.01 0.568 
PPIA1 Peptidylprolyl 
isomerase A 
-1.07 0.93 0.441 1.00 1.00 0.422 
UBC1 Ubiquitin C 1.00 1.00 0.994 1.00 1.00 0.816 
DRD2 Dopamine receptor 
D2 
-1.76 0.57 0.001 -2.14 0.47 0.001 
PRL Prolactin -1.23 0.81 0.001 -5.67 0.18 0.001 
PRLR Prolactin receptor -1.31 0.76 0.001 NA NA NA 
s-PRLR Prolactin receptor 
short isoform 
NA NA NA -1.20 0.83 0.210 
l- PRLR Prolactin receptor 
long isoform 
NA NA NA -1.29 0.78 0.062 
POU1F
1 
POU class 1 
homeobox 1 
-1.30 0.77 0.003 -1.47 0.68 0.038 
GAL Galanin/GMAP 
prepropeptide 
-1.34 0.74 0.009 -2.35 0.43 0.019 
VIP Vasoactive intestinal 
peptide 
-1.76 0.57 0.003 -2.08 0.48 0.045 
POMC Proopiomelanocortin -1.25 0.80 0.001 -2.27 0.44 0.006 
PCSK1 Proprotein 
convertase 
subtilisin/kexin type 
1 
-1.72 0.58 0.001 -2.02 0.5 0.001 
GH1 Growth Hormone 1 1.01 1.01 0.728 1.20 1.20 0.436 
TSHB Thyroid stimulating 
hormone beta 
1.00 1.00 0.999 1.14 1.14 0.418 
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Table 4.4 (continued)       
TBX19 T-Box 19 -1.14 0.88 0.104 -1.20 0.84 0.217 
NeuroD
1 
Neuronal 
differentiation 1 
1.19 1.19 0.178 1.18 1.18 0.415 
NR3C1 Nuclear receptor 
subfamily 3 group C 
member 1 
1.14 1.14 0.112 1.33 1.33 0.270 
CRHR1 Corticotropin-
releasing hormone 
receptor 1 
1.19 1.19 0.106 1.39 1.39 0.192 
1Expression reference genes. 
2Data are expressed as fold change in HE relative to LE expression. 
3Data are expressed as ratio of HE relative to LE expression. 
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Table 4.5. Predicted relationship between differentially-expressed mRNA of prolactin 
and ACTH pathway genes, including transcription factors (TF), transcription stimulators 
(TS), and transcription inhibitors (TI), known to be targets of microarray-identified 
differentially-expressed miRNAs (DEMs)1. 
Gene Symbol Gene Description DEM (P < 0.001)2,3 
PRL Prolactin  
PRLR Prolactin Receptor miR-329B, miR-380, miR-
544A, miR-2318, miR-2356 
DRD2 Dopamine Receptor D2  
POU1F1 (TF for PRL) POU Class 1 Homeobox 1 miR-544A 
VIP Vasoactive Intestinal Peptide miR-544A, miR-2400 
ESR1 (TF for PRL) Estrogen Receptor 1 miR-329B, miR-380, miR-
544A, miR-2356 
PREB (TF for PRL) Prolactin Regulatory Element 
Binding 
miR-544A, miR-2400 
EGF (TS for PRL) Epidermal Growth Factor miR-380, miR-544A, miR-
2356 
IKZF1 (TS for PRL) IKAROS Family Zinc Finger 
1 
miR-380, miR-544A, miR-
2400 
PKIA (TI for PRL) CAMP-Dependent Protein 
Kinase Inhibitor Alpha 
miR-329B, miR-380, miR-
544A, miR-2318, miR-2356, 
miR-2400 
POMC Proopiomelanocortin  
PCSK1 Proprotein Convertase 
Subtilisin/Kexin Type 1 
miR-380 
TBX19 (TF for POMC) T-Box 19 miR-380 
NEUROD1 (TF for 
POMC) 
Neuronal Differentiation 1 miR-380, miR-544A, miR-
2318 
JUN (TF for POMC) Jun Proto-Oncogene, AP-1 
Transcription Factor Subunit 
miR-2400 
LEP (TS for POMC) Leptin miR-544A 
LIF (TS for POMC) Leukemia Inhibitory Factor miR-2400 
NR3C1 (TI for POMC) Nuclear Receptor Subfamily 
3 Group C Member 1 
miR-380, miR-544A, miR-
2318, miR-2356 
SMARCA4 (TI for 
POMC) 
SWI/SNF Related, Matrix 
Associated, Actin Dependent 
Regulator Of Chromatin, 
Subfamily A, Member 4 
miR-329B 
HDAC2 (TI for 
POMC) 
Histone Deacetylase 2 miR-380, miR-2356 
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Table 4.5 (continued) 
1Putative gene targets of DEMs were identified using TargetScan (Release 7.1, 
http://www.targetscan.org). 
2miR-329B: GenBank accession number is NR_031209 and is known as miR-329 by 
TargetScan. 
3miR-544A: GenBank accession number is NR_031187 and is known as miR-544 by 
TargetScan. 
  
  
  
8
9
 
Table 4.6. Primer sets used for quantitative real-time RT-PCR analysis of the selected differentially expressed genes and 
reference genes. 
 
Gene 
 
Gene Name 
Primer & Accession number1 Sequence (5' to 3' direction) 
Amplicon 
length 
(bp) 
Product 
identity 
(%)2 
Actb Actin, beta  NM_173979.3    
       Forward GAGCGGGAAATCGTCCGTGAC 278 99  
       Reverse GTGTTGGCGTAGAGGTCCTTGC    
Ppia Peptidylprolyl 
isomerase A NM_178320.2    
       Forward GGCAAGTCCATCTATGGCGA 239 99  
       Reverse TTGCTGGTCTTGCCATTCCT    
Ubc Ubiquitin C NM_001206307.1    
       Forward TAGGGGTGGGTTAGAGTTCAAG 258 100  
       Reverse ACCACCTCCCTGCTGGTATT    
Drd2 Dopamine receptor 
D2 NM_174043.2    
       Forward CGACCTTTCTCTGGGGCTTT 234 100  
       Reverse TTGGGCTTCTGCTTCTCTGG    
Prl Prolactin NM_173953.2    
       Forward AGAACAAGCCCAACAGACCC 252 99  
       Reverse AGTCCTGACCACACAGGGTA    
  
  
9
0
 
Table 4.6 (continued)      
s-Prlr Short Prolactin 
receptor NM_174155.3   
 
 
       Forward GCCATCCTTTCTGCTGTCAT 151         99  
       Reverse AAGGCGAGAAGGCTGTGATA    
l-Prlr Long Prolactin 
receptor NM_001039726.2    
       Forward GCCATCCTTTCTGCTGTCAT 136 100  
       Reverse CCCTTCTCCAGCAGATGAAC    
Pou1f1 POU class 1 
homeobox 1 AH012495.1    
       Forward AAGCAAGAGGTTTGAAGTTTGGT 401 99  
       Reverse TGCTCTTTAGCCAGCCTTGA    
Gal Galanin/GMAP 
prepropeptide NM_173914.2     
       Forward CACCGGTGAAGGAGAAGAGAG 230 100  
       Reverse GGCGTCTTTGAGATGCAGGAA    
Vip Vasoactive intestinal 
peptide NM_173970.3     
       Forward CTGGTTCAGCTGTAAGGGCA 325 100  
       Reverse TCAGCCAGCGCATCTTGTAA    
Pomc Proopiomelanocortin NM_174151.1      
       Forward AGCTTCCCCGTGACAGAGC 317 99  
  
  
9
1
 
1The contents in the parentheses associated with each gene symbol are the accession numbers of the sequences retrieved from 
the NCBI RefSeq database and used as templates for designing primers and probes.   
2All the real-time RT-PCR products were validated by sequencing. The identity values (%) presented are the base-pair ratios 
between the number of identical base pairs and the total amplicon length.
Table 4.6 (continued)      
       Reverse CTGCTACCATTCCGACGGC    
 
Pcsk1 
Proprotein 
convertase 
sutilisin/kexin type 1      NM_174412.2      
       Forward TGATCGTGTGATATGGGCGG 277 100  
       Reverse GGCCTCCGGATCATAGTTGG    
    
   
   
9
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Table 4.7. List of differentially expressed pituitary genes (P < 0.001, 542 genes) collected from steers grazing high- (HE, n = 
8) or low- (LE, n = 8) endophyte-infected forages. 
Transcript 
ID 
Gene 
Symbol Gene assignment p-value 
False 
discovery 
Rate 
Ratio(HE 
vs.LE) 
Fold-
Change(HE vs. 
LE) 
12876894 GPX3  glutathione peroxidase 3 (plasma)  8.90E-10 2.37E-05 
0.479140
613 -2.08707 
12851243 ASB4  ankyrin repeat and SOCS box containing 4  1.73E-08 0.000230196 
0.526931
467 -1.89778 
12898500 EPHA7  EPH receptor A7  2.67E-08 0.000237549 
1.797668
783 1.79767 
12835339 COPA  coatomer protein complex, subunit alpha  5.72E-08 0.000332512 
0.906996
572 -1.10254 
12798282 CHL1 
 cell adhesion molecule with homology to 
L1CAM (close homolog of 6.23E-08 0.000332512 
0.532076
215 -1.87943 
12871398 
PLA2G
12A  phospholipase A2, group XIIA  9.95E-08 0.000387737 
0.761666
832 -1.31291 
12776100 CPS1  carbamoyl-phosphate synthase 1, mitochondrial  1.02E-07 0.000387737 
0.425693
135 -2.34911 
12721755 
MMP1
6 
 matrix metallopeptidase 16 (membrane-
inserted)  2.29E-07 0.000764464 
1.308422
71 1.30842 
12902267 
BHLH
B9 
 basic helix-loop-helix domain containing, class 
B, 9  4.95E-07 0.00146659 
0.712230
421 -1.40404 
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Table 4.7 (continued)      
12730735 DRD2  dopamine receptor D2  5.55E-07 0.00148011 
0.569216
758 -1.7568 
12737221 
FAM16
3A  family with sequence similarity 163, member A  8.61E-07 0.00192236 
0.532013
939 -1.87965 
12780430 PTPRN  protein tyrosine phosphatase, receptor type, N  9.71E-07 0.00192236 
0.776578
396 -1.2877 
12866683 
SLC41
A2  solute carrier family 41, member 2  1.12E-06 0.00192236 
0.753801
042 -1.32661 
12722069 CDH17  cadherin 17, LI cadherin (liver-intestine)  1.15E-06 0.00192236 
0.309513
198 -3.23088 
12826450 
UNC5
B  unc-5 homolog B (C. elegans)  1.15E-06 0.00192236 
0.617078
258 -1.62054 
12767970 NSF  N-ethylmaleimide-sensitive factor  1.20E-06 0.00192236 
0.856927
401 -1.16696 
12836423 
DIRAS
3  DIRAS family, GTP-binding RAS-like 3  1.26E-06 0.00192236 
0.731042
247 -1.36791 
12729629 
REXO
2 
 REX2, RNA exonuclease 2 homolog (S. 
cerevisiae)  1.30E-06 0.00192236 
0.638740
914 -1.56558 
12890848 RORB  RAR-related orphan receptor B  1.57E-06 0.00209906 
1.373516
945 1.37352 
12679305 LNP1  leukemia NUP98 fusion partner 1  1.62E-06 0.00209906 
0.838609
585 -1.19245 
12866960 
PLEK
HA5 pleckstrin homology domain containing A5 1.65E-06 0.00209906 
1.257116
853 1.25712 
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Table 4.7 (continued)      
12765517 
RPRM
L  reprimo-like  1.81E-06 0.00219319 
0.772260
406 -1.2949 
12821658 
ABLI
M1  actin binding LIM protein 1  2.06E-06 0.00230454 
1.308681
268 1.30868 
12909850 
SLITR
K2  SLIT and NTRK-like family, member 2  2.07E-06 0.00230454 
1.349001
537 1.349 
12876760 PAM 
 peptidylglycine alpha-amidating 
monooxygenase  2.21E-06 0.0023559 
0.516134
36 -1.93748 
12706637 
FAM98
A  family with sequence similarity 98, member A  2.85E-06 0.00292358 
0.814730
324 -1.2274 
12731709 ZW10 
 ZW10, kinetochore associated, homolog 
(Drosophila)  3.33E-06 0.00326731 
0.826111
74 -1.21049 
12722190 
MRPL
15  mitochondrial ribosomal protein L15  3.46E-06 0.00326731 
0.746246
381 -1.34004 
12883237 PCSK1  proprotein convertase subtilisin 3.55E-06 0.00326731 
0.580548
154 -1.72251 
12901396 PKIB 
 protein kinase (cAMP-dependent, catalytic) 
inhibitor beta 3.92E-06 0.00348198 
0.710292
854 -1.40787 
12844085 PEA15  phosphoprotein enriched in astrocytes 15  4.07E-06 0.00350175 
1.182574
062 1.18257 
12725728 EFR3A  EFR3 homolog A (S. cerevisiae)  4.33E-06 0.00350945 
0.759999
696 -1.31579 
12796976 
SLC6A
11 
 solute carrier family 6 (neurotransmitter 
transporter, GABA) 4.34E-06 0.00350945 
1.353280
691 1.35328 
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Table 4.7 (continued)      
12681884 
PLSCR
4  phospholipid scramblase 4  4.85E-06 0.00380365 
1.340186
152 1.34019 
12698445 ODC1  ornithine decarboxylase 1  5.00E-06 0.00381304 
0.720964
939 -1.38703 
12738110 
APOB
EC4 
 apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide- 5.77E-06 0.00411905 
0.584337
42 -1.71134 
12690836 RORA  RAR-related orphan receptor A  5.81E-06 0.00411905 
1.179369
061 1.17937 
12804415 PRL  prolactin  6.12E-06 0.00411905 
0.814617
496 -1.22757 
12884669 
DPYSL
3  dihydropyrimidinase-like 3  6.12E-06 0.00411905 
0.623526
918 -1.60378 
12820770 
TCF7L
2 
 transcription factor 7-like 2 (T-cell specific, 
HMG-box 6.28E-06 0.00411905 
1.215108
169 1.21511 
12681044 
ADPR
H  ADP-ribosylarginine hydrolase  6.55E-06 0.00411905 
0.792311
41 -1.26213 
12816646 
WBSC
R22 
 Williams Beuren syndrome chromosome region 
22  6.57E-06 0.00411905 
0.832625
602 -1.20102 
12909727 
GPR10
1  G protein-coupled receptor 101  6.64E-06 0.00411905 
0.372790
749 -2.68247 
12684305 ITSN1  intersectin 1 (SH3 domain protein)  7.11E-06 0.00423958 
1.169628
947 1.16963 
12694513 
HEAT
R4 HEAT repeat containing 4 7.15E-06 0.00423958 
1.248296
076 1.2483 
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Table 4.7 (continued)      
12854099 ASNS  asparagine synthetase (glutamine-hydrolyzing)  8.47E-06 0.00486962 
0.823092
688 -1.21493 
12835795 CD247  CD247 molecule  8.58E-06 0.00486962 
1.181139
563 1.18114 
12760666 CLTC  clathrin, heavy chain (Hc)  8.86E-06 0.00492327 
0.913567
389 -1.09461 
12891421 NFIB  nuclear factor I 9.41E-06 0.00512338 
1.240334
692 1.24033 
12796050 EXOG  endo 9.64E-06 0.00514056 
0.828665
186 -1.20676 
12744882 CIT  citron (rho-interacting, serine 9.90E-06 0.00518005 
0.789914
373 -1.26596 
12728901 SORL1 
 sortilin-related receptor, L(DLR class) A 
repeats contai 1.03E-05 0.00529555 
1.242348
685 1.24235 
12863173 
IQSEC
3  IQ motif and Sec7 domain 3  1.09E-05 0.00549229 
0.695574
753 -1.43766 
12754444 CPNE2  copine II  1.13E-05 0.00557045 
0.668847
108 -1.49511 
12772434 ENO3  enolase 3 (beta, muscle)  1.19E-05 0.0057655 
0.652213
613 -1.53324 
12849880 RINT1  RAD50 interactor 1  1.22E-05 0.00577337 
0.844045
68 -1.18477 
12845993 
CADM
3  cell adhesion molecule 3  1.24E-05 0.00577337 
1.336918
056 1.33692 
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Table 4.7 (continued)      
12862258 RNF41  ring finger protein 41  1.26E-05 0.00577337 
0.848874
816 -1.17803 
12760918 TIMP2  TIMP metallopeptidase inhibitor 2  1.36E-05 0.00592615 
0.828919
338 -1.20639 
12890327 LPPR1 
 lipid phosphate phosphatase-related protein 
type 1  1.36E-05 0.00592615 
0.703650
539 -1.42116 
12721605 FABP5 
 fatty acid binding protein 5 (psoriasis-
associated)  1.38E-05 0.00592615 
0.630250
777 -1.58667 
12772567 CDR2L  cerebellar degeneration-related protein 2-like  1.39E-05 0.00592615 
0.610884
744 -1.63697 
12818366 VGF  VGF nerve growth factor inducible  1.40E-05 0.00592615 
0.688477
638 -1.45248 
12909004 
KLHL1
3  kelch-like 13 (Drosophila)  1.42E-05 0.00592615 
0.647261
759 -1.54497 
12681831 BCL6  B-cell CLL 1.45E-05 0.00594922 
1.390644
578 1.39064 
12887101 
CLINT
1  clathrin interactor 1  1.51E-05 0.00611067 
0.902535
221 -1.10799 
12822767 GFRA1  GDNF family receptor alpha 1  1.57E-05 0.00625298 
1.370279
729 1.37028 
12825420 ACSL1 
 acyl-CoA synthetase long-chain family member 
1  1.60E-05 0.00628789 
1.263664
957 1.26366 
12744620 KSR2  kinase suppressor of ras 2  1.64E-05 0.00632783 
0.776831
769 -1.28728 
    
   
   
9
8
 
Table 4.7 (continued)      
12734598 PRELP  proline 1.68E-05 0.00640273 
1.297572
242 1.29757 
12812405 TPST1  tyrosylprotein sulfotransferase 1  1.70E-05 0.00640273 
0.755635
149 -1.32339 
12780755 
RCAN
3  RCAN family member 3  1.78E-05 0.00654189 
0.616663
481 -1.62163 
12830994 
LRRC1
0B  leucine rich repeat containing 10B  1.79E-05 0.00654189 
0.774521
346 -1.29112 
12717875 
LOC10
033586
7  uncharacterized LOC100335867  1.87E-05 0.00672986 
0.702864
171 -1.42275 
12852359 
CLEC2
L  C-type lectin domain family 2, member L  1.94E-05 0.00685045 
0.511872
892 -1.95361 
12851732 COBL  cordon-bleu homolog (mouse)  1.95E-05 0.00685045 
1.226814
735 1.22681 
12800654 
FAM19
A1 
 family with sequence similarity 19 (chemokine 
(C-C motif)-li 2.03E-05 0.00698948 
0.491956
511 -2.0327 
12791580 
SERPI
NA1 
 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, a 2.04E-05 0.00698948 
0.377025
57 -2.65234 
12914851   2.18E-05 0.00725635 
0.338304
149 -2.95592 
12894663 
KANK
1  KN motif and ankyrin repeat domains 1  2.22E-05 0.00725635 
1.228496
701 1.2285 
12880336 
RHOB
TB3  Rho-related BTB domain containing 3  2.22E-05 0.00725635 
0.778446
377 -1.28461 
    
   
   
9
9
 
Table 4.7 (continued)      
12690776 
C10H1
5orf61 
 chromosome 10 open reading frame, human 
C15orf61  2.25E-05 0.00725635 
0.822206
144 -1.21624 
12843689 IL6R  interleukin 6 receptor  2.26E-05 0.00725635 
1.272669
424 1.27267 
12785900 
SERF1
A  small EDRK-rich factor 1A (telomeric)  2.29E-05 0.00725635 
0.793361
154 -1.26046 
12900382 
IPCEF
1 
interaction protein for cytohesin exchange 
factors 1 2.32E-05 0.00729635 
0.665734
638 -1.5021 
12749473 
CLEC3
A  C-type lectin domain family 3, member A  2.40E-05 0.00744792 
0.495554
873 -2.01794 
12904860 
TMEM
35  transmembrane protein 35  2.56E-05 0.00786195 
0.773108
204 -1.29348 
12786942 SDHA 
 succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp)  2.60E-05 0.00788154 
0.907218
74 -1.10227 
12901161 
FAM46
A  family with sequence similarity 46, member A  2.69E-05 0.00802629 
0.648193
162 -1.54275 
12718471 
PCMT
D2 
 protein-L-isoaspartate (D-aspartate) O-
methyltransferase doma 2.71E-05 0.00802629 
1.159134
034 1.15913 
12743540 
GOLG
A3  golgin A3  2.92E-05 0.00856137 
0.858288
059 -1.16511 
12914547   3.08E-05 0.00876601 
0.788867
502 -1.26764 
12694561 SIX1  SIX homeobox 1  3.11E-05 0.00876601 
0.862529
973 -1.15938 
    
   
   
1
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Table 4.7 (continued)      
12845091 GIPC2 
 GIPC PDZ domain containing family, member 
2  3.11E-05 0.00876601 
0.749198
358 -1.33476 
12798897 SPCS1 
 signal peptidase complex subunit 1 homolog (S. 
cerevisiae)  3.12E-05 0.00876601 
0.826063
97 -1.21056 
12705554 
KCNIP
3  Kv channel interacting protein 3, calsenilin  3.19E-05 0.00885044 
0.337708
915 -2.96113 
12900949 CLVS2  clavesin 2  3.27E-05 0.00898575 
0.460095
884 -2.17346 
12865096 CPT1B  carnitine palmitoyltransferase 1B (muscle)  3.42E-05 0.00924483 
0.766530
224 -1.30458 
12730077 ART5  ADP-ribosyltransferase 5  3.43E-05 0.00924483 
0.702656
745 -1.42317 
12891381 RFX3 
 regulatory factor X, 3 (influences HLA class II 
expression)  3.65E-05 0.00967033 
1.154782
416 1.15478 
12718040 
BLCA
P  bladder cancer associated protein  3.66E-05 0.00967033 
1.149770
218 1.14977 
12885917 
ZNF30
0  zinc finger protein 300  3.75E-05 0.00979751 
0.591800
019 -1.68976 
12724574 
DENN
D3  DENN 3.80E-05 0.00985362 
0.761162
447 -1.31378 
12807840 
LOC51
0913  nose resistant to fluoxetine protein 6-like  3.97E-05 0.0101555 
0.378382
264 -2.64283 
12722987 AZIN1  antizyme inhibitor 1  4.01E-05 0.0101555 
0.893367
639 -1.11936 
    
   
   
1
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Table 4.7 (continued)      
12824358 TNKS 
 tankyrase, TRF1-interacting ankyrin-related 
ADP-ribose polymera 4.04E-05 0.0101555 
0.860067
085 -1.1627 
12772732 
PRKA
R1A 
 protein kinase, cAMP-dependent, regulatory, 
type I, alpha (t 4.26E-05 0.0105979 
0.915038
66 -1.09285 
12786113 FGF18  fibroblast growth factor 18  4.33E-05 0.0105979 
0.788562
687 -1.26813 
12815257 STX1B  syntaxin 1B  4.33E-05 0.0105979 
1.194260
86 1.19426 
12782974 
MFSD
6 
 major facilitator superfamily domain containing 
6  4.39E-05 0.0106441 
0.862009
517 -1.16008 
12703883 GFPT1  glutamine--fructose-6-phosphate transaminase 1  4.43E-05 0.0106441 
0.882378
893 -1.1333 
12808014 
SLC39
A6 
 solute carrier family 39 (zinc transporter), 
member 6  4.48E-05 0.0106789 
0.834675
77 -1.19807 
12709784 GPC5  glypican 5  4.72E-05 0.0110629 
0.715727
394 -1.39718 
12727699 
CREB3
L1 
 cAMP responsive element binding protein 3-
like 1  4.74E-05 0.0110629 
0.674427
074 -1.48274 
12681063 GNB4 
 guanine nucleotide binding protein (G protein), 
beta polypeptid 4.77E-05 0.0110629 
0.700461
604 -1.42763 
12733712 BDNF  brain-derived neurotrophic factor  4.81E-05 0.0110629 
0.659565
346 -1.51615 
12786160 
OXCT
1  3-oxoacid CoA transferase 1  4.89E-05 0.0111294 
0.823512
942 -1.21431 
    
   
   
1
0
2
 
Table 4.7 (continued)      
12867761 
COQ10
A  coenzyme Q10 homolog A (S. cerevisiae)  4.94E-05 0.0111294 
0.879855
704 -1.13655 
12706846 PREPL  prolyl endopeptidase-like  4.98E-05 0.0111294 
0.857581
449 -1.16607 
12816678 TRAP1  TNF receptor-associated protein 1  5.01E-05 0.0111294 
0.832729
604 -1.20087 
12771103 TRPV3 
 transient receptor potential cation channel, 
subfamily V, memb 6.00E-05 0.0132377 
0.691620
328 -1.44588 
12719676 
SLC17
A9  solute carrier family 17, member 9  6.24E-05 0.0136424 
0.676823
532 -1.47749 
12767584 
MAP2
K6  mitogen-activated protein kinase kinase 6  6.36E-05 0.0137836 
1.493379
847 1.49338 
12887812 
SHRO
OM1  shroom family member 1  6.41E-05 0.0137836 
1.109131
927 1.10913 
12791646 WARS  tryptophanyl-tRNA synthetase  6.57E-05 0.0140166 
0.859195
106 -1.16388 
12706360 SURF4  surfeit 4  6.81E-05 0.0143244 
0.867611
206 -1.15259 
12707532 
COX7
A2L 
 cytochrome c oxidase subunit VIIa polypeptide 
2 like  6.88E-05 0.0143244 
0.798607
229 -1.25218 
12861735 
C5H12
orf23 
 chromosome 5 open reading frame, human 
C12orf23  6.89E-05 0.0143244 
0.894958
698 -1.11737 
12677247   6.93E-05 0.0143244 
1.748212
016 1.74821 
    
   
   
1
0
3
 
Table 4.7 (continued)      
12844481 
POU2F
1  POU class 2 homeobox 1  7.08E-05 0.0144902 
1.152076
387 1.15208 
12737098 
B3GA
LT2 
 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypepti 7.16E-05 0.0144902 
0.626550
713 -1.59604 
12758081 
MYLK
3  myosin light chain kinase 3  7.18E-05 0.0144902 
0.704002
253 -1.42045 
12765456 
TOM1
L2  target of myb1-like 2 (chicken)  7.22E-05 0.0144902 
0.841078
262 -1.18895 
12690792 GNB5 
 guanine nucleotide binding protein (G protein), 
beta 5  7.90E-05 0.0157305 
0.901989
789 -1.10866 
12898520 SASH1  SAM and SH3 domain containing 1  7.98E-05 0.0157582 
1.279225
506 1.27923 
12741946 TCN2  transcobalamin II  8.15E-05 0.0159752 
0.818618
663 -1.22157 
12904911 
HNRN
PH2 
 heterogeneous nuclear ribonucleoprotein H2 
(H')  8.20E-05 0.0159752 
0.831213
738 -1.20306 
12713066 
SLITR
K6  SLIT and NTRK-like family, member 6  8.42E-05 0.016277 
0.526853
735 -1.89806 
12848963 
GNGT
1 
 guanine nucleotide binding protein (G protein), 
gamma transducing 8.57E-05 0.0163351 
0.471211
343 -2.12219 
12801704 
LOC51
1316 MEF2B neighbor pseudogene 8.58E-05 0.0163351 
0.822341
37 -1.21604 
12780398 TNS1  tensin 1  8.71E-05 0.0163351 
1.279664
216 1.27966 
    
   
   
1
0
4
 
Table 4.7 (continued)      
12831896 NRGN  neurogranin (protein kinase C substrate, RC3)  8.72E-05 0.0163351 
1.663730
183 1.66373 
12830772 SCYL1  SCY1-like 1 (S. cerevisiae)  8.79E-05 0.0163351 
0.873438
728 -1.1449 
12785083 PRLR  prolactin receptor  8.86E-05 0.0163351 
0.762951
095 -1.3107 
12771233 
LRRC4
8  leucine rich repeat containing 48  8.88E-05 0.0163351 
0.798103
706 -1.25297 
12778650 FIGN  fidgetin  9.04E-05 0.0165243 
1.271622
349 1.27162 
12693799 DIO2  deiodinase, iodothyronine, type II  9.17E-05 0.0166237 
0.592364
423 -1.68815 
12708635 AFF3  AF4 9.23E-05 0.0166237 
1.181992
579 1.18199 
12716197 
TM9SF
4  transmembrane 9 superfamily protein member 4  9.29E-05 0.0166237 
0.880211
955 -1.13609 
12822603 NRAP  nebulin-related anchoring protein  9.37E-05 0.0166607 
0.664721
249 -1.50439 
12844104 
FAM19
A3 
 family with sequence similarity 19 (chemokine 
(C-C motif)-li 9.43E-05 0.0166607 
0.766101
539 -1.30531 
12696210 
SLC27
A2 
 solute carrier family 27 (fatty acid transporter), 
member 2  9.63E-05 0.0167793 
0.653628
948 -1.52992 
12808788 
SETBP
1  SET binding protein 1  9.69E-05 0.0167793 
1.142543
759 1.14254 
    
   
   
1
0
5
 
Table 4.7 (continued)      
12891005 PTPRD  protein tyrosine phosphatase, receptor type, D  9.70E-05 0.0167793 
1.365526
998 1.36553 
12855122 TES  testis derived transcript (3 LIM domains)  9.75E-05 0.0167793 
0.898303
105 -1.11321 
12808491 
ZNF52
1  zinc finger protein 521  9.94E-05 0.0170016 
1.332127
314 1.33213 
12687743 NEO1  neogenin 1  
0.00010
109 0.0171237 
1.181993
977 1.18199 
12886016 
MFSD
12 
major facilitator superfamily domain containing 
12 
0.00010
1426 0.0171237 
0.867287
645 -1.15302 
12892540 
DMRT
1 
 doublesex and mab-3 related transcription 
factor 1  
0.00010
3381 0.0173439 
0.851382
645 -1.17456 
12899957 PERP  PERP, TP53 apoptosis effector  
0.00010
5136 0.0174711 
0.788774
166 -1.26779 
12908876 
MAGE
E2  melanoma antigen family E, 2  
0.00010
5449 0.0174711 
0.861898
072 -1.16023 
12681492 
CCDC
39  coiled-coil domain containing 39  
0.00010
8466 0.0178258 
1.283912
956 1.28391 
12880093 
UNC13
A  unc-13 homolog A (C. elegans)  
0.00010
8926 0.0178258 
0.842268
397 -1.18727 
12705423 
ANGP
TL2  angiopoietin-like 2  
0.00011
1958 0.0182103 
0.557637
402 -1.79328 
12843233 
AMY2
B  amylase, alpha 2B (pancreatic)  
0.00011
4346 0.0184009 
1.275196
285 1.2752 
    
   
   
1
0
6
 
Table 4.7 (continued)      
12735060 SRM  spermidine synthase  
0.00011
451 0.0184009 
0.790713
856 -1.26468 
12809293 
LAMA
1  laminin, alpha 1  
0.00011
5227 0.0184053 
1.402310
166 1.40231 
12738701 
SEC16
B  SEC16 homolog B (S. cerevisiae)  
0.00011
7318 0.0186278 
0.694391
401 -1.44011 
12817661 
KDEL
R2 
 KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retentio 
0.00011
9433 0.0188194 
0.880382
438 -1.13587 
12891796 
PALM
2  paralemmin 2  
0.00012
0481 0.0188194 
1.200413
903 1.20041 
12782240 
CLASP
1  cytoplasmic linker associated protein 1  
0.00012
1187 0.0188194 
1.139714
137 1.13971 
12908168 
MAGE
D1  melanoma antigen family D, 1  
0.00012
1347 0.0188194 
0.901233
789 -1.10959 
12792677 ITPK1  inositol-tetrakisphosphate 1-kinase  
0.00012
2759 0.0189282 
1.166775
371 1.16677 
12779964 4-Mar 
 membrane-associated ring finger (C3HC4) 4, 
E3 ubiquitin prote 
0.00012
5636 0.0191841 
0.672133
351 -1.4878 
12797483 
RBMS
3 
 RNA binding motif, single stranded interacting 
protein 3  
0.00012
5856 0.0191841 
1.173052
176 1.17305 
12895106 ACER2  alkaline ceramidase 2  
0.00012
8917 0.0195389 
0.770796
078 -1.29736 
12889108 CREB3  cAMP responsive element binding protein 3  
0.00013
0329 0.0196414 
0.899029
947 -1.11231 
    
   
   
1
0
7
 
Table 4.7 (continued)      
12758956 
CMTM
4 
 CKLF-like MARVEL transmembrane domain 
containing 4  
0.00013
5053 0.020239 
1.161127
315 1.16113 
12692964 
C10H1
4orf119 
 chromosome 10 open reading frame, human 
C14orf119  
0.00013
6188 0.020295 
0.865868
336 -1.15491 
12786958 ITGA2 
 integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor)  
0.00013
7653 0.0203994 
0.660161
872 -1.51478 
12875311 
MAPK
10  mitogen-activated protein kinase 10  
0.00013
9985 0.0204027 
0.876255
236 -1.14122 
12908904 
ZNF71
1  zinc finger protein 711  
0.00014
0058 0.0204027 
1.102853
191 1.10285 
12767689 
ATP5G
1 
 ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit 
0.00014
0519 0.0204027 
0.823506
16 -1.21432 
12892113 
CNTN
AP3  contactin associated protein-like 3  
0.00014
0735 0.0204027 
1.622823
388 1.62282 
12849870 
TMEM
213  transmembrane protein 213  
0.00014
1848 0.0204286 
1.513237
041 1.51324 
12863307 
METT
L21B  methyltransferase like 21B  
0.00014
2445 0.0204286 
0.848716
317 -1.17825 
12791435 
MIR38
0  microRNA mir-380  
0.00014
3776 0.0205093 
0.584730
352 -1.71019 
12678498 APP  amyloid beta (A4) precursor protein  
0.00014
9384 0.0211959 
1.122431
456 1.12243 
12865092 RPS26  ribosomal protein S26  
0.00015
0367 0.0212104 
0.728162
409 -1.37332 
    
   
   
1
0
8
 
Table 4.7 (continued)      
12689890 
MYO1
E  myosin IE  
0.00015
174 0.0212104 
1.152660
687 1.15266 
12741977 
ADRB
K2  adrenergic, beta, receptor kinase 2  
0.00015
2593 0.0212104 
1.166377
988 1.16638 
12851480 
C4H7o
rf25 
 chromosome 4 open reading frame, human 
C7orf25  
0.00015
2767 0.0212104 
0.800646
923 -1.24899 
12710335 LACC1 
 laccase (multicopper oxidoreductase) domain 
containing 1  
0.00015
3463 0.0212104 
0.829689
613 -1.20527 
12772085 
GPR14
2  G protein-coupled receptor 142  
0.00015
8547 0.0218002 
0.815693
952 -1.22595 
12710070 COG3  component of oligomeric golgi complex 3  
0.00015
9708 0.0218472 
0.919777
046 -1.08722 
12697991 RHOQ  ras homolog gene family, member Q  
0.00016
2447 0.0221085 
0.790039
186 -1.26576 
12822932 
SLC25
A28  solute carrier family 25, member 28  
0.00016
4111 0.0222217 
1.133959
128 1.13396 
12698264 
KCNIP
3  Kv channel interacting protein 3, calsenilin  
0.00016
7341 0.022473 
0.548047
307 -1.82466 
12900780 
SLC17
A5  solute carrier family 17 (anion 
0.00016
8625 0.022473 
0.783293
908 -1.27666 
12792547 
CCDC
88C  coiled-coil domain containing 88C  
0.00016
8772 0.022473 
1.191649
398 1.19165 
12679533 
TMEM
45A  transmembrane protein 45A  
0.00016
9337 0.022473 
0.721693
381 -1.38563 
    
   
   
1
0
9
 
Table 4.7 (continued)      
12691139 PAK6  p21 protein (Cdc42 
0.00017
4499 0.02303 
0.722982
157 -1.38316 
12760883 
PRKC
A  protein kinase C, alpha  
0.00017
5261 0.02303 
0.768338
315 -1.30151 
12821009 
KAZA
LD1  Kazal-type serine peptidase inhibitor domain 1  
0.00017
6297 0.0230525 
0.664442
997 -1.50502 
12782531 PDK1  pyruvate dehydrogenase kinase, isozyme 1  
0.00018
0959 0.023272 
0.927342
699 -1.07835 
12892001 KLHL9  kelch-like 9 (Drosophila)  
0.00018
1304 0.023272 
0.864296
765 -1.15701 
12862551 
GXYL
T1  glucoside xylosyltransferase 1  
0.00018
1488 0.023272 
1.110395
523 1.1104 
12901117 HEY2  hairy 
0.00018
3368 0.023272 
1.285266
095 1.28527 
12766850 
BT.624
30 angiotensin I converting enzyme 
0.00018
3914 0.023272 
0.877878
344 -1.13911 
12866811 
TAPBP
L  TAP binding protein-like  
0.00018
4045 0.023272 
1.184940
824 1.18494 
12755625 HP  haptoglobin  
0.00018
4395 0.023272 
0.471413
486 -2.12128 
12847578 
LOC61
6625 aquaporin 12B 
0.00018
6353 0.023272 
0.745701
034 -1.34102 
12890151 SHC3 
 SHC (Src homology 2 domain containing) 
transforming protein 3  
0.00018
6712 0.023272 
0.509126
085 -1.96415 
    
   
   
1
1
0
 
Table 4.7 (continued)      
12684272 
SLC25
A36  solute carrier family 25, member 36  
0.00018
6931 0.023272 
1.106474
981 1.10647 
12827916 
ZMYN
D17  zinc finger, MYND-type containing 17  
0.00018
7572 0.023272 
1.118304
293 1.1183 
12915057   
0.00019
3642 0.023814 
1.184233
588 1.18423 
12841186 
SEC22
B 
 SEC22 vesicle trafficking protein homolog B 
(S. cerevisiae)  
0.00019
4389 0.023814 
0.904543
522 -1.10553 
12749545 BCAM 
 basal cell adhesion molecule (Lutheran blood 
group)  
0.00019
4619 0.023814 
1.243713
031 1.24371 
12717993 SVIL  supervillin  
0.00019
8067 0.0241252 
0.704816
008 -1.41881 
12910551 
ZBTB3
3  zinc finger and BTB domain containing 33  
0.00019
9082 0.0241387 
0.883080
184 -1.1324 
12874907 
CDKL
2 
 cyclin-dependent kinase-like 2 (CDC2-related 
kinase)  
0.00020
1696 0.0243449 
0.804265
826 -1.24337 
12687032 
PTTG1
IP 
 pituitary tumor-transforming 1 interacting 
protein  
0.00020
402 0.0243844 
1.055259
731 1.05526 
12683071 
LSAM
P  neuronal growth regulator 1-like  
0.00020
4208 0.0243844 
1.356555
759 1.35656 
12716574 
GPR15
8  G protein-coupled receptor 158  
0.00020
4765 0.0243844 
0.740126
71 -1.35112 
12810467 
GALR
1  galanin receptor 1  
0.00021
7049 0.0256058 
0.630600
521 -1.58579 
    
   
   
1
1
1
 
Table 4.7 (continued)      
12809257 
COLE
C12  collectin sub-family member 12  
0.00021
9757 0.0256058 
1.294069
538 1.29407 
12749084 
LOC10
033650
2  aTPase, H+ 
0.00021
9966 0.0256058 
1.365702
299 1.3657 
12724853 EYA1  eyes absent homolog 1 (Drosophila)  
0.00022
0297 0.0256058 
1.265569
671 1.26557 
12801442 
SLC17
A1 
 solute carrier family 17 (sodium phosphate), 
member 1  
0.00022
0419 0.0256058 
0.595745
188 -1.67857 
12794552 
GTDC
2  glycosyltransferase-like domain containing 2  
0.00022
0781 0.0256058 
0.909057
852 -1.10004 
12865033 
BCL2L
14  BCL2-like 14 (apoptosis facilitator)  
0.00022
5534 0.0257878 
0.738312
513 -1.35444 
12773256 
LRRC4
6  leucine rich repeat containing 46  
0.00022
5769 0.0257878 
0.782981
122 -1.27717 
12771117 PDK2  pyruvate dehydrogenase kinase, isozyme 2  
0.00022
6165 0.0257878 
0.848968
503 -1.1779 
12824808 FGFR1  fibroblast growth factor receptor 1  
0.00022
6217 0.0257878 
1.206971
467 1.20697 
12887654 
LYSM
D3 
 LysM, putative peptidoglycan-binding, domain 
containing 3  
0.00023
0485 0.0261625 
0.806659
783 -1.23968 
12706345 
SEMA
4C 
 sema domain, immunoglobulin domain (Ig), 
transmembrane domain 
0.00023
2746 0.0263072 
1.191163
946 1.19116 
12703330 
PAIP2
B  poly(A) binding protein interacting protein 2B  
0.00023
5805 0.0265405 
1.222718
102 1.22272 
    
   
   
1
1
2
 
Table 4.7 (continued)      
12853653 YKT6  YKT6 v-SNARE homolog (S. cerevisiae)  
0.00023
8511 0.0266211 
0.846417
538 -1.18145 
12885519 SAR1B  SAR1 homolog B (S. cerevisiae)  
0.00023
8517 0.0266211 
0.860985
312 -1.16146 
12914859   
0.00024
1756 0.0266288 
0.864431
247 -1.15683 
12782451 4-Mar 
 membrane-associated ring finger (C3HC4) 4, 
E3 ubiquitin prote 
0.00024
2022 0.0266288 
0.734694
477 -1.36111 
12742060 
SEC14
L2  SEC14-like 2 (S. cerevisiae)  
0.00024
2347 0.0266288 
1.324896
393 1.3249 
12770437 AMZ2  archaelysin family metallopeptidase 2  
0.00024
2579 0.0266288 
0.894406
382 -1.11806 
12769323 
CAMK
K1  calcium 
0.00024
3731 0.0266456 
1.200349
062 1.20035 
12829453 
TM7SF
2  transmembrane 7 superfamily member 2  
0.00024
6126 0.0267976 
0.732681
247 -1.36485 
12893064 IL33  interleukin 33  
0.00024
9169 0.0270186 
0.537935
19 -1.85896 
12696484 
PNMA
1  paraneoplastic antigen MA1  
0.00025
0658 0.0270701 
0.829999
502 -1.20482 
12682682 LXN  latexin  
0.00025
2328 0.0270924 
0.561665
225 -1.78042 
12786382 
AMAC
R  alpha-methylacyl-CoA racemase  
0.00025
2896 0.0270924 
0.772194
809 -1.29501 
    
   
   
1
1
3
 
Table 4.7 (continued)      
12882320 
GALN
T10 
 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalac 
0.00025
4175 0.0271204 
1.232255
521 1.23226 
12842993 LMNA  lamin A 
0.00025
5266 0.0271245 
0.843106
341 -1.18609 
12771489 
SMTN
L2  smoothelin-like 2  
0.00025
6501 0.0271245 
1.243123
971 1.24312 
12816911 
GPRC5
B 
 G protein-coupled receptor, family C, group 5, 
member B  
0.00025
7662 0.0271245 
1.295618
736 1.29562 
12713584 CHGB  chromogranin B (secretogranin 1)  
0.00026
1051 0.0271245 
0.875013
125 -1.14284 
12713592 
NPBW
R2  neuropeptides B 
0.00026
1347 0.0271245 
0.822699
937 -1.21551 
12827434 USP54  ubiquitin specific peptidase 54-like  
0.00026
1364 0.0271245 
1.139607
633 1.13961 
12763243 FLII  flightless I homolog (Drosophila)  
0.00026
3057 0.0271245 
0.854525
567 -1.17024 
12771261 
SGK49
4  uncharacterized serine 
0.00026
3231 0.0271245 
1.282812
747 1.28281 
12807700 SEH1L  SEH1-like (S. cerevisiae)  
0.00026
3364 0.0271245 
0.899871
318 -1.11127 
12914903   
0.00026
9858 0.0276864 
0.922347
559 -1.08419 
12857261   
0.00027
2609 0.0278615 
0.919793
966 -1.0872 
    
   
   
1
1
4
 
Table 4.7 (continued)      
12797969 PLCD1  phospholipase C, delta 1  
0.00027
3898 0.0278806 
1.210662
547 1.21066 
12850085 
SEMA
3C 
 sema domain, immunoglobulin domain (Ig), 
short basic domain,  
0.00027
7219 0.0278806 
1.411187
613 1.41119 
12773855 
SP140
L  SP140 nuclear body protein-like  
0.00027
7568 0.0278806 
1.197123
074 1.19712 
12914733   
0.00027
7836 0.0278806 
1.170401
026 1.1704 
12782828 
PLEK
HM3 
 pleckstrin homology domain containing, family 
M, member 3  
0.00027
9063 0.0278806 
1.208707
529 1.20871 
12786990 
PIK3R
1 
 phosphoinositide-3-kinase, regulatory subunit 1 
(alpha)  
0.00027
9067 0.0278806 
1.153558
208 1.15356 
12908260 CA5B  carbonic anhydrase VB, mitochondrial  
0.00028
2571 0.027969 
1.219067
681 1.21907 
12872493 EMCN  endomucin  
0.00028
2722 0.027969 
1.359140
697 1.35914 
12718182 
ATP5C
1 
 ATP synthase, H+ transporting, mitochondrial 
F1 complex, gamm 
0.00028
3098 0.027969 
0.877446
98 -1.13967 
12829389 IGF2  insulin-like growth factor 2 (somatomedin A)  
0.00028
6834 0.0279962 
1.144147
742 1.14415 
12678652 COPB2 
 coatomer protein complex, subunit beta 2 (beta 
prime)  
0.00028
7375 0.0279962 
0.907490
426 -1.10194 
12734323 DHRS3  dehydrogenase 
0.00028
8108 0.0279962 
1.212640
075 1.21264 
    
   
   
1
1
5
 
Table 4.7 (continued)      
12791056 
GABR
G3 
 gamma-aminobutyric acid (GABA) A receptor, 
gamma 3  
0.00028
8477 0.0279962 
1.644139
219 1.64414 
12900549 
CITED
2  Cbp 
0.00028
8621 0.0279962 
1.225541
26 1.22554 
12755952 GOT2 
 glutamic-oxaloacetic transaminase 2, 
mitochondrial (aspartate amin 
0.00029
1414 0.0281648 
0.910158
277 -1.09871 
12814236 
PPP1R
35  protein phosphatase 1, regulatory subunit 35  
0.00029
461 0.0283708 
0.869860
213 -1.14961 
12708563   
0.00030
118 0.0288992 
0.782870
787 -1.27735 
12754277 
FAM65
A  family with sequence similarity 65, member A  
0.00030
6254 0.02923 
0.807591
359 -1.23825 
12833395 CTSF  cathepsin F  
0.00030
6819 0.02923 
1.121600
569 1.1216 
12730119 
MGC1
37098  uncharacterized protein MGC137098  
0.00031
3031 0.0297006 
0.808106
929 -1.23746 
12759391 MEIS3  Meis homeobox 3  
0.00031
4998 0.0297006 
0.752536
046 -1.32884 
12732959 
KIF18
A  kinesin family member 18A  
0.00031
5099 0.0297006 
0.782013
685 -1.27875 
12888569 
CDC42
SE2  CDC42 small effector 2  
0.00031
7296 0.0298024 
1.166652
861 1.16665 
12893911 APBA1 
 amyloid beta (A4) precursor protein-binding, 
family A, member  
0.00032
0335 0.0299822 
1.184337
375 1.18434 
    
   
   
1
1
6
 
Table 4.7 (continued)      
12726480 
MIR23
18  microRNA mir-2318  
0.00032
3937 0.0301913 
0.831234
466 -1.20303 
12720297 
TRPC4
AP 
 transient receptor potential cation channel, 
subfamily C, me 
0.00032
673 0.0301913 
0.892618
049 -1.1203 
12800376 PXK  PX domain containing serine 
0.00032
878 0.0301913 
0.834898
769 -1.19775 
12893958 
GABB
R2 
 gamma-aminobutyric acid (GABA) B receptor, 
2  
0.00032
8872 0.0301913 
1.395340
4 1.39534 
12897282 REV3L 
 REV3-like, catalytic subunit of DNA 
polymerase zeta (yeast)  
0.00032
9791 0.0301913 
1.147232
359 1.14723 
12789006 CHGA 
 chromogranin A (parathyroid secretory protein 
1)  
0.00033
0485 0.0301913 
1.318871
468 1.31887 
12726663 CD44  CD44 molecule (Indian blood group)  
0.00033
1275 0.0301913 
0.809742
826 -1.23496 
12682117 
C1H21
orf91 
 chromosome 1 open reading frame, human 
C21orf91  
0.00033
2146 0.0301913 
0.734845
646 -1.36083 
12678864 HTR1F  5-hydroxytryptamine (serotonin) receptor 1F  
0.00033
2755 0.0301913 
0.352941
592 -2.83333 
12723978 
MRPL
33  mitochondrial ribosomal protein L33  
0.00033
4872 0.0302245 
0.864012
995 -1.15739 
12883172 
HAPL
N1  hyaluronan and proteoglycan link protein 1  
0.00033
692 0.0302245 
0.732842
329 -1.36455 
12888990 
BT.863
27  ---  
0.00033
7588 0.0302245 
1.589499
133 1.5895 
    
   
   
1
1
7
 
Table 4.7 (continued)      
12863567 
LOC10
029746
8  cD24 molecule-like  
0.00033
7821 0.0302245 
0.579344
067 -1.72609 
12793713 
SPTSS
A  serine palmitoyltransferase, small subunit A  
0.00033
9183 0.0302245 
0.893335
716 -1.1194 
12725810 
CTHR
C1  collagen triple helix repeat containing 1  
0.00033
9919 0.0302245 
0.732960
501 -1.36433 
12847281 
UQCR
H  ubiquinol-cytochrome c reductase hinge protein  
0.00034
2227 0.0303286 
0.896772
516 -1.11511 
12828385 
OGDH
L  oxoglutarate dehydrogenase-like  
0.00034
3961 0.030344 
0.838033
303 -1.19327 
12890349 
ZNF46
2  zinc finger protein 462  
0.00034
4676 0.030344 
1.226116
778 1.22612 
12900759 
SLC18
B1  solute carrier family 18, subfamily B, member 1  
0.00035
1444 0.030838 
1.165346
329 1.16535 
12709313 IPO5  importin 5  
0.00035
3896 0.0309374 
0.884987
079 -1.12996 
12834259 
PANX
1  pannexin 1  
0.00035
5011 0.0309374 
0.870450
806 -1.14883 
12793325 FBLN5  fibulin 5  
0.00035
6055 0.0309374 
1.266757
62 1.26676 
12725994 
BAAL
C  brain and acute leukemia, cytoplasmic  
0.00035
8274 0.030978 
0.833583
408 -1.19964 
12735935 
SRGA
P2  SLIT-ROBO Rho GTPase activating protein 2  
0.00035
9732 0.030978 
1.136603
873 1.1366 
    
   
   
1
1
8
 
Table 4.7 (continued)      
12867984 TENC1 
 tensin like C1 domain containing phosphatase 
(tensin 2)  
0.00036
111 0.030978 
1.189908
151 1.18991 
12752761 
BT.303
26  ---  
0.00036
1226 0.030978 
0.883595
172 -1.13174 
12720820 C1QL3 
 complement component 1, q subcomponent-like 
3  
0.00036
2329 0.030978 
0.642153
526 -1.55726 
12870236 LPHN3  latrophilin 3  
0.00036
5286 0.031131 
1.481084
331 1.48109 
12850899 
CTTN
BP2 cortactin binding protein 2 
0.00036
9534 0.0311323 
1.173783
315 1.17378 
12782838 
FAM12
6B  family with sequence similarity 126, member B  
0.00037
0213 0.0311323 
0.877531
679 -1.13956 
12720176 FLRT3 
 fibronectin leucine rich transmembrane protein 
3  
0.00037
0258 0.0311323 
1.172379
673 1.17238 
12794461 COPG1  coatomer protein complex, subunit gamma  
0.00037
049 0.0311323 
0.887547
706 -1.1267 
12843700 
SLC44
A3  solute carrier family 44, member 3  
0.00037
1137 0.0311323 
1.231869
954 1.23187 
12852942 CFTR 
 cystic fibrosis transmembrane conductance 
regulator (ATP- 
0.00037
3023 0.0311924 
0.702740
689 -1.423 
12728764 
SCUB
E2 
signal peptide, CUB domain and EGF like 
domain containing 2  
0.00037
5739 0.0313214 
1.255415
549 1.25542 
12861868 RERG  RAS-like, estrogen-regulated, growth inhibitor  
0.00037
8144 0.031359 
0.717252
064 -1.39421 
    
   
   
1
1
9
 
Table 4.7 (continued)      
12696911 
IGDCC
4 
 immunoglobulin superfamily, DCC subclass, 
member 4  
0.00037
8541 0.031359 
1.283947
574 1.28395 
12843378 
ATP6V
0B 
 ATPase, H+ transporting, lysosomal 21kDa, V0 
subunit b 
0.00038
1171 0.0314791 
0.865239
022 -1.15575 
12684999 KCNJ6 
 potassium inwardly-rectifying channel, 
subfamily J, member 6  
0.00038
4105 0.0316235 
0.671118
419 -1.49005 
12874253 GAR1  GAR1 ribonucleoprotein homolog (yeast)  
0.00038
7854 0.0317025 
0.776614
582 -1.28764 
12827902 MICU1  mitochondrial calcium uptake 1  
0.00038
7935 0.0317025 
0.922773
118 -1.08369 
12787557 
SH3PX
D2B  SH3 and PX domains 2B  
0.00038
9192 0.0317025 
1.181724
396 1.18172 
12762367 
MAP3
K3 
 mitogen-activated protein kinase kinase kinase 
3  
0.00038
9819 0.0317025 
1.140518
754 1.14052 
12860901 
TMTC
1 
 transmembrane and tetratricopeptide repeat 
containing 1  
0.00039
24 0.0318053 
1.287070
858 1.28707 
12706012 EFR3B  EFR3 homolog B (S. cerevisiae)  
0.00039
4475 0.0318053 
0.716794
495 -1.3951 
12886767 KXD1  KxDL motif containing 1  
0.00039
5284 0.0318053 
0.882822
915 -1.13273 
12803164 GNMT  glycine N-methyltransferase  
0.00039
5853 0.0318053 
0.832015
975 -1.2019 
12693805 
RPS6K
A5 
 ribosomal protein S6 kinase, 90kDa, 
polypeptide 5  
0.00039
9962 0.032039 
1.180848
061 1.18085 
    
   
   
1
2
0
 
Table 4.7 (continued)      
12756690   
0.00040
5224 0.0323633 
0.789540
172 -1.26656 
12681327 
DYRK
1A 
 dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinas 
0.00040
7106 0.0324166 
1.099331
167 1.09933 
12748294 
ZNF60
5  zinc finger protein 605  
0.00040
9743 0.0325294 
1.119083
963 1.11908 
12861444 SYT10  synaptotagmin X  
0.00041
2261 0.0326171 
1.384230
569 1.38423 
12867796 
ACVR
1B  activin A receptor, type IB  
0.00041
3292 0.0326171 
1.118209
255 1.11821 
12911995   
0.00041
4571 0.0326215 
1.171847
993 1.17185 
12838286 
NOTC
H2  notch 2  
0.00041
6917 0.0327096 
1.201684
762 1.20169 
12711493 FRY  furry homolog (Drosophila)  
0.00041
9974 0.0328111 
1.190640
612 1.19064 
12885485 GLRX  glutaredoxin (thioltransferase)  
0.00042
1727 0.0328111 
0.836120
401 -1.196 
12782135 ERBB4 erb-b2 receptor tyrosine kinase 4  
0.00042
1901 0.0328111 
1.254325
856 1.25433 
12868475 
ANKS
1B 
 ankyrin repeat and sterile alpha motif domain 
containing 1B  
0.00042
4675 0.0329308 
1.225704
995 1.2257 
12873141 BTC  betacellulin  
0.00042
7725 0.0330202 
1.418270
731 1.41827 
    
   
   
1
2
1
 
Table 4.7 (continued)      
12885399 ERAP1  endoplasmic reticulum aminopeptidase 1  
0.00042
8303 0.0330202 
1.251945
21 1.25195 
12896756 QKI  QKI, KH domain containing, RNA binding  
0.00042
9992 0.0330549 
1.141169
516 1.14117 
12774157 
CNTN
AP5 contactin associated protein-like 5 
0.00043
4841 0.0333316 
1.387898
084 1.3879 
12899842 
MOXD
1  monooxygenase, DBH-like 1  
0.00043
675 0.0333433 
0.625480
838 -1.59877 
12858199 LRIG3 
 leucine-rich repeats and immunoglobulin-like 
domains 3  
0.00043
8412 0.0333433 
1.294873
853 1.29487 
12866171 
GOLT1
B  golgi transport 1B  
0.00043
8744 0.0333433 
0.869482
05 -1.15011 
12812980 RASA4  RAS p21 protein activator 4  
0.00044
0354 0.0333706 
1.145554
105 1.14555 
12790698 
PPP4R
4  protein phosphatase 4, regulatory subunit 4  
0.00044
1766 0.0333827 
1.247242
036 1.24724 
12778629 WIPF1  WAS 
0.00044
4035 0.0334594 
1.192497
758 1.1925 
12706299 
NCOA
1  nuclear receptor coactivator 1  
0.00044
6813 0.0335739 
1.123350
64 1.12335 
12867807 CSRP2  cysteine and glycine-rich protein 2  
0.00044
8135 0.0335786 
1.178117
18 1.17812 
12790124 ALPK3  alpha-kinase 3  
0.00045
0127 0.0336334 
0.798288
47 -1.25268 
    
   
   
1
2
2
 
Table 4.7 (continued)      
12815419 COG7  component of oligomeric golgi complex 7  
0.00045
5987 0.0339761 
0.866310
902 -1.15432 
12900189 DSE  dermatan sulfate epimerase  
0.00046
1485 0.03429 
0.774077
686 -1.29186 
12911809   
0.00046
7454 0.034637 
1.240011
706 1.24001 
12826094 
SEC24
C  SEC24 family, member C (S. cerevisiae)  
0.00046
9176 0.0346683 
0.891503
967 -1.1217 
12869248 ERBB3 
 v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (avi 
0.00047
2712 0.0348331 
1.190114
906 1.19011 
12834682 
HTATI
P2  HIV-1 Tat interactive protein 2, 30kDa  
0.00047
662 0.0350243 
0.861690
119 -1.16051 
12859857 
PLXN
C1  plexin C1  
0.00048
1822 0.0353093 
1.259598
138 1.2596 
12744300 
FBXW
7  F-box and WD repeat domain containing 7  
0.00048
4596 0.0354153 
0.870708
496 -1.14849 
12889697 RUSC2  RUN and SH3 domain containing 2  
0.00048
6642 0.0354677 
0.838391
629 -1.19276 
12865601 MARS  methionyl-tRNA synthetase  
0.00049
0565 0.0354978 
0.866626
224 -1.1539 
12850206 AGK  acylglycerol kinase  
0.00049
0801 0.0354978 
0.877454
679 -1.13966 
12907940 PDK3  pyruvate dehydrogenase kinase, isozyme 3  
0.00049
2327 0.0354978 
0.863490
748 -1.15809 
    
   
   
1
2
3
 
Table 4.7 (continued)      
12881048 
C7H5o
rf30  UNC119-binding protein C5orf30 homolog  
0.00049
2818 0.0354978 
0.853890
753 -1.17111 
12875407 RRH 
 retinal pigment epithelium-derived rhodopsin 
homolog  
0.00049
4206 0.0354978 
1.679247
026 1.67925 
12804713 
RPS4Y
1  ribosomal protein S4, Y-linked 1  
0.00049
504 0.0354978 
0.830378
57 -1.20427 
12786020 
C1QT
NF3  C1q and tumor necrosis factor related protein 3  
0.00049
7789 0.0355992 
0.548380
905 -1.82355 
12772050 KIF19  kinesin family member 19  
0.00050
1395 0.0357612 
1.367467
136 1.36747 
12862410 
PARV
B  parvin, beta  
0.00050
3447 0.035779 
0.525041
872 -1.90461 
12712868 MRP63  mitochondrial ribosomal protein 63  
0.00050
4327 0.035779 
0.850918
993 -1.1752 
12850925 
NACA
D NAC alpha domain containing  
0.00050
8742 0.0358703 
0.843198
759 -1.18596 
12842417 
LOC10
029879
3 
 cytochrome P450, family 2, subfamily J, 
polypeptide 2-l 
0.00051
1358 0.0358703 
1.419617
697 1.41962 
12851927 NME2 
 non-metastatic cells 2, protein (NM23B) 
expressed in  
0.00051
1441 0.0358703 
0.842829
209 -1.18648 
12711284 GAS6  growth arrest-specific 6  
0.00051
2288 0.0358703 
1.225511
222 1.22551 
12894461 
CHRN
A2 
 cholinergic receptor, nicotinic, alpha 2 
(neuronal)  
0.00051
2337 0.0358703 
0.635849
177 -1.5727 
    
   
   
1
2
4
 
Table 4.7 (continued)      
12914639   
0.00051
4411 0.0359212 
1.155110
556 1.15511 
12892374 
LOC10
029526
3  uncharacterized LOC100295263  
0.00051
6545 0.0359281 
1.114031
11 1.11403 
12746149 
SLC24
A6  solute carrier family 24 (sodium 
0.00051
7204 0.0359281 
1.179477
562 1.17948 
12860410 
EFCA
B4B  EF-hand calcium binding domain 4B  
0.00052
3419 0.0362076 
1.277811
569 1.27781 
12740926 
DUSP1
0  dual specificity phosphatase 10  
0.00052
7983 0.0362076 
1.221833
679 1.22183 
12857795 
AGAP
2 
 ArfGAP with GTPase domain, ankyrin repeat 
and PH domain 2  
0.00052
8276 0.0362076 
1.240577
812 1.24058 
12771875 
SRCIN
1 SRC kinase signaling inhibitor 1  
0.00052
8292 0.0362076 
1.208958
869 1.20896 
12898982 
MGC1
27538  uncharacterized protein MGC127538  
0.00052
9202 0.0362076 
0.669841
716 -1.49289 
12710496 
DCLK
1  doublecortin-like kinase 1  
0.00052
9371 0.0362076 
0.753698
777 -1.32679 
12765386 
SLC39
A11 
 solute carrier family 39 (metal ion transporter), 
member 11 
0.00053
1096 0.0362327 
0.822882
723 -1.21524 
12723165 
ADCY
8  adenylate cyclase 8 (brain)  
0.00053
4084 0.0363436 
0.791114
205 -1.26404 
12901045 
MAP3
K5 
 mitogen-activated protein kinase kinase kinase 
5  
0.00053
7613 0.0364217 
1.298559
638 1.29856 
    
   
   
1
2
5
 
Table 4.7 (continued)      
12740562 EPRS  glutamyl-prolyl-tRNA synthetase  
0.00053
7963 0.0364217 
0.890749
566 -1.12265 
12822071 MYOF  myoferlin  
0.00054
2297 0.0366068 
1.271674
095 1.27167 
12698500 
CNGA
3  cyclic nucleotide gated channel alpha 3  
0.00054
3441 0.0366068 
0.750632
408 -1.33221 
12710994 
SERT
M1 
 serine-rich and transmembrane domain 
containing 1  
0.00054
8783 0.0367467 
1.646334
436 1.64633 
12822230 
ALDH
18A1  aldehyde dehydrogenase 18 family, member A1  
0.00054
9551 0.0367467 
0.890376
807 -1.12312 
12728517 
LDLR
AD3 
 low density lipoprotein receptor class A domain 
containing 3 
0.00055
2262 0.0367467 
1.193025
573 1.19303 
12850342 TNS3  tensin 3  
0.00055
2327 0.0367467 
1.132020
793 1.13202 
12767297 
ARRB
2  arrestin, beta 2  
0.00055
2406 0.0367467 
1.205350
793 1.20535 
12692077 
RAD51
B  RAD51 homolog B (S. cerevisiae)  
0.00055
7082 0.0368933 
1.175414
098 1.17541 
12811667 
ACTL6
B  actin-like 6B  
0.00055
7477 0.0368933 
0.885206
43 -1.12968 
12784195 
WDFY
1  WD repeat and FYVE domain containing 1  
0.00055
8759 0.0368933 
1.167194
822 1.16719 
12856701 CS  citrate synthase  
0.00056
2572 0.0370533 
0.908694
388 -1.10048 
    
   
   
1
2
6
 
Table 4.7 (continued)      
12695573 
LOC52
7711  spectrin beta chain, erythrocyte-like  
0.00056
9403 0.0374109 
0.835470
746 -1.19693 
12721237 JAG1  jagged 1  
0.00057
1214 0.0374377 
1.236745
183 1.23675 
12699180 CRIM1 
 cysteine rich transmembrane BMP regulator 1 
(chordin-like)  
0.00057
5076 0.0375984 
1.227322
155 1.22732 
12755154   
0.00057
8463 0.037616 
0.816526
496 -1.2247 
12883643 
SLCO4
C1 
 solute carrier organic anion transporter family, 
member 4C1  
0.00057
9234 0.037616 
1.512333
076 1.51233 
12786303   
0.00058
0875 0.037616 
0.866130
82 -1.15456 
12857841 
AMDH
D1  amidohydrolase domain containing 1  
0.00058
0986 0.037616 
1.271539
886 1.27154 
12692448 B2M  beta-2-microglobulin  
0.00058
9776 0.0380545 
1.232003
509 1.232 
12753406 SYT5  synaptotagmin V  
0.00059
0611 0.0380545 
0.881694
264 -1.13418 
12896514 ESR1  estrogen receptor 1  
0.00059
5193 0.0382573 
1.235124
47 1.23512 
12759210 
U2AF1
L4  U2 small nuclear RNA auxiliary factor 1-like 4  
0.00059
8874 0.0383285 
1.111858
527 1.11186 
12879784 
PRELI
D1  PRELI domain containing 1  
0.00059
9175 0.0383285 
0.903481
113 -1.10683 
    
   
   
1
2
7
 
Table 4.7 (continued)      
12788870 
MIR32
9B  microRNA mir-329b  
0.00060
4208 0.0384602 
0.644932
443 -1.55055 
12773652 
LEPRE
L4  leprecan-like 4  
0.00060
462 0.0384602 
0.871528
05 -1.14741 
12899728 PGM3  phosphoglucomutase 3  
0.00060
5559 0.0384602 
0.862887
221 -1.1589 
12875625 
SMIM1
4  small integral membrane protein 14  
0.00061
2085 0.0386216 
0.895070
845 -1.11723 
12846438 UAP1 
 UDP-N-acteylglucosamine pyrophosphorylase 
1  
0.00061
3386 0.0386216 
0.840830
741 -1.1893 
12880280 
BT.349
56  ---  
0.00061
365 0.0386216 
0.816173
29 -1.22523 
12854454 
RAPG
EF5 
 Rap guanine nucleotide exchange factor (GEF) 
5  
0.00061
3892 0.0386216 
1.301354
71 1.30136 
12725367 
GRHL
2  grainyhead-like 2 (Drosophila)  
0.00062
1379 0.0388747 
1.251741
485 1.25174 
12880370 
PCDH
GB4  protocadherin gamma subfamily B, 4  
0.00062
1625 0.0388747 
1.152806
854 1.15281 
12700679 NBAS  neuroblastoma amplified sequence  
0.00062
2945 0.0388747 
0.882005
327 -1.13378 
12675621   
0.00062
4917 0.0388747 
1.576764
794 1.57677 
12696845 
SLC8A
3  solute carrier family 8 (sodium 
0.00062
5201 0.0388747 
0.655849
522 -1.52474 
    
   
   
1
2
8
 
Table 4.7 (continued)      
12807569 
ST8SI
A3 
 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransfe 
0.00062
9731 0.039007 
1.140526
558 1.14053 
12864912 
SHMT
2 
 serine hydroxymethyltransferase 2 
(mitochondrial)  
0.00063
0253 0.039007 
0.837527
952 -1.19399 
12752645 
SLC7A
6 
 solute carrier family 7 (amino acid transporter 
light chain,  
0.00063
368 0.0391193 
0.845437
176 -1.18282 
12686282 
FAM43
A  family with sequence similarity 43, member A  
0.00063
5002 0.0391193 
1.310209
018 1.31021 
12779984 
MIR23
56  microRNA mir-2356  
0.00064
1561 0.0394323 
1.375402
305 1.3754 
12831806 SYTL2  synaptotagmin-like 2  
0.00064
4972 0.0395509 
0.616614
049 -1.62176 
12857257 
SLC25
A3 
 solute carrier family 25 (mitochondrial carrier; 
phosphate carr 
0.00064
8197 0.0395957 
0.912508
669 -1.09588 
12714175 
PRKC
Q  protein kinase C, theta  
0.00064
9741 0.0395957 
0.680804
711 -1.46885 
12834738 
ZBTB4
4  zinc finger and BTB domain containing 44  
0.00065
0209 0.0395957 
1.095670
676 1.09567 
12898481 EYA4  eyes absent homolog 4 (Drosophila)  
0.00065
164 0.0395957 
1.304958
32 1.30496 
12824728 
MIR24
00  microRNA mir-2400  
0.00065
673 0.0397483 
1.079059
449 1.07906 
12683496 ITGB5  integrin, beta 5  
0.00065
7132 0.0397483 
1.246624
763 1.24662 
    
   
   
1
2
9
 
Table 4.7 (continued)      
12709172 
MCF2
L 
 MCF.2 cell line derived transforming sequence-
like  
0.00065
9204 0.0397834 
1.147817
024 1.14782 
12789506 PDE8A  phosphodiesterase 8A  
0.00066
136 0.0398234 
0.855073
579 -1.16949 
12813668 
CALN
1  calneuron 1  
0.00066
3369 0.0398544 
1.292863
265 1.29286 
12874507 NSG1  neuron specific gene family member 1  
0.00066
7118 0.0399896 
1.246686
929 1.24669 
12811457 
DNAS
E1  deoxyribonuclease I  
0.00066
9711 0.040055 
1.104228
089 1.10423 
12765442 YPEL2  yippee-like 2 (Drosophila)  
0.00067
5232 0.0402949 
0.797384
579 -1.2541 
12705319 
CHST1
0  carbohydrate sulfotransferase 10  
0.00067
6835 0.0403004 
0.872965
989 -1.14552 
12906927 
TBC1D
8B 
 TBC1 domain family, member 8B (with 
GRAM domain)  
0.00067
9038 0.0403415 
0.870958
751 -1.14816 
12803392 
SLC39
A7 
 solute carrier family 39 (zinc transporter), 
member 7  
0.00068
3522 0.0405177 
0.878757
788 -1.13797 
12851829 AMPH  amphiphysin  
0.00068
7146 0.0405511 
1.255626
777 1.25563 
12841921 
LOC10
084878
6 
 lipid phosphate phosphatase-related protein 
type 5-like 
0.00068
7415 0.0405511 
1.290663
982 1.29066 
12890580 
CNTR
L  centriolin  
0.00068
8646 0.0405511 
1.162593
327 1.16259 
    
   
   
1
3
0
 
Table 4.7 (continued)      
12859128 C1R  complement component 1, r subcomponent  
0.00069
0455 0.040568 
1.266630
863 1.26663 
12863934 BTG1  B-cell translocation gene 1, anti-proliferative  
0.00069
5771 0.0407905 
1.218942
86 1.21894 
12879860 
RASG
RF2 
 Ras protein-specific guanine nucleotide-
releasing factor 2  
0.00070
411 0.0411889 
1.155657
87 1.15566 
12698459 POMC  proopiomelanocortin  
0.00071
1262 0.0415162 
0.797441
807 -1.25401 
12731200 LGR4 
 leucine-rich repeat containing G protein-
coupled receptor 4  
0.00071
4431 0.0415858 
1.135924
756 1.13593 
12711615 COG6  component of oligomeric golgi complex 6  
0.00071
6027 0.0415858 
0.909173
561 -1.0999 
12845308 
TCTE
X1D1  Tctex1 domain containing 1  
0.00071
7131 0.0415858 
1.402495
039 1.4025 
12884927 PJA2  praja ring finger 2  
0.00072
1913 0.0416887 
0.919438
775 -1.08762 
12750642 
TERF2
IP 
 telomeric repeat binding factor 2, interacting 
protein  
0.00072
2031 0.0416887 
0.845408
586 -1.18286 
12803365   
0.00073
0378 0.0420796 
1.115262
365 1.11526 
12676495   
0.00073
4621 0.0422328 
1.381036
164 1.38104 
12691075 SV2C  synaptic vesicle glycoprotein 2C  
0.00074
0752 0.0424937 
0.453570
278 -2.20473 
    
   
   
1
3
1
 
Table 4.7 (continued)      
12900080 TCP1  t-complex 1  
0.00074
5803 0.0426916 
0.857728
563 -1.16587 
12780180 PKP4  plakophilin 4  
0.00075
7244 0.0431826 
1.084579
877 1.08458 
12715823 
ARMC
4  armadillo repeat containing 4  
0.00075
7617 0.0431826 
1.168029
173 1.16803 
12861001 SOX5  SRY (sex determining region Y)-box 5  
0.00075
9798 0.0432145 
1.193276
128 1.19328 
12746075 RFC5  replication factor C (activator 1) 5, 36.5kDa  
0.00076
2194 0.0432236 
1.077600
141 1.0776 
12801783 
LOC51
2672  major histocompatibility complex, class I  
0.00076
3198 0.0432236 
1.198532
038 1.19853 
12812837 ERCC4 
 excision repair cross-complementing rodent 
repair deficiency,  
0.00076
984 0.0435074 
1.096765
419 1.09677 
12695501 SCG3  secretogranin III  
0.00077
4345 0.0436695 
0.776934
372 -1.28711 
12752141 
MTSS1
L  metastasis suppressor 1-like  
0.00077
7449 0.0437029 
0.815281
639 -1.22657 
12826866 
LRRT
M3  leucine rich repeat transmembrane neuronal 3  
0.00077
9829 0.0437029 
1.573853
88 1.57385 
12782645 PADI6  peptidyl arginine deiminase, type VI  
0.00077
9854 0.0437029 
0.741383
273 -1.34883 
12688919 
LYSM
D2 
 LysM, putative peptidoglycan-binding, domain 
containing 2  
0.00078
5376 0.0437927 
0.785040
273 -1.27382 
    
   
   
1
3
2
 
Table 4.7 (continued)      
12904088 ALG13 
 asparagine-linked glycosylation 13 homolog (S. 
cerevisiae)  
0.00078
7521 0.0437927 
1.221019
111 1.22102 
12840703 
C3H1o
rf111 
 chromosome 3 open reading frame, human 
C1orf111  
0.00078
7783 0.0437927 
0.766618
37 -1.30443 
12792023 FES  feline sarcoma oncogene  
0.00079
0434 0.0437927 
1.212207
903 1.21221 
12722327 TSTA3  tissue specific transplantation antigen P35B  
0.00079
4299 0.0437927 
0.843355
204 -1.18574 
12835758 SV2A  synaptic vesicle glycoprotein 2A  
0.00079
551 0.0437927 
1.194972
988 1.19497 
12723553 
DEPT
OR 
 DEP domain containing MTOR-interacting 
protein  
0.00079
5644 0.0437927 
1.159042
677 1.15904 
12914751   
0.00079
6285 0.0437927 
0.751738
395 -1.33025 
12908846 
GABR
E 
 gamma-aminobutyric acid (GABA) A receptor, 
epsilon  
0.00079
8033 0.0437927 
1.281408
935 1.28141 
12716263 RPN2  ribophorin II  
0.00079
843 0.0437927 
0.885927
921 -1.12876 
12911099   
0.00080
2964 0.0437927 
1.160710
866 1.16071 
12876698 C3  complement component 3  
0.00080
3048 0.0437927 
1.471232
982 1.47123 
12740723 
LOC53
9953  denticleless protein homolog  
0.00080
336 0.0437927 
0.738029
167 -1.35496 
    
   
   
1
3
3
 
Table 4.7 (continued)      
12849407 MEST  mesoderm specific transcript homolog (mouse)  
0.00080
444 0.0437927 
0.843540
169 -1.18548 
12715842 TTPAL  tocopherol (alpha) transfer protein-like  
0.00081
0652 0.0439839 
0.888754
588 -1.12517 
12825112 
WHSC
1L1  Wolf-Hirschhorn syndrome candidate 1-like 1  
0.00081
1249 0.0439839 
1.069198
529 1.0692 
12828947 
JMJD1
C  jumonji domain containing 1C  
0.00081
7653 0.0442412 
1.109875
45 1.10988 
12678271 
TMEM
207  transmembrane protein 207  
0.00083
4653 0.0448318 
0.863490
748 -1.15809 
12902219 
GPRA
SP1 
 G protein-coupled receptor associated sorting 
protein 1  
0.00083
5727 0.0448318 
0.837773
533 -1.19364 
12824828 SFRP1  secreted frizzled-related protein 1  
0.00083
9379 0.0448318 
1.233955
494 1.23395 
12818938 GRK5  G protein-coupled receptor kinase 5  
0.00084
0328 0.0448318 
1.185206
256 1.18521 
12873401 
BMPR
1B  bone morphogenetic protein receptor, type IB  
0.00084
1157 0.0448318 
1.246388
589 1.24639 
12873854 PLAC8  placenta-specific 8  
0.00084
1599 0.0448318 
1.776075
902 1.77608 
12808035 CHST9 
 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 9  
0.00084
1858 0.0448318 
0.825157
399 -1.21189 
12790928 LRFN5 
 leucine rich repeat and fibronectin type III 
domain containing 
0.00084
2015 0.0448318 
1.449519
05 1.44952 
    
   
   
1
3
4
 
Table 4.7 (continued)      
12875951 
C6H4o
rf32 
 chromosome 6 open reading frame, human 
C4orf32  
0.00084
5028 0.0449026 
0.715358
752 -1.3979 
12861802 
PARP1
1 
 poly (ADP-ribose) polymerase family, member 
11  
0.00084
7815 0.0449612 
1.109924
725 1.10992 
12897014 FRK  fyn-related kinase  
0.00084
9767 0.0449753 
1.359885
552 1.35989 
12896683 
BCKD
HB 
 branched chain keto acid dehydrogenase E1, 
beta polypep 
0.00085
525 0.0449922 
0.870246
28 -1.1491 
12786321 ESM1  endothelial cell-specific molecule 1  
0.00085
6092 0.0449922 
0.556195
18 -1.79793 
12824753 PLAT  plasminogen activator, tissue  
0.00085
6745 0.0449922 
1.266149
74 1.26615 
12825144 
PPP1R
3B  protein phosphatase 1, regulatory subunit 3B  
0.00085
6834 0.0449922 
0.775716
956 -1.28913 
12698660 EPAS1  endothelial PAS domain protein 1  
0.00085
9307 0.0450334 
1.238233
684 1.23823 
12842746 
ATP1A
1  ATPase, Na+ 
0.00087
1202 0.0455673 
0.890971
783 -1.12237 
12692159 REEP5  receptor accessory protein 5  
0.00087
3341 0.0455898 
0.932392
239 -1.07251 
12787195 
SLC30
A5 
 solute carrier family 30 (zinc transporter), 
member 5  
0.00087
6799 0.0456334 
0.911294
585 -1.09734 
12915041   
0.00087
7599 0.0456334 
0.763918
597 -1.30904 
    
   
   
1
3
5
 
Table 4.7 (continued)      
12749816 GAS8  growth arrest-specific 8  
0.00089
2365 0.0462828 
1.171628
317 1.17163 
12892286 STOM  stomatin  
0.00089
4615 0.0462828 
1.156473
127 1.15647 
12832646 SRPR 
 signal recognition particle receptor (docking 
protein)  
0.00089
5292 0.0462828 
0.862522
533 -1.15939 
12875956 PLAC8  placenta-specific 8  
0.00089
9949 0.0464335 
1.357144
893 1.35714 
12829383 GNG3 
 guanine nucleotide binding protein (G protein), 
gamma 3  
0.00090
3666 0.0465251 
0.726738
905 -1.37601 
12741898 CPE  carboxypeptidase E  
0.00090
5212 0.0465251 
0.905764
284 -1.10404 
12897969 BAI3  brain-specific angiogenesis inhibitor 3  
0.00090
769 0.0465627 
1.217785
02 1.21778 
12915157   
0.00091
4302 0.046758 
0.823614
68 -1.21416 
12807710 
FAM59
A  family with sequence similarity 59, member A  
0.00091
5002 0.046758 
1.113502
667 1.1135 
12915155   
0.00091
9174 0.0468174 
0.845129
939 -1.18325 
12788800 
MIR54
4A  microRNA mir-544a  
0.00091
9675 0.0468174 
0.616431
601 -1.62224 
12747065 MSI1  musashi homolog 1 (Drosophila)  
0.00092
6472 0.0469521 
1.245961
527 1.24596 
    
   
   
1
3
6
 
Table 4.7 (continued)      
12910177 
MID1I
P1 
 MID1 interacting protein 1 (gastrulation 
specific G12 homolo 
0.00093
1189 0.0469521 
1.144915
374 1.14492 
12830490 
LOC51
2612  histone H2B type 1-like  
0.00093
122 0.0469521 
1.153970
871 1.15397 
12794684 CSPG5 
 chondroitin sulfate proteoglycan 5 (neuroglycan 
C)  
0.00093
1634 0.0469521 
1.378454
752 1.37846 
12787836 PELO  pelota homolog (Drosophila)  
0.00093
2739 0.0469521 
0.887839
266 -1.12633 
12682282 APOD  apolipoprotein D  
0.00093
4393 0.0469521 
1.471865
295 1.47186 
12836105 GNG12 
 guanine nucleotide binding protein (G protein), 
gamma 12  
0.00093
4642 0.0469521 
0.817795
224 -1.2228 
12834462 
PITPN
M1 
 phosphatidylinositol transfer protein, 
membrane-associated 1 
0.00093
8923 0.0470785 
0.827876
249 -1.20791 
12914259   
0.00094
4074 0.0471625 
0.793197
538 -1.26072 
12814004 
TMEM
204  transmembrane protein 204  
0.00094
4133 0.0471625 
1.160667
755 1.16067 
12679678 PLCL2  phospholipase C-like 2  
0.00094
8677 0.0473009 
1.155484
275 1.15548 
12765359 
FAM10
4A  family with sequence similarity 104, member A  
0.00095
2402 0.0473137 
0.900495
272 -1.1105 
12691043 TTLL5  tubulin tyrosine ligase-like family, member 5  
0.00095
2481 0.0473137 
1.133040
48 1.13304 
    
   
   
1
3
7
 
Table 4.7 (continued)      
12839347 WLS  wntless homolog (Drosophila)  
0.00096
0055 0.0476013 
1.161903
058 1.1619 
12761717 MSI2  musashi homolog 2 (Drosophila)  
0.00096
8534 0.0479326 
0.942871
421 -1.06059 
12729022 MADD  MAP-kinase activating death domain  
0.00097
2831 0.0480561 
0.872638
422 -1.14595 
12875914 
ABLI
M2 actin binding LIM protein family member 2  
0.00098
44 0.0485377 
1.292654
362 1.29265 
12700884 
CCDC
85A  coiled-coil domain containing 85A  
0.00099
5188 0.048979 
1.252536
386 1.25254 
    
   
  
1
3
8
 
Table 4.8. List of selected genes involved in prolactin or POMC/ACTH expression expressed by pituitaries collected from 
steers grazing high- (HE, n = 8) or low- (LE, n = 8) endophyte-infected forages. 
Transcript 
ID 
Gene 
Symbol Gene_assignment P-value 
False Discovery 
Rate 
Ratio (HE 
vs. LE) 
Fold-Change 
(HE vs. LE) 
12730735 DRD2 Dopamine receptor D2 5.55E-07 0.00148011 0.569216758 -1.7568 
12804415 PRL Prolactin 6.12E-06 0.00411905 0.814617496 -1.22757 
12785083 PRLR Prolactin receptor 8.86E-05 0.0163351 0.762951095 -1.3107 
12683485 POU1F1 POU class 1 homeobox 1 0.00350045 0.0919041 0.769538585 -1.29948 
12829370 GAL Galanin/GMAP prepropeptide 0.00857877 0.143484 0.745089858 -1.34212 
12896608 VIP Vasoactive intestinal peptide 0.00330761 0.0891485 0.568424044 -1.75925 
12698459 POMC Proopiomelanocortin 0.000711262 0.0415162 0.797441807 -1.25401 
12883237 PCSK1 
Proprotein convertase 
subtilisin/kexin type 1 3.55E-06 0.00326731 0.580548154 -1.72251 
    
   
  
1
3
9
 
Table 4.8 (continued)      
12766978 GH1 Growth Hormone 1 0.72773 0.91774 1.005162515 1.00516 
12842660 TSHB 
Thyroid stimulating hormone 
beta 0.999161 0.999934 1.000078006 1.00008 
12844718 TBX19 T-Box 19 0.104204 0.458935 0.881026219 -1.13504 
12778522 
NEUROD
1 Neuronal differentiation 1 0.177765 0.56633 1.188588599 1.18859 
12883226 NR3C1 
Nuclear receptor subfamily 3 
group C member 1 0.112395 0.473489 1.137451971 1.13745 
12760857 CRHR1 
Corticotropin releasing hormone 
receptor 1 0.106139 0.461876 1.19399706 1.194 
12850526 CRHR2 
Corticotropin releasing hormone 
receptor 2 0.724778 0.916408 1.028423571 1.02842 
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Figure 4.1. Canonical pathway network analysis. The red or green coloring represents 
down- or up-regulation, respectively, whereas no color indicates the molecule was added 
from the Ingenuity Knowledge Base (Ingenuity Pathway, Ingenuity Systems, Inc., 
Redwood City, CA). The intensity of the node color (light to dark) proportionally 
indicates the degree of differential expression. Straight lines represent binding only, 
whereas arrowheads symbolize action-on. A crosshead bar signifies inhibition.  Labels of 
interaction or relationship: A = Activation, CP = Canonical Pathway, E = Expression 
(includes metabolism or synthesis for chemicals), I = Inhibition, LO = Localization. The 
number in parenthesis for each interaction indicates the number of published references 
in the Ingenuity Knowledge Base that support the particular interaction. 
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ACTB: 
GAGCGGGAAATCGTCCGTGACATCAAGGAGAAGCTCTGCTACGTGGCCCTGG
ACTTCGAGCAGGAGATGGCCACCGCGGCCTCCAGCTCCTCCCTGGAGAAGAG
CTACGAGCTTCCTGACGGGCAGGTCATCACCATCGGCAATGAGCGGTTCCGC
TGCCCTGAGGCTCTCTTCCAGCCTTCCTTCCTGGGCATGGAATCCTGCGGCAT
TCACGAAACTACCTTCAATTCCATCATGAAGTGTGACGTCGACATCCGCAAG
GACCTCTACACCAACAC 
PPIA: 
GGCAAGTCCAATTATGGCGAGAAATTTGATGATGAGAATTTCATTTTGAAGC
ATACAGGTCCTGGCATCTTGTCCATGGCAAATGCTGGCCCCAACACAAATGG
TTCCCAGTTTTTCATTTGCACTGCCAAGACTGAGTGGTTGGATGGCAAGCACG
TGGTCTTTGGCAAGGTGAAAGAGGGCATGAATATTGTGGAAGCCATGGAGCG
CTTTGGGTCCAGGAATGGCAAGACCAGCAA 
UBC: 
TAGGGGTGGGTTAGAGTTCAAGGTTTTTGTTCTACCAGATGTTTTAGTAGTAA
TCTGGAGGTAAGAAATGTCAAGAAAACATGGCCTTAATTAGAACTGTAGTGG
GTGAGTATAAATAAAAAATTTGGAGGTTGTAGTTAGAATTCTCCATATGTAC
ACTCATATGTAGATCTACTTATAAGCTACTGATTTTTAAAAGCACACGTTTGG
GAGTTGTGCTTAAGAGTGGGAAAGTTTCTGGAATACCAGCAGGGAGGT 
DRD2: 
CGACCTTTCTCTGGGGCTTTGGGGCTCTGCGGCTGCGGGGCCAGTATCGAGGC
TCGGAGGCCTGGTTTTCACAGGCCATGCCGGAGCTGGTGGTGGGGAGGAGTG
GACAGTCACAGCCACCCAGGGCCCACACCTGAGAAGCCAGAGCTCTGGCCAC
GACCCCAGGCAGTGTCAAGCCTGGGAGACCCGCGTACACCCCAGGTCTGGAT
GGACCCCAGAGAAGCAGAAGCCCAA 
PRL: 
AGAACAAGCCCAACAGACCCACCATGAAGTCCTTATGAGCTTGATTCTTGGG
TTGCTGCGCTCCTGGAATGACCCTCTGTATCACCTAGTCACCGAGGTGCGGGG
TATGAAAGGAGCCCCAGATGCTATCCTATCGAGGGCCATAGAGATTGAGGAA
GAAAACAAACGACTTCTGGAAGGCATGGAGATGATATTTGGCCAGGTTATTC
CGAGCGCCAAAGAGACTGAGCCCTACCCTGTGTGGTCAGGACT 
s-PRLR: 
GCCATCCTTTCTGCTGTCATCTGTTTGATTATGGTCTGGGCAGTGGCTTTGAG
GGCTATAGCATGGTGACCTGCATCCTCCCACCAGTTCCAGGGCCAAAAATAA
AAGGATTTGATGTTCATCTGCTGGAGATATCACAGCCTTCTCGCCT 
l-PRLR: 
CCATCCTTTCTGCTGTCATCTGTTTGATTATGGTCTGGGCAGTGGCTTTGAAG
GGCTATAGCATGGTGACCTGCATCCTCCCACCAGTTCCAGGGCCAAAAATAA
AAGGATTTGATGTTCATCTGCTGGAGAAGGG 
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POU1F1 (Pit-1): 
AAGCAAGAGTGTTGAAGTTTGGTTTGATTTTTCTCTTTGACATGAAAAATAAG
TATCTTGTTTCATCACACTATGAAGAAAAGCAAGGCCAGTGAAAGTGTAGAA
ATAAATTTATTGAGAAGGTAAATAATGAGAGAATAAAATATATAGGGAAAGT
TTCTACACAATGTGGCATAGGTGTGAAGTGGTGAAATGATTCTTTTTAATGTA
TCCAGATTTTTTCCTGCTGTGCTATATACTGTAGTAATTATTCATGAATCATTT
TTACAACCTAATATAAGTGTAGCCAGAGCATTCGCACACACCGTTCTTTCTAG
TGAATAGCAAGCAATTGCTAGATGAACAATTTAATGTGATAAAAATTATCTA
CTTATATTAATGTCAAGGCTGGCTAAAGAGCA 
GAL: 
CACCGGTGAAGGAGAAGAGAGGCTGGACCCTGAACAGCGCTGGGTACCTTCT
CGGACCACATGCGCTCGACAGCCACAGGTCATTTCAAGACAAGCATGGCCTC
GCCGGCAAGCGGGAACTCGAGCCTGAAGACGAAGCCCGGCCAGGAAGCTTT
GACAGACCACTGGCGGAGAACAACGTCGTGCGCACGATAATCGAGTTTCTGA
CTTTCCTGCATCTCAAAGACGCC 
VIP: 
CTGGTTCAGCTGTAAGGGCAAGAGAACTCGTGAAGACTGTCGACTCCCAGGA
CTTCAACACCTGAGACAGCTCTCATAATCTCAACAGAAAGCTCTCAAAGAAC
ACTATTCGGCAAAGTCCTGCAATGGAAACAAGAAGTAAGCCCCAGCTTCTTG
TGTTCCTGACGCTGTTCAGCGTGCTCTTCTCCCAGACCTTGGCGTGGCCTCTTT
TTGGAGCACCTTCGGCTCTGAGGATGGGGGACAGAATACCATTTGAAGGAGC
GAATGAACCTGATCAAGTTTCGTTAAAAGCAGACACTGACATTTTACAAGAT
GCGCTGGCTGA 
POMC: 
AGCTTCCCCCTGACAGAGCCTCAGCCTGCCTGGAAGATGCCGAGACTGTGCA
GCAGTCGTTCGGGCGCCCTGCTGCTGGCCTTGCTGCTTCAGGCCTCCATGGAA
GTGCGTGGTTGGTGCCTGGAGAGCAGCCAGTGTCAGGACCTCACCACGGAAA
GTAACCTGCTGGCGTGCATCCGGGCCTGCAAGCCCGACCTCTCCGCCGAGAC
GCCGGTGTTCCCCGGCAACGGCGACGAGCAGCCGCTGACTGAGAACCCCCGG
AAGTACGTCATGGGCCATTTCCGCTGGGACCGCTTCGGCCGTCGGAATGGTA
GCAG 
PCSK1: 
TGATCGTGTGATATGGGCGGAACAACAGTATGAAAAAGAAAGAAGTAAACG
TTCAGTTCTAAGAGACTCAGCACTAGATCTCTTCAATGATCCGATGTGGAATC
AGCAGTGGTACTTGCAAGATACAAGGATGACTGCAACCCTGCCCAAGCTGGA
TCTCCATGTGATACCTGTTTGGCAAAAAGGCATCACAGGCAAAGGTGTTGTT
ATCACTGTATTGGATGATGGCTTGGAGTGGAATCACACAGACATCTATGCCA
ACTATGATCCGGAGGCC 
GH1: 
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CCCAGCAGAAAANCAGACTGGAGCTGCTTCGCATCTCaCTGCTCCTCATCCAG
TCGTGGCTTGGGCCCCTGCAGTTCCTCAGCAGAGTCTTCACCAACAGCTTGGT
GTTTGGCACCTCGGACCGTGTCTATGAGAAGCTGAAGGACCTGGAGGAAGGC
ATCCTGGCCCTGATGCGGGAGCTGGAAGATGGCACCCCCCGGGCTGGGCAGA
TCCTCAAGCAGACCTATGACAAATTTGACACAAACATGCNCAGTGACGA 
TSHB: 
TTTTTGGCCTTGCATGTGGACAAGCAATGTCTTTTTGTATtCcaACTGAGTATAT
GATGCATGTCGAAAGGAAAGAATGTGCTTACTGCCTAACCATCAACACCACC
GTCTGTGCTGGATATTGTATGACACGGGATGTCAACGGCAAGCTGTTTCTTCC
CAAATATGCCCTGTCTCAGGATGTCTGTACATACAGAGACTTCATGTACAAG
ACTGCAGAAATACCAGGATGCCCACGCCTGGTTACTCCT 
TBX19 (Tpit): 
CCATGCCATGCTGGCAACAAAAGTTCGTTGAGTACCTTCCTTGTGcCCTGACC
CTTACTCTCAAATGATTCTAGAAGGCTGCCCCTCCTGTTCTGTGGACATAGTG
TAAAGCTGGTAAGTGAGCTAAAAATTTACCTAGCCTAAGGCTACTGCATCAT
AACTTTGTACAGTCCTAAAGGTATGTGTAGCCACAGAGCTTCTGCTTTGAGAC
CAAGAGAGGGTGTAAGGCCATGGAGTGAAGTTAACAGAAGTAGAGTTAATT
ACATGTTATAGCACTGAGAATTGAGGAAATGAAATCATGTTGCTCCTTGSTCA
CAAAC 
NEUROD1: 
GGACAGCTCCCCAGTCTTCCACGTCAAGCCGCCGCCTCACGCCTACAGCGCA
GCGCTGGAACCTTTCTTTGAGAGCCCTCTGACTGACTGCACCAGCCCTTCCTT
TGACGGACCCCTCAGCCCGCCGCTCAGCATCAATGGCAACTTCTCTTTCAAAC
ACGAACCGTCCGCCGAGTTTGAGAAAAATTATGCCTTtACCATGCACTaTcCTG
CAGCGACCCTGGCAGGGGCCCAAAGCCMSGGGATCAGTC 
NR3C1 (Glucocorticoid receptor): 
AAAGAGCAGTGGGAGGACAGCACAATTATCTTTGTGCTGGAAGAAATGATTG
TATCATTGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATAGAAAA
TGCCTTCAAGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAGATA
AAAGGAATTCAGCAGGCCACTACGAGGAGTCTCGCANAGAAACATCTGAAA
ATCCTGCTAACAAAACAATAGTTCCTGCAACATTACCACAACTCCCCGACGC
T 
CRHR1: 
NNAGCAAGGNTCACTACCACATCGCTGTCATCATCAACTACCTAGGCCACTG
CATCTCCCTGGCGGCCCTCCTGGTGGCCTTTGTCCTCTTTCTGCGGCTCAGGA
GCATCCGGTGCCTGAGAAACATCATCCACTGGAACCTCATCTCAGCCTTCATC
CTGCGCAATGCCACGTGGTTCGTGGTCCAGCTCACCATGAGCCCCGAAGTCC
ATCAGAGCAACGTGGGCTGGTGCAGGCTGGTGACAGCCGCCTACAACTACTT
CCACGTGACCAACTTCTTCTGGATGTTCGGTGAGGGCTGCTACCTGCACACGG
CCATCGTGCTCACGTCTACCACAGACC 
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CRHR2: 
GCTGGTTTTGGAGGCTGGGGGCTGCCCCTGCACCCCGAGGGTCCCTACTCCTA
CTGCAACACGACCTTGGACCAGATCGGGACGTGCTGGCCCCGGAGCTCGGCC
GGAGCCCTGGTGGAGAGGCCGTGCCCCGAGTACTTCAACGGTGTCAAGTACA
ACACGACCCGGAATGCCTACCGAGAGTGCTTGGAGAATGGGACGTGGGCCTC
GCGGATCAACTACTCACA 
Figure 4.2. The sequences of the real-time RT-PCR products (5’ to 3’ orientation). 
Within a sequence, underlined nucleotides indicate the forward and reverse primer 
positions. 
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Figure 4.3. Principle component analysis of microarray transcriptome analysis of 16 
pituitary samples from steers grazing high- (HE, n = 8, red dots) or low- (LE, n = 8, blue 
dots) endophyte-infected forages. The red and blue dots represent linear combinations of 
the relative expression data, including expression values and variances, of the 26,675 
gene transcripts in each Bovine GeneChip. 
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Figure 4.4. Hierarchical cluster analysis of the 542 “focus” genes selected as 
differentially expressed (ANOVA P-values of < 0.001 and false discovery rates of ≤ 5%) 
by the pituitary of steers grazing high- (HE, n = 8) vs. low- (LE, n = 8) endophyte-
infected forages. As indicated by the legend color box, white color in the middle 
represents the mean value, 0; red color represents gene expression levels above the mean 
expression; and blue color denotes expression below the mean. The intensity of the color 
reflects the relative intensity of the fold change. 
  
   
147 
 
CHAPTER 5. Forms of Selenium in Vitamin-mineral Mixes Differentially Affect the 
Expression of Genes Responsible for Prolactin, ACTH, and α-MSH Synthesis and 
Mitochondrial Dysfunction in Pituitaries of Steers Grazing Endophyte-infected Tall 
Fescue1 
 
5.1 Abstract 
The goal of this study was to test the hypothesis that sodium selenite (inorganic 
Se, ISe), SEL-PLEX (organic forms of Se, OSe), vs. a 1:1 blend (MIX) of ISe and OSe in 
a basal vitamin-mineral (VM) mix would differentially alter pituitary transcriptome 
profiles in growing beef steers grazing an endophyte-infected tall fescue (E+) pasture. 
Predominately Angus steers (BW = 183 ± 34 kg) were randomly selected from fall-
calving cows grazing E+ pasture and consuming VM mixes that contained 35 ppm Se as 
ISe, OSe, or MIX forms. Steers were weaned, depleted of Se for 98 d, and subjected to 
summer-long common grazing of a 10.1 ha E+ pasture containing 0.51 ppm ergot 
alkaloids. Steers were assigned (n = 8 per treatment) to the same Se-form treatments on 
which they were raised. Selenium treatments were administered by daily top-dressing 85 
g of VM mix onto 0.23 kg soyhulls, using in-pasture Calan gates. As previously reported, 
serum prolactin was greater for MIX (52%) and OSe (59%) steers vs. ISe. Pituitaries 
were collected at slaughter and changes in global and selected mRNA expression patterns 
determined by microarray and real-time reverse transcription PCR analyses, respectively. 
The effects of Se treatment on relative gene expression were subjected to one-way 
ANOVA. The form of Se affected the expression of 542 annotated genes (P < 0.005). 
Integrated Pathway Analysis found a canonical pathway network between prolactin and 
pro-opiomelanocortin (POMC)/ACTH/ α-MSH synthesis-related proteins and that 
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mitochondrial dysfunction was a top-affected canonical pathway. Targeted reverse 
transcription-PCR analysis found that the relative abundance of mRNA encoding 
prolactin and POMC/ACTH/ α-MSH synthesis-related proteins was affected (P < 0.05) 
by the form of Se, as were (P ≤ 0.05) mitochondrial dysfunction-related proteins 
(CYB5A, FURIN, GPX4, PSENEN). OSe steers appeared to have a greater prolactin 
synthesis capacity (more PRL mRNA) vs. ISe steers through decreased dopamine type 
two receptor signaling (more DRD2 mRNA), whereas MIX steers had a greater prolactin 
synthesis capacity (more PRL mRNA) and release potential by increasing thyrotropin-
releasing hormone concentrations (less TRH receptor mRNA) than ISe steers. OSe steers 
also had a greater ACTH and α-MSH synthesis potential (more POMC, PCSK2, CPE, 
and PAM mRNA) than ISe steers. We conclude that form of Se in VM mixes altered 
expression of genes responsible for prolactin and POMC/ACTH/α-MSH synthesis, and 
mitochondrial function, in pituitaries of growing beef steers subjected to summer-long 
grazing an E+ pasture.  
 
1Published by Journal of animal science, 97: 631-643. doi: 10.1093/jas/sky438 
 
KEYWORDS: ACTH, cattle, fescue toxicosis, mitochondria, prolactin, selenium 
supplementation 
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5.2 Introduction 
Two simultaneous challenges faced by many south-eastern United States cattle 
producers are fescue toxicosis and Se deficiency. Fescue toxicosis results from 
consumption of ergot alkaloids found in Epichloe coenophialum-infected tall fescue 
(Lolium arundinaceum) pastures and is a clinical condition consisting of impaired 
metabolic, vascular, growth, and reproductive processes in cattle (Strickland et al., 2011). 
Reduced serum prolactin is a recognized marker of fescue toxicosis (Goetsch et al., 1987; 
Davenport et al., 1993). Selenium-poor soils in this same geographic region result in Se-
deficient forages necessitating the need to provide supplemental Se (Dargatz and Ross, 
1996). Inorganic Se (ISe, sodium selenite) is the most common form of Se supplemented 
in cattle diets, whereas organic forms of Se (OSe) derived from specially cultivated 
Saccharomyces cerevisiae also are available and approved for use in beef cattle diets.  
Serendipitously, it was found that expression of several genes downregulated in 
the liver (Liao et al., 2015) and pituitary (Li et al., 2017) of steers grazing high vs. low 
endophyte-infected forages were upregulated in cattle by consumption of a 1:1 blend of 
ISe:OSe (MIX) in vitamin-mineral (VM) mixes (Matthews and Bridges, 2014; Matthews 
et al., 2014). Moreover, it was determined subsequently that steers subjected to summer-
long grazing of endophyte-infected pasture and supplemented (3 mg/d) with MIX or OSe 
forms of Se had greater serum prolactin concentrations than ISe-supplemented steers (Jia 
et al., 2018). The first goal of the present study was to test the specific hypothesis that the 
amount of prolactin mRNA would be greater in the pituitary tissue of the same MIX and 
OSe vs. ISe steers, whereas the second goal was to test the general hypothesis that the 
form of supplemental Se would alter pituitary transcriptome profiles. 
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5.3 Materials and methods 
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. 
5.3.1 Animal model 
The animal management regimen and model for steers that yielded the pituitary 
tissue of the present experiment have been reported (Jia et al., 2018). Briefly, twenty-four 
predominantly Angus beef steers (BW, 182.6 ± 33.9 kg; age, 165.5 ± 14.2 d) were 
randomly selected from three Se phenotypic herds (8 steers/herd), which were managed 
under a typical forage-based (predominately endophyte-infected tall fescue), fall-calving, 
cow-calf production regimen. The three Se phenotypic herds had free access to VM 
premixes (UK Beef IRM Cow-Calf Mineral, Burkmann Feeds, Danville, KY) containing 
35 ppm of inorganic Se (ISe, sodium selenite, Prince Se Concentrate; Prince Agri 
Products, Inc., Quincy, IL, USA), organic Se (OSe, SEL-PLEX, Alltech Inc., 
Nicholasville, KY), and 1:1 mix of ISe:OSe (MIX). After depletion of Se and adaptation 
to consuming VM premixes from in-pasture Calan gate feeders, twenty-four steers with 
three Se phenotypes (n = 8) started (d 0) summer-long grazing of a 10.1-ha 
predominately endophyte-infected tall fescue-mixed pasture (0.51 μg/g total ergot 
alkaloids) (Jia et al., 2018). Three Se form treatments were administered using in-pasture 
Calan gate feeders to steers with the same Se phenotypes. All three Se form treatments 
contained a common basal VM premix that also contained 35 ppm Se as either ISe, OSe, 
or MIX. After the common 86-d grazing period on pastures, steers were slaughtered in 
the University of Kentucky Meat Laboratory (Lexington, KY) over a 26-d period. 
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Throughout the slaughter period, steers continued on their respective Se treatment. 
Details of the slaughter period and process have been reported (Jia et al., 2018). 
5.3.2 Sample collection and RNA preparation 
Steers were stunned by captive bolt pistol and exsanguinated. Within 10 to 12 min 
of death, the whole pituitary was collected from each animal, placed in a foil pack, flash-
frozen in liquid nitrogen, and stored at -80°C. Four pituitary glands (two ISe, one OSe, 
one MIX) were not used in the microarray analysis because of tissue damage incurred 
during the collection process. As a result, six pituitaries for ISe and seven pituitaries for 
both OSe and MIX treatment groups were subjected to RNA analyses. 
Total RNA was extracted from the whole frozen pituitary tissue and its purity and 
integrity determined as described (Li et al., 2017). Extracted RNA samples had an 
average concentration of 706 ng/µl and were of high purity with 260:280 nm absorbance 
ratios ranging from 1.85 to 2.05 and 260:230 nm absorbance ratios ranging from 2.09 to 
2.50. All RNA samples had 28S:18S rRNA absorbance ratios greater than 1.8 and RNA 
integrity numbers greater than 8.9.  
5.3.3 Microarray analysis 
The GeneChip Bovine Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA) 
was used to investigate the effect of Se treatment on bovine pituitary gene expression 
profiles. Microarray analysis was conducted according to the manufacturer’s standard 
protocol at the University of Kentucky Microarray Core Facility as described (Li et al., 
2017), using 3 g of RNA per sample (chip). All the GeneChip transcripts were 
annotated using the NetAffx annotation database for gene expression on Bovine 
GeneChip Array ST 1.0, provided by the manufacturer 
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(http://www.affymetrix.com/analysis/index.affx, last accessed in January 2018, 
annotation file last updated in May 2016). Quality control of the microarray hybridization 
and data presentation was performed by MA plot on all the gene expression values and 
by box plot on the control probe sets on the Affymetrix chips (data not shown). Pearson 
(Linear) Correlation generated the similarity matrix (last accessed in January 2018, PGS 
7.17.0918). The average correlation between any pair of the 20 GeneChips was 0.96 
(Supplementary Figure S1), and all GeneChips were further analyzed. Principal 
component analysis (PCA) was performed to elucidate the quality of the microarray 
hybridization and visualize the general data variation among the chips (Partek, 2009). To 
assess treatment effects (ISe vs. OSe vs. MIX) on the relative expression of the pituitary 
gene transcripts, qualified microarray data were subjected to one-way ANOVA using the 
same PGS software. To achieve a greater degree of confidence (i.e., a more conservative 
approach), transcripts showing treatment effects at the significance level of P < 0.005 
(false discovery rate of ≤ 18.8%) were defined as differentially expressed. These 
differentially expressed genes/gene transcripts (DEG) were subjected to hierarchical 
clustering analysis using PGS software and to canonical, functional, and network 
pathway analyses using the Core Analysis program of Ingenuity Pathway Analysis online 
software (IPA, Build version 470319M, Content version 43605602; 
http://www.ingenuity.com [accessed in March, 2018]; Ingenuity Systems, Inc., Redwood 
City, CA). 
All the microarray *.cel files collected by Command Console plus the GC Robust 
Multichip Averaging-corrected data processed by PGS software of this manuscript have 
been deposited in the National Center for Biotechnology Information’s Gene Expression 
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Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) [released May 25, 2018]), are 
compliant with the minimum information about a microarray experiment (MIAME) 
guidelines (Brazma et al., 2001), and are accessible through GEO series accession 
number GSE114893. 
5.3.4 Real-time reverse transcription (RT)-PCR analysis 
Primer sets for genes selected for real-time RT-PCR analysis (Supplementary 
Table S1) were designed using the NCBI Pick Primers online program against RefSeq 
sequences (accessed March to November 2017), except for s-PRLR and l-PRLR, which 
have been reported (Thompson et al., 2011). Real-time RT-PCR was performed as 
described (Li et al., 2017) using 1 μg of RNA used for each reverse transcription reaction. 
Gene expression was analyzed by the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
The resulting real-time RT-PCR products were purified using a PureLink Quick 
Gel Extraction Kit (Invitrogen) and sequenced at Eurofins Scientific (Eurofins, 
Louisville, KY). Sequences were compared with the corresponding RefSeq mRNA 
sequences used as the templates for primer set design. The sequences of the primers and 
the resulting sequence-validated real-time RT-PCR reaction amplicons for selected DEG 
and the endogenous control genes RPS11, TFRC, and UBC are presented in 
Supplementary Table S1 and Supplementary Figure S2, respectively. All sequenced 
amplicons had at least 98% identity with their template sequences. Three constitutively 
expressed genes (RPS11, TFRC, and UBC) were used and their CT values were not 
affected (P = 0.59, 0.51, 0.66; respectively) by Se-form treatments. Thus, the geometric 
mean expression of RPS11, TFRC, and UBC was used to normalize the relative 
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quantities of the selected DEG mRNA expression, and all RT-PCR reactions were 
conducted in triplicate. 
5.3.5 Statistical analysis 
Steers were the experimental units. To test for Se treatment effects on the relative 
expression of the pituitary gene transcripts, microarray hybridization data were subjected 
to one-way ANOVA using the PGS software as described in the “Microarray Analysis” 
section above. To determine the effects of treatment, the relative expression levels of 
selected DEG analyzed by real-time RT-PCR were subjected to one-way ANOVA using 
the GLM procedure of the SAS statistical software package (version 9.4; SAS Inst., Inc., 
Cary, NC), with the Se treatment as the fixed effect. For these data, significance was 
declared when P ≤ 0.05, and a tendency to differ was declared when 0.10 > P > 0.05. 
When P < 0.10, means were separated using Fisher’s LSD procedure. 
5.4 Results 
5.4.1 Differentially expressed genes 
Principal Component Analysis of all microarray data was performed to examine 
the correlation and variation among the chips, revealing a total variance of 25.53% 
(Supplementary Figure S3). The first principal component (PC #1, x-axis) explained a 
median degree of variance (10%), whereas PC #2 (y-axis) and PC #3 (z-axis) explained 
low degrees of variance (9.1% and 6.43%, respectively). Overall, PCA clearly 
demonstrated that the chips within each treatment group were clustered closely together. 
Individual ANOVA was conducted to identify altered expression of RNA 
transcripts in the pituitary tissue across Se form treatments. At the P < 0.01 level and a 
false discovery rate of < 21.5%, 948 annotated gene transcripts were identified. To refine 
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this analysis, 542 genes with the criteria of a false discovery rate of less than 18.8% and 
P < 0.005 were considered to be differentially expressed (Supplementary Table S2).  
Hierarchical cluster analysis of the 542 DEG revealed all steers segregated within 
their treatment group, except for one ISe steer, which displayed a DEG pattern similar to 
OSe and MIX steer groups (Supplementary Figure S4). 
5.4.2 Pathways and gene network analyses 
To determine the physiological significance of Se treatment-induced DEG 
(Supplementary Table S2), bioinformatic analysis of canonical, functional, and network 
pathway analyses were performed. Canonical pathway analysis (Table 1) revealed (P < 
0.005) that the top six pathways were ephrin receptor signaling (12 genes), Th1 and Th2 
activation pathway (11 genes), Th1 pathway (nine genes), breast cancer regulation by 
stathmin1 (11 genes), ephrin B signaling (six genes), and mitochondrial dysfunction (10 
genes).  
To gain insight into potentially interacting canonical pathways, canonical pathway 
network analysis (Figure 1) revealed one network that included four DEG (CPE, CSHL1, 
TGFB1, TRH) and seven other affected (P < 0.10) genes (DRD2, PCSK1, PCSK2, 
POMC, PRL, VEGFA, TRHR), all of which are related to either prolactin or 
POMC/ACTH/α-MSH synthesis or release. 
5.4.3 Real-time RT-PCR analysis of selected mRNA 
Real-time RT-PCR analysis was used to corroborate the microarray analysis-
identified DEG responsible for prolactin synthesis and secretion and POMC/ACTH 
production in Se treatment steers (Table 2). For the prolactin receptor (PRLR), unlike the 
microarray analysis, the RT-PCR analysis was designed to delineate the long (l-PRLR) 
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and short (s-PRLR) forms. With the exception of VEGFA, the ANOVA P-values for Se 
treatment effect were consistent between the two analytical techniques. For VEGFA, 
microarray analysis indicated that MIX steer expression of VEGFA tended to be greater 
(P =0.093), whereas RT-PCR analysis found no difference (P = 0.250). With regard to 
fold-changes, the direction of Se treatment-induced change was the same between 
microarray and RT-PCR analyses while the magnitude of the determined fold-changes 
typically was greater by RT-PCR analysis (Table 2).  
The relative expression of the nine genes that constituted the Mitochondrial 
Dysfunction pathway was analyzed by RT-PCR to corroborate the microarray analysis 
(Table 3). The trend of the numeric values of the two analyses was consistent for eight of 
nine evaluated genes, and statistically different for five of nine genes. Specifically, both 
analyses revealed that the content of CYB5A, FURIN, GPX4, and PSENEN mRNA was 
greater (P ≤ 0.052), or tended (P = 0.096) to be greater (COX7A2), in OSe vs. ISe steer 
pituitaries. In contrast, the contents of ATP5G1, LRRK2, NDUFA2, and SDHB mRNA 
did not differ (P > 0.130), as assessed by RT-PCR analysis. 
Because it has been reported that mitochondrial dysfunction is highly correlated 
to increased oxidative stress (Prabakaran et al., 2004; Calabrese et al., 2005; Lin and 
Beal, 2006), to evaluate the antioxidant response to oxidative stress, even though they 
were not identified as DEG by microarray analysis (Supplementary Table 2), the content 
of catalase (CAT) and superoxide dismutase 1 (SOD1) mRNA was evaluated by RT-PCR 
(Table 3). The amount of SOD1 in OSe pituitaries was greater (P = 0.018) than in ISe 
steers, whereas the amount of CAT mRNA did not differ (P = 0.138). 
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5.5 Discussion 
5.5.1 Animal model 
The reduction of serum prolactin by cattle consuming endophyte-infected tall 
fescue is a physiologic hallmark of fescue toxicosis. For example, the serum prolactin 
concentrations in growing beef steers subjected to summer-long grazing of high 
endophyte-infected tall fescue were decreased 85 to 90% relative to steers grazing low 
endophyte infected forage (Brown et al., 2009; Jackson et al., 2015). Unlike the well-
described suppression of serum prolactin in cattle consuming ergot alkaloids, the 
potential effect of supplemental Se form on serum prolactin and other indicators of fescue 
toxicosis has not been well-characterized. For reasons (Matthews and Bridges, 2014; 
Matthews et al., 2014) outlined in the Introduction, we conducted a trial comparing the 
potential ability of the form of Se in VM mixes (35 ppm) to ameliorate some of the 
characteristic effects of fescue toxicosis on growing beef steers. The results (Jia et al., 
2018) showed that OSe and MIX steers subjected to grazing of endophyte-infected 
pasture had 59% (P < 0.03) and 52% (P < 0.05) more serum prolactin than ISe steers, 
respectively. Using the pituitaries from the same animals, the overall goal of the present 
study was to determine the effect of the form of supplemental Se in VM mix on 
expression of pituitary targeted mRNA content transcriptome profiles to gain insight into 
mechanisms responsible for Se-form specific concentrations of serum prolactin.  
5.5.2 The content of prolactin mRNA is greater in OSe and MIX steer pituitaries 
The first goal of the present study was to test the specific hypothesis that the 
amount of prolactin mRNA would be greater in the pituitary tissue of the same (Jia et al., 
2018) MIX and OSe vs. ISe steers. As shown in Table 2, the content of prolactin mRNA 
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transcripts did not differ between MIX and ISe steers according to microarray analysis, 
whereas RT-PCR analysis found that MIX had 100% greater content of prolactin mRNA 
than ISe steers. In addition, OSe steers had 18% (microarray analysis) and 250% (RT-
PCR analysis) greater content of prolactin mRNA than ISe steers (Table 2). Thus, we 
accept the original hypothesis that the amount of prolactin mRNA would be greater in the 
pituitary tissue of MIX and OSe vs. ISe steers.  
To gain insight into the mechanisms by which MIX and OSe steers had greater 
amounts of serum prolactin, the second goal of this experiment was to identify candidate 
molecules and signaling pathways in pituitary tissue known to be associated with 
prolactin synthesis (Figure 2) using microarray and RT-PCR transcript analyses (Table 
2).  
5.5.3 OSe form of Se supplementation had greater prolactin synthesis capacity 
Dopamine is one of the most influential regulators of prolactin secretion. 
Activation of the dopamine type two receptor (DRD2) signaling by dopamine suppresses 
prolactin gene (PRL) expression via the inhibition of adenylyl cyclase and prolactin 
exocytosis through modification of several potassium and calcium channels (Fitzgerald 
and Dinan, 2008; Figure 2). Ergot alkaloids contained in endophyte-infected tall fescue 
resemble dopamine and trigger DRD2 signaling (Larson et al., 1999), resulting in 
decreased PRL transcription and serum prolactin concentrations (Strickland et al., 2011). 
In a previous summer-long grazing trial, the abundance of DRD2 mRNA was reduced in 
the pituitaries of steers that had decreased serum PRL as a result of grazing high versus 
low endophyte-infected tall fescue (Li et al., 2017). Consistent with this observation, 
consumption of endophyte-infected fescue seed reduced DRD2 mRNA and density in rat 
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brain (Larson et al., 1994). Moreover, DRD2 mRNA and protein levels were down-
regulated under constitutive hyperdopaminergia (Fauchey et al., 2000). Hence, agonists 
such as dopamine and ergot alkaloids negatively regulate DRD2 mRNA expression. 
Because OSe steers had more serum prolactin (Jia et al., 2018) and a greater pituitary 
content of PRL mRNA (Table 2) than ISe steers, we expected to find a greater pituitary 
DRD2 mRNA content in OSe steers. As expected, OSe steers did have greater pituitary 
DRD2 mRNA content than did ISe steers. Thus, it is possible that the serum prolactin 
difference between OSe and ISe steers (OSe > ISe) was caused by differential activation 
of DRD2 signaling (ISe > OSe) which was derived from different dopamine/ergot 
alkaloids concentrations (ISe > OSe) induced by different Se forms. This possibility also 
is consistent with the observation that consumption of ISe (selenite), but not OSe, 
resulted in increased dopamine concentrations in murine striatum (Tsunoda et al., 2000), 
where DRD2 mRNA is down-regulated by persistent stimulation of DRD2 (Chen et al., 
1993). 
Pituitary transcription factor Pit-1 (encoded by POU1F1) plays a pivotal role in 
PRL expression by binding to specific sites of promoter elements in the PRL gene and 
stimulating expression of prolactin mRNA (Fox et al., 1990). However, Pit-1 mRNA was 
not affected by Se treatment (Table 2, Figure 2). One explanation for the finding of no 
difference of Pit-1 mRNA but greater pituitary PRL mRNA in OSe vs. ISe steers could 
be that although Pit-1 is indispensable for prolactin production, an increase in Pit-1 
mRNA is not necessary to promote PRL gene expression. For example, in estrogen-
treated rats, lactotroph proliferation and enhanced expression of PRL mRNA but not an 
increase in Pit-1 mRNA have been observed (Tsukahara et al., 1994). 
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During DRD2-dependent inhibition of PRL gene expression, rapid histone 
deacetylation of prolactin promoter occurs after activation of DRD2 signaling, followed 
by inhibition of ERK1/2 activity, and an unchanged association between Pit-1 and the 
prolactin promoter (Liu et al., 2005). Hence, a Pit-1-independent, epigenetic mechanism 
of DRD2 signaling also may be responsible for the difference between prolactin mRNA 
expression levels of OSe and ISe steers. 
5.5.4 MIX form increased prolactin synthesis and release potential  
As found for OSe steers, MIX steers had a greater content of pituitary PRL 
mRNA (Table 2) and a greater serum prolactin concentration than ISe throughout the 
grazing period (Jia et al., 2018). However, in contrast to OSe steers, DRD2 mRNA 
content in MIX steers did not differ from ISe steers (Table 2), indicating the mechanisms 
by which both MIX and OSe steers had greater content of prolactin mRNA and serum 
prolactin levels likely differed. We have examined several other genes associated with 
prolactin secretion, and among them is thyrotropin-releasing hormone (TRH) the 
principle prolactin secretagogue, which has been reported to stimulate prolactin 
production in both rat pituitary cells and cow pituitary tissue (Kelly et al., 1973). TRH 
induces prolactin mRNA levels via activation of ERK signaling pathway with synergistic 
increase in intracellular Ca2+ (White and Bancroft, 1983; Kanasaki et al., 2002) (Figure 
2). TRH also was found to induce prolactin release from lactotrophs in a dose-dependent 
manner (Sheward et al., 1983; Lamberts and Macleod, 1990; Freeman et al., 2000). The 
way TRH stimulates prolactin release is via stimulation of Ca2+-dependent exocytosis in 
lactotrophs (Sikdar et al., 1989; Christian et al., 2007). It is known that TRHR mRNA 
expression is negatively regulated by TRH in rat pituitary (Oron et al., 1987; Narayanan 
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et al., 1992). Hence, we tested mRNA expression of TRH receptors (TRHR) which have 
been detected in rat lactotrophs (Hinkle and Tashjian, 1973) (Figure 2). Expression of 
TRHR decreased in MIX vs. ISe steers according to both microarray and real-time RT-
PCR analyses (Table 2). Hence, the greater serum prolactin concentrations of MIX vs. 
ISe steers might be due to greater TRH concentrations available in pituitaries of MIX vs. 
ISe steers, which may have stimulated more prolactin synthesis and release in MIX vs. 
ISe steers. 
Transforming growth factor-β1 (TGFB1) has been shown present in lactotrophs 
and is capable of inhibiting prolactin release and lactotroph proliferation (Minami and 
Sarkar, 1997). Selenite was reported to inhibit the expression of TGFB1 induced by LPS 
(Pei et al., 2010). In agreement with the above study, we found that both OSe and MIX 
steers had more TGFB1 mRNA than ISe steers (Table 2). This finding is contradictive to 
the observation that serum prolactin levels were greater in OSe and MIX vs. ISe steers. 
One explanation to the contradiction is that the low level of TGFB1 expression limited its 
inhibitory potential over prolactin release, as the magnitude of TGFB1 mRNA expression 
appears to be lower than other genes in this network (e.g. 64-fold less than POU1F1 
mRNA based on raw CT value, data not shown). 
As mentioned above, we conducted RT-PCR analysis of several other genes with 
regard to prolactin synthesis and release, including VIP, GAL, GHRHR, VEGFA, and 
CSH2 based on IPA network analysis (Figure 1) and a previous study (Li et al., 2017). 
We also evaluated PRLR mRNA expression of both short-form and long form. However, 
neither microarray nor RT-PCR showed mRNA expression of these genes above affected 
by Se treatment. 
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Besides synthesis and release, metabolic clearance of prolactin may contribute to 
the differences in serum prolactin concentrations. That is, the kidney has been reported to 
metabolize two-thirds of circulating prolactin (Emmanouel et al., 1981). Hence, future 
studies need to examine potential Se treatment-induced differences in prolactin clearance 
using the same steer model. 
5.5.5 OSe form of Se supplementation increased POMC/ACTH/α-MSH synthesis 
potential 
Pro-opiomelanocortin (POMC) is a precursor polypeptide encoded by gene 
POMC and is synthesized mainly by corticotrophs of the anterior pituitary. 
Adrenocorticotropic hormone and alpha-melanocyte-stimulating hormone (α-MSH) are 
two important hormones derived from POMC and secreted by the anterior pituitary and 
intermediate lobe of the pituitary, respectively (Figure 3). Adrenocorticotropic hormone 
induces the adrenal cortex to secrete glucocorticoids (Schwyzer, 1977), whereas α-MSH 
affects feeding behavior, energy homeostasis, and inflammation (Gantz and Fong, 2003). 
Previous research found that the liver tissue of beef steers grazing high vs. low 
endophyte-infected tall fescue and consuming ad libitum amounts of ISe-containing VM 
mix had increased amounts of mitochondrial mass, capacity for ATP synthesis, and 
amino acid-derived gluconeogenesis (Brown et al., 2009; Liao et al., 2015). These 
processes may have been coordinated through the glucocorticoid receptor-mediated 
pathway (Liao et al., 2015). A subsequent gene expression study of the pituitaries from 
these same steers (Li et al., 2017) found that the potential for pituitary POMC/ACTH 
synthesis was reduced in steers consuming forage with the high amounts of endophyte-
infected tall fescue. This understanding, plus the finding that selenite inhibited 
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glucocorticoid receptor hormone binding (Tashima et al., 1989), led to the general 
hypothesis of the present study that the form of supplemental Se would differentially 
affect mRNA content of pituitary genes related to POMC/ACTH synthesis in steers 
grazing endophyte-infected tall fescue. 
In pituitary corticotrophs, proprotein convertase 1 (encoded by the PCSK1 gene) 
is expressed and cleaves POMC, producing ACTH1-39, β-endorphin, β-lipotrophin, 
amino-terminal peptide, and joining peptide (Millington, 2007). That the abundance of 
both POMC and PCSK1 mRNA was increased in pituitaries of OSe vs. ISe steers (Table 
2) indicates that OSe steers possessed a greater POMC/ACTH synthesis capacity in OSe 
steers. To complete the assessment of Se treatment effects on the POMC/ACTH/α-MSH 
synthesis pathway (Figures 1 and 3) the expression of PCSK2, CPE, and PAM was 
evaluated (Table 2). Collectively, the results indicate that OSe steers possess greater 
POMC, ACTH, and α-MSH synthesis potential than ISe steers, and a greater α-MSH 
synthesis potential than MIX steers. As for prolactin, the exact physiological 
consequences of Se form-altered expression of ACTH and α-MSH remains to be 
determined. 
5.5.6 Functional analysis of the genes involved in mitochondrial dysfunction and 
antioxidant defense 
As noted above, gene expression profiling indicated that the liver of steers grazing 
high vs. low endophyte-infected tall fescue and consuming ISe as a Se source had 
increased mitochondrial mass and respiratory chain mediated ATP synthetic capacity 
(Liao et al., 2015). The role that Se plays in preserving mitochondrial function is 
controversial. Whereas Se induces apoptosis associated with ROS accumulation and 
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mitochondrial dysfunction (Guan et al., 2009), and selenite is detrimental to 
mitochondrial membrane potential by induction of mitochondrial permeability transition 
through thiol-oxidation (Kim et al., 2002), Se also is known to attenuate apoptosis (of at 
least damaged spinal cord tissue) through protection of mitochondrial function (Yeo et 
al., 2008) and shows a protective effect on cadmium-induced apoptosis in mice kidney 
(Wang et al., 2013). Because canonical pathway analysis of pituitary DEG identified 
“mitochondrial dysfunction” as one of the top pathways affected by Se treatment (Table 
1), expression of DEG involved in mitochondrial dysfunction pathways was further 
examined by RT-PCR analysis, along with two genes (SOD1 and CAT) encoding key 
antioxidant enzymes. 
Although microarray analysis showed that OSe steers expressed more NDUFA2, 
COX7A2, SDHB, and ATP5G1 mRNA content than ISe steers, RT-PCR analysis (Table 
3) corroborated increased expression of NDUFA2 and COX7A2. Collectively, these data 
indicate that ISe had a reduced electron transport chain capacity than OSe steers, thereby 
likely less ATP generation and more damaging ROS in mitochondria (Bosetti et al., 
2002; Musatov and Robinson, 2012; Saito et al., 2016;). In terms of mitigating oxidative 
stress, genes involved with control of ROS production (LRRK2, CYB5A, PSNENEN) 
and antioxidant production and use (FURIN, CAT, SOD1, GPx4) were evaluated. OSe 
pituitaries expressed greater levels of SOD1, GPx4, and PSENEN than ISe steers and 
CYB5A and FURIN than ISe and MIX steers. Collectively, these findings strongly 
indicate that the pituitaries of OSe steers had a greater capacity to manage oxidative 
stress vs. ISe steers (Mates et al., 1999; Zangar et al., 2004; Heo et al., 2010). 
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In summary, consumption of 3 mg Se/d in VM mixes as OSe, MIX, or ISe 
differentially affected the expression of genes responsible for the synthesis or release of 
prolactin and POMC/ACTH/α-MSH, and for mitochondrial function, in the pituitaries of 
growing beef steers grazing an endophyte-infected tall fescue pasture. Consumption of 
OSe resulted in a greater prolactin synthesis capacity, whereas consumption of MIX 
resulted in increased prolactin synthesis and release potential, both of which resulted in 
greater serum prolactin concentrations in OSe and MIX steers vs. ISe steers, respectively. 
In addition, consumption of OSe resulted in greater POMC/ACTH/α-MSH synthesis 
potential than consumption of ISe and MIX forms of Se, and a better capacity to manage 
against mitochondrial dysfunction and oxidative stress, than consumption of ISe. The 
implications from these findings are that the inclusion of an organic form of Se in free-
choice vitamin-mineral mixes can partially ameliorate the negative impact of fescue 
toxicosis on growing beef steers by restoration of both prolactin and POMC/ACTH 
synthesis capacities. In addition, because the role of prolactin is best understood in 
regulating lactation (Lamberts and Macleod, 1990; Freeman et al., 2000), it may be of 
especial commercial importance to evaluate the potential effect of MIX and OSe forms of 
Se in VM mixes to ameliorate the negative effects of grazing endophyte-infected tall 
fescue in lactating/sucking cow/calf pairs. 
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Table 5.1. Top six IPA-identified canonical pathways of genes differentially expressed by 
pituitary tissue of steers grazing endophyte-infected tall fescue and supplemented with 3 
mg Se/d in vitamin-mineral mixes as either sodium selenite (ISe), SEL-PLEX (OSe), or a 
1:1 mix of ISe and OSe (MIX). 
Canonical 
Pathway 
Number
1 
Gene Symbol Ratio2 
-log (P-
value) 
Ephrin 
Receptor 
Signaling 
12 ROCK2,EPHB6,ITGA3,SDC2,RACK
1,LIMK2,EFNB3,STAT3,RAP1A,EP
HA2,GRINA,LIMK1 
0.068 3.57 
Th1 and Th2 
Activation 
Pathway 
11 PSENEN,TGFB1,IL1RL1,LTA,IL6R,
mir-
155,VAV1,IL27RA,STAT3,IFNAR1,IL
18R1 
0.060 2.83 
Th1 Pathway 9 PSENEN,LTA,IL6R,mir-
155,VAV1,IL27RA,STAT3,IFNAR1,IL
18R1 
0.066 2.74 
Breast Cancer 
Regulation by 
Stathmin1 
11 ROCK2,TUBB4B,PPP2R3A,PPP1R1
4D,PRKCD,RACK1,ARHGEF1,LIM
K2,ARHGEF3,PPP1CA,LIMK1 
0.053 2.43 
Ephrin B 
Signaling 
6 ROCK2,EPHB6,RACK1,VAV1,EFNB
3,LIMK1 
0.080 2.38 
Mitochondria
l Dysfunction 
10 FURIN,SDHB,ATP5G1,PSENEN,CO
X7A2,LRRK2,CYB5A,GPX4,NDUFA
B1,NDUFA2 
0.053 2.29 
1The number of genes (listed in the “Symbol” column) associated with the particular 
canonical pathway. 
2The ratio is calculated as the number of genes in a given pathway that meet cutoff 
criteria (e.g., the ANOVA P-value for the differential expression among Se groups is less 
than 0.005) divided by the total number of genes that make up that pathway. 
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Table 5.2. Comparison of microarray- and real-time RT-PCR (RT-PCR)-determined 
relative expression of prolactin and POMC/ACTH synthesis related genes in pituitary 
tissue of steers grazing endophyte-infected tall fescue and supplemented with 3 mg Se/d 
in vitamin-mineral mixes as either sodium selenite (ISe), SEL-PLEX (OSe), or a 1:1 mix 
of ISe and OSe (MIX). 
Gene Gene Name 
Microarray1 RT-PCR2 
Treatment3,4 P-
value 
Treatment3,4 P-
value ISe MIX OSe ISe MIX OSe 
Item 
Prolactin Synthesis 
Related Genes 
        
DRD2 
Dopamine 
receptor D2 
1.00a 1.15ab 1.27b 0.027 1.13a 1.64ab 2.48b 0.039 
POU1F
1 
POU class 1 
homeobox 1 
1.00 1.06 1.05 0.530 1.02 1.11 0.87 0.277 
PRL Prolactin 1.00a 1.12ab 1.18b 0.022 1.02a 2.08b 3.67b 0.007 
TRHR Thyrotropin 
releasing 
hormone 
receptor 
1.00a 0.76b 0.83ab 0.045 1.00a 0.71b 
0.81a
b 
0.039 
VIP 
Vasoactive 
intestinal 
peptide 
1.00 1.64 1.43 0.331 1.21 1.74 2.31 0.311 
GAL 
Galanin/GM
AP 
prepropeptid
e 
1.00 1.03 1.00 0.821 1.32 2.10 2.35 0.182 
VEGF
A 
Vascular 
endothelial 
growth 
factor A 
1.00a 1.15b 1.05ab 0.093 1.01 1.18 1.03 0.250 
TGFB1 Transformin
g growth 
factor beta 1 
1.00a 1.46b 1.30b 0.001 1.02a 1.78b 2.06c 0.005 
GHRH
R 
Growth 
Hormone 
Releasing 
Hormone 
Receptor 
1.00 0.93 1.00 0.532 1.01 1.07 1.29 0.166 
CSH2 
 
Chorionic 
Somatomam  
1.00 1.09 0.97 0.173 1.10 0.74 0.87 0.279 
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Table 5.2 (continued) 
 motropin 
Hormone 2 
PRLR 
Prolactin 
receptor 
1.00 1.13 1.23 0.141 NA NA NA NA 
L-
PRLR 
Prolactin 
receptor 
long isoform 
NA NA NA NA 1.01 0.95 1.17 0.376 
S-
PRLR 
Prolactin 
receptor 
short 
isoform 
NA NA NA NA 1.01 1.01 1.09 0.761 
POMC/ACTH/α-MSH Synthesis Related Gene 
POMC 
Proopiomela
nocortin 
1.00a 1.10ab 1.23b 0.045 1.14a 1.91a 4.06b 0.002 
PCSK1 
Proprotein 
convertase 
subtilisin/ke
xin type 1 
1.00a 1.09ab 1.44b 0.059 1.03a 1.48ab 1.68b 0.076 
PCSK2 Proprotein 
convertase 
subtilisin/ke
xin type 2 
1.00a 1.13ab 1.33b 0.074 1.03a 1.14ab 1.41b 0.048 
CPE Carboxypept
idase E 
1.00a 0.98a 1.04b 0.002 1.01a 1.01a 1.31b 0.003 
PAM Peptidylglyc
ine alpha-
amidating 
monooxyge
nase 
1.00a 1.04a 1.29b 0.044 1.06a 1.28a 1.96b 0.008 
1The abundance of gene transcripts are reported relative to the mean expression of the ISe 
treatment group and are expressed as fold-change of the untransformed intensity value.  
2The abundance of gene transcripts are reported relative to the geometric mean 
expression of the reference genes. 
3Values are least squares means (n = 6 for ISe, n = 7 for OSe and MIX) 
4Means within a row that lack a common letter differ (P < 0.05).  
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Table 5.3. Comparison of microarray and real-time RT-PCR (RT-PCR) identification of 
mitochondrial dysfunction related genes by pituitary tissue of steers grazing endophyte-
infected tall fescue and supplemented with 3 mg Se/d in vitamin-mineral mixes as either 
sodium selenite (ISe), SEL-PLEX (OSe), or a 1:1 mix of ISe and OSe (MIX). 
Gene Gene Name 
Microarray1 RT-PCR2 
Treatment3,4 P-
valu
e 
Treatment3,4 P-
valu
e 
ISe 
MI
X 
OSe ISe MIX OSe 
Item 
Mitochondrial Dysfunction Related Genes 
ATP5G1 
ATP Synthase, 
H+ Transporting, 
Mitochondrial Fo 
Complex Subunit 
C1 (Subunit 9) 
1.00
a 
1.22
b 
1.26
b 
0.00
4 
1.04 1.24 1.31 
0.26
6 
COX7A
2 
Cytochrome C 
Oxidase Subunit 
7A2 
1.00
a 
1.05
a 
1.24
b 
0.00
1 
1.00
a 
1.20a
b 
1.29
b 
0.09
6 
CYB5A 
Cytochrome B5 
Type A 
1.00
a 
1.00
a 
1.13
b 
0.00
2 
1.02
a 
1.02a 
1.27
b 
0.02
4 
FURIN 
Paired Basic 
Amino Acid 
Cleaving Enzyme 
1.00
a 
1.04
a 
1.12
b 
0.00
2 
1.04
a 
1.33a 
1.81
b 
0.01
1 
GPX4 
Glutathione 
peroxidase 4 
1.00
a 
1.21
b 
1.23
b 
0.00
4 
1.03
a 
1.32a
b 
1.56
b 
0.05
2 
LRRK2 
Leucine Rich 
Repeat Kinase 2 
1.00
a 
0.88
b 
0.79
c 
0.00
1 
1.00 0.88 0.85 
0.13
0 
NDUFA
2 
NADH:Ubiquino
ne 
Oxidoreductase 
Subunit A2 
1.00
a 
1.18
b 
1.16
b 
0.00
3 
1.01 1.16 1.23 
0.14
2 
PSENE
N 
Presenilin 
Enhancer 
Gamma-Secretase 
Subunit 
1.00
a 
1.13
b 
1.24
c 
0.00
1 
1.01
a 
1.17a
b 
1.32
b 
0.03
2 
SDHB 
Succinate 
Dehydrogenase 
Complex Iron 
Sulfur Subunit B 
1.00
a 
1.03
a 
1.12
b 
0.00
3 
1.23 1.71 1.46 
0.57
3 
Antioxidant Enzyme-encoding Genes 
CAT Catalase 1.00 1.00 1.04 
0.12
7 
1.02 1.05 1.24 
0.13
8 
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Table 5.3 (continued)         
SOD1 
Superoxide 
Dismutase 1 
1.00 1.06 1.04 
0.11
5 
1.05
a 
1.35a
b 
1.80
b 
0.01
8 
1The abundance of gene transcripts are reported relative to the mean expression of the ISe 
treatment group and are expressed as fold-change of the untransformed intensity value. 
2The abundance of gene transcripts are reported relative to the geometric mean 
expression of the reference genes. 
3Values are least squares means (n = 6 for ISe, n = 7 for OSe and MIX) 
4Means within a row that lack a common letter differ (P < 0.05).
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Table 5.4. Primer sets used for quantitative real-time RT-PCR analysis of the selected differentially expressed genes and 
reference genes. 
Gene Gene Name 
Template Accession 
number1 
Oligonucleotide Primer Design (5’ to 3’ 
direction) 
Amplicon length 
(bp) 
Product 
identity 
(%)2 
RPS11 
Ribosomal 
protein S11 
NM_001024568.2 
F: AAGATGGCGGACATTCAGAC 
R: GCCCTCGAATGGAGACATTA 
214 99% 
TFRC 
Transferrin 
Receptor 
NM_001206577.1 
F: CCAGGTTTAGTCTGGCTCGG 
R: GGTCTGCCCAGAATATGCGA 
339 99% 
UBC Ubiquitin C NM_001206307.1 
F: TAGGGGTGGGTTAGAGTTCAAG 
R: ACCACCTCCCTGCTGGTATT 
258 100% 
DRD2 
Dopamine 
receptor D2 
NM_174043.2 
F: CGACCTTTCTCTGGGGCTTT 
R: TTGGGCTTCTGCTTCTCTGG 
234 100% 
POU1F1 
POU class 1 
homeobox 1 
NM_174579 
F: AGCTGTGCATGGCTCTGAAT 
R: AGGCTTGTCTTCACCCGTTT 
354 100% 
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Table 5.4 (continued) 
PRL Prolactin NM_173953.2 
F: AGAACAAGCCCAACAGACCC 
R: AGTCCTGACCACACAGGGTA 
252 99% 
TRHR 
Thyrotropin 
releasing 
hormone 
receptor 
M_174203.1   
F: GCGATCTGTCACCCCATCAA 
R: ATCCGTAGAGGACAGTGGCT 
262 100% 
VIP 
Vasoactive 
intestinal 
peptide 
NM_173970.3 
F: CTGGTTCAGCTGTAAGGGCA 
R: TCAGCCAGCGCATCTTGTAA 
325 100% 
GAL 
Galanin/GM
AP 
prepropepti
de 
NM_173914.2 
F: CACCGGTGAAGGAGAAGAGAG 
R: GGCGTCTTTGAGATGCAGGAA 
230 100% 
VEGFA 
Vascular 
endothelial 
growth 
factor A 
NM_174216.2 
F: GCAAGAAAATCCCTGTGGGC 
R: CGTCTGGTTCCCGAAACCCT 
210 100% 
TGFB1 
Transformin
g growth 
factor beta 1 
NM_001166068.1 
F: GCGGCCAGATTTTGTCCAAG 
R: GCTGTGCGAGCTAGACTTCA 
242 98% 
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Table 5.4 (continued) 
GHRHR 
Growth 
Hormone 
Releasing 
Hormone 
Receptor 
NM_181020.3 
F: CTGTAACAGTCCTGTGTAAGGT 
R: GTCTTCGAAGGCCAACTTGC 
218 100% 
CSH2 
Chorionic 
Somatomam
motropin 
Hormone 2 
NM_181007.2 
F: CCCCATGCTAAGCCCACAAT 
R:TTTCTCTCAGAGGTAGGGATGG
A 
243 100% 
L-PRLR 
Prolactin 
receptor 
long 
isoform 
NM_001039726.2 
F: GCCATCCTTTCTGCTGTCAT 
R: CCCTTCTCCAGCAGATGAAC 
136 100% 
S-PRLR 
Prolactin 
receptor 
short 
isoform 
NM_174155.3 
F: GCCATCCTTTCTGCTGTCAT 
R: AAGGCGAGAAGGCTGTGATA 
151 99% 
POMC 
Proopiomel
anocortin 
NM_174151.1 
F: AGCTTCCCCGTGACAGAGC 
R: CTGCTACCATTCCGACGGC 
317 99% 
PCSK1 
Proprotein 
convertase 
subtilisin/ke
xin type 1 
NM_174412.2 
F: TGATCGTGTGATATGGGCGG 
R: GGCCTCCGGATCATAGTTGG 
277 99% 
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Table 5.4 (continued) 
PCSK2 
Proprotein 
convertase 
subtilisin/ke
xin type 2 
NM_174413.3 
F: TGGTTTTTGCATCTGCTGAG 
R: CCTCTTTACCCTGGGGTCTC 
233 97% 
CPE 
Carboxypep
tidase E 
NM_173903.4 
F: GCTTAGCTCGGGCATACTCA 
R: CACAGAGAGGGTGGCGTTAG 
347 99% 
PAM 
Peptidylglyc
ine alpha-
amidating 
monooxyge
nase 
NM_173948.2 
F: ACCAACACCGTGTGGAAGTT 
R: GTTCAGAATCTCCAAAGGCCC 
301 99% 
ATP5G
1 
ATP 
Synthase, 
H+ 
Transportin
g, 
Mitochondri
al Fo 
Complex 
Subunit C1 
(Subunit 9) 
NM_176649.3 
F: CACCGGGGCACTACTCATTT 
R: AAGAGCCCCATAGCCTCAGA 
363 99% 
COX7A
2 
Cytochrome 
C Oxidase 
Subunit 7A2 
NM_175807.1 
F: ACTGAGCCAAGATGCTACGG 
R: ACCCAACTGATTGCTGGGAG 
295 99% 
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Table 5.4 (continued) 
CYB5A 
Cytochrome 
B5 Type A 
NM_174033.3 
F: AAGACTGCTTTGGTCCAGGG 
R: GACAGCTCAGCATGGTGGTA 
263 99% 
FURIN 
Paired Basic 
Amino Acid 
Cleaving 
Enzyme 
NM_174136 
F: GCATCGAGAAGAACCACCCA 
R: CTCCACGGCATCTGTCACTT 
245 100% 
GPX4 
Glutathione 
peroxidase 4 
NM_174770.3 
F: GATCAAAGAGTTCGCCGCTG 
R: CCATACCGCTTCACCACACA 
198 100% 
LRRK2 
Leucine 
Rich Repeat 
Kinase 2 
NM_001206086.2 
F: AGGAATCCGATGCTTTGGCA 
R: ACTGCAATGCTGGGTCTTGA 
300 99% 
NDUFA
2 
Oxidoreduct
ase Subunit 
A2 
NM_175815.2 
F: CGTATCCATTTGTGCCAGCG 
R: ACGTTCTCCAGGGCTCTAGT 
224 100% 
PSENE
N 
Presenilin 
Enhancer 
Gamma-
Secretase 
Subunit 
NM_001008669.1 
F: GCGTGGTTGTTTGTGATCCT 
R: TTGATTTGGCTCTGCTCCGT 
251 100% 
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Table 5.4 (continued) 
SDHB 
Succinate 
Dehydrogen
ase 
Complex 
Iron Sulfur 
Subunit B 
NM_001040483.1 
F: AGAGACGACTTCACGGAGGA 
R: CTGAAGGAACTCAGGGGTGA 
238 99% 
CAT Catalase NM_001035386.2 
F: CTATCCTGACACTCACCGCC 
R: GAAAGTCCGCACCTGAGTGA 
268 99% 
SOD1 
Superoxide 
Dismutase 1 
NM_174615.2 
F: TTGGAGACCTGGGCAATGTG 
R: TTACACCACAGGCCAAACGG 
204 99% 
1The contents in the parentheses associated with each gene symbol are the accession numbers of the sequences retrieved from 
the NCBI RefSeq database and used as templates for designing primers and probes.   
2All the real-time RT-PCR products were validated by sequencing. The identity values (%) presented are the base-pair ratios 
between the number of identical base pairs and the total amplicon length. 
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Table 5.5. DEG list (P < 0.005, 542 annotated genes), expressed by pituitaries collected from steers grazing endophyte-
infected tall fescue and supplemented with 3 mg Se/d in vitamin-mineral mixes as either sodium selenite (ISe), SEL-PLEX 
(OSe), or a 1:1 mix of ISe and OSe (MIX). 
Dietary Se treatment 
Transcript ID Gene Symbol Gene Description ISe OSe MIX SEM P-value 
12815073 ABCC6 ATP-binding cassette, sub-
family C (CFTR 
1.00 a -1.10 b -1.19 c 0.024 0.003072 
12812150 ABHD11 abhydrolase domain 
containing 11 
1.00 a 1.31 b 1.20 c 0.036 0.000158 
12763396 ABR active BCR-related gene 1.00 a 1.12 b 1.09 b 0.023 0.002440 
12681108 ACAD11 acyl-CoA dehydrogenase 
family, member 11 
1.00 a -1.13 b -1.09 b 0.021 0.000701 
12843399 ACADM acyl-CoA dehydrogenase, C-
4 to C-12 straight chain 
1.00 a -1.13 b -1.03 a 0.021 0.001467 
12714006 ACOT8 acyl-CoA thioesterase 8 1.00 a 1.19 b 1.08 c 0.032 0.003085 
12860803 ACSS3 acyl-CoA synthetase short-
chain family member 3 
1.00 a -1.17 b -1.09 c 0.027 0.003610 
12811304 ACTB actin, beta 1.00 a 1.06 b 1.13 c 0.021 0.002141 
12703348 ACTR1B ARP1 actin-related protein 1 
homolog B, centractin beta 
(yeas 
1.00 a 1.12 b 1.04 a 0.018 0.000423 
12700297 ADAM17 ADAM metallopeptidase 
domain 17 
1.00 a -1.20 b -1.11 c 0.029 0.003166 
12819148 ADD3 adducin 3 (gamma) 1.00 a -1.19 b -1.13 b 0.026 0.000332 
12714706 ADIG adipogenin 1.00 a -1.00 a -1.16 b 0.029 0.004786 
12823127 AFAP1L2 actin filament associated 
protein 1-like 2 
1.00 a -1.05 a -1.14 b 0.015 0.001903 
12816222 AGFG2 ArfGAP with FG repeats 2 1.00 a 1.10 b 1.03 a 0.018 0.003134 
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Table 5.5 (continued)          
12785796 AGXT2 alanine--glyoxylate 
aminotransferase 2 
1.00 a 1.34 b -1.00 a 0.052 0.003621 
12701187 AHSA2 AHA1, activator of heat 
shock 90kDa protein ATPase 
homolog 2 ( 
1.00 a -1.06 a 1.22 b 0.028 0.004122 
12839104 AMIGO1 adhesion molecule with Ig-
like domain 1 
1.00 a 1.11 b -1.06 a 0.033 0.003137 
12681779 AMOTL2 angiomotin like 2 1.00 a 1.18 b -1.03 a 0.035 0.001440 
12770437 AMZ2 archaelysin family 
metallopeptidase 2 
1.00 a 1.21 b 1.15 b 0.031 0.000537 
12758448 ANKRD11 ankyrin repeat domain 11 1.00 a -1.12 b 1.06 a 0.031 0.003210 
12693457 APEX1 APEX nuclease 
(multifunctional DNA repair 
enzyme) 1 
1.00 a 1.19 b 1.16 b 0.033 0.004432 
12729444 API5 apoptosis inhibitor 5 1.00 a -1.09 b 1.04 a 0.021 0.002289 
12699389 APLF aprataxin and PNKP like 
factor 
1.00 a -1.25 b -1.17 b 0.033 0.001334 
12842977 APOA1BP apolipoprotein A-I binding 
protein 
1.00 a 1.14 b 1.19 b 0.028 0.001339 
12757598 APRT adenine 
phosphoribosyltransferase 
1.00 a 1.20 b 1.09 c 0.033 0.002713 
12696328 AQR aquarius homolog (mouse) 1.00 a -1.07 b 1.01 a 0.016 0.004085 
12712642 ARGLU1 arginine and glutamate rich 1 1.00 a -1.13 b -1.08 c 0.013 0.000477 
12731455 ARHGAP42 Rho GTPase activating 
protein 42 
1.00 a -1.12 b 1.02 a 0.023 0.002245 
12757115 ARHGEF1 Rho guanine nucleotide 
exchange factor (GEF) 1 
1.00 a 1.15 b 1.12 b 0.026 0.004440 
12797402 ARHGEF3 Rho guanine nucleotide 
exchange factor (GEF) 3 
1.00 a -1.25 b -1.18 b 0.025 0.000387 
12878680 ARID3A AT rich interactive domain 
3A (BRIGHT-like) 
1.00 a 1.19 b 1.34 c 0.042 0.002240 
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Table 5.5 (continued)          
12680069 ARL13B ADP-ribosylation factor-like 
13B 
1.00 a -1.15 b -1.07 c 0.024 0.001274 
12818542 ARL6IP1 ADP-ribosylation factor-like 
6 interacting protein 1 
1.00 a -1.18 b -1.05 a 0.025 0.000310 
12798781 ARL6IP5 ADP-ribosylation-like factor 
6 interacting protein 5 
1.00 a 1.09 b 1.00 a 0.016 0.001479 
12872066 ARL9 ADP-ribosylation factor-like 
9 
1.00 a 1.33 b 1.44 b 0.069 0.004465 
12730790 ARRB1 arrestin, beta 1 1.00 a 1.18 b 1.09 c 0.032 0.003087 
12885849 ARRDC2 arrestin domain containing 2 1.00 a -1.31 b -1.15 c 0.051 0.002569 
12793470 ARRDC4 arrestin domain containing 4 1.00 a -1.31 b -1.17 c 0.041 0.000442 
12857545 ART4 ADP-ribosyltransferase 4 
(Dombrock blood group) 
1.00 a -1.26 b -1.36 b 0.056 0.003082 
12861962 ASCL1 achaete-scute complex 
homolog 1 (Drosophila) 
1.00 a 1.38 b 1.25 b 0.051 0.000848 
12854099 ASNS asparagine synthetase 
(glutamine-hydrolyzing) 
1.00 a 1.21 b 1.15 c 0.021 0.000033 
12810391 ASXL3 additional sex combs like 3 
(Drosophila) 
1.00 a 1.03 a 1.18 b 0.022 0.000595 
12871836 ATP10D ATPase, class V, type 10D 1.00 a 1.28 b 1.22 b 0.042 0.001896 
12909023 ATP11C ATPase, class VI, type 11C 1.00 a -1.24 b -1.06 a 0.042 0.003799 
12880589 ATP13A1 ATPase type 13A1 1.00 a 1.15 b 1.18 b 0.031 0.002721 
12749501 ATP1A3 ATPase, Na+ 1.00 a 1.15 b 1.07 c 0.025 0.002322 
12767689 ATP5G1 ATP synthase, H+ 
transporting, mitochondrial 
Fo complex, subunit 
1.00 a 1.26 b 1.22 b 0.051 0.003783 
12761235 ATP6V0A1 ATPase, H+ transporting, 
lysosomal V0 subunit a1 
1.00 a 1.09 b 1.02 a 0.017 0.003025 
12848186 ATP8B2 ATPase, class I, type 8B, 
member 2 
1.00 a 1.22 b 1.18 b 0.034 0.000823 
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Table 5.5 (continued)          
12862844 ATXN7L3B ataxin 7-like 3B 1.00 a 1.11 b 1.10 b 0.024 0.003916 
12700080 B3GNT2 UDP-GlcNAc:betaGal beta-
1,3-N-
acetylglucosaminyltransferas
e 2 
1.00 a -1.33 b -1.21 b 0.051 0.001367 
12892724 B4GALT1 UDP-Gal:betaGlcNAc beta 
1,4- galactosyltransferase, 
polypeptide 
1.00 a 1.15 b 1.19 b 0.030 0.001027 
12805572 BAK1 BCL2-antagonist 1.00 a 1.13 b 1.15 b 0.028 0.003007 
12751423 BANP BTG3 associated nuclear 
protein 
1.00 a -1.34 b -1.01 a 0.050 0.001295 
12801533 BAT3 HLA-B associated transcript 
3 
1.00 a 1.18 b 1.16 b 0.037 0.004401 
12858722 BAZ2A bromodomain adjacent to 
zinc finger domain, 2A 
1.00 a 1.03 a 1.21 b 0.021 0.000476 
12718315 BCAS1 breast carcinoma amplified 
sequence 1 
1.00 a -1.16 b -1.22 b 0.034 0.002844 
12837242 BCAS2 breast carcinoma amplified 
sequence 2 
1.00 a -1.03 a 1.05 b 0.018 0.004750 
12790583 BDKRB1 bradykinin receptor B1 1.00 a -1.35 b -1.14 c 0.043 0.002912 
12798575 BHLHE40 basic helix-loop-helix family, 
member e40 
1.00 a 1.52 b 1.43 b 0.043 0.000044 
12801465 BMP5 bone morphogenetic protein 5 1.00 a -1.31 b -1.38 b 0.067 0.004115 
12873825 BOD1L biorientation of chromosomes 
in cell division 1-like 
1.00 a -1.12 b 1.01 a 0.020 0.000800 
12813925 BOLA2B bolA homolog 2B (E. coli) 1.00 a 1.19 b 1.14 b 0.029 0.003782 
12754924 BOSTAUV1R43
0 
vomeronasal 1 receptor 
bosTauV1R430 
1.00 a 1.34 b 1.04 a 0.042 0.003031 
12754921 BOSTAUV1R43
1 
vomeronasal 1 receptor 
bosTauV1R431 
1.00 a 1.44 b 1.02 a 0.058 0.001756 
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Table 5.5 (continued) 
12714979 BTBD3 BTB (POZ) domain 
containing 3 
1.00 a -1.22 b -1.13 b 0.032 0.001981 
12694170 C10H14orf37 chromosome 14 open reading 
frame 37 ortholog 
1.00 a 1.02 a -1.15 b 0.020 0.001281 
12698893 C11H2orf56 protein midA homolog, 
mitochondrial 
1.00 a -1.15 b -1.12 b 0.026 0.001585 
12741467 C16H1orf156 chromosome 1 open reading 
frame 156 ortholog 
1.00 a -1.12 b 1.01 a 0.028 0.004246 
12740403 C16H1ORF55 chromosome 1 open reading 
frame 55 ortholog 
1.00 a -1.19 b -1.02 a 0.025 0.000270 
12828575 C1orf124 zinc finger RAD18 domain-
containing protein C1orf124 
homolo 
1.00 a -1.15 b -1.02 a 0.018 0.000467 
12806978 C23H6orf130 chromosome 6 open reading 
frame 130 ortholog 
1.00 a -1.17 b -1.09 c 0.028 0.003790 
12781409 C2H1orf144 chromosome 1 open reading 
frame 144 ortholog 
1.00 a 1.13 b 1.17 b 0.027 0.001946 
12776233 CAB39 calcium binding protein 39 1.00 a -1.13 b -1.02 a 0.022 0.000792 
12846417 CAPZA1 capping protein (actin 
filament) muscle Z-line, 
alpha 1 
1.00 a -1.04 a 1.08 b 0.020 0.001444 
12753658 CBFB core-binding factor, beta 
subunit 
1.00 a -1.16 b 1.04 a 0.035 0.000799 
12868256 CCDC53 coiled-coil domain containing 
53 
1.00 a -1.23 b -1.15 b 0.036 0.002356 
12860511 CCDC77 coiled-coil domain containing 
77 
1.00 a -1.21 b -1.17 b 0.027 0.004501 
12767023 CCL2 chemokine (C-C motif) 
ligand 2 
1.00 a 1.88 b 1.73 b 0.098 0.000670 
12774476 CCL20 chemokine (C-C motif) 
ligand 20 
1.00 a -1.08 a -1.34 b 0.045 0.000806 
12870891 CCNG2 cyclin G2 1.00 a -1.24 b -1.21 b 0.023 0.000890 
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Table 5.5 (continued)          
12857478 CD63 CD63 molecule 1.00 a 1.16 b 1.15 b 0.025 0.000494 
12841117 CDC42SE1 CDC42 small effector 1 1.00 a 1.14 b 1.28 c 0.049 0.003235 
12808806 CDH19 cadherin 19, type 2 1.00 a -2.34 b -1.49 c 0.142 0.002230 
12683809 CDV3 CDV3 homolog (mouse) 1.00 a -1.01 a 1.09 b 0.022 0.002642 
12884966 CDX1 caudal type homeobox 1 1.00 a 1.12 b -1.08 a 0.038 0.004126 
12698371 CEL carboxyl ester lipase (bile 
salt-stimulated lipase) 
1.00 a 1.12 b -1.10 c 0.038 0.002547 
12741130 CENPL centromere protein L 1.00 a -1.12 b 1.07 a 0.037 0.004458 
12690629 CGRRF1 cell growth regulator with 
ring finger domain 1 
1.00 a -1.08 b 1.11 c 0.027 0.001127 
12723011 CHD7 chromodomain helicase DNA 
binding protein 7 
1.00 a -1.02 a 1.12 b 0.020 0.002943 
12791729 CHRNA7 cholinergic receptor, 
nicotinic, alpha 7 
1.00 a 1.25 b 1.07 a 0.039 0.002142 
12705319 CHST10 carbohydrate sulfotransferase 
10 
1.00 a 1.16 b 1.17 b 0.034 0.002818 
12681827 CLRN1 clarin 1 1.00 a 1.32 b 1.18 c 0.038 0.000486 
12694413 CMTM5 CKLF-like MARVEL 
transmembrane domain 
containing 5 
1.00 a -1.04 a -1.20 b 0.031 0.001544 
12758174 CNOT3 CCR4-NOT transcription 
complex, subunit 3 
1.00 a 1.16 b 1.13 b 0.031 0.003299 
12858172 CNPY2 canopy 2 homolog (zebrafish) 1.00 a 1.23 b 1.22 b 0.044 0.004584 
12740915 CNST consortin, connexin sorting 
protein 
1.00 a -1.23 b 1.00 a 0.038 0.000705 
12895030 CNTFR ciliary neurotrophic factor 
receptor 
1.00 a 1.22 b 1.14 b 0.036 0.004783 
12894487 CNTLN centlein, centrosomal protein 1.00 a -1.25 b -1.11 c 0.039 0.003100 
12908781 COL4A6 collagen, type IV, alpha 6 1.00 a -1.24 b -1.19 b 0.044 0.004031 
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Table 5.5 (continued)          
12864037 COPZ1 coatomer protein complex, 
subunit zeta 1 
1.00 a 1.16 b 1.13 b 0.027 0.002766 
12867761 COQ10A coenzyme Q10 homolog A 
(S. cerevisiae) 
1.00 a 1.19 b 1.20 b 0.035 0.001360 
12742723 CORO1C coronin, actin binding 
protein, 1C 
1.00 a -1.23 b -1.06 a 0.026 0.000245 
12756789 COX4NB COX4 neighbor 1.00 a 1.19 b 1.26 b 0.031 0.000128 
12899530 COX7A2 cytochrome c oxidase subunit 
VIIa polypeptide 2 (liver) 
1.00 a 1.24 b 1.05 a 0.031 0.000448 
12741898 CPE carboxypeptidase E 1.00 a 1.04 b -1.02 a 0.012 0.002100 
12678420 CPNE4 copine IV 1.00 a -1.23 b -1.25 b 0.048 0.002398 
12798341 CRELD1 cysteine-rich with EGF-like 
domains 1 
1.00 a 1.19 b 1.28 b 0.050 0.003031 
12780237 CRYGB crystallin, gamma B 1.00 a 1.30 b 1.14 c 0.044 0.004510 
12807461 CYB5A CYB5 protein 1.00 a 1.13 b 1.00 a 0.022 0.001616 
12755641 CYBA cytochrome b-245, alpha 
polypeptide 
1.00 a 1.29 b 1.05 a 0.045 0.001481 
12696721 DCP2 DCP2 decapping enzyme 
homolog (S. cerevisiae) 
1.00 a -1.14 b 1.01 a 0.024 0.000526 
12860523 DCTN2 dynactin 2 (p50) 1.00 a 1.13 b 1.06 c 0.024 0.003064 
12826569 DDIT4 DNA-damage-inducible 
transcript 4 
1.00 a -1.41 b -1.14 a 0.065 0.003211 
12806211 DDR1 discoidin domain receptor 
tyrosine kinase 1 
1.00 a 1.20 b 1.04 a 0.039 0.004325 
12728696 DDX10 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 10 
1.00 a -1.15 b -1.02 a 0.021 0.001767 
12861406 DDX23 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 23 
1.00 a -1.03 a 1.14 b 0.034 0.003180 
12793017 DDX24 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 24 
1.00 a 1.09 b 1.14 c 0.018 0.000124 
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Table 5.5 (continued)          
12721139 DEFB122 beta-defensin 122 1.00 a 1.24 b -1.05 a 0.040 0.002239 
12730301 DENND5A DENN 1.00 a -1.02 a 1.10 b 0.024 0.004598 
12719581 DHTKD1 dehydrogenase E1 and 
transketolase domain 
containing 1 
1.00 a -1.08 b 1.01 a 0.012 0.000218 
12880985 DNAJB1 DnaJ (Hsp40) homolog, 
subfamily B, member 1 
1.00 a -1.21 b 1.04 a 0.037 0.002945 
12813289 DOC2A double C2-like domains, 
alpha 
1.00 a -1.03 a -1.43 b 0.068 0.001517 
12706234 DPM2 dolichyl-phosphate 
mannosyltransferase 
polypeptide 2, regulator 
1.00 a 1.23 b 1.21 b 0.042 0.003130 
12683999 DSCR3 Down syndrome critical 
region protein 3 
1.00 a 1.27 b 1.29 b 0.047 0.002664 
12810528 DTNA dystrobrevin, alpha 1.00 a -1.17 b -1.11 b 0.030 0.002934 
12844671 DUSP23 dual specificity phosphatase 
23 
1.00 a 1.12 b 1.08 b 0.022 0.004302 
12765609 EFNB3 ephrin-B3 1.00 a 1.02 a -1.18 b 0.022 0.000204 
12753121 EGLN2 egl nine homolog 2 (C. 
elegans) 
1.00 a 1.08 b 1.07 b 0.015 0.002486 
12761624 EIF4A1 eukaryotic translation 
initiation factor 4A1 
1.00 a 1.16 b 1.27 b 0.045 0.004284 
12777883 EIF4G3 eukaryotic translation 
initiation factor 4 gamma, 3 
1.00 a -1.07 b 1.03 a 0.013 0.000365 
12887939 ELAVL1 ELAV (embryonic lethal, 
abnormal vision, Drosophila)-
like 1 ( 
1.00 a 1.03 a 1.13 b 0.018 0.000510 
12910733 ELK1 ELK1, member of ETS 
oncogene family 
1.00 a 1.15 b 1.15 b 0.024 0.000991 
12740756 ELK4 ELK4, ETS-domain protein 
(SRF accessory protein 1) 
1.00 a -1.08 b 1.09 c 0.030 0.001377 
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Table 5.5 (continued)          
12894451 ENTPD4 ectonucleoside triphosphate 
diphosphohydrolase 4 
1.00 a 1.20 b 1.17 b 0.027 0.000244 
12783685 EPC2 enhancer of polycomb 
homolog 2 (Drosophila) 
1.00 a -1.18 b -1.14 b 0.020 0.000161 
12776360 EPHA2 EPH receptor A2 1.00 a 1.20 b 1.20 b 0.042 0.004164 
12850821 EPHB6 EPH receptor B6 1.00 a 1.30 b 1.16 c 0.041 0.001008 
12796560 ERC2 ELKS 1.00 a -1.24 b -1.21 b 0.042 0.001783 
12789922 ERICH1 glutamate-rich 1 1.00 a -1.23 b 1.07 a 0.040 0.003205 
12735710 ERRFI1 ERBB receptor feedback 
inhibitor 1 
1.00 a -1.39 b -1.17 c 0.054 0.001031 
12835715 F3 coagulation factor III 
(thromboplastin, tissue factor) 
1.00 a -1.45 b -1.03 a 0.074 0.003769 
12858708 FAIM2 Fas apoptotic inhibitory 
molecule 2 
1.00 a 1.15 b 1.27 c 0.037 0.001604 
12905719 FAM127A family with sequence 
similarity 127, member A 
1.00 a 1.14 b 1.17 b 0.024 0.001104 
12904144 FAM50A family with sequence 
similarity 50, member A 
1.00 a 1.16 b 1.17 b 0.032 0.002315 
12855431 FERD3L Fer3-like (Drosophila) 1.00 a 1.18 b -1.00 a 0.028 0.003052 
12866953 FGFR1OP2 FGFR1 oncogene partner 2 1.00 a -1.20 b -1.01 a 0.030 0.000464 
12771502 FOXK2 forkhead box K2 1.00 a 1.09 b 1.12 b 0.019 0.001962 
12791616 FURIN furin (paired basic amino acid 
cleaving enzyme) 
1.00 a 1.12 b 1.04 a 0.021 0.001610 
12761345 G6PC3 glucose 6 phosphatase, 
catalytic, 3 
1.00 a 1.13 b 1.09 b 0.017 0.004554 
12767655 GABARAP GABA(A) receptor-
associated protein 
1.00 a 1.08 b 1.08 b 0.017 0.002289 
12893958 GABBR2 gamma-aminobutyric acid 
(GABA) B receptor, 2 
1.00 a -1.19 b 1.04 a 0.036 0.003717 
           
   
 
 
1
8
6
 
Table 5.5 (continued) 
12834169 GAL3ST3 galactose-3-O-
sulfotransferase 3 
1.00 a 1.24 b 1.17 b 0.034 0.003248 
12889125 GCNT1 glucosaminyl (N-acetyl) 
transferase 1, core 2 
1.00 a -1.38 b -1.18 c 0.041 0.000080 
12708565 GEN1 Gen homolog 1, 
endonuclease (Drosophila) 
1.00 a -1.24 b -1.21 b 0.046 0.004141 
12885268 GLT25D1 glycosyltransferase 25 
domain containing 1 
1.00 a 1.05 a 1.18 b 0.023 0.000582 
12738803 GLTPD1 glycolipid transfer protein 
domain containing 1 
1.00 a 1.21 b 1.17 b 0.029 0.000196 
12883393 GNB2L1 guanine nucleotide binding 
protein (G protein), beta po 
1.00 a 1.17 b 1.05 a 0.021 0.001275 
12802708 GNL1 guanine nucleotide binding 
protein-like 1 
1.00 a 1.17 b 1.32 c 0.047 0.002236 
12803164 GNMT glycine N-methyltransferase 1.00 a 1.28 b 1.22 b 0.043 0.000946 
12755952 GOT2 glutamic-oxaloacetic 
transaminase 2, mitochondrial 
(aspartate amin 
1.00 a 1.11 b 1.13 b 0.027 0.003948 
12877228 GPX4 glutathione peroxidase 4 
(phospholipid 
hydroperoxidase) 
1.00 a 1.23 b 1.21 b 0.046 0.003630 
12873015 GRID2 glutamate receptor, 
ionotropic, delta 2 
1.00 a -1.38 b -1.37 b 0.047 0.000396 
12724789 GRINA glutamate receptor, 
ionotropic, N-methyl D-
aspartate-associate 
1.00 a 1.18 b 1.18 b 0.036 0.002192 
12825077 GTF2E2 general transcription factor 
IIE, polypeptide 2, beta 
34kDa 
1.00 a -1.10 b 1.02 a 0.020 0.001706 
12816165 GTF3C1 general transcription factor 
IIIC, polypeptide 1, alpha 
220kD 
1.00 a 1.16 b 1.13 b 0.025 0.003275 
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Table 5.5 (continued)          
12703161 GTF3C5 general transcription factor 
IIIC, polypeptide 5, 63kDa 
1.00 a 1.13 b 1.16 b 0.028 0.001932 
12862551 GXYLT1 glucoside xylosyltransferase 
1 
1.00 a -1.18 b -1.06 a 0.031 0.003297 
12812382 HBA hemoglobin, alpha 2 1.00 a -1.02 a -1.21 b 0.028 0.003829 
12780512 HDAC1 histone deacetylase 1 1.00 a 1.09 b 1.09 b 0.018 0.001750 
12753593 HERPUD1 homocysteine-inducible, 
endoplasmic reticulum stress-
inducib 
1.00 a 1.12 b 1.19 b 0.021 0.000777 
12881065 HIST3H2A histone cluster 3, H2a 1.00 a -1.47 b -1.34 b 0.052 0.000539 
12714795 HM13 histocompatibility (minor) 13 1.00 a 1.25 b 1.19 b 0.047 0.003844 
12859274 HMOX1 heme oxygenase (decycling) 
1 
1.00 a 1.24 b 1.21 b 0.038 0.002913 
12707032 HNRPLL heterogeneous nuclear 
ribonucleoprotein L-like 
1.00 a -1.12 b -1.03 a 0.021 0.002408 
12848151 HOOK1 hook homolog 1 (Drosophila) 1.00 a -1.22 b -1.12 c 0.032 0.000791 
12724458 HSF1 heat shock transcription 
factor 1 
1.00 a 1.16 b 1.13 b 0.029 0.002434 
12900016 HSF2 heat shock transcription 
factor 2 
1.00 a -1.29 b -1.14 c 0.043 0.001935 
12793338 IFI27L2 family with sequence 
similarity 14, member A 
1.00 a 1.35 b 1.34 b 0.038 0.000062 
12683438 IFNAR1 interferon (alpha, beta and 
omega) receptor 1 
1.00 a -1.06 b 1.06 c 0.014 0.000244 
12698826 IL18R1 interleukin 18 receptor 1 1.00 a -1.29 b -1.17 b 0.044 0.004298 
12700517 IL1RL1 interleukin 1 receptor-like 1 1.00 a -1.68 b -1.11 a 0.088 0.000887 
12885382 IL27RA interleukin 27 receptor, alpha 1.00 a 1.15 b 1.20 b 0.027 0.001254 
12843689 IL6R interleukin 6 receptor 1.00 a -1.27 b -1.10 c 0.028 0.001777 
12699444 IMMT inner membrane protein, 
mitochondrial 
1.00 a 1.12 b 1.15 b 0.024 0.001104 
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Table 5.5 (continued)          
12850129 ING3 inhibitor of growth family, 
member 3 
1.00 a -1.11 b -1.04 a 0.021 0.004107 
12757444 IRF3 interferon regulatory factor 3 1.00 a 1.20 b 1.19 b 0.032 0.000674 
12691723 ISCA2 iron-sulfur cluster assembly 2 
homolog (S. cerevisiae) 
1.00 a -1.16 b 1.02 a 0.033 0.002982 
12768879 ITGA3 integrin, alpha 3 (antigen 
CD49C, alpha 3 subunit of 
VLA-3 recepto 
1.00 a 1.09 a 1.24 b 0.032 0.002297 
12894663 KANK1 KN motif and ankyrin repeat 
domains 1 
1.00 a -1.17 b -1.05 a 0.029 0.002600 
12826028 KCNK1 potassium channel, subfamily 
K, member 1 
1.00 a 1.33 b 1.42 b 0.073 0.004316 
12890299 KIAA0020 KIAA0020 1.00 a 1.02 a 1.20 b 0.030 0.002070 
12893285 KIAA1539 btKIAA1539 1.00 a 1.13 b 1.13 b 0.023 0.002496 
12687612 KLHL33 kelch-like 33 (Drosophila) 1.00 a 1.17 b -1.06 a 0.047 0.003897 
12699829 KLRAQ1 KLRAQ motif containing 1 1.00 a -1.15 b -1.06 c 0.025 0.001191 
12840822 KRTCAP2 keratinocyte associated 
protein 2 
1.00 a 1.25 b 1.19 b 0.042 0.004089 
12872678 LAP3 leucine aminopeptidase 3 1.00 a -1.06 a 1.14 b 0.027 0.000199 
12791099 LASS3 LAG1 homolog, ceramide 
synthase 3 
1.00 a -1.19 b -1.19 b 0.024 0.000248 
12817910 LIMK1 LIM domain kinase 1 1.00 a 1.17 b 1.11 b 0.025 0.001312 
12742621 LIMK2 LIM domain kinase 2 1.00 a 1.23 b 1.31 b 0.041 0.002188 
12731643 LIN7C lin-7 homolog C (C. elegans) 1.00 a -1.16 b -1.05 a 0.028 0.004324 
12842993 LMNA lamin A 1.00 a 1.15 b 1.23 b 0.041 0.003505 
12733478 LMO2 LIM domain only 2 
(rhombotin-like 1) 
1.00 a 1.17 b 1.00 a 0.030 0.001104 
12709937 LNX2 ligand of numb-protein X 2 1.00 a 1.03 a 1.18 b 0.025 0.001035 
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Table 5.5 (continued) 
12876135 LOC100124511 hypothetical protein 
LOC100124511 
1.00 a -1.15 b -1.10 b 0.019 0.001463 
12902720 LOC100125231 melanoma antigen family D, 
4-like 
1.00 a 1.20 b 1.17 b 0.037 0.004444 
12682890 LOC100139345 similar to mCG67939 1.00 a -1.16 b -1.02 a 0.033 0.003398 
12766595 LOC100139452 similar to Ras-related protein 
Rab-37 
1.00 a 1.08 a -1.16 b 0.046 0.004560 
12842284 LOC100139518 hypothetical protein 
LOC100139518 
1.00 a 1.09 a -1.13 b 0.039 0.004535 
12692887 LOC100140532 similar to novel ankyrin 
repeat domain containing 
prote 
1.00 a 1.03 a -1.16 b 0.038 0.004864 
12811041 LOC100297063 hypothetical protein 
LOC100297063 
1.00 a 1.26 b 1.06 a 0.028 0.000464 
12693130 LOC100298870 hypothetical protein 
LOC100298870 
1.00 a 1.15 a -1.40 b 0.091 0.002192 
12856434 LOC100300099 hypothetical LOC100300099 1.00 a 1.05 a -1.15 b 0.038 0.004210 
12829208 LOC100300295 hypothetical protein 
LOC100300295 
1.00 a -1.09 b 1.07 a 0.024 0.004601 
12755419 LOC100300479 similar to zinc finger protein 
347 
1.00 a -1.33 b -1.08 a 0.040 0.003708 
12902540 LOC100302527 hypothetical protein 
LOC100302527 
1.00 a 1.22 b -1.13 a 0.048 0.001531 
12713427 LOC100335935 hypothetical protein 
LOC100335935 
1.00 a -1.42 b -1.54 b 0.093 0.003451 
12774061 LOC100336279 hypothetical protein 
LOC100336279 
1.00 a 1.08 b 1.19 c 0.024 0.002733 
12906652 LOC100336560 Wiskott-Aldrich syndrome 
protein-like 
1.00 a 1.12 b -1.12 c 0.035 0.002516 
12902777 LOC100337433 SRY-box containing gene 3-
like 
1.00 a 1.11 b -1.04 a 0.030 0.003986 
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Table 5.5 (continued)          
12849524 LOC504276 similar to purine-rich element 
binding protein B 
1.00 a -1.15 b -1.02 a 0.022 0.002575 
12761528 LOC504773 regakine 1 1.00 a 1.39 b 1.37 b 0.066 0.003907 
12884493 LOC509184 transmembrane emp24 
protein transport domain 
contain 
1.00 a 1.20 b 1.12 c 0.026 0.000422 
12735389 LOC510860 C4b-binding protein alpha-
like 
1.00 a 1.32 b 1.71 c 0.081 0.000751 
12705756 LOC514980 similar to Epididymal-
specific lipocalin-9 precursor 
1.00 a 1.03 a -1.13 b 0.023 0.001007 
12735655 LOC515150 similar to C4b-binding 
protein alpha chain precursor 
(C4bp) ( 
1.00 a 1.12 a 1.32 b 0.053 0.004827 
12822330 LOC518801 similar to CG17687 
CG17687-PA 
1.00 a -1.67 b -1.42 b 0.083 0.000545 
12892254 LOC521877 ADAM metallopeptidase 
domain 21 
1.00 a -1.16 b -1.23 b 0.033 0.001347 
12879658 LOC522449 hypothetical LOC522449 1.00 a -1.20 b -1.08 a 0.032 0.003881 
12685045 LOC522736 similar to aryl hydrocarbon 
receptor 2 
1.00 a 1.19 b 1.02 a 0.033 0.002377 
12850554 LOC523019 similar to Sp4 transcription 
factor 
1.00 a -1.17 b -1.15 b 0.019 0.000531 
12689874 LOC523056 similar to BCL2-like 10 
(apoptosis facilitator) 
1.00 a -1.26 b -1.30 b 0.038 0.003795 
12900759 LOC529052 similar to F55A4.8a 1.00 a -1.19 b -1.21 b 0.037 0.004408 
12710062 LOC532698 hypothetical protein 
LOC532698 
1.00 a -1.12 b -1.04 a 0.025 0.004882 
12686282 LOC539374 similar to Family with 
sequence similarity 43, 
membe 
1.00 a -1.25 b -1.24 b 0.054 0.004346 
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Table 5.5 (continued) 
12826933 LOC540046 similar to Protein GCAP14 
homolog 
1.00 a -1.07 b -1.04 c 0.014 0.002327 
12700376 LOC540073 TER94-like 1.00 a -1.14 b -1.05 a 0.019 0.002229 
12803402 LOC540812 hypothetical LOC540812 1.00 a -1.30 b -1.15 c 0.042 0.000947 
12828800 LOC540918 hypothetical protein 
LOC540918 
1.00 a -1.30 b -1.16 c 0.034 0.000172 
12834845 LOC613830 similar to C11orf61 protein 1.00 a -1.11 b -1.04 a 0.017 0.001919 
12707896 LOC614219 similar to ribosomal protein 
S23 
1.00 a -1.01 a -1.28 b 0.032 0.002266 
12823043 LOC614416 similar to Chondroitin sulfate 
proteoglycan 5 (neuroglycan 
1.00 a -1.27 b 1.02 a 0.031 0.000371 
12905745 LOC616201 hypothetical protein 1.00 a -1.23 b -1.08 a 0.029 0.002123 
12737570 LOC617545 similar to hCG19301 1.00 a -1.11 b -1.17 b 0.031 0.004218 
12910436 LOC781486 similar to melanoma antigen 
family B, 2 
1.00 a 1.05 a -1.17 b 0.028 0.000853 
12759762 LOC783144 similar to RPL13 protein-like 1.00 a 1.28 b 1.09 a 0.050 0.003017 
12902133 LOC783232 similar to fertilin alpha 1.00 a -1.04 a -1.29 b 0.041 0.003357 
12862952 LOC783379 KIAA1033-like 1.00 a -1.18 b -1.13 b 0.030 0.001896 
12848053 LOC784007 similar to LOC496253 
protein 
1.00 a -1.22 b -1.04 a 0.040 0.003430 
12748325 LOC784783 similar to GTP-binding 
nuclear protein Ran (GTPase 
Ran) (R 
1.00 a -1.16 b -1.17 b 0.030 0.001113 
12784693 LOC786771 similar to 40S ribosomal 
protein SA (p40) (34 
1.00 a 1.21 b -1.04 a 0.048 0.004530 
12882396 LOC787836 similar to EGF-like module-
containing mucin-like 
hormone r 
1.00 a 1.52 b 1.14 a 0.070 0.001167 
12882506 LOC789554 similar to olfactory receptor, 
family 7, subfamily A, memb 
1.00 a 1.12 b -1.07 a 0.026 0.003809 
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Table 5.5 (continued)          
12745320 LRAT lecithin retinol 
acyltransferase 
(phosphatidylcholine--retinol 
O-a 
1.00 a -1.13 b 1.18 c 0.034 0.000322 
12831438 LRP5 low density lipoprotein 
receptor-related protein 5 
1.00 a 1.20 b 1.11 c 0.029 0.003349 
12861337 LRP6 low density lipoprotein 
receptor-related protein 6 
1.00 a -1.11 b 1.01 a 0.026 0.003775 
12877145 LRRC25 leucine rich repeat containing 
25 
1.00 a 1.26 b 1.10 a 0.039 0.002285 
12846866 LRRC8D leucine rich repeat containing 
8 family, member D 
1.00 a -1.08 b 1.08 c 0.022 0.002475 
12867385 LRRK2 leucine-rich repeat kinase 2 1.00 a -1.27 b -1.14 c 0.038 0.001168 
12804382 LTA lymphotoxin alpha (TNF 
superfamily, member 1) 
1.00 a 1.14 b -1.07 a 0.039 0.003022 
12784665 LYPLA2 lysophospholipase II 1.00 a 1.24 b 1.15 c 0.026 0.000027 
12688919 LYSMD2 LysM, putative 
peptidoglycan-binding, 
domain containing 2 
1.00 a 1.27 b 1.19 b 0.043 0.001660 
12846097 MAGI3 membrane associated 
guanylate kinase, WW and 
PDZ domain contai 
1.00 a 1.06 a 1.19 b 0.031 0.004709 
12879542 MAN2A1 mannosidase, alpha, class 2A, 
member 1 
1.00 a -1.06 a 1.07 b 0.030 0.004885 
12788277 MARVELD2 MARVEL domain containing 
2 
1.00 a -1.07 a 1.09 b 0.027 0.002638 
12886733 MAST3 microtubule associated serine 1.00 a 1.20 b 1.09 c 0.027 0.001472 
12721094 MAVS mitochondrial antiviral 
signaling protein 
1.00 a 1.07 b 1.13 c 0.018 0.002325 
12877798 MCOLN1 mucolipin 1 1.00 a 1.27 b 1.10 c 0.029 0.000309 
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Table 5.5 (continued) 
12705668 MFSD9 major facilitator superfamily 
domain containing 9 
1.00 a -1.33 b -1.07 a 0.041 0.002199 
12899003 MGC137021 hypothetical protein 
MGC137021 
1.00 a -1.41 b -1.07 a 0.047 0.000875 
12714218 MGC138976 hypothetical LOC506205 1.00 a -1.24 b -1.04 a 0.035 0.002616 
12891753 MGC140340 RMI1, RecQ mediated 
genome instability 1, 
homolog (S. cere 
1.00 a -1.21 b 1.11 a 0.050 0.004331 
12707543 MGC142792 similar to Lims E protein 1.00 a -1.10 b 1.02 a 0.025 0.003458 
12694035 MGC152585 hypothetical LOC507035 1.00 a -1.09 b -1.02 a 0.017 0.004624 
12696838 MGC159550 hypothetical LOC540184 1.00 a -1.32 b -1.13 c 0.036 0.000227 
12747213 MGC165715 hypothetical LOC530484 1.00 a -1.24 b -1.25 b 0.039 0.001040 
12711935 MGC165939 Uncharacterized protein 
C13orf18 homolog 
1.00 a -1.52 b -1.15 a 0.042 0.000201 
12688769 MGC166084 hypothetical LOC509393 1.00 a -1.13 b -1.00 a 0.016 0.000579 
12879792 MIDN midnolin 1.00 a 1.26 b 1.32 b 0.049 0.001746 
12698235 MIR1301 microRNA mir-1301 1.00 a -1.29 b -1.04 a 0.032 0.000028 
12683006 MIR155 microRNA mir-155 1.00 a -1.18 b -1.13 b 0.022 0.001071 
12791562 MIR211 microRNA mir-211 1.00 a 1.03 a -1.14 b 0.033 0.002774 
12708822 MIR2303 microRNA mir-2303 1.00 a -1.14 b -1.10 b 0.023 0.001388 
12794243 MIR2372 microRNA mir-2372 1.00 a -1.09 a 1.21 b 0.047 0.001670 
12842451 MIR2416 microRNA mir-2416 1.00 a 1.06 a 1.29 b 0.028 0.000081 
12892478 MIR2473 microRNA mir-2473 1.00 a -1.32 b -1.02 a 0.059 0.002304 
12679724 MIS18A protein Mis18-alpha 1.00 a 1.16 b -1.04 a 0.017 0.000292 
12859364 MLF2 myeloid leukemia factor 2 1.00 a 1.16 b 1.17 b 0.034 0.003484 
12846912 MLLT11 myeloid 1.00 a 1.23 b 1.36 b 0.055 0.004406 
12721755 MMP16 matrix metallopeptidase 16 
(membrane-inserted) 
1.00 a -1.25 b -1.05 a 0.025 0.000112 
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Table 5.5 (continued)          
12732358 MPZL3 myelin protein zero-like 3 1.00 a -1.12 b -1.02 a 0.022 0.004128 
12818395 MRPS34 mitochondrial ribosomal 
protein S34 
1.00 a 1.22 b 1.12 c 0.034 0.001237 
12896461 MTHFD1L methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 1- 
1.00 a 1.19 b 1.33 b 0.042 0.002110 
12710450 MTMR6 myotubularin related protein 
6 
1.00 a -1.09 b -1.09 b 0.016 0.003962 
12697268 MTX3 metaxin 3 1.00 a -1.25 b -1.19 b 0.037 0.000538 
12745765 MVK mevalonate kinase 1.00 a 1.04 b -1.04 c 0.015 0.001540 
12896715 MYB v-myb myeloblastosis viral 
oncogene homolog (avian) 
1.00 a -1.29 b -1.01 a 0.047 0.001758 
12686285 MYNN myoneurin 1.00 a -1.12 b -1.01 a 0.027 0.003876 
12710371 NAA16 N(alpha)-acetyltransferase 
16, NatA auxiliary subunit 
1.00 a -1.14 b -1.08 b 0.026 0.002728 
12830931 NAA40 N(alpha)-acetyltransferase 
40, NatD catalytic subunit, 
homolog 
1.00 a 1.19 b 1.22 b 0.039 0.002047 
12781710 NAB1 NGFI-A binding protein 1 
(EGR1 binding protein 1) 
1.00 a -1.11 b 1.06 a 0.029 0.001415 
12864496 NAB2 NGFI-A binding protein 2 
(EGR1 binding protein 2) 
1.00 a 1.25 b 1.42 b 0.073 0.004579 
12854527 NAMPT nicotinamide 
phosphoribosyltransferase 
1.00 a -1.19 b -1.06 a 0.026 0.000542 
12891577 NANS N-acetylneuraminic acid 
synthase 
1.00 a 1.14 b 1.19 b 0.034 0.004953 
12883428 NDUFA2 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 2, 8kDa 
1.00 a 1.16 b 1.18 b 0.031 0.003240 
12815307 NDUFAB1 NADH dehydrogenase 
(ubiquinone) 1, alpha 
1.00 a 1.21 b 1.12 c 0.027 0.001157 
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Table 5.5 (continued)          
12774890 NEB nebulin 1.00 a -1.17 b -1.17 b 0.033 0.003038 
12887575 NFIC nuclear factor I 1.00 a 1.11 b 1.12 b 0.020 0.003140 
12791746 NFKBIA nuclear factor of kappa light 
polypeptide gene enhancer in 
B- 
1.00 a -1.44 b -1.24 b 0.065 0.004582 
12803223 NFYA nuclear transcription factor Y, 
alpha 
1.00 a 1.03 a 1.10 b 0.015 0.001019 
12775945 NINJ1 ninjurin 1 1.00 a 1.21 b 1.14 b 0.032 0.003704 
12815983 NLRC3 NLR family, CARD domain 
containing 3 
1.00 a 1.04 a -1.17 b 0.034 0.000468 
12851927 NME1-NME2 NME1-NME2 readthrough 1.00 a 1.36 b 1.26 b 0.050 0.000390 
12910154 NONO non-POU domain containing, 
octamer-binding 
1.00 a 1.08 b 1.03 a 0.011 0.003000 
12718233 NOP56 NOP56 ribonucleoprotein 
homolog (yeast) 
1.00 a 1.09 b 1.12 b 0.022 0.004132 
12752495 NPAS1 neuronal PAS domain protein 
1 
1.00 a 1.14 b -1.12 c 0.032 0.001194 
12713592 NPBWR2 neuropeptides B 1.00 a 1.01 a -1.17 b 0.034 0.004519 
12679345 NPHP3 nephronophthisis 3 
(adolescent) 
1.00 a -1.15 b -1.08 c 0.025 0.003137 
12821454 NT5C2 5'-nucleotidase, cytosolic II 1.00 a -1.19 b -1.16 b 0.034 0.004432 
12791125 NUBPL nucleotide binding protein-
like 
1.00 a -1.21 b -1.14 b 0.040 0.002994 
12794079 NUP210 nucleoporin 210 1.00 a 1.12 b 1.01 a 0.014 0.001641 
12858331 NUP50 nucleoporin 50kDa 1.00 a -1.02 a 1.16 b 0.021 0.000159 
12753711 NUTF2 nuclear transport factor 2 1.00 a 1.07 b 1.10 b 0.020 0.003096 
12836937 OMA1 OMA1 homolog, zinc 
metallopeptidase (S. 
cerevisiae) 
1.00 a -1.37 b -1.18 c 0.058 0.002711 
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Table 5.5 (continued) 
12686108 OSBPL11 oxysterol binding protein-like 
11 
1.00 a -1.26 b -1.10 c 0.020 0.000218 
12851380 OSBPL3 oxysterol binding protein-like 
3 
1.00 a 1.09 a 1.38 b 0.055 0.004536 
12776601 OSGEPL1 O-sialoglycoprotein 
endopeptidase-like 1 
1.00 a -1.31 b -1.01 a 0.032 0.000349 
12731077 P4HA3 prolyl 4-hydroxylase, alpha 
polypeptide III 
1.00 a -1.36 b -1.08 a 0.057 0.003208 
12832821 PAG11 pregnancy-associated 
glycoprotein 11 
1.00 a -1.34 b -1.32 b 0.059 0.003888 
12882286 PALM paralemmin 1.00 a 1.15 b -1.02 a 0.035 0.004348 
12787282 PANK3 pantothenate kinase 3 1.00 a -1.17 b -1.00 a 0.034 0.001657 
12884529 PCDH1 protocadherin 1 1.00 a 1.12 b 1.08 b 0.016 0.000485 
12876146 PCDHGC3 protocadherin gamma 
subfamily C, 3 
1.00 a 1.27 b 1.21 b 0.041 0.000861 
12693599 PCK2 phosphoenolpyruvate 
carboxykinase 2 
(mitochondrial) 
1.00 a 1.19 b 1.12 b 0.027 0.003696 
12825212 PCM1 pericentriolar material 1 1.00 a -1.12 b -1.07 b 0.022 0.003172 
12853639 PDK4 pyruvate dehydrogenase 
kinase, isozyme 4 
1.00 a -1.76 b -1.47 b 0.119 0.003779 
12761334 PEMT phosphatidylethanolamine N-
methyltransferase 
1.00 a 1.16 b 1.10 b 0.028 0.004954 
12682676 PFN1 profilin 1 1.00 a 1.23 b 1.24 b 0.046 0.002123 
12732120 PGM2L1 phosphoglucomutase 2-like 1 1.00 a -1.40 b -1.41 b 0.067 0.002707 
12812393 PHKG2 phosphorylase kinase, gamma 
2 (testis) 
1.00 a 1.15 b 1.09 b 0.024 0.002756 
12860985 PICK1 protein interacting with 
PRKCA 1 
1.00 a 1.19 b 1.24 b 0.033 0.000841 
12772901 PITPNA phosphatidylinositol transfer 
protein, alpha 
1.00 a 1.13 b 1.20 b 0.035 0.003281 
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Table 5.5 (continued)          
12771785 PMP22 peripheral myelin protein 22 1.00 a -1.16 b -1.31 c 0.047 0.001497 
12819454 PNLIPRP2 pancreatic lipase-related 
protein 2 
1.00 a 1.13 b -1.02 a 0.016 0.002468 
12779481 POLR2D polymerase (RNA) II (DNA 
directed) polypeptide D 
1.00 a 1.05 a 1.24 b 0.028 0.000124 
12702934 POMT1 protein-O-
mannosyltransferase 1 
1.00 a 1.18 b 1.11 b 0.031 0.002608 
12724871 POP1 processing of precursor 1, 
ribonuclease P 
1.00 a 1.10 b 1.24 c 0.034 0.002457 
12813437 POR P450 (cytochrome) 
oxidoreductase 
1.00 a 1.14 b 1.18 b 0.034 0.003956 
12866906 PPHLN1 periphilin 1 1.00 a -1.11 b 1.01 a 0.028 0.004763 
12844589 PPIH peptidylprolyl isomerase H 
(cyclophilin H) 
1.00 a 1.11 b 1.20 b 0.034 0.003938 
12833867 PPP1CA protein phosphatase 1, 
catalytic subunit, alpha 
isozyme 
1.00 a 1.16 b 1.15 b 0.029 0.002950 
12697381 PPP1R14D protein phosphatase 1, 
regulatory (inhibitor) subunit 
14D 
1.00 a 1.07 a 1.22 b 0.027 0.000926 
12687438 PPP2R3A protein phosphatase 2 
(formerly 2A), regulatory 
subunit B'', 
1.00 a -1.13 b -1.01 a 0.025 0.002523 
12809449 PPP4R1 protein phosphatase 4, 
regulatory subunit 1 
1.00 a 1.04 a 1.13 b 0.014 0.002877 
12798367 PPP4R2 protein phosphatase 4, 
regulatory subunit 2 
1.00 a -1.19 b -1.01 a 0.030 0.000689 
12896699 PREP prolyl endopeptidase 1.00 a -1.16 b -1.00 a 0.031 0.003455 
12798533 PRKCD protein kinase C, delta 1.00 a 1.25 b 1.25 b 0.043 0.001261 
12757145 PRPF31 PRP31 pre-mRNA processing 
factor 31 homolog (S. cerevis 
1.00 a 1.22 b 1.10 c 0.030 0.000416 
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Table 5.5 (continued)          
12843627 PRPF38A PRP38 pre-mRNA processing 
factor 38 (yeast) domain 
containin 
1.00 a -1.14 b 1.02 a 0.033 0.004499 
12805379 PRPF4B PRP4 pre-mRNA processing 
factor 4 homolog B (yeast) 
1.00 a -1.06 b 1.03 a 0.013 0.004034 
12813522 PRR14 proline rich 14 1.00 a 1.19 b 1.18 b 0.028 0.003635 
12817104 PRSS27 protease, serine 27 1.00 a -1.00 a -1.22 b 0.036 0.000775 
12691536 PRTG protogenin 1.00 a -1.38 b -1.00 a 0.056 0.000335 
12749769 PSENEN presenilin enhancer 2 
homolog (C. elegans) 
1.00 a 1.24 b 1.13 c 0.026 0.000202 
12751335 PSMD8 proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 8 
1.00 a 1.23 b 1.14 b 0.036 0.001973 
12808197 PSMG2 proteasome (prosome, 
macropain) assembly 
chaperone 2 
1.00 a 1.12 b 1.23 c 0.039 0.002869 
12819493 PSTK phosphoseryl-tRNA kinase 1.00 a -1.45 b -1.18 c 0.051 0.000141 
12809935 PSTPIP2 proline-serine-threonine 
phosphatase interacting 
protein 2 
1.00 a -1.18 b 1.08 a 0.048 0.004152 
12698053 PUM2 pumilio homolog 2 
(Drosophila) 
1.00 a -1.15 b -1.05 a 0.021 0.001237 
12707977 PUS10 pseudouridylate synthase 10 1.00 a -1.21 b -1.11 c 0.030 0.000513 
12818183 QPRT quinolinate 
phosphoribosyltransferase 
1.00 a 1.16 b 1.17 b 0.024 0.001686 
12843452 RAB25 RAB25, member RAS 
oncogene family 
1.00 a 1.28 b 1.29 b 0.051 0.002290 
12748015 RAB35 RAB35, member RAS 
oncogene family 
1.00 a 1.15 b 1.17 b 0.031 0.002854 
12882589 RAB8A RAB8A, member RAS 
oncogene family 
1.00 a 1.11 b 1.17 b 0.030 0.002103 
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Table 5.5 (continued)          
12705580 RALGDS ral guanine nucleotide 
dissociation stimulator 
1.00 a 1.18 b 1.22 b 0.039 0.001348 
12842709 RAP1A RAP1A, member of RAS 
oncogene family 
1.00 a -1.17 b -1.02 a 0.029 0.002002 
12762096 RASD1 RAS, dexamethasone-
induced 1 
1.00 a -1.68 b -1.34 c 0.084 0.001633 
12893594 RASEF RAS and EF-hand domain 
containing 
1.00 a -1.46 b -1.13 a 0.043 0.002794 
12873681 RASGEF1B RasGEF domain family, 
member 1B 
1.00 a -1.37 b -1.18 c 0.040 0.000074 
12867519 RASSF3 Ras association (RalGDS 1.00 a -1.30 b -1.14 c 0.038 0.000443 
12722010 RBM12B RNA binding motif protein 
12B 
1.00 a -1.14 b -1.07 c 0.025 0.004241 
12849958 RBM33 RNA binding motif protein 
33 
1.00 a 1.05 a -1.07 b 0.023 0.004934 
12907794 RBMX RNA binding motif protein, 
X-linked 
1.00 a -1.11 b -1.05 c 0.021 0.002635 
12875984 RELL1 RELT-like 1 1.00 a -1.01 a 1.18 b 0.033 0.001447 
12901006 REPS1 RALBP1 associated Eps 
domain containing 1 
1.00 a -1.19 b -1.08 c 0.023 0.001435 
12693205 RHEB Ras homolog enriched in 
brain 
1.00 a 1.09 b 1.09 b 0.019 0.003562 
12839908 RIT1 Ras-like without CAAX 1 1.00 a -1.24 b -1.05 a 0.022 0.000106 
12879151 RMND5B required for meiotic nuclear 
division 5 homolog B (S. 
cerevis 
1.00 a 1.19 b 1.10 c 0.024 0.000397 
12841126 RNF115 ring finger protein 115 1.00 a -1.07 b 1.04 a 0.013 0.002442 
12705891 RNF181 ring finger protein 181 1.00 a 1.13 b 1.15 b 0.020 0.001115 
12698562 ROCK2 Rho-associated, coiled-coil 
containing protein kinase 2 
1.00 a -1.12 b -1.03 a 0.026 0.004939 
12757517 RPGRIP1L RPGRIP1-like 1.00 a -1.22 b -1.11 c 0.032 0.002587 
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Table 5.5 (continued)          
12697019 RPL36AL ribosomal protein L36a-like 1.00 a 1.13 b 1.02 a 0.017 0.003333 
12802388 RPL7L1 ribosomal protein L7-like 1 1.00 a 1.13 b 1.12 b 0.023 0.001063 
12743489 RSRC2 arginine 1.00 a -1.15 b -1.08 c 0.021 0.000678 
12689648 RTF1 Rtf1, Paf1 1.00 a -1.06 b 1.01 a 0.014 0.003807 
12765283 RUNDC3A RUN domain containing 3A 1.00 a 1.19 b 1.23 b 0.041 0.001828 
12825048 RWDD4 RWD domain containing 4 1.00 a -1.14 b 1.02 a 0.024 0.002495 
12695025 SAV1 salvador homolog 1 
(Drosophila) 
1.00 a -1.13 b 1.04 a 0.038 0.004911 
12843873 SCP2 sterol carrier protein 2 1.00 a -1.21 b -1.25 b 0.046 0.004580 
12726044 SDC2 syndecan 2 1.00 a 1.02 a 1.21 b 0.039 0.003408 
12774661 SDHB succinate dehydrogenase 
complex, subunit B, iron 
sulfur (Ip) 
1.00 a 1.12 b 1.03 a 0.025 0.003311 
12782736 SDPR serum deprivation response 1.00 a -1.17 b -1.18 b 0.034 0.003571 
12798942 SEC13 SEC13 homolog (S. 
cerevisiae) 
1.00 a 1.24 b 1.19 b 0.041 0.001450 
12770064 SEC14L1 SEC14-like 1 (S. cerevisiae) 1.00 a 1.09 a 1.26 b 0.039 0.002855 
12742060 SEC14L2 SEC14-like 2 (S. cerevisiae) 1.00 a 1.26 b 1.32 b 0.041 0.000822 
12826094 SEC24C SEC24 family, member C (S. 
cerevisiae) 
1.00 a 1.08 b 1.12 b 0.016 0.002926 
12870423 SEC24D SEC24 family, member D (S. 
cerevisiae) 
1.00 a 1.21 b 1.18 b 0.034 0.001266 
12798378 SEC61A1 Sec61 alpha 1 subunit (S. 
cerevisiae) 
1.00 a 1.24 b 1.22 b 0.041 0.002461 
12761154 SERPINF2 serpin peptidase inhibitor, 
clade F (alpha-2 antiplasmin, 
pigm 
1.00 a -1.02 a -1.21 b 0.022 0.000315 
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Table 5.5 (continued) 
12727477 SERPINH1 serpin peptidase inhibitor, 
clade H (heat shock protein 
47) 
1.00 a 1.22 b 1.33 b 0.040 0.000301 
12779743 SESTD1 SEC14 and spectrin domains 
1 
1.00 a -1.18 b -1.08 c 0.028 0.003866 
12811815 SEZ6L2 seizure related 6 homolog 
(mouse)-like 2 
1.00 a 1.17 b 1.08 c 0.032 0.004676 
12795342 SFMBT1 Scm-like with four mbt 
domains 1 
1.00 a -1.07 b 1.09 c 0.028 0.002702 
12899008 SFRS18 splicing factor, arginine 1.00 a -1.14 b -1.08 c 0.026 0.003542 
12819502 SFXN3 sideroflexin 3 1.00 a 1.25 b 1.29 b 0.042 0.000607 
12761383 SHBG sex hormone-binding 
globulin 
1.00 a 1.16 b 1.11 b 0.017 0.002561 
12864912 SHMT2 serine 
hydroxymethyltransferase 2 
(mitochondrial) 
1.00 a 1.29 b 1.22 b 0.041 0.000848 
12790177 SIN3A SIN3 homolog A, 
transcription regulator (yeast) 
1.00 a 1.11 b 1.11 b 0.016 0.000442 
12710363 SLAIN1 SLAIN motif family, member 
1 
1.00 a -1.26 b -1.07 a 0.036 0.000341 
12769217 SLC25A39 solute carrier family 25, 
member 39 
1.00 a 1.17 b 1.20 b 0.037 0.001891 
12696210 SLC27A2 solute carrier family 27 (fatty 
acid transporter), member 2 
1.00 a 1.08 a -1.15 b 0.039 0.002407 
12758460 SLC27A5 solute carrier family 27 (fatty 
acid transporter), member 5 
1.00 a 1.15 b 1.00 a 0.027 0.004638 
12729666 SLC35C1 solute carrier family 35, 
member C1 
1.00 a 1.26 b 1.42 b 0.050 0.000826 
12900723 SLC35F1 solute carrier family 35, 
member F1 
1.00 a -1.52 b -1.26 c 0.054 0.003264 
12691151 SLC39A9 solute carrier family 39 (zinc 
transporter), member 9 
1.00 a 1.03 a 1.17 b 0.027 0.004127 
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Table 5.5 (continued)          
12739370 SLC45A1 solute carrier family 45, 
member 1 
1.00 a 1.15 b 1.21 b 0.026 0.004130 
12722615 SLC45A4 solute carrier family 45, 
member 4 
1.00 a 1.14 b -1.01 a 0.017 0.000066 
12777931 SLC4A3 solute carrier family 4, anion 
exchanger, member 3 
1.00 a 1.21 b 1.16 b 0.036 0.002173 
12798802 SLC4A7 solute carrier family 4, 
sodium bicarbonate 
cotransporter, me 
1.00 a -1.23 b -1.09 c 0.031 0.000333 
12867619 SLC4A8 solute carrier family 4, 
sodium bicarbonate 
cotransport 
1.00 a -1.16 b -1.02 a 0.030 0.001077 
12683494 SLC5A3 solute carrier family 5 
(inositol transporters), 
member 3 
1.00 a -1.13 b 1.00 a 0.024 0.004110 
12883870 SLC5A5 solute carrier family 5 
(sodium iodide symporter), 
memb 
1.00 a 1.04 a -1.18 b 0.037 0.002054 
12864073 SLC6A15 solute carrier family 6 
(neutral amino acid 
transporter), membe 
1.00 a 1.21 b -1.16 a 0.052 0.003426 
12843025 SLC6A17 solute carrier family 6, 
member 17 
1.00 a 1.32 b 1.11 c 0.037 0.001031 
12700968 SLC9A2 solute carrier family 9 
(sodium 
1.00 a -1.30 b 1.05 a 0.039 0.000107 
12820519 SLK STE20-like kinase 1.00 a -1.15 b -1.06 c 0.022 0.000793 
12822402 SMNDC1 survival motor neuron 
domain containing 1 
1.00 a -1.16 b -1.04 a 0.031 0.003826 
12895130 SMU1 smu-1 suppressor of mec-8 
and unc-52 homolog (C. 
elegans) 
1.00 a -1.13 b -1.05 c 0.016 0.002719 
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Table 5.5 (continued) 
12761769 SNF8 SNF8, ESCRT-II complex 
subunit, homolog (S. 
cerevisiae) 
1.00 a 1.12 b 1.12 b 0.025 0.001929 
12705102 SNRNP200 small nuclear 
ribonucleoprotein 200kDa 
(U5) 
1.00 a 1.13 b 1.16 b 0.024 0.001534 
12681751 SPATA16 spermatogenesis associated 
16 
1.00 a -1.51 b -1.59 b 0.104 0.003659 
12880047 SPINK5 serine peptidase inhibitor, 
Kazal type 5 
1.00 a -1.07 a -1.20 b 0.030 0.001911 
12690591 SPINT1 serine peptidase inhibitor, 
Kunitz type 1 
1.00 a 1.13 b 1.14 b 0.030 0.004018 
12809817 SPIRE1 spire homolog 1 (Drosophila) 1.00 a -1.09 b 1.06 c 0.016 0.000004 
12781179 SPOPL speckle-type POZ protein-
like 
1.00 a -1.19 b -1.09 c 0.027 0.002507 
12738745 SPSB1 splA 1.00 a 1.08 a 1.25 b 0.044 0.004244 
12736354 SRP9 signal recognition particle 
9kDa 
1.00 a -1.21 b -1.06 a 0.037 0.002371 
12861559 SRSF2IP serine 1.00 a -1.14 b -1.04 a 0.017 0.000956 
12716125 SRXN1 sulfiredoxin 1 1.00 a 1.20 b 1.51 c 0.072 0.003800 
12837024 SSR2 signal sequence receptor, beta 
(translocon-associated protein 
b 
1.00 a 1.18 b 1.14 b 0.026 0.001949 
12903267 SSR4 signal sequence receptor, 
delta (translocon-associated 
protein 
1.00 a 1.20 b 1.10 c 0.028 0.002520 
12704183 ST6GALNAC2 ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-
galactosyl-1,3)-N-ac 
1.00 a 1.18 b 1.19 b 0.034 0.002065 
12852887 ST7 suppression of tumorigenicity 
7 
1.00 a 1.14 b 1.13 b 0.029 0.004896 
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Table 5.5 (continued)          
12809232 ST8SIA5 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 5 
1.00 a 1.22 b 1.22 b 0.042 0.003404 
12718263 ST8SIA6 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 6 
1.00 a -1.39 b -1.25 b 0.067 0.004024 
12768925 STAT3 signal transducer and 
activator of transcription 3 
(acute-phas 
1.00 a 1.05 a 1.19 b 0.032 0.003168 
12719219 STAU1 staufen, RNA binding 
protein, homolog 1 
(Drosophila) 
1.00 a -1.03 a 1.08 b 0.015 0.001211 
12831915 STIP1 stress-induced-
phosphoprotein 1 (Hsp70 
1.00 a 1.10 b 1.18 c 0.035 0.003472 
12776910 STK16 serine 1.00 a 1.19 b 1.15 b 0.032 0.002165 
12838532 STK40 serine 1.00 a 1.11 b 1.21 c 0.028 0.002233 
12719749 STX16 syntaxin 16 1.00 a -1.24 b -1.11 c 0.027 0.001370 
12891106 STX17 syntaxin 17 1.00 a -1.16 b -1.08 c 0.023 0.003178 
12898392 STXBP5 syntaxin binding protein 5 
(tomosyn) 
1.00 a -1.15 b -1.05 a 0.018 0.003925 
12746819 SUHW2 suppressor of hairy wing 
homolog 2 
1.00 a 1.10 a 1.87 b 0.102 0.002525 
12678716 SYNJ1 synaptojanin 1 1.00 a -1.13 b -1.07 c 0.012 0.000062 
12695481 SYNJ2BP synaptojanin 2 binding 
protein 
1.00 a -1.07 b 1.02 a 0.011 0.003501 
12875470 SYNPO2 synaptopodin 2 1.00 a -1.46 b -1.38 b 0.068 0.003691 
12831287 TAF6L TAF6-like RNA polymerase 
II, p300 
1.00 a 1.17 b 1.17 b 0.022 0.000169 
12764103 TANC2 tetratricopeptide repeat, 
ankyrin repeat and coiled-coil 
conta 
1.00 a 1.17 b 1.11 b 0.025 0.001075 
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Table 5.5 (continued)          
12806911 TAP2 transporter 2, ATP-binding 
cassette, sub-family B (MDR 
1.00 a -1.35 b -1.38 b 0.056 0.003005 
12845308 TCTEX1D1 Tctex1 domain containing 1 1.00 a -1.40 b -1.11 a 0.064 0.004251 
12827943 TFAM transcription factor A, 
mitochondrial 
1.00 a -1.20 b -1.09 c 0.030 0.002470 
12755803 TGFB1 transforming growth factor, 
beta 1 
1.00 a 1.30 b 1.46 b 0.048 0.000291 
12825460 THAP1 THAP domain containing, 
apoptosis associated protein 1 
1.00 a -1.26 b -1.10 c 0.031 0.000187 
12780012 THSD7B thrombospondin, type I, 
domain containing 7B-like 
1.00 a -1.52 b -1.26 c 0.051 0.000539 
12686567 TIPARP TCDD-inducible poly(ADP-
ribose) polymerase 
1.00 a -1.63 b -1.24 c 0.078 0.000537 
12709691 TM9SF2 transmembrane 9 superfamily 
member 2 
1.00 a 1.11 b 1.07 b 0.017 0.002635 
12818583 TMC7 transmembrane channel-like 
7 
1.00 a -1.48 b -1.10 a 0.061 0.000428 
12770490 TMEM101 transmembrane protein 101 1.00 a 1.13 b 1.09 b 0.026 0.004874 
12830423 TMEM179B transmembrane protein 179B 1.00 a 1.14 b 1.03 a 0.021 0.000600 
12737891 TMEM9 transmembrane protein 9 1.00 a 1.23 b 1.15 b 0.030 0.001120 
12690496 TMOD3 tropomodulin 3 (ubiquitous) 1.00 a -1.17 b -1.02 a 0.021 0.000091 
12885622 TMPRSS9 transmembrane protease, 
serine 9 
1.00 a 1.02 a -1.20 b 0.043 0.002912 
12833169 TNNI2 troponin I type 2 (skeletal, 
fast) 
1.00 a 1.11 b -1.13 c 0.036 0.002979 
12856205 TPK1 thiamin pyrophosphokinase 1 1.00 a -1.15 b -1.13 b 0.027 0.001791 
12682407 TRA2B transformer 2 beta homolog 
(Drosophila) 
1.00 a -1.09 b 1.00 a 0.014 0.000534 
12800251 TRH thyrotropin-releasing 
hormone 
1.00 a -1.19 b -1.07 a 0.031 0.001559 
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Table 5.5 (continued)          
12696584 TRIM36 tripartite motif-containing 36 1.00 a -1.22 b -1.00 a 0.028 0.000671 
12730210 TRIM44 tripartite motif-containing 44 1.00 a -1.13 b 1.01 a 0.019 0.001088 
12706838 TSC1 tuberous sclerosis 1 1.00 a -1.15 b -1.10 b 0.017 0.000680 
12786004 TTC33 tetratricopeptide repeat 
domain 33 
1.00 a -1.24 b -1.29 b 0.051 0.001320 
12707414 TUBB2C tubulin, beta 2C 1.00 a 1.18 b 1.27 b 0.047 0.003575 
12679811 TXLNA taxilin alpha 1.00 a 1.03 a 1.16 b 0.035 0.003683 
12837120 TXNDC12 thioredoxin domain 
containing 12 (endoplasmic 
reticulum) 
1.00 a 1.09 b 1.10 b 0.020 0.002815 
12801023 TXNDC5 thioredoxin domain 
containing 5 (endoplasmic 
reticulum) 
1.00 a 1.26 b 1.34 b 0.050 0.001771 
12837074 TXNIP thioredoxin interacting 
protein 
1.00 a -1.48 b -1.35 b 0.056 0.000389 
12857179 TXNRD1 thioredoxin reductase 1 1.00 a -1.04 a 1.12 b 0.024 0.000666 
12748228 UBE2L3 ubiquitin-conjugating enzyme 
E2L 3 
1.00 a 1.07 b 1.12 b 0.016 0.002914 
12759033 UBE2M ubiquitin-conjugating enzyme 
E2M (UBC12 homolog, 
yeast) 
1.00 a 1.13 b 1.21 b 0.032 0.001375 
12849657 UBE3C ubiquitin protein ligase E3C 1.00 a -1.18 b 1.01 a 0.025 0.000117 
12767886 UBTF upstream binding 
transcription factor, RNA 
polymerase I 
1.00 a 1.02 a 1.10 b 0.014 0.003852 
12846641 UFC1 ubiquitin-fold modifier 
conjugating enzyme 1 
1.00 a 1.13 b 1.08 b 0.023 0.003688 
12884383 UIMC1 ubiquitin interaction motif 
containing 1 
1.00 a -1.11 b 1.03 a 0.022 0.002515 
12732418 USP2 ubiquitin specific peptidase 2 1.00 a -1.43 b -1.11 a 0.052 0.000622 
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Table 5.5 (continued)          
12764643 USP32 ubiquitin specific peptidase 
32 
1.00 a -1.09 b 1.04 a 0.021 0.000580 
12874296 USP46 ubiquitin specific peptidase 
46 
1.00 a -1.17 b 1.00 a 0.029 0.001474 
12789378 UTP14A UTP14, U3 small nucleolar 
ribonucleoprotein, homolog 
A (yeast 
1.00 a -1.25 b -1.16 b 0.045 0.003745 
12876570 VAV1 vav 1 guanine nucleotide 
exchange factor 
1.00 a 1.15 b -1.01 a 0.035 0.003709 
12861191 VEZT vezatin, adherens junctions 
transmembrane protein 
1.00 a -1.16 b -1.05 a 0.021 0.000873 
12818366 VGF VGF nerve growth factor 
inducible 
1.00 a 1.48 b 1.17 a 0.068 0.001709 
12800230 VHL von Hippel-Lindau tumor 
suppressor 
1.00 a -1.12 b -1.00 a 0.021 0.001920 
12797505 VPRBP Vpr (HIV-1) binding protein 1.00 a 1.00 a 1.14 b 0.019 0.000268 
12759936 VSIG10L V-set and immunoglobulin 
domain containing 10 like 
1.00 a 1.00 a -1.20 b 0.032 0.002217 
12828515 WAPAL wings apart-like homolog 
(Drosophila) 
1.00 a -1.05 b 1.07 c 0.015 0.000234 
12797242 WDR48 WD repeat domain 48 1.00 a -1.11 b -1.12 b 0.023 0.002130 
12845185 WDR63 WD repeat domain 63 1.00 a -1.32 b -1.22 c 0.026 0.000016 
12788246 WDR70 WD repeat domain 70 1.00 a -1.08 b 1.06 c 0.020 0.000388 
12699220 WDR85 WD repeat domain 85 1.00 a 1.19 b 1.23 b 0.029 0.000525 
12718416 WFDC3 WAP four-disulfide core 
domain 3 
1.00 a 1.09 b -1.07 a 0.028 0.004584 
12747918 XBP1 X-box binding protein 1 1.00 a 1.08 a 1.25 b 0.044 0.004947 
12822034 XPNPEP1 X-prolyl aminopeptidase 
(aminopeptidase P) 1, soluble 
1.00 a 1.07 a 1.25 b 0.040 0.000931 
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Table 5.5 (continued) 
12903280 XPNPEP2 X-prolyl aminopeptidase 
(aminopeptidase P) 2, 
membrane 
1.00 a -1.07 a -1.16 b 0.030 0.004889 
12872296 YTHDC1 YTH domain containing 1 1.00 a -1.13 b -1.07 c 0.022 0.002949 
12783927 YTHDF2 YTH domain family, member 
2 
1.00 a -1.05 b 1.08 c 0.015 0.000152 
12713839 YWHAB tyrosine 3-monooxygenase 1.00 a 1.04 b 1.08 c 0.014 0.003731 
12712681 ZC3H13 zinc finger CCCH-type 
containing 13 
1.00 a -1.08 b 1.02 a 0.014 0.000542 
12704370 ZC3H6 zinc finger CCCH-type 
containing 6 
1.00 a -1.28 b -1.31 b 0.057 0.004386 
12773866 ZDBF2 zinc finger, DBF-type 
containing 2 
1.00 a -1.93 b -1.20 a 0.092 0.000044 
12891224 ZDHHC21 zinc finger, DHHC-type 
containing 21 
1.00 a -1.28 b -1.09 a 0.053 0.004585 
12720538 ZEB1 zinc finger E-box binding 
homeobox 1 
1.00 a -1.15 b 1.01 a 0.028 0.000738 
12892852 ZFAND5 zinc finger, AN1-type domain 
5 
1.00 a -1.34 b -1.26 b 0.055 0.002168 
12881969 ZFR2 zinc finger RNA binding 
protein 2 
1.00 a 1.06 a -1.07 b 0.022 0.003757 
12907005 ZFX zinc finger protein, X-linked 1.00 a -1.17 b -1.08 c 0.030 0.004194 
12827158 ZMIZ1 zinc finger, MIZ-type 
containing 1 
1.00 a 1.18 b 1.15 b 0.033 0.003687 
12891595 ZNF189 zinc finger protein 189 1.00 a -1.20 b -1.06 a 0.034 0.001038 
12753490 ZNF45 zinc finger protein 45 1.00 a -1.27 b -1.16 c 0.034 0.001503 
12706050 ZNF638 zinc finger protein 638 1.00 a -1.07 b 1.05 a 0.021 0.004503 
12861600 ZNF641 zinc finger protein 641 1.00 a -1.21 b -1.01 a 0.044 0.003618 
12840762 ZNF644 zinc finger protein 644 1.00 a -1.12 b -1.05 c 0.025 0.004517 
12750954 ZNF773 zinc finger protein 773 1.00 a 1.02 a 1.16 b 0.031 0.002895 
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Table 5.5 (continued)          
12702562 ZNF79 zinc finger protein 79 1.00 a -1.06 b 1.11 c 0.023 0.000293 
Se supplement treatments that contained 3 mg Se/day in the form of sodium selenite (ISe), Sel-Plex (OSe), or a 1:1 mix of ISe 
and OSe (MIX) were top-dressed onto enough of a common cottonseed hull/soybean hull/cracked corn-based diet 
The abundance of gene transcripts is reported relative to the mean expression of the ISe group and are expressed as the fold 
change of non-transformed data 
P-values were obtained from one-way ANOVA F test 
Means with different superscripted letters differ (P < 0.1) 
The presented SEM values were pooled (averaged) from that of ISe (n = 6), OSe (n = 7), and MIX (n = 7) treatment group 
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Figure 5.1. Canonical pathway network analysis. Shaded color indicates differentially 
expressed genes (P < 0.005). Non-shaded color indicates genes added from the Ingenuity 
Knowledge Base (Ingenuity Pathway, Ingenuity Systems, Inc., Redwood City, CA). 
Arrowheads symbolize action-on. Labels of interaction or relationship: A = Activation, E 
= Expression (includes metabolism or synthesis for chemicals), I = Inhibition, L = 
Molecular Cleavage, LO = Localization, T= Transcription. The number in parenthesis for 
each interaction indicates the number of published references in the Ingenuity Knowledge 
Base that support the particular interaction. 
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Figure 5.2. Mechanisms, and mRNA expression responses to Se form treatments, by 
which dopamine and TRH affect prolactin synthesis and release. AC, adenylyl cyclase; 
CRE, cAMP response element; CREB, cAMP response element binding protein; DAG, 
diacylglycerol; DRD2, dopamine receptor D2; EA, ergot alkaloid; ERK, extracellular 
signal-regulated kinase; IP3, inositol trisphosphate; ISe, sodium selenite; MEK, mitogen-
activated protein kinase kinase; MIX, 1:1 mix of ISe and OSe; OSe, SEL-PLEX; Pit-1, 
pituitary-specific positive transcription factor 1; PKA, protein kinase A; PKC, protein 
kinase C; PLC, phospholipase C; PRL, prolactin; TRH, thyrotropin-releasing hormone; 
TRHR, thyrotropin-releasing hormone receptor. A line with arrowhead signifies 
interaction. A crosshead bar signifies inhibition. A dash line with arrowhead signifies 
transportation between cellular organelles. Adapted from Ben-Jonathan and Hnasko 
(2001) and Kanasaki et al. (2015). Sodium selenite (ISe), SEL-PLEX (OSe), or a 1:1 mix 
of ISe and OSe (MIX). 
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Figure 5.3. Regional biosynthesis of ACTH and α-MSH from POMC in the pituitary. 
CPE, carboxypeptidase E; MSH, melanocyte-stimulating hormone; N-AT, N-
acetyltransferase; PAM, peptidylglycine α-amidating monooxygenase; PCSK: proprotein 
convertase subtilisin/kexin. Adapted from Getting (2006) and Cawley et al. (2016). 
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Figure 5.4. Correlation between microarray chips based on intensity values. 
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RPS11: 
AAGATGGCGGACATTCAGACAGAACGTGCGTACCAAAAGCAACCGACCATC
TTTCAAAATAAAAAGAGGGTCCTGCTTGGAGAAACTGGCAAAGAAAAGCTCC
CTCGATACTACAAGAACATTGGTCTGGGCTTCAAGACTCCAAAGGAGGCCAT
CGAGGGCACCTACATTGACAAGAAATGCCCTTTTACGGGTAATGTCTCATTCG
AGGGC 
TFRC: 
CCAGGTTTAGTCTGGCTCGGCAAGTAGATGGTGATAACAGTCATGTGGAGAT
GAAATTAGCTGCAGATGAAGAAGAANAATGTTGACAGTAACATGAGGGGCA
ACCAAACCAGTATCGCAAAACCGAAAAGGTTAAATGGATATGTCTGCTACGG
GATCATTGCTGTAATCGTCTTTTTCTTGATTGGATTTATGATTGGCTACTTGGG
CTATTGTAGACGTGTGGAATCACAAGATTGTGGGAAAGAGGCAGGAACACA
GCCTTCGTGCCCAGGAGGAGACAGAAACTTTCGAATCAGAAGAGCAACTCCC
TGGAGTACCTCGCATATTCTGGGCAGACC 
UBC: 
TAGGGGTGGGTTAGAGTTCAAGGTTTTTGTTCTACCAGATGTTTTAGTAGTAA
TCTGGAGGTAAGAAATGTCAAGAAAACATGGCCTTAATTAGAACTGTAGTGG
GTGAGTATAAATAAAAAATTTGGAGGTTGTAGTTAGAATTCTCCATATGTAC
ACTCATATGTAGATCTACTTATAAGCTACTGATTTTTAAAAGCACACGTTTGG
GAGTTGTGCTTAAGAGTGGGAAAGTTTCTGGAATACCAGCAGGGAGGT 
DRD2: 
CGACCTTTCTCTGGGGCTTTGGGGCTCTGCGGCTGCGGGGCCAGTATCGAGGC
TCGGAGGCCTGGTTTTCACAGGCCATGCCGGAGCTGGTGGTGGGGAGGAGTG
GACAGTCACAGCCACCCAGGGCCCACACCTGAGAAGCCAGAGCTCTGGCCAC
GACCCCAGGCAGTGTCAAGCCTGGGAGACCCGCGTACACCCCAGGTCTGGAT
GGACCCCAGAGAAGCAGAAGCCCAA 
POU1F1 (Pit-1): 
AGCTGTGCATGGCTCTGAATTCAGTCAAACAACTATCTGCCGATTTGAAAACC
TGCAGCTCAGCTTCAAAAATGCATGCAAACTAAAAGCAATATTATCCAAATG
GCTGGAGGAAGCCGAGCAAGTAGGAGCTTTATACAATGAGAAAGTTGGTGC
AAATGAAAGAAAAAGGAAACGGAGAACAACAATCAGTATTGCTGCTAAAGA
CGCCCTGGAGAGACACTTTGGAGAACAGAATAAGCCTTCCTCTCAGGAGATC
CTGCGGATGGCTGAAGAACTAAACCTGGAGAAAGAAGTGGTGAGGGTTTGGT
TTTGTAACCGAAGGCAGAGAGAAAAACGGGTGAAGACAAGCCT 
PRL: 
AGAACAAGCCCAACAGACCCACCATGAAGTCCTTATGAGCTTGATTCTTGGG
TTGCTGCGCTCCTGGAATGACCCTCTGTATCACCTAGTCACCGAGGTGCGGGG
 215 
 
TATGAAAGGAGCCCCAGATGCTATCCTATCGAGGGCCATAGAGATTGAGGAA
GAAAACAAACGACTTCTGGAAGGCATGGAGATGATATTTGGCCAGGTTATTC
CGAGCGCCAAAGAGACTGAGCCCTACCCTGTGTGGTCAGGACT 
TRHR: 
GCGATCTGTCACCCCATCAAAGCCCAGTTTCTCTGCACATTTTCCAGAGCCAA
AAAGATAATCATCTTTGTCTGGGCTTTCACATCCATTTACTGTATGCTCTGGTT
CTTCTTGCTGGATCTCAATATTAGCACCTATAAAGATGCTATTGTAGTGTCCT
GTGGCTACAAGATCTCCAGGAATTACTACTCACCTATTTACCTAATGGACTTT
GGTGTCTTTTATGTTGTGCCAATGATCCTAGCCACTGTCCTCTACGGAT 
VIP: 
CTGGTTCAGCTGTAAGGGCAAGAGAACTCGTGAAGACTGTCGACTCCCAGGA
CTTCAACACCTGAGACAGCTCTCATAATCTCAACAGAAAGCTCTCAAAGAAC
ACTATTCGGCAAAGTCCTGCAATGGAAACAAGAAGTAAGCCCCAGCTTCTTG
TGTTCCTGACGCTGTTCAGCGTGCTCTTCTCCCAGACCTTGGCGTGGCCTCTTT
TTGGAGCACCTTCGGCTCTGAGGATGGGGGACAGAATACCATTTGAAGGAGC
GAATGAACCTGATCAAGTTTCGTTAAAAGCAGACACTGACATTTTACAAGAT
GCGCTGGCTGA 
GAL: 
CACCGGTGAAGGAGAAGAGAGGCTGGACCCTGAACAGCGCTGGGTACCTTCT
CGGACCACATGCGCTCGACAGCCACAGGTCATTTCAAGACAAGCATGGCCTC
GCCGGCAAGCGGGAACTCGAGCCTGAAGACGAAGCCCGGCCAGGAAGCTTT
GACAGACCACTGGCGGAGAACAACGTCGTGCGCACGATAATCGAGTTTCTGA
CTTTCCTGCATCTCAAAGACGCC 
 
VEGFA: 
GCAAGAAAATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTA
CAAGATCCGCAGACGTGTAAATGTTCCTGCAAAAACACAGACTCGCGTTGCA
AGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGCAGATGTGACAAGCCGAG
GCGGTGAGCCGGGCTGGAGGAAGGAGCCTCCCTCAGGGTTTCGGGAACCAG
ACG 
TGFB1: 
GCGGCCAGATTTGTCCAAGCTTCGGCTCGCCAGCCCCCCGAGCCAGGGGGAT
GTGCCACCCGGCCCGCTGCCCGAGGCCATACTGGCCCTTTACAACAGTACCC
GCGACCGGGTGGCCGGGGAAAGTGCCGAAACGGAGCCTGAGCCAGAGGCGG
ACTACTACGCCAAGGGAGGTCACCCGCGTGCTAAWGGTGGAATACGGCAAC
AAAATCTATGACAAAATGAAGTCTAGCCTCGCACAGC 
 
 216 
 
GHRHR: 
CTGTAACAGTCCTGTGTAAGGTTTCTGTGGCCACTTCCCATTTCGCTACCATG
ACCAACTTCAGCTGGCTGCTGGCAGAAGCTGTGTACCTGACCTGCCTCTTAGT
CTCCACATTGCCCAGCACAAGGAGGGTCTTCTGGTGGCTGGTTCTCGCTGCCT
GGGGGCTTCCTCTGCTCTTTACCGGCATGTGGGTGGGTTGCAAGTTGGCCTTC
GAAGAC 
CSH2: 
CCCCATGCTAAGCCCACAATTAACCCAACCAGTCCTGAGATGGTTAGTGATG
ATCCATCCCGTCAAAAGCTTCTTTGAGTTTTATAGCTCTTTAATGCATGTTTGG
GTGTAATGGGTCTCATCTGAAACAAAATAAACACAGATTCTGTAGAGATGTC
AAAATCTAAGAAGGAAATTTGTCAATGTCTTTATCTTCATTTAATAGAAAATC
AAAATAAAATCCATCCCTACCTCTGAGAGAAA 
L-PRLR: 
CCATCCTTTCTGCTGTCATCTGTTTGATTATGGTCTGGGCAGTGGCTTTGAAG
GGCTATAGCATGGTGACCTGCATCCTCCCACCAGTTCCAGGGCCAAAAATAA
AAGGATTTGATGTTCATCTGCTGGAGAAGGG 
S-PRLR: 
GCCATCCTTTCTGCTGTCATCTGTTTGATTATGGTCTGGGCAGTGGCTTTGAG
GGCTATAGCATGGTGACCTGCATCCTCCCACCAGTTCCAGGGCCAAAAATAA
AAGGATTTGATGTTCATCTGCTGGAGATATCACAGCCTTCTCGCCT 
POMC: 
AGCTTCCCCCTGACAGAGCCTCAGCCTGCCTGGAAGATGCCGAGACTGTGCA
GCAGTCGTTCGGGCGCCCTGCTGCTGGCCTTGCTGCTTCAGGCCTCCATGGAA
GTGCGTGGTTGGTGCCTGGAGAGCAGCCAGTGTCAGGACCTCACCACGGAAA
GTAACCTGCTGGCGTGCATCCGGGCCTGCAAGCCCGACCTCTCCGCCGAGAC
GCCGGTGTTCCCCGGCAACGGCGACGAGCAGCCGCTGACTGAGAACCCCCGG
AAGTACGTCATGGGCCATTTCCGCTGGGACCGCTTCGGCCGTCGGAATGGTA
GCAG 
PCSK1: 
TGATCGTGTGATATGGGCGGAACAACAGTATGAAAAAGAAAGAAGTAAACG
TTCAGTTCTAAGAGACTCAGCACTAGATCTCTTCAATGATCCGATGTGGAATC
AGCAGTGGTACTTGCAAGATACAAGGATGACTGCAACCCTGCCCAAGCTGGA
TCTCCATGTGATACCTGTTTGGCAAAAAGGCATCACAGGCAAAGGTGTTGTT
ATCACTGTATTGGATGATGGCTTGGAGTGGAATCACACAGACATCTATGCCA
ACTATGATCCGGAGGCC 
PCSK2: 
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TGGTTTTTGCATCTGCTGAGAGACCGGTCTTCACGAATCATTTTCTTGTGGAG
TTGCACAGGGGGRAGAAGGAAGAAGCTCGCCAAGTTGCAGCAGAGCACGGT
TTTGGAGTCCGAAAGCTCCCCTTTGCTGAAGGCCTGTACCATTTTTATCACAA
TGGCCTGGCCAAGGCCAAGAGAAGACGCAGCCTACAGCATCAGCAGCAGCT
GGAGAGAGACCCCAGGGTAAAGAGG 
CPE: 
GCTTAGCTCGGCATACTCATCCTTCAACCCCCCAATGTCGGACCCAGATCGGC
CCCCATGTCGCAAGAATGATGATGACAGCAGCTTTGTAGAAGGAACGACCAA
TGGYGCTGCATGGTACAGCGTGCCTGGAGGAATGCAAGATTTCAATTACCTC
AGCAGCAACTGCTTTGAGATTACTGTGGAGCTTAGCTGTGAAAAGTTTCCACC
TGAAGAGACTTTGAAGAACTAYTGGGAGGATAACAAAAACTCCCTCATTAGC
TACATTCAGCAGATACACCGAGGAGTAAAGGATTTGTCCGAGATCTTCAGGG
TAACCCAATTGCTAACGCCCCCTCTCTGTG 
PAM: 
ACCAACACCGTGTGGAAGTTCACCTCGACCGAAAAAATGGAACATCGATCAG
TTAAGAAGGCTGGCATTGAGGTTCAGGAAATCAAAGAATCCGAGGCAGTTGT
TGAAACCAAAATGGAGAACAAGCCCGCCTCCTCAGAATTtGCAGAAGATACA
AGAGAAACAGAAGCTGGTCAAAGAGCCGGGCTCCGGAGTGCCGGCTGTTCTC
ATTACAACCCTTCTGGTTATTCCTGTGGTTGTCCTGCTGGCCATTGCCTTATTT
ATTCGGTGGAAAAAATCAAGGGCCTTTGGAGATTCTGAAC 
ATP5G1: 
CACCGGGGCACTACTCATTTCTCCTGCTCTGATCCGTTCTTGTACCAGGGGTC
TGATCAGGCCTGTGTCTGCCTCCTTCCTGAGTAGGCCAGAGATCCAATCTGTA
CAGCCTTCCTACAGCAGTGGCCCACTGCAGGTGGCCCGGCGGGAATTCCAGA
CCAGTGTTGTCTCCCGGGACATTGACACAGCGGCCAAGTTTATTGGCGCTGG
GGCTGCCACAGTTGGTGTGGCGGGTTCAGGGGCTGGTATTGGAACAGTGTTT
GGCAGCTTGATCATTGGCTATGCCAGGAACCCGTCTCTGAAGCAGCAGCTCT
CTCCTATGCCATTCTGGGCTTTGCCCTGTCTGAGGCTATGGGGCTCTT 
COX7A2: 
ACTGAGCCAAGATGCTACGGAATCTTCTGGCTCTCCGTCAGATTGCTAAGAG
GACCATAAGTACTTCTTCACGCAGGCAGTTTGAAAATAAGGTTCCAGAGAAA
CAAAAGCTGTTTCAGGAGGATAATGGAATTCCAGTGCATCTGAAGGGTGGGA
TAGCTGATGCCCTCCTGTATAGAGCCACCMTGATTCTTACAGTTGGTGGAAC
GGCATATGCCATGTATGAACTGGCTGTGGCTTCATTCCCAAGAAGCAGGATT
GACTTGAGTTTATCCTCCCAGCAATCAGTTGGGT 
CYB5A: 
AAGACTGCTTTGGTCCAGGGAGAAAGAAGCCACCACTCTTAACTTCAACTGA
CAACCCTTCACCTGAAAATAATCTGAATACACCTATTTTCCTTTCCTCCTACAT
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TAGACACAAAACAAACCATAACTGTTCCATTCTTTGGACTATTGAACTTCTAA
AGTGTGCCTTCTTATTCACCAACTTTGTTTTGCTGTTCCATCACTACATCATTT
GCTTATTGTGGACATGATCTTTTAAAACATACCACCATGCTGAGCTGTC 
FURIN: 
GCATCGAGAAGAACCACCCAGACTTGGCAGGCAATTATGATCCTGGGGCCAG
CTTCGATGTCAATGATCAGGACCCTGACCCCCAGCCCCGGTACACACAGATG
AATGACAACAGGCATGGCACACGGTGTGCAGGAGAGGTGGCTGCGGTGGCC
AACAATGGTGTCTGTGGCGTAGGCGTGGCCTACAATGCCCGAATTGGAGGGG
TGCGCATGCTGGATGGCGAAGTGACAGATGCCGTGGAG 
GPX4: 
GATCAAAGAGTTCGCCGCTGGCTATAACGTCAAATTCGATTTGTTCAGCAAG
ATCTGTGTAAATGGGGACGACGCCCACCCTCTGTGGAAATGGATGAAAGTCC
AGCCCAAGGGGAGAGGCATGCTGGGAAACGCCATCAAATGGAACTTCACCA
AGTTCCTCATTGACAAGAACGGCTGTGTGGTGAAGCGGTATGG 
LRRK2: 
AGGAATCCGATGCTTTGGCAAAACTTCGGAAAACCATCATCAATGAGAGCCT
TAATTTCAAGATCCGAGATCAGCCTGTTGTTGGGGCAGCTGATTCCAGACTGC
TACGTAGAACTTGAGAAAATCATTTTATCAGAGCGTAAAAATGTGCCAATTG
AATTTCCTGTAATTGACCGGAAACGATTATTACAACTTGTGAGAGAACATCA
GCTGCAGTTAGATGAAAATGAGCTTCCTCATGCAGTTCACTTTCTAAATGAAT
CAGGGGTCCTTCTTCATTTTCAAGACCCAGCATTGCAGT 
NDUFA2: 
CGTATCCATTTGTGCCAGCGCTCGCCCGGCAGCCAGGGCGTCAGGGACTTCA
TTGAGAAACGCTATGTGGAGCTGAAGAAAGCGAATCCCGACCTGCCCATCCT
AATCCGCGAGTGCTCGGATGTGCAGCCCAAGCTCTGGGCCCGCTACGCATTT
GGCCAAGAGAAGAATGTCTCTCTGAACAATTTCAGTGCTGATCAGGTAACTA
GAGCCCTGGAGAACGT 
PSENEN: 
GCGTGGTTGTTTGTGATCCTTGGATCTGTCACTTAGGGTCAGGACTTGGGTCT
TGCCCCAGACCCTCGGAAGACCGGCCCCAGCGCAACTATGAACTTGGAGCGG
GTGTCCAACGAAGAGAAGTTGAACCTCTGCCGGAAGTACTACCTGGGTGGGT
TTGCCTTCCTGCCTTTTCTCTGGTTGGTCAACATTTTCTGGTTCTTCCGAGAGG
CCTTCATTGTCCCGGCATACACGGAGCAGAGCCAAATCAA 
SDHB: 
AGAGACGACTTCACGGAGGAGCGCCTGGCCAAGCTGCAGGACMCCTTCTCTC
TCTACCGCTGCCACACCATCATGAACTGCACGCAGACCTGCCCCAAGGGGCT
GAATCCTGGGAAAGCTATTGCTGAAATCAAGAAGATGATGGCAACCTATAAA
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GAGAAGCAGGCTTCTGCTTAACTGCCGTGCTCAGCCTGACTGGAGCCGGCTC
AGAATGCAGTTCACCCCTGAGTTCCTTCAG 
CAT: 
CTATCCTGACACTCACCGCCACCGCCTGGGACCCAACTATCTCCAGATACCTG
TGAACTGTCCCTACCGTGCTCGAGTGGCCAACTACCAGCGTGACGGCCCCAT
GTGCATGATGGACAATCAGGGTGGGGCTCCAAATTACTACCCCAATAGCTTT
AGTGCTCCCGAGCATCAGCCTTCTGCCCTGGAACACAGGACCCACTTCTCTGG
GGATGTACAGCGCTCAACAGTGCCAACGATGACAATGTCACTCAGGTGCGGA
CTTTC 
SOD1: 
TTGGAGACCTGGGCAATGTGACAGCTGACAAAAACGGTGTTGCCATCGTGGA
TATTGTAGATCCTCTGATTTCACTCTCAGGAGAATATTCCATCATTGGCCGCA
CGATGGTGGTCCATGAAAAACCAGATGACTTGGGCAGAGGTGGAAATGAAG
AAAGTACAAAGACTGGAAACGCTGGAAGCCGTTTGGCCTGTGGTGTAA 
Figure 5.5. The sequences of the real-time RT-PCR products (5’ to 3’ orientation). 
Within a sequence, underlined nucleotides indicate the forward and reverse primer 
positions.  
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Figure 5.6. Principle component analysis of microarray transcriptome analysis of 20 
pituitary samples from steers grazing endophyte-infected tall fescue and supplemented 
with 3 mg Se/d in vitamin-mineral mixes as either sodium selenite (ISe, n = 6, red dots), 
SEL-PLEX (OSe, n = 7, blue dots), or a 1:1 mix of ISe and OSe (MIX, n = 7, green dots). 
The red, blue, and green dots represent linear combinations of the relative expression 
data, including expression values and variances, of the 26,773 gene transcripts in each 
Bovine Chip. 
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Figure 5.7. Hierarchical cluster analysis of the 542 “focus” genes selected as 
differentially expressed (ANOVA P-values of < 0.005 and false discovery rates of ≤ 
18.8%) by the pituitary of steers grazing endophyte-infected tall fescue and supplemented 
with 3 mg Se/d in vitamin-mineral mixes as either sodium selenite (ISe, n = 6), SEL-
PLEX (OSe, n = 7), or a 1:1 mix of ISe and OSe (MIX, n = 7). As indicated by the legend 
color box, black color in the middle represents the mean value, 0; red color represents 
gene expression levels above the mean expression; and blue color denotes expression 
below the mean. The intensity of the color reflects the relative intensity of the fold 
change. 
  
 222 
 
CHAPTER 6. Selenoprotein Gene Expression Profiles in the Pituitary and Liver of 
Growing Steers Grazing Endophyte-Infected Tall Fescue Are Sensitive to Different 
Forms of Supplemental Selenium 
 
6.1 Abstract  
The goal of this study was to test the hypothesis that the gene expression profiles of 25 
selenoproteins in the pituitaries and livers of growing beef steers commonly grazing an 
endophyte-infected tall fescue (HE) pasture would differ after consuming different forms 
of selenium (sodium selenite (ISe), SEL-PLEX (OSe), vs. a 1:1 blend (MIX) of ISe and 
OSe) in a basal vitamin-mineral (VM) mix. Predominately-Angus steers (BW = 183 ± 34 
kg) were randomly selected from herds of fall-calving cows grazing HE pasture and 
consuming VM mixes that contained 35 ppm Se as ISe, OSe, or MIX forms. Steers were 
weaned, depleted of Se for 98 d, and subjected to summer-long common grazing of a 
10.1 ha HE pasture containing 0.51 ppm ergot alkaloids. Steers were assigned (n = 8 per 
treatment) to the same Se-form treatments on which they were raised. Selenium 
treatments were administered by daily top-dressing 85 g of VM mix onto 0.23 kg 
soyhulls, using in-pasture Calan gates. As previously reported, whole blood Se was 
higher for OSe (11%) and MIX (7.5%) steers vs. ISe. Pituitaries and livers were collected 
at slaughter and changes in selenoprotein mRNA expression patterns determined by 
microarray and real-time reverse-transcription PCR analyses, respectively. The effects of 
Se treatment on relative gene expression were subjected to one-way ANOVA. In the 
pituitary, mRNA contents of 7 selenoproteins and two selenoprotein P receptors differed 
among Se treatments, whereas two selenoproteins were affected in liver. OSe steers may 
have a greater capacity to manage against oxidative damage, maintain cellular redox 
 223 
 
balance, and have a better quality control of protein-folding in their pituitaries than ISe 
steers. In contrast, the liver tissue of MIX steers may have a greater capacity for redox 
signaling and a greater ability to manage oxidative stress than ISe steers. We conclude 
that the form of Se in vitamin-mineral mixes alters the selenoprotein transcriptome of 
both the pituitary and liver of growing steers consuming HE forage, in an ostensibly 
positive manner.  
 
KEYWORDS: cattle, fescue toxicosis, liver, pituitary, selenium supplementation, 
selenoprotein profile 
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6.2 Introduction 
Selenium (Se) is an important trace element for many southeastern United States 
cattle producers due to low-Se soils (Dargatz and Ross, 1996). Selenium deficiency 
causes a variety of negative effects on beef cattle production including increased 
incidence of early embryonic death, retained placentas, cystic ovaries and weak heat 
periods (Corah, 1996), and reduced growth rate and immune responses (Cerny et al., 
2016). Se-poor soils result in Se-deficient forages necessitating the need to provide 
supplemental Se (Dargatz and Ross, 1996). Inorganic Se (ISe, sodium selenite) is the 
most common form of Se supplemented in cattle diets, whereas organic forms of Se 
(OSe) derived from specially cultivated Saccharomyces cerevisiae also are available and 
approved for beef cattle production (Juniper et al., 2008). 
The other challenge faced by many southeastern United States cattle producers is 
fescue toxicosis, which results from consumption of ergot alkaloids found in Epichloe 
coenophialum-infected tall fescue (Lolium arundinaceum) pastures and is a clinical 
condition consisting of impaired metabolic, vascular, growth, and reproductive processes 
in cattle (Strickland et al., 2011). Serendipitously, it was found that expression of several 
genes downregulated in the liver (Liao et al., 2015) and pituitary (Li et al., 2017) of steers 
grazing high vs. low endophyte-infected forages were upregulated in cattle by 
consumption of a 1:1 blend of ISe:OSe (MIX) in vitamin-mineral (VM) mixes (Matthews 
and Bridges, 2014; Matthews et al., 2014).  
It is widely believed that Se exerts its biological functions through selenoproteins, 
most of which are redox enzymes. There are 25 identified mammalian selenoprotein 
genes (Kryukov et al., 2003). The goal of the present study was to test the hypothesis that 
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the form of supplemental Se would alter selenoprotein transcriptome profiles in 
pituitaries and livers of growing steers subjected to summer-long grazing of endophyte-
infected pasture. 
6.3 Materials and methods 
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. 
6.3.1 Animals model 
The animal management regimen and model for steers that yielded the pituitary 
and liver tissues of the present experiment have been reported (Jia et al., 2018). Briefly, 
twenty-four predominantly Angus beef steers (BW, 182.6 ± 33.9 kg; age, 165.5 ± 14.2 
d) were randomly selected from 3 Se phenotypic herds (8 steers/herd), which were 
managed under a typical forage-based (predominately endophyte-infected tall fescue), 
fall-calving, cow-calf production regimen. The 3 Se phenotypic herds had free access to 
VM premixes (UK Beef IRM Cow-Calf Mineral, Burkmann Feeds, Danville, KY) 
containing 35 ppm of inorganic Se (ISe, sodium selenite, Prince Se Concentrate; Prince 
Agri Products, Inc., Quincy, IL, USA), organic Se (OSe, SEL-PLEX, Alltech Inc., 
Nicholasville, KY), and 1:1 mix of ISe:OSe (MIX). After adapted to consuming VM 
premixes from in-pasture Calan gate feeders, twenty-four steers with 3 Se phenotypes (n 
= 8) started (d 0) summer-long grazing (86 d) of a 10.1-ha predominately endophyte-
infected tall fescue-mixed pasture (0.51 μg/g total ergot alkaloids) (Jia et al., 2018). The 3 
Se form treatments were administered using in-pasture Calan gate feeders to steers with 
the same Se phenotypes. All 3 Se form treatments contained a common basal VM premix 
with added 35 ppm Se as either ISe, OSe, or MIX. During this 86-d period, two ISe steers 
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were removed from the trial due to a bad hoof and failure to consume their mineral 
treatment. After the common 86-d grazing period on pastures, steers were slaughtered in 
the University of Kentucky Meat Laboratory (Lexington, KY) over a 26-d period (from 
day 93 to 119, 8 slaughter d, 1 steer from each treatment/d). Throughout the slaughter 
period, steers continued to maintain their respective Se treatment. Details of the slaughter 
period and process have been reported (Jia et al., 2018). 
6.3.2 Sample collection and RNA preparation 
Steers were stunned by captive bolt pistol and exsanguinated. Within 15 to 20 
minutes of death, the whole pituitary and liver samples collected from mid-lower right 
lobe were collected from each animal, placed in a foil pack, flash-frozen in liquid 
nitrogen, and stored at -80°C. Two pituitary glands (1 OSe and 1 MIX) were not used 
because of tissue damage incurred during the collection process. As a result, six 
pituitaries (n = 6) and six liver samples (n = 6) for ISe, and seven pituitaries (n = 7) and 
eight liver samples (n = 8) for both OSe and MIX treatment groups were subjected to 
RNA analyses.  
Total RNA was extracted from the whole frozen pituitary and liver tissue using 
TRIzol Reagent (Invitrogen Corporation, Carlsbad, CA) following the manufacturer’s 
instructions. The RNA concentrations were determined using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), which revealed that all 
samples had an average concentration of 706 ng/µL for pituitary and 1.05 µg/µL for liver 
samples, and were of high purity with 260:280 nm absorbance ratios ranging from 1.85 to 
2.05 and 260:230 nm absorbance ratios ranging from 1.89 to 2.50. The integrity of total 
RNA was examined by gel electrophoresis using an Agilent 2100 Bioanalyzer System 
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(Agilent Technologies, Santa Clara, CA) at the University of Kentucky Microarray Core 
Facility. All RNA samples had 28S:18S rRNA absorbance ratios greater than 1.8 and 
RNA integrity numbers greater than 8.7.  
6.3.3 Microarray analysis 
The GeneChip Bovine Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA) 
was used to investigate the effect of Se treatment on bovine pituitary and liver gene 
expression profiles. Microarray analysis was conducted according to the manufacturer’s 
standard protocol at the University of Kentucky Microarray Core Facility. Briefly, 3 g 
of RNA for each sample was first reverse-transcribed (RT) to cDNA and then from 
cDNA (double-stranded) to complementary RNA (cRNA; single-stranded), which was 
then labeled with biotin. The biotinylated cRNAs were further fragmented and used as 
probes to hybridize the gene chips in the GeneChip Hybridization Oven 640 
(Affymetrix), using 1 chip per RNA sample. After hybridization, the chips were washed 
and stained on a GeneChip Fluidics Station 450 (Affymetrix). The reaction image and 
signals were read with a GeneChip Scanner (GCS 3000, 7G; Affymetrix), and data were 
collected using the Command Console. The raw expression intensity values from the 
Command Console (i.e., 20 *.cel files from the raw methylation measurements) were 
imported into Partek Genomics Suite software (PGS 7.17.0918; Partek Inc., St. Louis, 
MO). For GeneChip background correction, the algorithm of Robust Multichip 
Averaging adjusted with probe length and GC oligo contents was implemented (Irizarry 
et al., 2003; Wu et al., 2004). The background-corrected data were further converted into 
expression values using quantile normalization across all the chips and median polish 
summarization of multiple probes for each probe set. 
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All the GeneChip transcripts were annotated using the NetAffx annotation 
database for gene expression on Bovine GeneChip Array ST 1.0, provided by the 
manufacturer (http://www.affymetrix.com/analysis/index.affx, last accessed in January 
2018, annotation file last updated in May 2016). Quality control of the microarray 
hybridization and data presentation was performed by MA plot on all the gene expression 
values and by box plot on the control probe sets on the Affymetrix chips (data not 
shown). To assess treatment effects (ISe vs. OSe vs. MIX) on the relative expression of 
the pituitary and liver gene transcripts, qualified microarray data were subjected to one-
way ANOVA using the same PGS software. 
All the microarray *.cel files collected by Command Console plus the GC Robust 
Multichip Averaging-corrected data processed by PGS software of this manuscript have 
been deposited in the National Center for Biotechnology Information’s Gene Expression 
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) [released May 25, 2018]), are 
minimum information about a microarray experiment (MIAME) compliant (Brazma et 
al., 2001), and are accessible through GEO series accession number GSE114893 
(pituitary) and GSE115802 (liver). 
6.3.4 Real-time RT-PCR analysis 
Primer sets for genes selected for real-time reverse transcription (RT) PCR 
analysis (Table 6.3) were designed using the NCBI Pick Primers online program against 
RefSeq sequences. Real-time RT-PCR was performed using an Eppendorf Mastercycler 
ep realplex2 system (Eppendorf, Hamburg, Germany) with iQ SYBR Green Supermix 
(Bio-RAD, Hercules, CA), as described (Bridges et al., 2012). Briefly, cDNA was 
synthesized using the SuperScript III 1st Strand Synthesis System (Invitrogen), with 1 μg 
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of RNA used for each reverse transcription reaction. Real-time RT-PCR was performed 
with a total volume of 25 μL per reaction, with each reaction containing 5 μL of cDNA, 1 
μL of a 10 μM stock of each primer (forward and reverse), 12.5 μL of 2× SYBR Green 
PCR Master Mix, and 5.5 μL of nuclease-free water. Gene expression was analyzed by 
the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
The resulting real-time RT-PCR products were purified using a PureLink Quick 
Gel Extraction Kit (Invitrogen) and sequenced at Eurofins Scientific (Eurofins, 
Louisville, KY). Sequences were compared with the corresponding RefSeq mRNA 
sequences used as the templates for primer set design. The sequences of the primers and 
the resulting sequence-validated real-time RT-PCR reaction amplicons for selected DEG 
and the endogenous control genes (RPS11, TFRC, and UBC for pituitary; GAPDH, 
PCK2, and SDHA for liver) are presented in Table 6.3 and Figure 6.3, respectively. All 
sequenced amplicons had at least 98% identity with their template sequences. Three 
constitutively expressed housekeeping genes for pituitary (RPS11, TFRC, and UBC; P = 
0.59, 0.51, 0.66; respectively) and liver (GAPDH, PCK2, and SDHA; P = 0.60, 0.78, 
0.75; respectively) were used and their CT values were not affected by Se-form 
treatments. Thus, the geometric mean expression of 3 housekeeping genes was used to 
normalize the relative quantities of the selenoprotein mRNA expression, and all RT-PCR 
reactions were conducted in triplicate. 
6.3.5 Statistical analysis 
Steers were the experimental units. To test for Se treatment effects on the relative 
expression of the selenoprotein gene transcripts analyzed by microarray hybridization, 
data were subjected to one-way ANOVA using the PGS software as described in the 
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“Microarray Analysis” section above. To determine the effects of treatment on the 
relative expression levels of selenoprotein gene analyzed by real-time RT-PCR, data were 
subjected to one-way ANOVA using the GLM procedure of the SAS statistical software 
package (version 9.4; SAS Inst., Inc., Cary, NC), with the Se treatment as the fixed 
effect. For these data, significance was declared when P ≤ 0.05, and a tendency to differ 
was declared when 0.10 > P > 0.05. When P < 0.10, means were separated using Fisher’s 
LSD procedure. Principal component analysis (PCA) was performed using JMP Pro 
software (version 14; SAS Inst. Inc.). As appropriate, Se concentration, glutathione 
(GSH) content, glutamine synthetase (GS) activity, and relative mRNA abundance of 
selenoproteins in liver were used as input variables for PCA. 
6.4 Results 
6.4.1 Microarray and real-time RT-PCR analyses of selenoprotein mRNA 
 In the pituitary, real-time RT-PCR analysis corroborated the microarray analysis 
that the relative expression of GPX3, LRP2, LRP8, SELENON, SEPHS2, TXNRD1 
differed (P < 0.05) among Se treatment steers (Table 6.1). In addition, both techniques 
showed that the relative expressions of DIO1, DIO2, DIO3, GPX1, GPX2, SELENOI, 
SELENOK, SELENOP, SELENOT, SELENOV, SELENOW, SEPHS1, and TXNRD3 
were not affected by Se treatment (Table 6.1).  The relative expression of GPX4, 
MSRB1, and TXNRD2 differed (P < 0.05) based on microarray analysis, whereas RT-
PCR results showed their tendency to differ (P < 0.1). In contrast, RT-PCR showed 
SELENOM mRNA affected by Se treatment (P < 0.05), but according to microarray, 
SELENOM mRNA had the tendency to change (P < 0.1). There was inconsistency 
between microarray and RT-PCR results for 4 genes. The relative expression of GPX6, 
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SELENOF, and SELENOS differed or tended to differ by RT-PCR analysis, but not by 
microarray analysis. In addition, RT-PCR found that SELENOO was affected by Se 
treatment, but this gene is not included in the microarray chip design. With regard to 
fold-changes, the direction of Se treatment-induced change was the same between 
microarray and RT-PCR analyses whereas the magnitude of the determined fold-changes 
typically was greater by RT-PCR analysis. 
In liver, real-time RT-PCR analysis corroborated the microarray analysis finding 
that the relative expression of SELENOT differed (P < 0.05) and that of GPX4 tended to 
differ (P < 0.1) among Se treatment steers (Table 6.2). In addition, both techniques 
showed that the relative expression of DIO1, GPX1, GPX2, GPX3, LRP2, LRP8, 
MSRB1, SELENOF, SELENOI, SELENOK, SELENON, SELENOV, SELENOW, 
SEPHS1, and TXNRD3 was not affected by Se treatment (Table 6.2).  The relative 
expressions of SELENOS and TXNRD1 tended to differ (P < 0.1) based on microarray 
analysis, whereas RT-PCR results showed that they do differ (P < 0.05) among Se 
treatment steers. As for the pituitary, inconsistencies existed between results of 
microarray and RT-PCR analyses. The relative expressions of DIO3, SELENOP, 
SEPHS2, and TXNRD2 differed or tended to differ by RT-PCR analysis, but not by 
microarray. Whereas microarray analysis showed that relative expressions of DIO2, 
GPX6, and SELENOM were affected by Se treatment (P < 0.1), but RT-PCR analysis did 
not.  RT-PCR also found that SELENOO was affected by Se treatment but, as noted 
above, this gene is lacking in the GeneChip Bovine Gene 1.0 ST Array.  
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6.4.2 Principal component analysis 
 Principal component analysis of the potential correlation between mRNA contents 
of selenoproteins and other analytes (Se concentration, glutathione content, and 
glutamine synthetase activity) in liver indicated that PC1 and PC2 explained 37.7% of the 
variation (Figure 6.1 and 6.2). All steers with ISe supplementation segregated within the 
negative quadrants of PC2, whereas three steers from both OSe and MIX groups 
segregated into the negative quadrants of PC2 (Figure 6.1). Relative mRNA expression of 
GPX2, SELENOP and SELENOV, GSH content, and Se concentration clustered in the 
PC1-positive and PC2-negative quadrant (Figure 6.2). They were either weakly or not 
correlated with PC1 and PC2. 
6.5 Discussion 
It is widely accepted that Se exerts its biological function mainly through 
selenoproteins. However, most studies focusing on effect of supplemental Se on 
selenoprotein expression or activity used the Se deficiency vs. Se supplementation model. 
Using a Se-adequate model, our laboratory has shown that forms of supplemental dietary 
Se affected the expression of certain genes in the livers of maturing beef heifers 
(Matthews et al., 2014), neonatal testes (Cerny et al., 2016), and pituitaries of growing 
beef steers (Chapter 5). We also have shown that consumption of HE forage decreases 
the expression of at least 7 selenoproteins by the liver or pituitaries of growing steers 
(Matthews and Bridges, 2014; Liao et al., 2015; Li et al., 2017) that are upregulated by 
MIX or OSe forms of supplemental Se. However, to our knowledge, the potential effects 
of forms of supplemental Se on the selenoprotein transcriptome of the pituitary and liver 
of cattle grazing HE forages has not been reported. To obtain this information and 
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elaborate the findings of Chapter 5, we conducted microarray and RT-PCR analyses of 25 
selenoprotein genes in both pituitary and liver tissues collected from previously described 
(Chapter 5) beef steers, which had consumed VM mixes that contained 35 ppm Se as ISe, 
OSe, or MIX forms while subjected to summer-long grazing of high endophyte-infected 
tall fescue (Jia et al., 2018). That OSe and MIX steers had 11% and 7.5% more whole 
blood Se than ISe steers, respectively, and did not differ from each other, as expected, 
validated the successful administration of the Se treatments. 
In pituitary tissue, the expression of 5 selenoproteins (GPX3, GPX4, MSRB1, 
SELENON, TXNRD1) were increased (P ≤ 0.05) and one (SEPHS2) decreased (P ≤ 
0.04) by Se treatments, based on both microarray and RT-PCR analyses. In addition, one 
selenoprotein (SELENOO), solely evaluated by RT-PCR, was increased (P = 0.03). Also, 
the expression of the two receptors for selenoprotein P (LPR2, LPR8) was affected (P ≤ 
0.04) in the pituitary. In the liver, the expression of only two selenoproteins (SELENOO, 
SELENOT) was affected (increased, P ≤0.04), according to both microarray and RT-
PCR, or only RT-PCR. Inconsistencies existed between the results of the microarray and 
RT-PCR analyses, especially in liver. Possible explanations for these inconsistencies 
include differences in the sites and number of nucleotides measured for a given transcript, 
gene normalization procedures, and inherent technique-specific pitfalls (Bustin, 2002; 
Chuaqui et al., 2002; Morey et al., 2006). Because RT-PCR often is considered the more 
accurate technique for quantification of gene expression, due to its greater sensitivity and 
specificity (Schmittgen et al., 2008; Derveaux et al., 2010), when there was a conflict 
between microarray and RT-PCR results, we used the RT-PCR finding as the definitive 
finding.  
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Glutathione peroxidases 
The family of glutathione peroxidases (GPx) catalyze the reduction of hydrogen 
peroxide (H2O2) or hydroperoxides to water (at the expense of oxidizing 2 GSH to 
GSSG) to maintain cellular redox homeostasis (Margis et al., 2008). The five known 
mammalian GPx are all selenoproteins. Cytosolic glutathione peroxidase (GPx1) is the 
first identified mammalian selenoprotein, which scavenges toxic H2O2 and soluble 
organic peroxides (Rotruck et al., 1973). GPx1 is expressed in all cell types and is most 
abundant in the liver and kidney. Functionally, GPx2 highly resembles GPx1. However, 
unlike GPx1 which is a ubiquitously expressed, GPx2 is expressed mainly in the 
epithelium of gastrointestinal tract and somewhat in liver (Arthur, 2001). Glutathione 
peroxidase 3 and GPx4 are expressed by a wide range of cell types and tissues. GPx3 is 
the only extracellular GPx isoform and is secreted mainly by the kidney. Importantly, as 
the concentration of plasma GSH is fairly low, GPx3 can utilize thioredoxin or 
glutaredoxin as reductants in addition to GSH (Björnstedt et al., 1994). Unlike GPx1, 
GPx2, and GPx3, which are all homotetramers, GPx4 is ubiquitously present in the 
cytosol as a monomer, which enables its unique reduction function of complex 
phospholipid hydroperoxides in membranes (Herbette et al., 2007; Labunskyy et al., 
2014). Glutathione peroxidase 4 also uses protein thiols as alternate substrates besides 
GSH (Ursini et al., 1999). Glutathione peroxidase 6 is the last identified Sec-containing 
glutathione peroxidase, and its mRNA has been reported to be only found in embryos and 
olfactory epithelium (Kryukov et al., 2003).  
In the pituitary, RT-PCR analysis found that OSe steers had more GPx3 (180%) 
and GPx4 (51%) mRNA than ISe and MIX steers, whereas MIX steers had less GPx6 
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(54%) than ISe steers. In the liver, GPx4 mRNA content was greater (55%) in MIX vs. 
ISe steers (Table 6.2). Collectively, these findings suggest that OSe and MIX steers had a 
greater capacity to prevent oxidative damage and to maintain cellular redox balance 
better in their pituitaries and livers, respectively. 
In liver, PCA indicated that GSH content was closely associated with Se 
concentration (Figure 6.2). The mRNA content of GPx2 was closely associated with 
hepatic GSH content in the PC1-positive and PC2-negative quadrant. In addition, the 
mRNA content of GPx1 (the most abundant mammalian selenoprotein), also existed in 
that quadrant and closely associated with GPx2. In contrast, GPx4 (another abundant 
liver glutathione reductase) and other GSH-interacting selenoproteins TXNRD2 and 
SELENOW were not closely associated with hepatic GSH content (Figure 6.2). Hence, it 
is possible that hepatic Se concentration affected hepatic GSH content by regulating the 
expression of GPx1 and GPx2. Interestingly, PCA also indicated that glutamine 
synthetase activity was present in the opposite quadrant of GSH. This finding seems to 
support a previous suggestion that the GSH synthesis enzyme γ-glutamylcysteine ligase 
and glutamine synthetase may directly compete for hepatic Glu (Huang et al., 2018). 
Thioredoxin reductases 
Thioredoxins (TXNRD) are a class of small, ubiquitously-expressed redox 
proteins present in all living cells, protecting cells from oxidative stress and facilitating 
redox signaling by catalyzing the dithiol-disulfide exchange reactions of other proteins. 
Oxidized thioredoxins need to be reduced to exert their functions again, and the NADPH-
dependent reduction is catalyzed by the flavoenzyme thioredoxin reductases (Arnér, 
2009). There are three known thioredoxin reductases in mammals, all of which are 
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selenoproteins (Labunskyy et al., 2014). Thioredoxin reductase 1 is primarily present in 
cytosol, and is the major protein disulfide reductase in mammalian cells (Arnér and 
Holmgren, 2000). Thioredoxin reductase 2 is localized to mitochondria and expressed in 
various cell types (Rundlöf et al., 2001; Lillig and Holmgren, 2007), and thioredoxin 
reductase 3 exists primarily in testes (Arnér, 2009).  
In the pituitary, the abundance of TXNRD1 and TXNRD2 mRNA was greater in 
MIX steers than both ISe and OSe steers. (Table 6.1). In liver, that MIX and OSe steers 
had more TXNRD1 mRNA than ISe steers and that ISe, and MIX steers had more 
TXNRD2 mRNA than OSe steers (Table 6.2), suggests that MIX steers may have had 
better thioredoxin-thioredoxin reductase system in both pituitary and liver tissues.  
Selenoprotein P and its receptors 
Unlike most other selenoproteins which usually contain one Sec residue, 
selenoprotein P (SelP) contains 9-12 Sec residues per protein molecule in mammals 
(Read et al., 1990). Bovine SelP contains 12 Sec residues (Mostert, 2000). This unique 
property enables SelP to account for approximately 50% of the total Se in plasma (Burk 
and Hill, 2005). It has been suggested that the main role of SelP is in selenium transport, 
delivery, and storage (Burk et al., 1991; Saito and Takahashi, 2002). Selenoprotein P is 
mainly synthesized in liver, although its mRNA can be found in all tissues (Labunskyy et 
al., 2014). There are two endocytic receptors for SelP from low-density lipoprotein 
receptor family facilitating SelP entering into extrahepatic cells in a tissue-specific 
manner, the major receptor apolipoprotein E receptor-2 (apoER2) (Olson et al., 2007) and 
the minor receptor megalin (Olson et al., 2008). ApoER2 is expressed highly in testis, 
bone marrow, placenta, brain, and muscle; moderately in other tissues like thymus and 
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spleen; and minimally in liver and kidney (Burk and Hill, 2015). It is suggested the tissue 
hierarchy for Se in largely determined by SelP binding to apoER2 (Burk and Hill, 2015). 
The other SelP receptor megalin plays an essential role for uptake of plasma SelP in 
kidney, and the uptake is proposed to provide Se for GPx3 synthesis in kidney proximal 
tubules (Avissar et al., 1994).  
 The SELENOP mRNA content in the pituitary was not affected by Se treatment. 
However, MIX steers had more apoER2 mRNA and less megalin mRNA than ISe steers, 
suggesting that MIX steers may have had more Se uptake in their pituitaries than ISe 
steers. In the liver, OSe (19%) and MIX (16%) steers tended to have less SELENOP 
mRNA than ISe steers, whereas the concentration of hepatic Se did not differ among 
OSe, ISe, and MIX steers (data not shown). PCA showed that mRNA of SELENOP and 
hepatic Se concentration were present in the same quadrant but not associated with each 
other very closely (Figure 6.2). These findings above indicated that SelP synthesis may 
not be a direct reflection of hepatic Se content. 
Methionine sulfoxide reductase B1 (Selenoprotein R) 
Selenoprotein R (SelR), also known as methionine sulfoxide reductase B1 
(MSRB1) or selenoprotein X, is a zinc-containing stereospecific methionine R sulfoxide 
reductase. It is predominantly localized in the nucleus and cytosol (Kim and Gladyshev, 
2004). SelR is sensitive to dietary Se intake (Novoselov et al., 2005). It is the major 
mammalian methionine sulfoxide reductase B with the highest activity in liver and 
kidney (Kim and Gladyshev, 2004). SelR catalyzes the specific reduction of R-isomer of 
oxidized methionine in proteins. Therefore, it is required for repair of oxidative damaged 
proteins (Kryukov et al., 2002). In addition, it is reported that SelR is important for 
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regulation of cellular functions by reduction of methionine residues of regulatory proteins 
(Lee et al., 2013). That both OSe and MIX steers had more MSRB1 than ISe steers 
(Table 6.1) suggests that OSe and MIX steers may handle oxidative-damaged proteins 
better than ISe steers in pituitary. 
15-kDa selenoprotein (Selenoprotein F) 
The 15-kDa selenoprotein (Sep15) is one of the earliest identified selenoproteins. 
It is named for its molecular mass (Behne et al., 1997). A single Sec residue is located in 
the middle of the protein (Gladyshev et al., 1998). Sep15 is expressed in a wide range of 
tissues in mammals, with the highest levels in liver, kidney, prostate, and testis 
(Kumaraswamy et al., 2000). Its expression is sensitive to dietary Se intake (Ferguson et 
al., 2006). Sep15 has a thioredoxin-like domain, and N-terminal signal peptide, which is 
consistent with its location to the ER (Labunskyy et al., 2014). In addition, Sep15 
interacts with the UDP-glucose: glycoprotein glycosyltransferases (UGGT) to form a 
tight complex. UGGT is an ER-resident chaperone which is involved in N-linked 
glycoproteins folding in the ER (Hebert et al., 1995; Molinari and Helenius, 1999). 
Hence, Sep15 is involved in disulfide-bond formation and quality control of some 
glycoproteins in the ER (Labunskyy et al., 2007). Moreover, studies also suggest that 
Sep15 may be involved in cancer etiology in various types of tissues (Kumaraswamy et 
al., 2000; Hu et al., 2001; Apostolou et al., 2004; Nasr et al., 2004; Irons et al., 2010). 
That the pituitaries of OSe steers tended to possess more SEP15 mRNA than ISe steers 
(Table 6.1) suggests that OSe steers may have had a better quality control of protein-
folding than ISe steers. 
Selenophosphate synthetase 2 
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Selenophosphate synthetase 2 (SPS2, encoded by SEPHS2) is homologous to 
selenophosphate synthetase 1 (SPS1) in mammals. However, unlike SPS1 in which the 
putative active center Sec is replaced by threonine, SPS2 belongs to the selenoprotein 
family (Low et al., 1995). Selenophosphate synthetase 2 (SPS2) catalyzes the conversion 
of selenide to active Se donor selenophosphate, which is required for Sec biosynthesis 
(Xu et al., 2007). SPS2 is an interesting selenoprotein in that it possibly regulates its own 
biosynthesis (Guimarães et al., 1996), thereby playing an auto-regulatory role in 
selenoprotein synthesis (Kim et al., 1997). The significance of a reduced content of 
SEPHS2 mRNA in OSe and MIX steers (Table 6.1) is unclear. Although it is a necessary 
component for the Sec synthesis machinery, whether SPS2 regulates expression of other 
selenoproteins and other aspects of SPS2 biological function remains to be determined.  
Other selenoproteins 
The mRNA content of selenoprotein M, N, O, and S were differentially expressed 
in pituitaries (Table 6.1), as were selenoproteins O, S, T in livers (Table 6.2), of Se 
treatment groups. However, their biochemical functions of these proteins have not been 
definitively determined. Selenoprotein M is proposed to be involved in neuroprotection 
against oxidative damage by H2O2 and regulation of Ca2+ release from ER in neurons 
(Reeves et al., 2010). Selenoprotein N plays a role in maintenance of muscle progenitor 
satellite cells and regeneration of impaired skeletal muscle (Castets et al., 2011), but its 
role in other tissues is still in a mystery. Selenoprotein S is localized to the ER membrane 
and proposed to be involved in degradation of misfolded proteins (Labunskyy et al., 
2014) and regulation of inflammatory and immune response (Curran et al., 2005; Gao et 
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al., 2006). The proposed roles that selenoprotein T is involved in include: endocrine 
homeostasis, brain development and function, and neuroprotection (Youssef et al., 2018). 
Both microarray and RT-PCR analyses revealed no difference in mRNA 
expression of selenoprotein I, K, V, and W, in both pituitary and liver tissues among Se 
treatment groups. In addition, microarray analysis found selenoprotein H mRNA 
unchanged in both pituitary and liver (Table 6.1 and 6.2). SelW may play a role in redox-
related process regulation because it binds GSH to form a complex with very high 
affinity (Beilstein et al., 1996). Although the expression of SelW is reported to be 
regulated by the availability of dietary Se (Howard et al., 2013) and by form of Se 
(Matthews et al., 2015), in this study the form of Se did not affect expression of 
SELENOW in either pituitary of liver tissue. 
In summary, consumption of 3 mg Se/d in VM mixes as OSe, MIX, or ISe 
differentially affected the expression of selenoprotein profiles in both pituitaries and 
livers of growing beef steers commonly grazing an endophyte-infected tall fescue 
pasture. Most of the affected selenoproteins were either up-regulated by OSe or MIX 
supplementation relative to ISe supplementation. The change in selenoprotein gene 
expression in pituitaries indicates that OSe steers have a greater potential capacity to 
manage against oxidative damage, maintain cellular redox balance, and have a better 
quality control of protein-folding in their pituitaries than ISe steers. The change in 
selenoprotein gene expression by the liver indicates that MIX steers have a greater redox 
signaling capacity and capacity to manage oxidative damage than ISe steers. 
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Table 6.1. Microarray and real-time RT-PCR (RT-PCR) analyses of the effect of 
consuming 3 mg Se/d in vitamin-mineral mixes as either sodium selenite (ISe), SEL-
PLEX (OSe), or a 1:1 mix of ISe and OSe (MIX) during summer-long grazing of 
endophyte-infected tall fescue on pituitary selenoprotein gene expression by growing 
beef steers. 
Gene Gene Name 
Microarray1 RT-PCR2 
Treatment3,4 P-
valu
e 
Treatment3,4 P-
valu
e 
ISe MIX OSe ISe MIX OSe 
DIO1 Iodothyronine 
Deiodinase 1 
1.00 1.04 1.07 0.52
3 
1.17 1.37 0.93 0.40
4 
DIO2 Iodothyronine 
Deiodinase 2 
1.00 1.15 1.13 0.45
6 
1.09 1.42 1.42 0.39
3 
DIO3 Iodothyronine 
Deiodinase 3 
1.00 0.84 0.95 0.11
8 
1.08 1.17 1.47 0.21
9 
GPX1 Glutathione 
Peroxidase 1 
1.00 1.11 1.06 0.47
4 
1.06 1.09 1.04 0.95
5 
GPX2 Glutathione 
Peroxidase 2 
1.00 0.96 0.89 0.48
3 
1.03 0.91 0.85 0.35
1 
GPX3 Glutathione 
Peroxidase 3 
1.00
a 
1.46b 1.57b 0.02
0 
1.17
a 
1.86a 3.28b 0.01
0 
GPX4 Glutathione 
Peroxidase 4 
1.00
a 
1.21b 1.23b 0.00
4 
1.03
a 
1.32a
b 
1.56b 0.05
2 
GPX6 Glutathione 
Peroxidase 6 
1.00 0.95 0.95 0.78
0 
1.14
a 
0.53b 0.79a
b 
0.02
8 
LRP2 
(Megalin) 
LDL Receptor 
Related 
Protein 2 
1.00
a 
0.92b 0.99a 0.03
8 
1.08
a 
0.53b 0.74a
b 
0.01
6 
LRP8 
(APOER2
) 
LDL Receptor 
Related 
Protein 8 
1.00
a 
1.26b 1.14a
b 
0.02
0 
1.01
a 
1.67b 1.34a
b 
0.02
8 
MSRB1 
(SEPX1) 
Methionine 
Sulfoxide 
Reductase B1 
1.00
a 
1.23b 1.19b 0.01
1 
1.05
a 
1.81b 1.92b 0.05
3 
SELENO
F (SEP15) 
Selenoprotein 
F 
1.00 0.99 0.96 0.40
9 
1.02
a 
1.24a
b 
1.37b 0.08
2 
SELENO
H 
Selenoprotein 
H 
1.00 1.16 1.06 0.19
2 
NA NA NA NA 
SELENOI 
(EPT1) 
Selenoprotein 
I 
1.00 1.10 0.96 0.13
5 
1.06 1.41 1.07 0.19
2 
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Table 6.1 (continued) 
SELENO
K 
Selenoprotein 
K 
1.00 1.10 1.12 0.16
5 
1.19 1.57 1.70 0.55
0 
SELENO
M 
Selenoprotein 
M 
1.00
a 
1.13a
b 
1.26b 0.07
7 
3.19
a 
7.57a
b 
11.69
b 
0.00
5 
SELENO
N 
Selenoprotein 
N 
1.00
a 
1.13b 1.06a
b 
0.01
3 
1.10
a 
2.20b 1.77a
b 
0.01
5 
SELENO
O 
Selenoprotein 
O 
NA NA NA NA 1.01
a 
1.29a
b 
1.64b 0.03
3 
SELENO
P 
Selenoprotein 
P 
1.00 1.00 1.00 0.98
2 
1.01 1.11 1.10 0.56
5 
SELENO
S 
Selenoprotein 
S 
1.00 1.08 1.02 0.27
7 
1.02
a 
1.25a
b 
1.41b 0.06
7 
SELENO
T 
Selenoprotein 
T 
1.00 1.03 1.00 0.48
9 
1.01 1.08 1.17 0.46
1 
SELENO
V 
Selenoprotein 
V 
1.00 1.01 1.05 0.85
0 
1.04 1.12 1.12 0.81
0 
SELENO
W 
Selenoprotein 
W 
1.00 1.03 1.01 0.91
0 
1.02 1.10 1.03 0.83
0 
SEPHS1 Selenophospha
te Synthetase 1 
1.00 1.03 0.99 0.54
8 
1.07 1.03 1.03 0.96
5 
SEPHS2 Selenophospha
te Synthetase 2 
1.00
a 
0.93a
b 
0.88b 0.04
5 
1.01
a 
0.74b 0.81b 0.01
9 
TXNRD1 Thioredoxin 
Reductase 1 
1.00
a 
1.12b 0.97a 0.00
1 
1.00
a 
1.42b 0.98a 0.00
5 
TXNRD2 Thioredoxin 
Reductase 2 
1.00
a 
1.15b 1.03a 0.03
6 
1.05
a 
1.82b 1.66a
b 
0.08
4 
TXNRD3 Thioredoxin 
Reductase 3 
1.00 0.92 0.95 0.28
6 
1.02 1.35 1.49 0.13
0 
1The abundance of gene transcripts are reported relative to the mean expression of the ISe 
treatment group (untransformed microarray data).  
2The abundance of gene transcripts are reported relative to the geometric mean 
expression of the reference genes. 
3Values are least squares means (n = 6 for ISe, n = 7 for OSe and MIX) 
4Means within a row that lack a common letter differ (P < 0.1).  
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Table 6.2. Microarray and real-time RT-PCR (RT-PCR) analyses of the effect on liver 
selenoprotein gene expression by growing beef steers consuming 3 mg Se/d in vitamin-
mineral mixes as either sodium selenite (ISe), SEL-PLEX (OSe), or a 1:1 mix of ISe and 
OSe (MIX) during summer-long grazing of endophyte-infected tall fescue. 
Gene Gene Name 
Microarray1 RT-PCR2 
Treatment3,4 P-
valu
e 
Treatment3,4 P-
valu
e 
ISe 
MI
X 
OSe ISe 
MI
X 
OSe 
DIO1 Iodothyronine 
Deiodinase 1 
1.00 1.32 1.57 0.23
9 
1.22 1.89 1.87 0.38
2 
DIO2 Iodothyronine 
Deiodinase 2 
1.00
a 
1.11
b 
1.03a
b 
0.07
5 
1.22 1.13 1.12 0.90
0 
DIO3 Iodothyronine 
Deiodinase 3 
1.00 1.04 0.93 0.35
5 
1.04a 0.67
b 
0.81a
b 
0.09
2 
GPX1 Glutathione 
Peroxidase 1 
1.00 0.93 0.91 0.28
0 
1.02 0.96 0.91 0.73
0 
GPX2 Glutathione 
Peroxidase 2 
1.00 0.99 1.03 0.72
4 
1.04 0.77 1.09 0.13
3 
GPX3 Glutathione 
Peroxidase 3 
1.00 0.68 1.16 0.22
1 
1.35 0.55 0.87 0.21
0 
GPX4 Glutathione 
Peroxidase 4 
1.00 1.22 1.08 0.09
6 
1.01a 1.57
b 
1.32a
b 
0.06
7 
GPX6 Glutathione 
Peroxidase 6 
1.00
a 
1.21
b 
1.17b 0.02
0 
1.79 0.66 0.98 0.27
5 
LRP2 
(Megalin) 
LDL Receptor 
Related Protein 
2 
1.00 0.90 0.85 0.31
2 
1.81 1.61 0.74 0.19
5 
LRP8 
(APOER2
) 
LDL Receptor 
Related Protein 
8 
1.00 1.02 1.03 0.87
7 
1.04 0.81 1.15 0.28
2 
MSRB1 
(SEPX1) 
Methionine 
Sulfoxide 
Reductase B1 
1.00 1.05 0.98 0.50
5 
1.01 1.00 0.87 0.47
2 
SELENO
F (SEP15) 
Selenoprotein 
F 
1.00 1.07 1.06 0.25
7 
1.01 0.94 0.85 0.18
7 
SELENO
H 
Selenoprotein 
H 
1.00 0.92 0.94 0.39
4 
NA NA NA NA 
SELENOI 
(EPT1) 
Selenoprotein I 1.00 1.00 1.00 1.00
0 
1.02 1.07 1.01 0.87
3 
SELENO
K 
Selenoprotein 
K 
1.00 1.03 1.03 0.91
9 
1.14 1.17 1.19 0.99
0 
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Table 6.2 (continued) 
SELENO
M 
Selenoprotein 
M 
1.00
a 
0.89
b 
0.98a
b 
0.08
0 
3.44 3.03 3.28 0.93
9 
SELENO
N 
Selenoprotein 
N 
1.00 0.96 1.03 0.15
0 
1.00 1.12 1.16 0.38
8 
SELENO
O 
Selenoprotein 
O 
NA NA NA NA 1.01a 1.21
b 
1.01a 0.04
0 
SELENO
P 
Selenoprotein 
P 
1.00 0.93 0.96 0.12
7 
1.01a 0.85
b 
0.82b 0.05
8 
SELENO
S 
Selenoprotein 
S 
1.00
a 
1.19
b 
1.05a
b 
0.07
9 
1.02a 1.47
b 
1.13a 0.00
1 
SELENO
T 
Selenoprotein 
T 
1.00
a 
1.09
b 
1.09b 0.02
1 
1.00a 1.35
b 
1.40b 0.00
5 
SELENO
V 
Selenoprotein 
V 
1.00 0.92 1.01 0.51
1 
1.17 1.20 1.01 0.76
9 
SELENO
W 
Selenoprotein 
W 
1.00 0.91 0.91 0.18
6 
1.01 0.86 0.85 0.44
5 
SEPHS1 Selenophospha
te Synthetase 1 
1.00 1.06 1.01 0.65
8 
1.01 1.24 1.10 0.16
1 
SEPHS2 Selenophospha
te Synthetase 2 
1.00 1.02 1.03 0.89
0 
1.02a
b 
1.18
a 
0.96b 0.09
2 
TXNRD1 Thioredoxin 
Reductase 1 
1.00
a 
1.15
b 
1.13a
b 
0.08
1 
1.01a 1.36
b 
1.37b 0.04
9 
TXNRD2 Thioredoxin 
Reductase 2 
1.00 0.98 0.97 0.90
2 
1.01a 0.95
a 
0.80b 0.02
1 
TXNRD3 Thioredoxin 
Reductase 3 
1.00 1.05 1.05 0.44
6 
1.02 1.04 0.98 0.88
6 
1The abundance of gene transcripts are reported relative to the mean expression of the ISe 
treatment group (untransformed microarray data).  
2The abundance of gene transcripts are reported relative to the geometric mean 
expression of the reference genes. 
3Values are least squares means (n = 6 for ISe, n = 8 for OSe and MIX) 
4Means within a row that lack a common letter differ (P < 0.1). 
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Table 6.3. Primer sets used for quantitative real-time RT-PCR analysis of the selected differentially expressed genes and 
reference genes. 
Gene Gene Name 
Template 
Accession 
number1 
Oligonucleotide Primer Design (5’ to 3’ 
direction) 
Amplicon 
length (bp) 
Product 
identity 
(%)2 
GAPDH 
Glyceraldehyde
-3-phosphate 
dehydrogenase 
NM_001034034.2 
F: ACATCAAGTGGGGTGATGCT 
R: GGCATTGCTGACAATCTTGA 
201 99% 
PCK2 
Phosphoenolpyr
uvate 
carboxykinase 2 
NM_001205594.1 
F: GCAAGCTGTGGATGAGAGGT 
R: TGACAAAGTCGCCATCTCCC 
203 99% 
RPS11 
Ribosomal 
protein S11 
NM_001024568.2 
F: AAGATGGCGGACATTCAGAC 
R: GCCCTCGAATGGAGACATTA 
214 99% 
SDHA 
Succinate 
dehydrogenase 
complex 
flavoprotein 
subunit A 
NM_174178.2 
F: GCAGAACCTGATGCTTTGTG 
R: CGTAGGAGAGCGTGTGCTT 
185 99% 
TFRC 
Transferrin 
receptor 
NM_001206577.1 
F: CCAGGTTTAGTCTGGCTCGG 
R: GGTCTGCCCAGAATATGCGA 
339 99% 
  
 
2
4
6
 
Table 6.3 (continued)     
UBC Ubiquitin C NM_001206307.1 
F: TAGGGGTGGGTTAGAGTTCAAG 
R: ACCACCTCCCTGCTGGTATT 
258 100% 
DIO1 
Iodothyronine 
deiodinase 1 
NM_001122593.2   
F: ATTGCCCAGTTCTAGGTGCC 
R: CAGAAGGAAATGCAGCGTGT 
273 100% 
DIO2 
Iodothyronine 
deiodinase 2 
NM_001010992.4 
F: GATGGGCATCCTCAGCGTAG 
R: TTCTCCTGGGCACCATTTCC 
315 100% 
DIO3 
Iodothyronine 
deiodinase 3 
NM_001010993.3 
F: AAGTGGAGCTCAACAGCGAT 
R: AGTCGAGGATGTGCTGGTTC 
213 100% 
GPX1 
Glutathione 
peroxidase 1 
NM_174076.3 
F: AAACGCCAAGAACGAGGAGA 
R: GTCGGTCATGAGAGCAGTGG 
184 99% 
GPX2 
Glutathione 
peroxidase 2 
NM_001163139.2 
F: AACAGCCTCAAGTACGTCCG 
R: TCGGTCATGAGGGAAAACGG 
158 100% 
  
 
2
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Table 6.3 (continued)     
GPX3 
Glutathione 
peroxidase 3 
NM_174077.4 
F: AGGAGAAGTCGAAGACGGACT 
R: CTCAGTAGCTGGCCACGTTGA 
147 100% 
GPX4 
Glutathione 
peroxidase 4 
NM_174770.3 
F: GATCAAAGAGTTCGCCGCTG 
R: CCATACCGCTTCACCACACA 
198 100% 
GPX6 
Glutathione 
peroxidase 6 
NM_001163142.1 
F: CACTGTTCCTGGTCGGCTTA 
R: CCCAGCACAACTACACCGAA 
259 99% 
LRP2 
LDL receptor 
related protein 2 
XM_015462263.1 
F: GTGGTTTGGGTTACCGTTGC 
R: GGCACCCTGTTAGCTGTGAT 
304 98% 
LRP8 
LDL receptor 
related protein 8 
NM_001097565.1 
F: AGCCACCCTTTTGGGATAGC 
R: AAGGCACAGGTACTCACAGC 
231 98% 
MSRB1 
Methionine 
sulfoxide 
reductase B1 
NM_001034810.2 
F: GAACCACTTTGAGCCGGGTA 
R: GGCCATCGTTCAGGAACTCA 
221 100% 
  
 
2
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Table 6.3 (continued)     
SELENOF Selenoprotein F NM_001034759.2 
F: GGGAGATGCCTGATGTGAGT 
R: TCCAGTGCCTGATCCAAAGC 
174 100% 
SELENOH Selenoprotein H NM_001321327.1 
F: CACGAGCTGACGAGTCTACG 
R: CTTCTTCAGCTCCTCCAGCA 
235 100% 
SELENOI Selenoprotein I NM_001075257.2 
F: TACCTGACGTGTTGGCAGAC 
R: CACTTGTGAAAAAGGCCGCA 
341 100% 
SELENOK Selenoprotein K NM_001037489.3 
F: CCGTTTTGTCGATTCACGGC 
R: CAGATGAGCTTCCGTAGCCT 
278 100% 
SELENOM 
Selenoprotein 
M 
NM_001163171.2 
F: CCCACTCTACCACAACCTGG 
R: ACCTAAAGGTCTGCGTGGTC 
249 100% 
SELENON Selenoprotein N NM_001114976.2 
F: GTGGCCATGTACCCCTTCAA 
R: GGGATGGGTTCTCCTGGTTG 
265 100% 
  
 
2
4
9
 
Table 6.3 (continued)     
SELENOO Selenoprotein O NM_001163193.2 
F: TGGACAGGTATGACCCCGAT 
R: ATCTTCTGCAGGTAGTGCCG 
202 100% 
SELENOP Selenoprotein P NM_174459.3 
F: TCAGGTCTTCATCACCACCA 
R: GTGGCAACAGCAGCTACTCA 
201 100% 
SELENOS Selenoprotein S NM_001046114.3 
F: CCCACCCTCGAGACCGA 
R: GCCCAGGACTGTCTTCTTCC 
394 100% 
SELENOT Selenoprotein T NM_001103103.2 
F: TGGTCACCTTCCATCCATGC 
R: AAGAGGTACAACGAGCCTGC 
240 100% 
SELENOV Selenoprotein V NM_001163244.2 
F: ACTCCATTGGCCACCGATTT 
R: AGGCCACAGTAAACCACTCG 
224 100% 
SELENO
W 
Selenoprotein 
W 
NM_001163225.1 
F: AGTGTTCGTAGCGGGAAAGC 
R: CGCGAGAACATCAGGGAAGG 
233 98% 
  
 
2
5
0
 
Table 6.3 (continued)     
SEPHS1 
Selenophosphat
e synthetase 1 
NM_001075316.1 
F: CAAAGCGAACCGGTGGATCT 
R: GAGGTCACTGAGGACGTTGG 
422 99% 
SEPHS2 
Selenophosphat
e synthetase 2 
NM_001114732.2 
F: GATCCCTACATGATGGGGCG 
R: GTTTACCACCGTTTGCCCAC 
219 100% 
TXNRD1 
Thioredoxin 
reductase 1 
NM_174625.3 
F: AAGGCCGCGTTATTTGGGTA 
R: CCTGGTGTCCCTGCTTCAAT 
306 98% 
TXNRD2 
Thioredoxin 
reductase 2 
NM_174626.2 
F: CAAATGGCTTCGCTGGTCAC 
R: TTCGTATGCACACCAGCCTT 
230 100% 
TXNRD3 
Thioredoxin 
reductase 3 
XM_015468824.1 
F: CGGCGTATGACTACGACCTC 
R: GACTGTACTCCCAGCCGAAC 
249 99% 
1The contents in the parentheses associated with each gene symbol are the accession numbers of the sequences retrieved from 
the NCBI RefSeq database and used as templates for designing primers and probes.   
2All the real-time RT-PCR products were validated by sequencing. The identity values (%) presented are the base-pair ratios 
between the number of identical base pairs and the total amplicon length.
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Figure 6.1. Score plot from principal component analysis of steer (ISe, OSe, and MIX) 
parameters showing the correlation of the first two principal components (Components 1 
and 2) among Se concentration, glutathione (GSH) content, glutamine synthetase (GS) 
activity, and relative mRNA abundance of selenoproteins in liver. 
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Figure 6.2. Loading plot from principal component analysis of steer (ISe, OSe, and MIX) 
parameters showing the correlation of the first two principal components (Components 1 
and 2) among Se concentration, glutathione (GSH) content, glutamine synthetase (GS) 
activity, and relative mRNA abundance of selenoproteins in liver. 
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GAPDH: 
ACATCAATGGGGTGATGCTGGTGCTGAGTATGTGGTGGAGTCCACTGGGGTC
TTCACTACCATGGAGAAGGCTGGGGCTCACTTGAAGGGTGGCGCCAAGAGGG
TCATCATCTCTGCACCTTCTGCCGATGCCCCCATGTTGTGATGGGCGTGAACC
ACGAGAAGTATAACAACACCCTCAAGATTGTCAGCAATGCC 
PCK2: 
GCAAGCTGTGGATGAGAGGTTTCCAGGCTGCATGCTGKGCCSAACATGTACG
TGATTCCGTTCAGCATGGGTCCCGTGGGCTCCCCGCTGTCCCGCATCGGAGTG
CAGCTCACGGACTCTGCCTACGTGGTGGCAAGCATGCGGATTATGACTCGGT
TGGGGACACCTGTGCTTCAGGCCCTGGGAGATGGCGACTTTGTCA 
RPS11: 
AAGATGGCGGACATTCAGACAGAACGTGCGTACCAAAAGCAACCGACCATC
TTTCAAAATAAAAAGAGGGTCCTGCTTGGAGAAACTGGCAAAGAAAAGCTCC
CTCGATACTACAAGAACATTGGTCTGGGCTTCAAGACTCCAAAGGAGGCCAT
CGAGGGCACCTACATTGACAAGAAATGCCCTTTTACGGGTAATGTCTCATTCG
AGGGC 
SDHA: 
CGTAGGAGAGCGTGTGCTTCCTCCAGTGCTGCTCAAAGGGCTTCTTCTGCTGC
CCCTGGATGGGCTTGGAGTAATCGTACTCGTCAACCCTCTCCTTGAAGTCCTC
CCTGGCGTGGGCGCCGCGCGACTCCTtCCGGGCCTCCGCTCCGTAGATGGTCT
GCAGAGCACAAAGCATCAGGTTCTGC 
TFRC: 
CCAGGTTTAGTCTGGCTCGGCAAGTAGATGGTGATAACAGTCATGTGGAGAT
GAAATTAGCTGCAGATGAAGAAGAANAATGTTGACAGTAACATGAGGGGCA
ACCAAACCAGTATCGCAAAACCGAAAAGGTTAAATGGATATGTCTGCTACGG
GATCATTGCTGTAATCGTCTTTTTCTTGATTGGATTTATGATTGGCTACTTGGG
CTATTGTAGACGTGTGGAATCACAAGATTGTGGGAAAGAGGCAGGAACACA
GCCTTCGTGCCCAGGAGGAGACAGAAACTTTCGAATCAGAAGAGCAACTCCC
TGGAGTACCTCGCATATTCTGGGCAGACC 
UBC: 
TAGGGGTGGGTTAGAGTTCAAGGTTTTTGTTCTACCAGATGTTTTAGTAGTAA
TCTGGAGGTAAGAAATGTCAAGAAAACATGGCCTTAATTAGAACTGTAGTGG
GTGAGTATAAATAAAAAATTTGGAGGTTGTAGTTAGAATTCTCCATATGTAC
ACTCATATGTAGATCTACTTATAAGCTACTGATTTTTAAAAGCACACGTTTGG
GAGTTGTGCTTAAGAGTGGGAAAGTTTCTGGAATACCAGCAGGGAGGT 
DIO1: 
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ATTGCCCAGTTCTAGGTGCCCAACCTGAGGGCCCCTTAAGGCTTGGTTTGACC
CCCATCCCAGCTGACATTTACCTCTTGACCTGTGTTCCCAGTTGAATCACTAG
CCTGGATTTTTCTGATCCAAGCAAACAATTGTTGCAATGAGAAAATGAAGCC
ACAAGTAAGCTGAGTATTAAAGAAGGTATAATTTCGTACTGCTCCTACCATG
GAGACTGTGTTCATTGCACAGCATTCTAAGAATGAGAGCAGGTACACGCTGC
ATTTCCTTCTG 
DIO2: 
GATGGGCATCCTCAGCGTAGACTTGCTGATCACACTGCAGATTCTGCCAGTTT
TTTTCTCCAACTGCCTCTTCCTGGCGCTCTATGACTCGGTCATTCTCCTCAAGC
ACGTGGTGCTGCTGCTGAGCCGCTCCAAGTCCACTCGCGGGCAGTGGAGGCG
CATGCTGACCTCAGAAGGAATGCGCTGCATCTGGAAAAGCTTCCTCCTCGAC
GCCTACAAACAGGTGAAACTGGGTGAAGATGCCCCCAATTCCAGCGTGGTGC
ATGTCTCCAGTCCGGAAGGAGGTGACACCAGTGGAAATGGTGCCCAGGAGA
A 
DIO3: 
AAGTGGAGCTCAACAGCGATGGCGAGGAGGTGCCCCCCGACGACCCGCCTGT
CTGCGTGTCCGACGACAACCGCCTGTGCACCTTGGCGTCGCTGAGGGCCGTC
TGGCACGGCCAGAAGTTGGATTTCTTCAAGCAGGCGCATGAAGGCGGGCCGG
CGCCCAACTCTGAGGTGGTCCTGCCCGACGGCTTCCAGAACCAGCACATCCT
CGACT 
GPX1: 
AAACGCCAAGAACGAGGAGATCCTGAATTGCCTGAAGTACGTCCGACCAGG
CGGCGGGTTCGAGCCCAACTTTATGCTCTTCGAAAAGTGCGAGGTGAATGGC
GAGAAGGCGCATCCGCTCTTCGCCTCCTTCGGGAGGTTCTGCCCACGCCAAG
TGACGACGCCACTGCTCTCATGACCGAC 
GPX2: 
AACAGCCTCAAGTACGTCCGCCCCGGGGGTGGGTTCCAGCCCACCTTCACCC
TTGTCCAGAAGTGTGATGTGAATGGTCAGAATGAGCATCCTGTCTTTGCCTAC
CTGAAGGATAAGCTCCCCTACCCTTATGATGACCCGTTTTCCCTCATGACCGA 
GPX3: 
AGGAGAAGTCGAAGACGGACTGCCACGCTGGTGTGGGTGGCACCATCTATGA
GTACGGGGCCCTCACCATCGATGGGGAGGAGTACATCCCCTTTAAGCAGTAC
GCTGGCAAATACATCCTCTTCGTCAACGTGGCCAGCTACTGAG 
GPX4: 
GATCAAAGAGTTCGCCGCTGGCTATAACGTCAAATTCGATTTGTTCAGCAAG
ATCTGTGTAAATGGGGACGACGCCCACCCTCTGTGGAAATGGATGAAAGTCC
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AGCCCAAGGGGAGAGGCATGCTGGGAAACGCCATCAAATGGAACTTCACCA
AGTTCCTCATTGACAAGAACGGCTGTGTGGTGAAGCGGTATGG 
GPX6: 
CACTGTTCCTGGTCGCTTAGCTCAGCTGACTCCGAAGCAGCAACAGATGAAG
GTGGATTGCTATAAGGGGGTGACAGGCACCATCTATGAGTATGGAGCCCTCA
CCCTCAATGGTGAGGAGTATATCCAGTTCAAGCAGTATGTGGGCAAGCATGT
CCTGTTTGTCAATGTGGCCACCTATTGAGGCTTGACAGCTCAGTTCCAGAACT
GAATGCACTACAGGAGGAGCTGAAGCCTTTCGGTGTAGTTGTGCTGGG 
LRP2: 
GTGGTTTGGGTTACCGTTGCAAGTGTAGGCTTTGCGAACTTCGGATTGGGATG
ACTATCACTGTGTTGCTGCTGAGCGGTTTCTGCTCTTTTCATCTACATCTGGCT
GTTCGTGGCATCCCACTCACCCTCTCTCACCAGACGGAGGTCATCCTTCCAGT
GACAGGATCTTCTTCCATCTTCCTTGGGATCGATTTTGATGCCCGCGAGAAGG
CTATCTTTTTTTCAGATACAAAGAAAAACATTATTTATAGACAAAAGCTCGAT
GGTACAGGAAGAGAAATTATCACAGCTAACAGGGTGCC 
LRP8: 
AGCCACCCTTTTGGGATAGCTGTGTTTGAGGACAAVGTGTTCTGGACGGACCT
GGAGAATGAGGCCATTTTCAGTGCAAATCGGCTCAATGGCCTGGAAATCTCC
GTCCTAGCTGAGAACCTCAACAACCCGCATGATATAGTCATCTTCCATGAGCT
GAAGCAGCCAAGAGCTGCAGATGCCTGAGCGAGGCCCAGCCCAATGGAGGC
TGTGAGTACCTGTGCCTT 
MSRB1: 
GAACCACTTTGAGCCGGGTATCTACGTGTGTGCCAAGTGTGGCTATGAGCTCT
TCTCCAGCCGCTCCAAGTACGCACACTCATCCCCATGGCCGGCGTTCACTGAG
ACCATCCATGCTGACAGTGTGGCCAAGCGGCCAGAGCACAATCGGCCTGGAG
CCATAAAGGTATCCTGTGGCAGGTGTGGCAACGGGCTGGGCCATGAGTTCCT
GAACGATGGCC 
SELENOF: 
GGGAGATGCCTGATGTGAGTTATCGAAAGGACCCAGTGACTTCATATTTACA
TCAAGTGTAAAGTTTTTGCTCACCTTTAAGCTTACATATGCCCGTAGTTAATG
CCCGTCTCCTCAGAATAAGAGACTTGATGGCAGCGGCCTTTAGCAGCCTGCTT
TGGATCAGGCACTGGA 
SELENOH: 
CACGAGCTGACGAGTCTACGGGCGCAACGCCGCGGCCCTGAGCCAGGCGCtG
CGCCTGCAGGCCCCCGAGCTGACGGTGAAGGTGAACCCCGCCAGGCCGCGG
AGGGGCAGCTTCGAGGTGACGTTGCTGCGCGCCGACGGCAGCAGCGCGGAG
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CTCTGGACGGGTCTTAAGAAGGGGCCCCCACGCAAACTCAAGTTTCCGGAGC
CTCACGTGGTGCTGGAGGAGCTGAAGAAG 
SELENOI: 
TACCTGACGTGTTGGCAGACAGTTGCTTTAGGATATATGGTAAATCATGGTTG
TCTAGCTTTTCCAGAGAAAGTGGCAGTGTGTTTACTTTTTCCTTTGTGTGGAG
CCGTGGGAATTGGACTTATTGGCTAATTCATCTCCATTGTTTCTGTGGTGCAC
GGTAAACAACCTTTTAAAGCTGCATACTAGTAATGCTTTCCTTTTTAATAAAT
ATGCGAAAGACAGTAATCTAGCCAATTGTTTTTAAGTAGATGCTTGCTCTTTT
TTCAGACATACCTTAAATGAACTAATATTTCGGGTAGCATAAGAAGTTTTGGC
ATTTGCGGCCTTTTTCACAAGTG 
SELENOK: 
CCGTTTTGTCGATTCACGGCCTGTGATGTAAGAGGGAGGCGCGGAGGGAGAT
AAGGAATCCAAGAGGGGTCAGGCGTCGCCGTCGCCCTGAAGACGGAGGAGG
GGCAAGATGGTTTACATCTCGAATGGACAAGTGTTGGACAGCAGGAGTCAGT
CCCCATGGAGATTATCTTTTATAACAGATTTCTTCTGGGGAATAGCTGAGTTT
GTGGTTTTGTTTTTCAGAACTCTGCTTCAACAAGATGTGAAAAAGAGAAGAG
GCTACGGAAGCTCATCTG 
SELENOM: 
CCCACTCTACCACAACCTGGTGATGAAACACCTGCCGGGGGCCGACCCAGAG
CTCGTGTTGCTCGGCCACCGCTTTGAGGAACTGGAGCGAATTCCACTCAGCG
ACATGACCCGCGAGGAGATCAACGCGCTGGTGCAGGAGCTCGGCTTCTACCG
CAAGGCGTCGCCCGACGAGCCTGTGCCCCCGGAGTACCTTCGGGCGCCCGCT
AGGCCCGCCGGAGACGCTCCTGACCACGCAGACCTTTAGGT 
SELENON: 
GTGGCCATGTACCCCTTCAAGAAGGTCACCTACCTGCCGTTCACCGAGGCCTT
TGACCAAGCCAAGGCCAAGAACAAGCTGGTGCACTCAATCCTGCTGTGGGGG
GCCCTGGACGACCAGTCCTGCTGAGGTTCGGGGCGGACTCTCCGGGAGACCG
TCCTGGAAAGTTCGCCCATCCTCGCCCTCCTCAATGAGAGCTTCATCAGCACC
TGGTCCCTGGTGAAGGAGCTGGAGGACCTGCAGAACAACCAGGAGAACCCA
TCCC 
SELENOO: 
TGGACAGGTATGACCCCGATCACGTGTGCAACGCCTCCGACACCGCCGGGCG
CTACTCGTACAGCAAGCAGCCCGAGGTGTGCAAGTGGAACCTGCAGAAGCTG
GCCGAGGCCCTGGACCCCGCGCTGCCCCTCGAGCTGGCCGAGGCCATCCTGG
CAGAGGAGTTCGACGCCGAGTTCGGCCGGCACTACCTGCAGAAGAT 
SELENOP: 
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TCAGGTCTTCATCACCACCACCACAGGCACAAGGGTCCCCAAAGACAGGGTC
ACTCAGATAACTGTGATACACCAGTAGGAAGTGAAAGTTTACAACCTTCTCTT
CCACAAAAGAAGCTCTGACGAAAGAGATGCATAAATCAGTTACTCTGACAGT
TTCCCAAAGATTCAGAATCTGCTTTGAGTAGCTGCTGTTGCCAC 
SELENOS: 
CCCACCCTCGAGACCGAGGGGCTGCGTTTCCTTCACGTCACGGTGGGCTCCCT
GCTGGCCACTTACGGCTGGTACATCGTCTTCAGCTGCATCCTTCTCTACGTGG
TGTTTCAGAAGCTTTCCACCCGGTTGAGGGCCTTGAGGCAGAGGCACTTAGA
TCAAGCTGCCGCTGCTCTGGAACCTGATATTGTTGTTAAACGACAGGAGGCTT
TAGCAGCTGCTCGTTTGAAAATGCAAGAAGAATTAAATGCACAAGTTGAAAA
GCATAAAGAGAAATTAAGACAGCTTGAAGAAGAAAAAAGGAGACAGAAGAT
CGAAATGTGGGATAGCATGCAAGAAGGAAAAAGTTATAAAGGAAATACAAG
AAAGCCTCAGGAAGAAGACAGTCCTGGGC 
SELENOT: 
TGGTCACCTTCCATCCATGCAACAGCTGGTTCAAATTCTTGACAATGAAATGA
AGCTCAACGTGCATATGGATTCAATCCCACACCATCGATCATAGCCCCAACT
ATCAGCACTGAAAACTCTTTTACATTAAGGGATTTTTGCAAGAGCAGCGTGA
CTGACATTATGAAGGCCTGTACTGAAGACAGCAAGCTGTTAGTACAGACCAG
ATGCTTTCTTGGCAGGCTCGTTGTACCTCTT 
SELENOV: 
ACTCCATTGGCCACCGATTTACGGTCCCCATCCCTCGGGTCCCCTCTGAGGAC
AGACACATCGACCACCAATTTGATAGCTTCTTCTTCTGGACATGTCCCAGGGA
CGCCCATCCTAGGGGCCATCCAGGCCATCTTACCGGTTCCTGCCACCGCATTA
GCTTCCATCAGTGGGAACCTCAAAGAGGAAAACAAGATCATGATTCGAGTGG
TTTACTGTGGCCT 
SELENOW: 
AGTGTTTGTAGCGGGAAAGCTGGTTCACTCCAAGAAGGGAGGCGATGGCTAC
GTGGACACGGAGAGCAAGTTTCTGAAGCTGGTGGCCGCCATCAAAGCCGCTT
TGGCTCAGGCCTGATGTGGCCTGAAGGCAGAGACCAGTAATCGTGGCCCAGC
CCCTCTCGGCAGACGCTTCATGACAGGAAGGACGAAAGTCTCTTGGACGCCT
GGTCCTTCCCTGATGTTCTCGCG 
SEPHS1: 
CAAAGCGAACCGGTGGATCTATAAAGAAACCAGCTGCGTAGGAGAAGGAGG
GGAGGAGCCCGGCCGTGAGGTGTGTGGGCCCAAGAACCATGTCTGCACGGG
AGTCCTTTAACCCGGAAAGTTATGAATTGGACAAGAGTTTCCGGTTAACCAG
ATTCACTGAACTGAAGGGCACTGGCTGCAAAGTGCCCCAAGATGTCCTGCAG
AAATTGCTGGAGTCCTTACAGGAGAACCACTTCCAAGAAGATGAGCAGTTTC
TTGGAGCAGTTATGCCAAGACTTGGCATCGGGATGGACACCTGTGTCATTCCT
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CTGAGGCACGGCGGCCTTTCCTTGGTTCAAACCACAGATTACATTTATCCCAT
CGTCGATGACCCNTACATGATGGGCAGGATAGCCTGTGCCAACGTCCTCAGT
GACCTC 
SEPHS2: 
GATCCCTACATGATGGGGCGCATCGCATGTGCCAACGTGCTGAGTGACCTTT
ACGCGATGGGCATTACTGAGTGTGACAACATGTTGATGCTACTCAGCGTCAG
CCAGAGTATGCCTGAGGAGGAGCGAGAAAAGATAACACCACTCATGATCAA
AGGCTTTCGAGATGCTGCCGAGGAAGGAGGGACTGCAGTGACTGGTGGGCA
AACGGTGGTAAAC 
TXNRD1: 
AAGGCCGCGTTATTTGGGTATCCCCGGTGACAAAGAATACTGTAtYMGCAGT
GATGATCTTTTCTCTCTACCTTATTGCCCGGGTAAGACCCTGGTGGTTGGAGC
ATCCTATGTTGCTTTGGAATGTGCTGGATTTCTTGCTGGTATTGGTTTAGACGT
CACTGTTATGGTACGATCCATTCTCCTAAGAGGATTTGACCAGGACATGGCCA
ACAAAATTGGTGAACATATGCAAGAACATGGTATCAAGTTCATAAGACAGTG
ACAATAAAAGTTGAACAAATTGAAGCAGGGACACCAGG 
TXNRD2: 
CAAATGGCTTCGCTGGTCACCGAGCACATGGCTGGCCACGGCACCCGGATCC
TACGGGGCTGCGCCCCCGAGAAGGTAGAGAAACTCCCAGGCCAGCAGCTCC
GCGTCACCTGGGTGGACCTCACCTCGGACCGGAAGGACGCGGGCACCTTTGA
CACGGTGCTCTGGGCCATAGGCCGAGTTCCAGAAACCGCAAGTCTGAATTTG
GAAAAGGCTGGTGTGCATACGAA 
TXNRD3: 
CGGCGTATGACTACGACCTCATCGTCATCGGTGGGGGCTCCGGGGGCCTCTC
GTGTGCTCAGGAAGCCGCCGTCCTGGGGAGGAAGGTCATGGTGCTGGACTTC
GTGGTCCCGTCCCCCCGTGGCACGGCCTGGGGTCTTGGTGGCACGTGTGTGA
ATGTTGGCTGTATCCCGAAGAAGCTGATGCACCAGGCCGCGCTGCTGGGGCA
GGCACTGACCGACTCCAGGAAGTTCGGCTGGGAGTACAGTC 
Figure 6.3. The sequences of the real-time RT-PCR products (5’ to 3’ orientation). 
Within a sequence, underlined nucleotides indicate the forward and reverse primer 
positions.  
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CHAPTER 7. Summary and Conclusions 
Improvement of growth performance of growing beef steers grazing endophyte-
infected tall fescue has been hindered by a lack of fundamental knowledge about how 
ergot alkaloids exert their deleterious effects on bovine pituitary function. In addition, 
knowledge regarding the effects of forms of supplemental Se on pituitary function of 
growing beef steers grazing endophyte-infected tall fescue has not been reported. The 
overall objective of this dissertation was to determine whether transcriptome profiles 
differed between whole pituitaries of growing beef steers grazing pastures containing HE 
or LE amounts of toxic endophyte-infected tall fescue, and to test whether ISe, OSe, vs. 
MIX in a basal VM mix would differentially alter pituitary transcriptome profiles in 
growing beef steers grazing endophyte-infected tall fescue. 
In the first experiment of the current study (Chapter 4), the findings indicate that 
anterior pituitary functions were globally impaired in steers consuming high-toxic 
endophyte-infected tall fescue. In addition to inhibiting the abilities to synthesize and 
secrete prolactin (a function of lactotrophs), ACTH synthesis capacity (a function of 
corticotrophs) might have been reduced. Canonical pathway analysis also indicated that 
growth hormone signaling and GnRH signaling were altered in HE vs. LE steers. With 
the identification of putative ergot alkaloid sensitive mechanisms within the pituitary 
gland, this new knowledge may help to develop dietary treatments that ameliorate the 
effects of ergot alkaloid ingestion. To our knowledge, this is the first report to describe 
the impart of consumption of toxic tall fescue on bovine pituitary transcriptome.  
In the second experiment of the current study (Chapter 5), the findings indicate 
that consumption of 3 mg Se/d in VM mixes as OSe, MIX, or ISe differentially affected 
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the expression of genes responsible for the synthesis or release of prolactin and 
POMC/ACTH/α-MSH, and for mitochondrial function, in the pituitaries of growing beef 
steers commonly grazing an endophyte-infected tall fescue pasture. Consumption of OSe 
resulted in greater prolactin synthesis capacity, whereas consumption of MIX resulted in 
increased prolactin synthesis and release potential, both of which resulted in greater 
serum prolactin concentrations in OSe and MIX steers vs. ISe steers, respectively. In 
addition, consumption of OSe resulted in greater POMC/ACTH/α-MSH synthesis 
potential, and a better capacity to manage against mitochondrial dysfunction and 
oxidative stress, than did consumption of MIX or ISe forms of Se. To our knowledge, this 
is the first report to evaluate the impact of forms of supplemental Se on bovine pituitary 
transcriptome.  
In the third experiment of the current study (Chapter 6), the findings indicate that 
consumption of 3 mg Se/d in VM mixes as OSe, MIX, or ISe differentially affected the 
expression of selenoprotein profiles in both pituitaries and livers of growing beef steers 
commonly grazing an endophyte-infected tall fescue pasture. Compared with liver, the 
pituitary is more responsive to Se treatment in terms of change in expressions of 
selenoprotein. For most of the affected selenoproteins, they were either up-regulated by 
OSe or MIX supplementation when compared to ISe supplementation. Generally, OSe 
steers may manage against oxidative damage, maintain cellular redox balance, and have a 
better quality control of protein-folding in their pituitaries than ISe steers. Meanwhile, 
MIX steers may have more thyroid hormone T3 and better redox signaling, and handle 
oxidative damage better in livers than ISe steers. This is the first time to describe the 
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effects on forms of supplemental Se on bovine selenoprotein expression profile in 
pituitary and liver. 
In conclusion, these findings above suggest that consumption of endophyte-
infected tall fescue negatively impact bovine pituitary function (e.g. prolactin and ACTH 
synthesis), and inclusion of the organic form of Se in free-choice vitamin-mineral mixes 
can ameliorate the negative impact of fescue toxicosis on beef cattle by restoration of 
both prolactin and POMC/ACTH synthesis capacities to a certain extent. In addition, by 
identification of genes that are susceptible to ergot alkaloids contained in endophyte-
infected tall fescue, a larger implication of this research may be that it allows for selective 
breeding for genotypes with a higher resistance to endophyte toxicosis. 
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APPENDIX. Example of SAS Analysis 
Analysis of mRNA expression of UBC in pituitary tissue of steers grazing endophyte-
infected tall fescue and supplemented with 3 mg Se/d in vitamin-mineral mixes as either 
sodium selenite (ISe), SEL-PLEX (OSe), or a 1:1 mix of ISe and OSe (MIX) (Chapter 5) 
1. Representative of SAS editor programming language using PROC GLM 
procedure 
proc means data=SCApituitary MEAN MIN MAX STD STDERR; 
class trt; 
proc glm data=SCApituitary plots=diagnostics;; 
class trt; 
model UBC=trt; 
lsmeans trt/diff; 
run;quit; 
 
2. SAS output 
3. The SAS System 
 
The MEANS Procedure 
Analysis Variable : UBC UBC 
trt N Obs Mean Minimum Maximum Std Dev Std Error 
B 7 23.8142857 23.0600000 24.2800000 0.3923798 0.1483056 
G 7 23.7642857 23.5150000 23.9350000 0.1665440 0.0629477 
R 6 23.9116667 23.4200000 24.1400000 0.2583344 0.1054646 
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The SAS System 
 
The GLM Procedure 
Class Level Information 
Class Levels Values 
trt 3 B G R 
 
Number of Observations Read 20 
Number of Observations Used 20 
 
The SAS System 
 
The GLM Procedure 
  
Dependent Variable: UBC UBC 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 2 0.07165381 0.03582690 0.43 0.6588 
Error 17 1.42387619 0.08375742     
Corrected Total 19 1.49553000       
 
R-Square Coeff Var Root MSE UBC Mean 
0.047912 1.214676 0.289409 23.82600 
 
Source DF Type I SS Mean Square F Value Pr > F 
trt 2 0.07165381 0.03582690 0.43 0.6588 
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Source DF Type III SS Mean Square F Value Pr > F 
trt 2 0.07165381 0.03582690 0.43 0.6588 
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The SAS System 
 
The GLM Procedure 
Least Squares Means 
trt UBC LSMEAN LSMEAN Number 
B 23.8142857 1 
G 23.7642857 2 
R 23.9116667 3 
 
Least Squares Means for effect trt 
Pr > |t| for H0: LSMean(i)=LSMean(j) 
Dependent Variable: UBC 
i/j 1 2 3 
1   0.7505 0.5533 
2 0.7505   0.3728 
3 0.5533 0.3728   
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